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vAcute myeloid leukemia (AML) is the most common type of leukemia. The Cancer Genome 
Atlas Research Network has demonstrated the increasing genomic complexity of AML. In 
addition, the network has facilitated our understanding of the molecular events leading to 
this deadly form of malignancy for which the prognosis has not improved over past decades. 
AML is a highly heterogeneous disease, and cytogenetic and molecular analysis of the vari-
ous chromosome aberrations including deletions, duplications, aneuploidy, balanced recip-
rocal translocations, and fusion of transcription factor genes and tyrosine kinases has led to 
a better understanding and identification of subgroups of AML with different prognoses. 
Furthermore, molecular classification based on mRNA expression profiling has facilitated 
the identification of novel subclasses and defined high-, poor-risk AML based on specific 
molecular signatures. However, despite increased understanding of AML genetics, the out-
come for AML patients whose number is likely to rise as the population ages has not 
changed significantly. Until it does, further investigation of the genomic complexity of the 
disease and advances in drug development are needed. In this review, leading AML clini-
cians and research investigators provide an up-to-date understanding of the molecular biol-
ogy of the disease addressing advances in diagnosis, classification, prognostication, and 
therapeutic strategies that may have significant promise and impact on overall patient 
survival.
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Chapter 1
Molecular Malfeasance Mediating Myeloid Malignancies: 
The Genetics of Acute Myeloid Leukemia
Rebecca L. King and Adam Bagg
Abstract
A remarkable number of different, but recurrent, structural cytogenetic abnormalities have been observed 
in AML, and the 2016 WHO AML classification system incorporates numerous distinct entities associated 
with translocations or inversions, as well as others associated with single gene mutations into a category 
entitled “AML with recurrent genetic abnormalities.” The AML classification is heavily reliant on cytoge-
netic and molecular information based on conventional genetic techniques (including karyotype, fluores-
cence in situ hybridization, reverse transcriptase polymerase chain reaction, single gene sequencing), but 
large-scale next generation sequencing is now identifying novel mutations. With targeted next generation 
sequencing panels now clinically available at many centers, detection of mutations, as well as alterations in 
epigenetic modifiers, is becoming part of the routine diagnostic evaluation of AML and will likely impact 
future classification schemes.
Key words Acute myeloid leukemia, 2016 WHO AML classification, Acute promyelocytic leukemia, 
NGS, Karyotype, FISH, RT-PCR, Epigenetics
1 Introduction
Acute myeloid leukemia (AML) is a complex and heterogeneous 
disease that was first subclassified in 1976 according to the French- 
American- British (FAB) scheme which was primarily a morphology- 
based system [1]. Since then, cytogenetic and molecular techniques 
have resulted in the discovery of numerous recurrent genetic 
abnormalities in AML. These recurrent genetic abnormalities have 
not only advanced our ability to subclassify this disease, but have in 
many cases provided prognostic markers and even therapeutic tar-
gets. The World Health Organization (WHO) now recognizes an 
AML classification which is heavily reliant on cytogenetic and 
molecular information [2]. While the majority of the genetic aber-
rations discussed in the current WHO classification rely primarily 
on conventional cytogenetic techniques such as karyotype or 
 fluorescence in situ hybridization (FISH) and reverse transcriptase 
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2polymerase chain reaction (RT-PCR)-based or conventional 
sequencing techniques, the literature is abound with novel muta-
tions identified in large-scale next generation sequencing (NGS) 
studies. With targeted NGS panels now clinically available at many 
centers, detection of mutations, as well as alterations in epigenetic 
modifiers, is becoming part of the routine diagnostic evaluation of 
AML and will likely influence future classification schemes.
2 WHO Classification of AML: Recurrent Translocations and Genetic 
Rearrangements
A remarkable number (>300) of different, but recurrent, structural 
cytogenetic abnormalities have been observed in AML, some of 
which are highlighted in Table 1. The current (2016) WHO AML 
classification system incorporates numerous distinct entities associ-
ated with translocations or inversions, as well as several others asso-
ciated with single gene mutations into a category entitled “AML 
with recurrent genetic abnormalities” [2, 3].
A discussion of the relevance of genetics in AML must begin with 
acute promyelocytic leukemia (APL) which by far demonstrates 
the most compelling genotype–phenotype correlation and repre-
sents a success story for genetically targeted cancer therapy. APL is 
an acute leukemia of neoplastic promyelocytes that accounts for 
5–10% of AML cases [2]. There are two morphologic variants, the 
classic hypergranular form in which the neoplastic cells have abun-
dant pink granules and numerous Auer rods, and the microgranu-
lar variant in which the cells have bi-lobed nuclei and a paucity of 
granules. Both variants are associated with the PML-RARA 
t(15;17)(q24;q21) translocation in 99% of cases, with the remain-
ing 1% demonstrating variant translocations involving the disrup-
tion of the retinoic acid receptor alpha (RARA) gene at 17q21. 
The PML-RARA fusion, which is not always accompanied by a 
grossly karyotypically evident t(15;17) translocation, is considered 
“disease defining,” meaning that it is diagnostic of AML regardless 
of blast percentage [4]. In the t(15;17), the RARA gene is fused 
to the promyelocytic leukemia (PML) gene which encodes a 
protein normally localized to nuclear bodies or PODs (PML 
Oncogenic Domains) within the nucleus. The resultant fusion pro-
tein represses transcription of genes involved in normal myeloid 
differentiation by freeing the cell from normal transcriptional reg-
ulatory control by physiologic levels of retinoic acid [5]. One of 
the remarkable success stories of modern oncology was the discov-
ery that this blockage could be overcome by supraphysiologic lev-
els of retinoic acid in the form of all-trans retinoic acid (ATRA) 
therapy [5]. Treatment with this agent has resulted in cure rates 
that exceed 90% in some series [6]. FLT3-internal tandem 
2.1 Acute 
Promyelocytic 
Leukemia 
with PML-RARA
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3duplication mutations have been described in 20–40% of patients 
with APL; while typically associated with poor prognosis, their 
prognostic impact here is controversial [7].
RARA can be translocated to various gene partners other than 
PML [8] (Table 1). WHO no longer considers these variants as 
“definitional” of APL. From a clinical perspective, the t(11;17)
(q23;q21) ZBTB16-RARA and t(17;17)(q11;q21) STAT5-RARA 
translocations are critical to note as they may show resistance to 
ATRA therapy [8–12]. In the former, the ZBTB16 gene itself acts 
as a transcriptional repressor that cannot be abrogated by 
Table 1 
Examples of recurrent chromosomal abnormalities in acute myeloid leukemia with frequencies and 
prognostic relevance
Genetic lesion Chromosomal abnormality
Frequencya  
(%)
Prognostic 
significance
Abnormalityb
Complex karyotype Variable; ≥3 abnormalities ~10–15 Unfavorable
Monosomal karyotype ≥2 autosomal monosomies or 1  
autosomal monosomy with any  
other structural abnormality
~5–10 Unfavorable
RUNX1-RUNX1T1 t(8;21)(q22;q22) ~5–10 Favorable
PML-RARA t(15;17)(q24;q21) ~5–10 Favorable
MYH11-CBFB inv(16)(p13q22) ~5–10 Favorable
KMT2A-V t(11;v)(q23;v) ~5 Unfavorable
MLLT3-KMT2A t(9;11)(p22;q23) ~2 Intermediate
DEK-NUP214 t(6;9)(p23;q34) ~1–2 Unfavorable
GATA2-MECOM inv(3)(q21q26) ~1–2 Unfavorable
RBM15-MKL1 t(1;22)(p13;q13) <1 Unfavorable
ZBTB16-RARA t(11;17)(q23;q21) <1 Unfavorable
NPM1-RARA t(5;17)(q35;q21) <1 Favorable
NUMA-RARA t(11;17)(q13;q21) <1 Favorable
STAT5-RARA t(17;17)(q11;q21) <1 Unfavorable
BCR-ABL1 t(9;22)(q34q11.2) <1 Unfavorable
NUP98-V t(11;V)(p15;v) <1 Unfavorable
KAT6A-V t(8;V)(p11;v) <1 Unfavorable
aReported frequencies have been averaged from a number of multicenter studies, and usually reflect those reported in 
adults <60 years
bV or v—variable fusion partners/chromosomal breakpoints
Molecular Malfeasance Mediating Myeloid Malignancies: The Genetics…
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4ATRA. Other variants including NPM1-RARA t(5;17)(q35;q21) 
and NUMA-RARA t(11;17)(q13;q21) are typically ATRA 
responsive [8, 9, 12]. In the current diagnostic era, conventional 
karyotype and FISH are critical in detection of these variants, as 
they will be missed by RT-PCR assays targeted for the PML-RARA 
translocation.
Although the t(15;17) is easily detectable by karyotype, FISH 
and RT-PCR-based methods are often used for rapid diagnosis and 
the latter can be employed in a quantitative fashion for minimal 
residual disease (MRD) detection. With regard to diagnosis of the 
common t(15;17) translocation, the breakpoints in RARA are 
well conserved in intron 2, while there are three breakpoints in the 
PML gene in intron 3 (bcr-3), intron 6 (bcr-1), and exon 6 (bcr- 
2). These give rise to the short, long, and variable fusion tran-
scripts, respectively. Since the breakpoints in exon 6 are relatively 
uncommon (5%), a single downstream RARA primer and two 
upstream PML primers can be used to detect greater than 90% of 
PML-RARA fusion transcripts [13].
AMLs involving the RUNX1-RUNX1T1 t(8;21)(q22;q22) and 
MYH11-CBFB inv(16)(p13q22)/t(16;16)(p13;q22) abnormali-
ties are collectively referred to as core binding factor (CBF) leuke-
mias due to their involvement of the CBFA2 subunit (RUNX1) 
and CBFB subunit, respectively. The CBF subunits form a tran-
scriptional protein that is critical for normal hematopoiesis. As 
such, both of these translocations result in disruption of the tran-
scriptional complex resulting in a fusion protein that acts in a 
dominant- negative fashion to repress transcription of important 
hematopoietic targets including MPO, GMCSF, IL3, and the TRB 
[14]. Like the t(15;17), these two rearrangements are diagnostic 
of AML regardless of blast percentage [4]. The presence of either 
of these translocations in adult AML imparts a favorable prognosis 
[15] (Table 1).
The t(8;21) is common in AML accounting for approximately 
5–10% of cases [15]. These leukemias often, but not always, show 
a characteristic morphologic phenotype including myeloid blasts 
with peri-nuclear hofs and large, salmon colored granules, as well 
as long tapered Auer rods [2].
Detection of the t(8;21) can be easily performed using karyo-
type, FISH, and RT-PCR. The breakpoints cluster within a single 
intron of both genes, so that similar RUNX1/RUNXT1 chimeric 
transcripts are usually generated in every case. Thus, a simple 
RT-PCR assay, using a RUNX1 primer and an RUNX1T1 primer, 
is sufficient to detect this translocation at a molecular level.
AML with inv(16)/t(16;16) accounts for 5–10% of all AML 
[15]. The inv(16)(p13q22) or t(16;16)(p13;q22) results in a 
fusion protein involving a myosin heavy chain gene (MYH11) and 
the beta subunit of the CBF protein complex. This rearrangement 
sequesters the CBFB protein in the cytoplasm impeding its ability 
2.2 Core Binding 
Factor AML: RUNX1- 
RUNX1T1 t(8;21)
(q22;q22) and MYH11- 
CBFB inv(16)(p13q22)
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5to function normally as part of the transcription factor complex. 
The most common morphologic association with this type of AML 
is that of the former FAB M4-eo in which the blasts have a myelo-
monocytic phenotype and there are associated abnormal eosino-
phils with basophilic granules [2].
Because the inv(16) can be subtle on karyotypic analysis, 
RT-PCR and/or FISH testing is integral to detecting this rear-
rangement. Interestingly, gain of chromosome 22 is the most com-
mon secondary karyotypic abnormality in patients with inv(16), 
but is uncommon in other situations, and thus should alert one to 
the presence of an inv(16) [16]. From a molecular perspective, the 
breakpoints in the two genes on chromosome 16 are heteroge-
neous, with at least 10 different fusion transcripts generated. While 
99% of breakpoints in CBFB occur in intron 5 of that gene, the 
breakpoint heterogeneity is quite marked in the MYH11 gene, 
with seven different exons (7 through 13) variably included in the 
fusion transcripts [17]. Fortunately, the most common form—des-
ignated type A—accounts for approximately 90% of cases with this 
genetic fusion, while two other transcripts (types D and E) account 
for an additional 5% [18].
Both the t(8;21) and inv(16) impart a favorable prognosis in 
AML [15]. Interestingly, cases of inv(16) AML with the +22 may 
have an even more favorable prognosis. However, point mutations 
in the KIT and FLT3 genes (discussed below) impart a worse 
prognosis in patients with t(8;21) or inv(16) [19, 20], albeit not to 
the degree that they will shift these CBF AMLs into a inferior 
prognostic category.
The MLL (KMT2A) gene located on chromosome 11q23 is 
involved in over 100 different translocations with various gene 
partners in AML as well as acute lymphoblastic leukemia (ALL), 
and myelodysplastic syndromes (MDS) [21, 22]. Of the numerous 
translocation partners, the most common in AML are MLLT3 
(AF9) on 9q21 in the t(9;11) translocation, and one of three genes 
(MLLT1/ENL, ELL or EEN/SH3GL1) on 19p13 in the different 
t(11;19) translocations [23]. In the WHO 2016 classification, the 
t(9;11) (p22;q23) MLLT3-KMT2A translocation is recognized as 
a distinct, genetically defined subtype of AML and accounts for 2% 
of adult AML but up to 10% of AML in children, especially infants 
[2]. Most cases demonstrate monoblastic differentiation. There is 
also a high rate of KMT2A translocations in patients who develop 
leukemia secondary to topoisomerase-II inhibitors (therapy-related 
AML) [24]. In general, KMT2A translocations in AML predict for 
poor outcomes, with the t(9;11) representing an exception with a 
more intermediate prognosis [15]. More recently, groups have 
shown that the t(6;11)(q27;q23) (KMT2A-MLLT4/AF6) is asso-
ciated particularly with dismal prognosis [25], while the t(1;11)
(9q21;q23) portends an especially good outcome, with a greater 
than 90% event-free survival [23].
2.3 AML 
with Translocations 
Involving MLL 
(KMT2A) at 11q23
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6The KMT2A gene codes for a histone-lysine methyltransferase 
protein that acts to modulate gene expression via chromatin 
remodeling. With its myriad translocation partners, KMT2A gen-
erates fusion proteins that bind histones and upregulate leukemic 
gene expression via DOT1L-induced methylation of the histone 
H3K79 [26]. Adding to the complexity of this process is the role 
of other transcriptional regulators, including PU.1, which acts in a 
fusion-gene-independent fashion to promote leukemogenesis in 
these leukemias [27, 28]. The breakpoints in KMT2A tend to clus-
ter in a relatively small (8.3-kb) area spanning exons 5–11, referred 
to as a breakpoint cluster region (BCR) [21]. Interestingly, 
KMT2A translocations in de novo leukemias tend to cluster in the 
5′ region of the BCR, while those in therapy-related and infant 
AMLs occur more often in the 3′ region [29].
Because of the many translocation partners, screening for 
KMT2A rearrangements is most effectively done by FISH using a 
KMT2A break-apart probe strategy followed by dual-fusion probes 
to identify the partner gene. Molecular methods can also be used 
to target the most common translocations.
The t(6;9)(p23;q34) translocation is present in a low percentage 
(1–2%) of AML, and is often associated with multilineage dysplasia 
and basophilia [2]. Overall survival in this subgroup is poor [15, 30].
The translocation results in an oncofusion protein DEK- 
NUP214 that globally increases translational activity secondary to 
phosphorylation of the translational initiation protein EIF4E [31, 
32]. Detection of this translocation can be effectively performed 
by karyotype, FISH, and RT-PCR, with the breakpoints clustering 
within a single intron in both genes, allowing for straightforward 
detection by RT-PCR.
AML with inv(3) and the related t(3;3) account for approximately 
1–2% of AML cases. This genetic abnormality may arise in MDS, 
as well as de novo AML. Both often display megakaryocytic dyspla-
sia, especially forms with mono- or binucleation [2]. This subtype 
of AML is associated with poor prognosis [15, 33].
The translocation results in the juxtaposition of a GATA2 
enhancer to the MECOM gene, a complex zinc finger protein that 
acts as a transcriptional regulator. This event results in upregulation 
of MECOM by the enhancer, thereby promoting leukemogenesis 
[34]. Karyotype can detect the rearrangement, although it may be 
missed if metaphases are of poor quality. Due to variable breakpoints, 
FISH is more effective in detecting the translocation than RT-PCR 
and acts as a useful adjunct to conventional karyotype [35].
Occurring primarily in infants and children, AML with the t(1;22)
(p13;q13) is rare (<1% of AML cases) [36, 37]. These leukemias 
typically have megakaryoblastic differentiation [36]. Although 
2.4 AML with DEK- 
NUP 214 t(6;9)
(p23;q34)
2.5 AML with GATA2- 
MECOM inv(3)
(q21q26.2) or t(3;3)
(q21;q26.2)
2.6 AML 
with RBM15-MKL1 
t(1;22)(p13;q13)
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7challenging to study due to their rarity, patients have an intermedi-
ate prognosis with intensive chemotherapy [38].
The t(1;22) results in an in-frame fusion of RBM15 (1p13) 
and MKL1 (22q13) that contains almost the entire coding 
region of both genes. RBM15-MKL1 may modulate Notch sig-
naling through interactions with RBPJ [39]. Detection of the 
translocation can be accomplished via karyotype, FISH, or 
RT-PCR.
While AML can arise from pre-existing chronic myeloid leukemia 
(CML), there is increasing evidence that de novo BCR-ABL1- 
associated AML exists and represents a unique biologic category. 
The WHO 2016 recognizes this as a provisional entity. These 
patients seem to have a poor prognosis and must be recognized for 
appropriate inclusion of tyrosine kinase inhibitors in the therapeu-
tic regimen [40, 41].
Detection of the t(9;22) can be performed using standard 
karyotype and FISH, as well as a RT-PCR, with the BCR break-
point most commonly occurring after e13/e14, generating the 
p210 protein that is characteristic of CML, but seen less frequently 
in acute lymphoblastic leukemia (ALL) [40, 42]. Recent studies 
using array Comparative Genomic Hybridization (aCGH) suggest 
that loss of IKZF1 and CDKN2A, common abnormalities in BCR- 
ABL1- positive ALL, is also found in this group of AMLs [41]. In 
addition, unique deletions of antigen receptor genes (IGH and 
TCR) may distinguish de novo BCR-ABL1-positive AML from 
transformed CML [41].
In addition to translocations, numerous other cytogenetic abnor-
malities can occur in AML (Table 1). While not all of these are 
recognized currently as distinct WHO entities, their presence is 
important to note for prognostic purposes and/or therapeutic 
purposes.
AML with ≥3 cytogenetic abnormalities is considered to have 
a complex karyotype (AML-CK) and is associated with poor prog-
nosis. These cases most often fall into one of two WHO subgroups: 
AML with myelodysplasia-related changes (AML-MRC) and 
therapy- related AML (t-AML), the latter under the umbrella term 
of therapy-related myeloid neoplasms [2].
AML with a monosomal karyotype (AML-MK), defined as the 
presence of at least two autosomal monosomies or a single mono-
somy plus an additional structural abnormality, confers an extremely 
poor prognosis [23, 43, 44].There is considerable overlap with 
cases of AML-CK. AML-MK cases account for 5–10% of AML, 
and are enriched in patients older than 60 years [44].
Finally, a number of myelodysplasia-associated genetic abnor-
malities can be seen in AML, and confer an inferior prognosis. 
2.7 AML with t(9;22)
(q34;q11.2) BCR-ABL1
2.8 Other 
Cytogenetic Changes 
in AML
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8Examples include whole or partial deletions of chromosomes 5, 7, 
and 17 (15). Additional abnormalities sufficient to merit classifica-
tion as AML-MRC are listed in Table 2.
3 Somatic Mutations in AML
In addition to the chromosomal abnormalities discussed above, a 
number of somatic mutations have been identified in AML, and 
the rate of discovery is increasing with the introduction of NGS 
technology. These include FLT3 abnormalities, KMT2A partial 
tandem duplications, and NPM1, DNMT3A, CEBPA, RUNX1, 
KIT, ASXL1, TET2, IDH1/IDH2, WT1, and RAS mutations. 
Evaluation for mutations in a number of these genes such as FLT3, 
Table 2 
Cytogenetic abnormalities sufficient to diagnose AML with 
myelodysplasia-related changes when blasts are ≥20% in blood or bone 
marrow
Complex karyotypea
Unbalanced abnormalities
–7/del(7q)
–5/del(5q)
i(17q)/t(17p)
−13/del(13q)
del(11q)
del(12p)/t(12p)
idic(X)(q13)
Balanced abnormalities
t(11;16)(q23;p13.3)
t(3;21)(q26.2;q22.1)
t(1;3)(p36.3;q21.1)
t(2;11)(p21;q23)
t(5;12)(q33;p12)
t(5;7)(q33;q11.2)
t(5;17)(q33;p13)
t(5;10)(q33;q21)
t(3;5)(q25;q34)
a≥3 Abnormalities
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9NPM1, and CEPBA is now standard of care in the workup of 
AML, due to their prognostic and indeed diagnostic significance. 
Mutations in these genes overlap with several of the genetically 
defined categories listed above (although they are enriched in the 
45% of AMLs that are cytogenetically normal), but in the case of 
NPM1 and CEPBA, also have earned their own WHO diagnostic 
categories. RUNX1 mutated cases have additionally been recog-
nized as a provisional diagnostic entity in the WHO 2016. In addi-
tion to these, a number of the genes listed above have already been 
shown to have prognostic, and in some cases potentially therapeu-
tic, relevance [Table 3].
Nearly all AMLs have mutations in one of nine categories of 
genes grouped by their biologic function, including transcription 
factor fusions (18% of cases); the gene encoding 
nucleophosmin/NPM1 (27%); tumor-suppressor genes (16%); 
DNA-methylation–related genes (44%); signaling genes (59%); 
chromatin modifying genes (30%); myeloid transcription factor 
genes (22%); cohesin-complex genes (13%); and spliceosome- 
complex genes (14%) [45–48]. Patterns of cooperation and mutual 
exclusivity suggested strong biologic relationships among several 
of the genes and categories. For example, FLT3, NPM1, and 
DNMT3A tend to occur together, while transcription factor 
fusions and mutations of NPM1, RUNX1, TP53, and CEBPA are 
mutually exclusive [46]. In addition, many of the genes discussed 
below, as well as those listed in Table 3, show enrichment in spe-
cific morphologic or genetically defined AML subgroups such as 
KIT mutations in CBF AMLs.
Nucleophosmin (NPM1) is the most commonly mutated gene in 
cytogenetically normal (CN) AML. The WHO 2016 recognizes 
AML with mutated NPM1 as a distinct entity [3]. The protein 
functions as a nuclear phosphoprotein that actively shuttles between 
the nucleus and cytoplasm and interacts as a chaperone with a 
number of tumor suppressors (CDKN2A/p14ARF and P53) [49]. 
The most common NPM1 mutation (80% of cases) results in a 4 
base pair duplication in the coding region of exon 12 (50). 
Mutations in NPM1 alter tryptophan residues required for proper 
nucleolar localization and create a nuclear export signal at the 
C-terminus of the protein [50]. Consequently, the mutant nucleo-
phosmin protein is sequestered in the cytoplasm, and through 
dimerization, causes the sequestration of the wild-type protein as 
well. Because of its role as a chaperone protein, this leads to the 
mislocalization of p14ARF and ultimately to the inhibition of p53 
activity [49].
Approximately 40% of NPM1 mutated AMLs also harbor FLT3 
internal tandem duplication (FLT3-ITD) mutations (see below), 
a feature which seems to significantly affect the prognostic relevance 
of NPM1 [51]. Those with NPM1 mutations and without 
3.1 NPM1 Mutations
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Table 3 
Examples of recurrent mutations in AML
Gene target
Approximate 
frequency in 
AMLa (%)
Prognostic  
significance
Putative consequence/
altered biologic 
mechanism
Associations 
(morphologic, 
genetic, or 
demographic)
NPM1 25–30 Favorable Cytoplasmic 
mislocalization; 
dysregulated P53
Cup-like nuclear 
invaginations
CD34-FLT3-ITD
DNMT3A 20 Unfavorable Epigenetic b
FLT3-ITD 15 Unfavorable ↑Signal transduction Cup-like nuclear 
invaginations
WT1 10–15 Unclear/unfavorable ↓Transcription –
RAS 10–15 None ↑Signal transduction CBF AML
TET2 10–15 Unfavorable DNA methylation –
CEBPA 10 Favorable  
(when bialleic)
↓Transcription Coexpression of 
T-cell antigens
IDH1 10 Unclear Oncometabolite/DNA 
methylation
Monosomy 8
Cup-like nuclear 
invaginations
IDH2 10 Unclear Oncometabolite/DNA 
methylation
Cup-like nuclear 
invaginations
ASXL1 10 Unfavorable Chromatin modification AML-MRC
TP53 5–10 Unfavorable DNA damage repair Complex 
karyotype
Cohesins
(STAG1/2, 
SMC1A, 
SMC3, 
RAD21)
5–10 Unclear/unfavorable Chromatid separation Down syndrome
RUNX1 5–10 Unfavorable ↓Transcription Minimal 
differentiation
ND4 5 Favorable Electron transport –
PHF6 5 Unfavorable Epigenetic Males
U2AF1 5 Unfavorable Spliceosome AML-MRC
FLT3-TKD 5 None/unclear ↑Signal transduction –
KIT 5 Unfavorable ↑Signal transduction CBF AML
KMT2A- PTD 5 Unfavorable Chromatin modification Trisomy 11
CBL 1 Unclear ↑Signal transduction CBF AML
AML acute myeloid leukemia, CBF Core binding factor, PTD partial tandem duplication, MRC myelodysplasia-related 
changes
aMutation frequency of some mutations may be up to twofold higher in CN AML
bHigh dose daunorubicin improves outcomes for patients with DNMT3A mutations
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FLT3-ITD mutations have an overall favorable prognosis, similar to 
the CBF AMLs [51]. In fact, the presence of an NPM1 mutation 
seems to supersede the negative prognostic value of  multilineage 
dysplasia in the absence of cytogenetic abnormalities [52]. In con-
trast, NPM1 mutations in the presence of the FLT3- ITD have a 
poor prognosis. Evaluation of newly diagnosed AML for NPM1 
mutations has become standard of care at most centers.
FLT3 is a receptor tyrosine kinase whose activation via ligand 
binding and homodimerization results in phosphorylation of 
downstream effectors in the STAT5 and MAPK signaling pathways 
[53]. Through these pathways, FLT3 acts to affect growth induc-
tion and apoptosis inhibition. Mutations in the FLT3 gene occur in 
one of two ways: internal tandem duplication (ITD) of the juxta-
membranous (JM) domain and a missense mutation in the tyrosine 
kinase activation domain (TKD), typically at amino acid D835 
[53, 54]. Functionally both lead to constitutive activation of the 
tyrosine kinase and thus a pro-growth and anti-apoptotic signal for 
the cell. The ITD is more common, occurring in 25–30% of AMLs 
(again enriched in CN AML), with the TKD point mutation occur-
ring in 5% [54]. Interestingly only the ITD mutation seems to have 
prognostic relevance [54].
The FLT3-ITD mutation is associated with poor overall sur-
vival in AML, and this influence is usually independent of a num-
ber of previously discussed recurrent cytogenetic abnormalities 
[54]. It is important to determine the allelic ratio of mutant:wild- 
type DNA, as this affects its prognostic impact. As noted above, 
the FLT3-ITD often co-occurs with the NPM1 mutation, with the 
badness of the former trumping the goodness of the latter.
Because of its prognostic relevance, testing for FLT3 muta-
tions in all new AMLs is critical and a number of PCR-based assays 
are available. Targeted therapies against FLT3 have been developed 
and may prove a useful adjunct to more conventional chemother-
apy [55].
CEPBA (CCAT enhancer binding protein alpha) encodes a leucine 
zipper transcription factor that homodimerizes to regulate granu-
locytic differentiation. Mutations result in increased cellular prolif-
eration and inhibition of differentiation, thus promoting myeloid 
leukemogenesis. Mutations typically occur as either N-terminal 
frame shift that acts in a dominant-negative fashion or as C-terminal 
in-frame deletions/insertions that affect DNA binding [56]. Only 
when mutations are biallelic and different does their presence pre-
dict for a favorable prognosis [57].
CEPBA mutations occur in 15–18% of CN AML, and approxi-
mately 10% of AML cases, overall. However, up to 45% of these, in 
3.2 FLT3 Mutations
3.3 CEPBA Mutations
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some series, are monoallelic [57]. In the 2016 WHO classification, 
AML with biallelic mutation of CEPBA is recognized as a distinct 
entity [3]. Also important to note is that the presence of biallelic 
CEPBA mutations now supersedes the presence of multilineage 
dysplasia in cases of AML without concurrent MDS-associated 
cytogenetic abnormalities [3, 58].
The RUNX1 gene, located at 21q22, has been previously dis-
cussed with regard to its involvement in t(8;21)-associated 
AML. Distinct from these cases, inactivating point mutations can 
be found in the RUNX1 gene in 5–10% of AMLs [59]. In contrast 
to the favorable prognosis imparted by the t(8;21), RUNX1 point 
mutations predict for worse overall survival and therapy resistance 
[59]. AML with RUNX1 mutations is now recognized as a provi-
sional entity in the WHO 2016 [3]. However, these cases should 
only be classified as such in the absence of MDS-related cytoge-
netic abnormalities or other recurrent translocations shown in 
Tables 1 and 2 [3].
KIT mutations are especially common in core binding factor 
AMLs (t(8;21) and inv.(16)), occurring in approximately 20% of 
these cases. KIT mutations typically occur in exons 8 or 17 result-
ing in constitutive activation of the tyrosine kinase [20]. The pres-
ence of a KIT mutation in these cases is associated with a poor 
prognosis [20].
KMT2A is another gene implicated not only in structural rear-
rangements but also in cryptic abnormalities. Mutations in KMT2A 
are usually partial tandem duplication (PTD) and occur in approxi-
mately 10% of CN AMLs, but they are especially enriched in the 
setting of trisomy 11 where they occur in 90% of cases. The 
KMT2A PTD is readily detected by RT-PCR and is associated with 
an unfavorable outcome [60].
4 Germline Predisposition
Although most AMLs are sporadic diseases, a subset may be famil-
ial [61]. The 2016 WHO classification includes acknowledgement 
of AML and other myeloid neoplasms in which there is a germ line 
mutation or predisposition syndrome (Table 4). The underlying 
predisposing genetic lesion should be included in the diagnosis of 
these rare cases.
3.4 RUNX1 Mutations
3.5 KIT Mutations
3.6 MLL (KMT2A) 
Mutations
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5 Beyond the Genome: Epigenetic Changes in AML
The most common epigenetic mechanisms include histone 
 modification and DNA CpG methylation. While a number of gene 
mutations in AML impact these functions, global changes in DNA 
methylation have also been described in AML and may provide the 
basis for subclassification in the future [47, 62, 63].
One specific gene, DNMT3A, is a DNA methyltransferase that 
is mutated in ~20% of AMLs resulting in increased cellular prolif-
eration. Mutations in this gene have been shown to impact meth-
ylation patterns in AML [64, 65]. While most studies have shown 
DNMT3A mutation to be a poor prognostic marker, others have 
refuted this association [64, 65]. Interestingly, however, DNMT3A 
mutations (in particular the most frequent one, R882) may persist 
in remission without adversely affecting prognosis [66].
DNA hydroxymethylation is one mechanism by which CpG 
methylation can be reversed. Several genes involved in this process, 
such as TET2, IDH1, and IDH2, are commonly mutated in AML.
Genes affecting histone proteins, common targets of epigene-
tic changes, are frequently mutated in AML. The MLL/KMT2A 
gene encodes an epigenetic modifier of histone proteins and is 
involved in both mutations and translocations in AML. Another 
protein, ASXL1, is also involved in methylation of histone pro-
teins, and ASXL1 is mutated in ~10% of AMLs. These mutations 
are associated with AML-MRC and generally show a poor progno-
sis [48]. Finally, EZH2 codes for a catalytic enzyme involved in 
methylation of histone tails. EZH2 mutations have been described 
in AML, albeit rarely [67].
6 Conclusion
In this era of NGS and other molecular technologies, our rate of 
discovery of new genetic aberrations in AML has skyrocketed, and 
complemented our already extensive knowledge about the cytoge-
netic landscape in this disease. This newfound wealth of information 
has not only impacted classification schemes but also provided new 
insights into disease pathogenesis and options for targeted therapy.
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Chapter 2
Cytochemical Staining
Michele E. Paessler, Marybeth Helfrich, and Gerald B.W. Wertheim
Abstract
Historically, the diagnosis and classification of acute leukemia involved morphologic review of blasts in the 
peripheral blood and bone marrow smears and cytochemical staining. Cytochemical stains, which are enzymatic 
colorimetric reactions that occur in the cells of interest, were necessary to assign and confirm myeloid and lym-
phoid lineage. In the current WHO 2008 Classification of leukemia, immunophenotyping and cytogenetic 
analysis have largely replaced cytochemical staining in the characterization of acute leukemias. Nonetheless, 
cytochemical testing remains a useful adjunct assay for the proper classification of acute leukemia in a number of 
diagnostic settings. This chapter reviews the principles of the most common cytochemical stains, their procedures 
and guides to interpretation, and results in acute myeloid leukemia.
Key words Acute myeloid leukemia, Bone marrow, Cytochemical stains
1 Introduction
Acute leukemia is characterized by a proliferation of immature 
hematopoietic elements (i.e., blasts) that undergo a maturation 
arrest and do not develop into fully differentiated cells (i.e., neu-
trophils, monocytes, lymphocytes) [1]. The diagnosis of acute leu-
kemia relies on distinguishing blasts with myeloid differentiation 
from those with lymphoid differentiation. The current WHO clas-
sification system broadly segregates acute leukemia into acute 
myeloid (AML), B-lymphoblastic (B-ALL), and T-lymphoblastic 
(T-ALL) leukemia, with subclasses therein [2]. Accurate pheno-
typic characterization of acute leukemia as myeloid or lymphoid is 
essential for proper treatment; therapy for AML and ALL is mark-
edly distinct [3, 4]. Current classification of leukemia relies heavily 
on the immunophenotypic profile of leukemic cells [2]. Thus, 
antibody-based detection of specific B-cell, T-cell, and myeloid 
markers is essential at diagnosis; the methods for detection include 
flow cytometry of fresh cells or immunohistochemistry of formalin 
fixed paraffin embedded (FFPE) tissue. Additionally, in-depth 
genetic analysis using massively parallel DNA sequencing 
paolo.fortina@jefferson.edu
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 techniques is being developed for the classification based on recur-
rent mutations [5]. However, the earliest techniques for lineage 
assignment (and the techniques on which much of the classifica-
tion of acute leukemia is based) involve cytochemical stains for cel-
lular components that characterize different hematopoietic lineages 
[6]. These include stains for the myeloid markers myeloperoxidase 
(MPO), Sudan Black B (SBB), and chloroacetate esterase (CAE); 
the monocytic and megakaryocytic marker of nonspecific esterase 
(NSE); acid phosphatase (AP), which shows a typical pattern in T 
cells; and periodic acid Schiff stain (PAS), which identifies B lym-
phoblasts and atypical erythroid precursors.
Cytochemical stains are based on chemical colorimetric reactions 
that occur within the cells of interest. These reactions rely on either 
substrates within the cells (such as PAS and Sudan Black B staining) or 
enzymatic activity that the cells possess (such as myeloperoxidase or 
chloroacetate esterase activity) [6]. The stains used in leukemia classi-
fication deposit a colored product at the site of the reaction that can 
be fixed (chemically cross-linked) in place and then examined by light 
microscopy. The presence, intensity, and pattern of staining—taken in 
context with morphologic, immunophenotypic, and clinical assess-
ments—can indicate the lineage of the leukemic cells.
Most diagnostic laboratories do not routinely perform 
cytochemical stains on peripheral blood smears or bone mar-
row aspirates from patients with acute leukemia. Instead, 
immunophenotypic results from either flow cytometry or 
immunohistochemistry are usually sufficient for accurate clas-
sification of myeloid, B-lymphoid of T-lymphoid acute leuke-
mia. However, cytochemistry has not been entirely replaced by 
immunophenotypic assays. Cytochemistry has the advantage 
over flow cytometry in that it provides simultaneous examina-
tion of cellular differentiation and morphology. Thus, these 
cytochemical stains may be useful when fresh aspirate material 
is not available for flow cytometry or when flow cytometry 
yields inconclusive results. Additionally, they may be used in 
assessing immature cells that cannot be readily distinguished 
from their more mature forms by routine flow cytometry (such 
as promonocytes vs. mature monocytes). Although immuno-
histochemical staining of marrow biopsy cores may allow 
pathologists to circumvent the need for cytochemical stains on 
these occasions, there are certain instances in which this stain-
ing may be unreliable or not possible. These include immuno-
histochemical stains for myeloperoxidase [7], which have been 
shown to yield false positive results, or bone marrow studies of 
infants with leukemia for whom biopsies are frequently not 
obtained. Thus, although not frequently performed, cyto-
chemical testing continues to remain a useful adjunct assay for 
the proper classification of acute leukemia [8].
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2 Materials
Unless otherwise described, all reagents are stored at room tem-
perature (20–26 °C).
 1. Staining rack.
 2. Mini-Coplin jar (10 mL) or Coplin jar (60 mL).
 3. Water bath set to 37 °C and shielded from light.
 4. Incubator/oven.
 5. #1 Whatman filter paper.
 1. Formaldehyde, 37%.
 2. Ethanol. Dilute with ddH2O to make 70% ethanol.
 3. Acetone.
 4. Sodium nitrite. Make 100 mM and 4% w/v solutions with 
ddH2O.
 5. Potassium phosphate, monobasic, KH2PO4.
 6. Sodium phosphate, dibasic, Na2HPO4.
 7. Buffered formalin/acetone fixative: 20 mg Na2HPO4; 100 mg 
KH2PO4; 30 mL ddH2O; 45 mL Acetone; 25 mL 37% 
Formaldehyde. Na2HPO4 and KH2PO4 are added to ddH2O 
and mix until dissolved prior to adding acetone and formalde-
hyde. Store at 4 °C.
 8. Cytoseal 60 mounting medium (Thermo Scientific #8310-4).
 1. Hydrogen peroxide 3%.
 2. Trizmal buffer pH 6.3 (Sigma-Aldrich #903C). Discard if tur-
bidity develops.
 3. Trizmal working buffer. Mix 50 mL of Trizmal buffer pH 6.3 
with 450 mL of ddH2O.
 4. Peroxidase Indicator Reagent (Sigma-Aldrich #3901), pre- 
aliquoted in vials. Store at 4 °C.
 5. Acid Hematoxylin solution (Sigma-Aldrich #2652).
Sudan Black B staining system (Sigma-Aldrich #308B). Contains 
Sudan Black B staining reagent and Gill’s #3 hematoxylin solution. 
Sudan Black B stain may be returned to stock bottle and reused. 
When control is no longer positive, discard stock bottle. Protect 
hematoxylin from light.
 1. Hydrochloric acid, HCl, 37%.
 2. Pararosaniline base.
 3. Methyl Green.
2.1 Equipment
2.2 Reagents 
for Multiple Stains
2.3 Reagents 
for Specific Stains
2.3.1 MPO
2.3.2 Sudan Black B
2.3.3 CAE/NSE
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 4. Sodium fluoride, NaF.
 5. 2-Methoxyethanol, ethylene glycol monomethyl ether.
 6. N,N-Dimethylformamide.
 7. Alpha-Naphthyl acetate.
 8. Naphthol AS-D Chloroacetate.
 9. Fast Blue BB Base (Sigma-Aldrich #F3378). Store at −20 °C.
 10. 1/15 M Na2HPO4 stock buffer. Dissolve 9.5 g Na2HPO4 in 
900 mL ddH2O. Add ddH2O to 1 L.
 11. 1/15 M KH2PO4 stock buffer. Dissolve 9.1 g KH2PO4 in 
900 mL ddH2O. Add ddH2O to 1 L.
 12. 1/15 M Phosphate working buffer, pH 7.4. Mix 80.4 mL of 
1/15 M Na2HPO4 stock buffer with 19.6 mL of 1/15 M 
KH2PO4 stock buffer.
 13. 1/15 M Phosphate working buffer, pH 6.3. Mix 22.4 mL of 
1/15 M Na2HPO4 stock buffer with 77.6 mL of 1/15 M 
KH2PO4 stock buffer.
 14. Sodium Nitrite solution: dissolve 4 g of sodium nitrite in dis-
tilled water. Bring to final volume of 100 mL. No expiration 
date. Good until cloudy.
 15. 4% Pararosaniline solution: Dissolve 1 g pararosaniline in 5 mL 
of concentrated HCl with gentle warming. Slowly add 20 mL 
distilled water with constant stirring. Allow to cool. Filter 
when cool. No expiration date.
 16. 1% Methyl Green Solution (Methyl Violet Free): Add 1 g 
methyl green to 100 mL distilled water. Mix well and filter 
before initial use. No expiration date. May be returned to con-
tainer and reused until the time required to obtain an adequate 
stain exceeds 15 min.
 1. Citrate solution (Sigma-Aldrich #915).
 2. Citrate/acetone/formaldehyde fixative. To 25 mL Citrate 
Solution, add 65 mL acetone and 8 mL of 36% formaldehyde. 
Place in glass bottle and cap tightly. Store at 4 °C. Warm to 
room temperature prior to use.
 3. 2.5 M Acetate solution, pH 5.2 (Sigma-Aldrich #3863). Store 
at 4 °C. Discard if turbidity develops.
 4. Naphthol AS-BI Phosphoric acid solution (Sigma-Aldrich 
#1802). Store at −20 °C. Warm to 37 °C and mix well prior to 
use. Discard if reagent turns yellow.
 5. Fast garnet GBC base solution (Sigma-Aldrich #3872). Store 
at 4 °C.
 6. Methylene Blue solution (Sigma-Aldrich #1808). Store tightly 
capped.
2.3.4 Acid Phosphatase
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 7. Methylene Blue counterstain: Add 1 mL methylene blue solu-
tion to 9 mL of ddH2O. Mix well. Prepare fresh.
 8. Aqua-mount mounting medium (VWR #41799–008).
 1. Formalin/Alcohol fixative. Mix 10 mL of 36% formaldehyde 
with 90 mL of 100% ethanol. Store in a tightly sealed glass 
bottle.
 2. Periodic acid (Sigma-Aldrich #375810). Dissolve 1 g periodic 
acid in 100 mL of ddH2O.
 3. Schiff ’s reagent (Sigma-Aldrich #3952016). Store in refrigera-
tor (2–4 °C) in tightly sealed container protected from light. 
Discard if solution turns pink. Warm to room temperature 
(20–26 °C) before use.
 4. Mayer’s Hematoxylin stain (Sigma-Aldrich #MHS16). Filter 
before use with Whatman #1 filter paper. Store protected from 
light.
3 Procedure
Coverslips or slide smears prepared from peripheral blood, bone 
marrow aspirate, or body fluid that is either non-anticoagulated or 
anticoagulated with heparin or EDTA. For body fluids, cytocentri-
fuge preparations may be used. If the specimen is not anticoagu-
lated, slides or coverslips must be made immediately after the 
specimen is collected from the patient. Preparations from antico-
agulated specimens should be made within 2 h of specimen collec-
tion. Smears should be air dried, stored at room temperature, and 
protected from light and humidity until staining is performed. If 
properly stored, these smears are stable for at least 2 months [9].
For quality control, freshly prepared coverslip smears of non-
leukemic bone marrow or peripheral blood should be stained as 
positive controls each time a patient sample is evaluated. If the 
control cells are not positive, reagents should be replaced (see Note 1). 
The control results should be reported to document they were 
performed.
The evaluation of the patient samples requires identification of 
the blast cells present. These are the only cells that are reported as 
positive or negative. A description of the staining pattern should be 
given, as should the percentage of the positive blasts. Positive nor-
mal cells are not reported.
Myeloperoxidase is present in neutrophils, monocytes, and their 
precursors but not in lymphoid cells [10]. The MPO stain is highly 
specific and a positive stain is sufficient for reporting myeloid differ-
entiation (i.e., AML Acute myeloid leukemia (AML) or acute leuke-
mia Leukemia of ambiguous lineage) [2]. Classical methods for 
2.3.5 PAS
3.1 General 
Procedure for All 
Stains
3.2 Procedures 
for Specific Stains
3.2.1 MPO Principle
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determining the presence of myeloperoxidase involved the use of 
benzidine or diaminobenzidine, which are highly carcinogenic. In 
1977, Hanker et al. described the use of p-phenylenediamine and 
catechol to detect the presence of peroxidase [11].
 1. Prewarm 50 mL of Trizmal Dilute Buffer in 37 °C water bath.
 2. Place smears in Coplin jar and fill with formalin/alcohol fixa-
tive. Incubate at room temperature for 30 s. Appropriately dis-
card fixative and wash smears three times with ddH2O.
 3. Prepare Peroxidase Indicator Reagent solution by adding 1 vial 
of Peroxidase Indicator Reagent and 0.2 mL of 3% hydrogen 
peroxide to the prewarmed Trizmal Dilute Buffer. Mix 
thoroughly.
 4. Add Peroxidase Indicator Reagent solution to Coplin jar with 
fixed smears. Protect from light (see Note 2) and incubate for 
30 min at 37 °C. After incubation, properly discard the reagent 
and wash smears three times with ddH2O.
 5. Add Acid Hematoxylin solution to Coplin jar with fixed 
smears. Incubate for 15 min at room temperature. After incu-
bation, properly discard the stain and wash smears three times 
with ddH2O.
 6. Air-dry and mount with Cytoseal 60.
Although myeloperoxidase is generally considered a marker for 
cells of myeloid lineage, monocytic cells may also display weak pos-
itivity [10, 12]. Neutrophils and their precursors should show 
brown-black cytoplasmic granulation that should be darker than 
background staining of the red blood cells. Monocytes may be 
weakly positive while lymphocytes and red cell precursors are 
negative.
3.2.2 Procedure
3.2.3 Expected Results 
(Tables 1 and 2)
Table 1 
Stain and counterstain colors
Stain Positive Counterstain
Sudan Black Black Purple
Myeloperoxidase Dark brown Purple
PAS Red Purple
Acid phosphatase Red Green
CAE Blue Green
α-Napthyl acetate Red brown Green
ANA-Megka Red brown Green
α-Napthyl butyrate Red brown Green
Michele E. Paessler et al.
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Peroxidase activity may be decreased or absent in the mature 
neutrophils of patients with myelodysplastic syndromes or acute 
myeloid leukemia (see Note 3) [13]. MPO staining may also be 
used to diagnose hereditary myeloperoxidase deficiency in which 
all neutrophils and monocytes are deficient but eosinophils are 
unaffected [14]. In cases of homozygous deficiency, neutrophil 
peroxidase is undetectable, whereas heterozygous cases show 
decreased staining relative to normal controls.
Sudan Black B stains several lipids including phospholipids and 
neutral fats that are contained in the granules of the neutrophil 
series [15]. Since cells that are committed to lymphoid maturation 
do not contain these granules, lymphoblasts typically are negative, 
whereas cells undergoing myeloid maturation will be positive. 
Sudan Black B is, therefore, a useful adjunct for myeloperoxidase 
and CAE stains.
 1. Place smears into slots in the Coplin jar. Fill Coplin jar with 
buffered formalin/acetone fixative solution and incubate for 
1 min at room temperature. Appropriately discard fixative and 
wash smears three times with ddH2O.
 2. Fill Coplin jar with Sudan Black B Staining Reagent and stain 
for 15 min at room temperature. Appropriately discard stain-
ing reagent and wash smears three times with ddH2O.
 3. Fill Coplin jar with 70% ethanol. Incubate for 2 min at room 
temperature. Appropriately discard and wash smears three 
times with ddH2O.
 4. Counterstain by filling the Coplin jar with Gill #3 Hematoxylin 
solution. Incubate for 15 min at room temperature. Return 
stain to bottle when done. Wash smears three times with 
ddH2O.
 5. Air-dry and mount with Cytoseal 60.
Maturing myeloid precursors will show black or dark blue intracel-
lular staining at the site of primary and secondary granule forma-
tion. Although Sudan Black B is generally considered to be a 
myeloid marker, monocytic appearing cells may display weak posi-
tivity [16]. This usually occurs in myelomonocytic leukemia. 
Normal lymphocytes do not stain with Sudan Black B, yet several 
reports have documented rare instances of B lymphoblastic leuke-
mia that stain for Sudan Black B [17]. Hence, Sudan Black B stain-
ing should be interpreted in the context of other phenotypic 
results.
Cytochemical reactions for esterases distinguish between the cells 
of the monocyte series and the neutrophil series. The leukocyte 
esterases hydrolyze an ester derived from naphthalene to release a 
3.3 Sudan Black B
3.3.1 Principle
3.3.2 Procedure
3.3.3 Expected Results 
(Tables 1 and 2)
3.4 NSE/CAE 
Principle
Michele E. Paessler et al.
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naphthol compound, which then combines with the diazonium 
salt present in the reaction mixture to form a colored precipitate at 
the site of enzyme activity [10]. The reaction for nonspecific ester-
ases using alpha-naphthyl acetate as the substrate is strongly posi-
tive in monocytes and monocyte precursors and demonstrates a 
punctate positivity pattern in megakaryocytes and megakaryocyte 
precursors [10]. A sodium fluoride (NaF) inhibition step may be 
incorporated into the nonspecific esterase stain procedure to allow 
distinction between monocytic and megakaryocytic lineages, since 
NaF completely inhibits the monocytic enzyme while the mega-
karyocyte enzyme is only partially inhibited [10, 18]. The reaction 
using naphthol AS-D chloroacetate as substrate is positive in neu-
trophils and neutrophil precursors and negative in monocytes and 
monocyte precursors.
 1. Place smears in slots of two Coplin jars, one marked NSE and 
the other marked NaF.
 2. Fill both jars with cold buffered Formalin/Acetone Fixative 
and incubate for 30 s. Appropriately discard fixative and wash 
smears three times with ddH2O.
 3. Air-dry for 15 min.
 4. Prepare hexazotized pararosaniline by mixing 100 μL of 4% 
Sodium Nitrite solution with 100 μL 4% pararosaniline solu-
tion (see Note 4). Let stand at room temperature for at least 
1 min before adding to the incubation mixture.
 5. Prepare incubation mixtures for nonspecific esterase. Label 
two conical tubes as NSE and NSE/NaF. Add the reagents in 
Table 3 in the order listed, mixing well after each addition. 
Assure that solids have dissolved prior to proceeding to the 
next addition (see Note 5).
 6. Filter solutions through #1 filter paper into new conical tubes 
(see Note 6).
3.4.1 Procedure
Table 3 
Nonspecific esterase staining (NSE)
NSE NSE/NAF
α-Naphthyl acetate 10 mg 10 mg
Ethyleneglycolmonomethyl ether 0.5 mL 0.5 mL
1/15 M phosphate buffer pH 6.3 9.5 mL 9.5 mL
Hexazotized pararosaniline 0.05 mL 0.05 mL
Sodium fluoride None 15 mg
Cytochemical Staining
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 7. Add solutions to the appropriate Coplin jars with smears and 
incubate at 37 °C for 50 min. Appropriately discard staining 
solution and wash smears three times with ddH2O.
 8. Prepare the CAE incubation mixture by adding the reagents in 
Table 4 in the order listed, mixing well after each addition. As 
with the NSE mixture, be sure that all solids are dissolved prior 
to the next addition (see Note 7).
 9. Add the CAE incubation mixture to Coplin jars containing 
smears stained for NSE. Incubate for 10 min at room tempera-
ture. Appropriately discard staining solution and wash smears 
three times with ddH2O.
 10. Prepare dilute counterstain by adding 1 mL of 1% Methyl 
Green to 9 mL of ddH2O. Fill Coplin jars containing the NSE 
and CAE stained smears with dilute methyl green. Incubate at 
room temperature for 5 min. Properly discard the stain and 
wash smears three times with ddH2O.
 11. Air-dry and mount with Cytoseal 60.
These two esterase stains are used primarily to distinguish AML of 
granulocytic, monocytic, and megakaryocytic lineages [19, 20]. 
CAE is present in the granules myeloid cells and is insensitive to 
NaF inhibition. The pattern of CAE staining should parallel those 
of Sudan Black and Peroxidase, both in normal and leukemic 
myeloid cells. Normal myeloblasts are negative for CAE, but 
myeloblasts in some cases of AML are positive. CAE is negative in 
eosinophils, lymphocytes, plasma cells, erythroblasts, megakaryo-
cytes, and mature monocytes.
NSE stain is strongest in monocytes, macrophages, megakaryo-
cytes, and platelets. Weak activity is present in granulocytes and T 
lymphocytes (see Note 8). Activity in monocytes and macrophages is 
completely inhibited by sodium fluoride, while stain is retained, 
though diminished in intensity, in granulocytes and megakaryocytes.
Acid phosphatase in hematopoietic cells can hydrolyze a variety of 
hydroxynaphtholic anilides, releasing insoluble naphthols, which 
couple efficiently at acid pH with diazonium salts [19, 21]. The 
resultant product forms a colored precipitate at the enzyme 
location.
3.4.2 Expected Results 
(Tables 1 and 2)
3.5 Acid 
Phosphatase
3.5.1 Principle
Table 4 
Chloroacetate esterase staining (CAE)
Naphthol AS-D chloroacetate 1 mg
N,N-dimethylformamide 0.5 mL
1/15 M phosphate buffer pH 7.4 9.5 mL
Fast Blue BB 5 mg
Michele E. Paessler et al.
paolo.fortina@jefferson.edu
29
 1. Prewarm a bottle of ddH2O at 37 °C.
 2. Place smears into a Coplin jar. Fill Coplin jar with Citrate/
Acetone/Formaldehyde Fixative. Incubate at room tempera-
ture for 30 s. Properly discard the fixative and wash smears 
three times with ddH2O.
 3. Prepare the incubation mixture by mixing 0.2 mL of sodium 
nitrite solution to 0.2 mL of fast garnet GBC base solution. 
Mix gently and let stand for at least 2 min.
 4. Add the incubation mixture above to 7.6 mL of prewarmed 
ddH2O.
 5. Add 1 mL acetate solution.
 6. Add 1 mL Naphthol AS-BI Phosphoric acid solution and mix 
well (see Note 9).
 7. Fill the Coplin jar containing the samples, with fresh mixture 
from step 8. Cap tightly and place in the 37 °C incubator for 
1 h. Properly discard the staining solution and wash smears 
three times with ddH2O.
 8. Make methylene blue counterstain by adding 1 mL methylene 
blue solution to 9 mL ddH2O and mix well.
 9. Add the dilute methylene blue counterstain to the Coplin jar 
and incubate for 2 min at room temperature. Properly discard 
the staining solution and wash smears three times with ddH2O.
 10. Air-dry and mount with Aqua-mount (see Note 10).
Acid phosphatase activity is indicated by red granular precipitate 
and is diffusely positive in the cytoplasm of most cells of the hema-
topoietic system. Moderate staining is seen in plasma cells, mega-
karyocytes, and monocytes. Weak reactions are present normally in 
the myeloid series. Histiocytes and osteoclasts should be strongly 
granular positive. Very little acid phosphatase activity is present in 
erythroid precursors. In T-cell leukemia acid phosphatase is char-
acteristically strong and localized in the Golgi area, so focal (dot- 
like) staining of the blasts suggests T-cell lineage [22]. 
Megakaryoblasts may also show focal staining [20, 23]. Correlation 
with other phenotyping assays is necessary for definitive lineage 
assignment.
Periodic acid oxidizes cellular glycols and related compounds to 
their cognate aldehydes. These aldehydes can then react with the 
Schiff ’s reagent (leukofuchsin) releasing fuchsin [24]. These reac-
tions result in bright pink staining of the cellular component that 
originally contained the oxidizable compounds. In blood and bone 
marrow cells, glycogen is the compound primarily responsible for 
PAS staining.
3.5.2 Procedure
3.5.3 Expected Results 
(Tables 1 and 2)
3.6 PAS Principle
Cytochemical Staining
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 1. Place smears into slots in the Coplin jar.
 2. Fill the Coplin jar with formalin/alcohol fixative and incubate 
for 5 min at room temperature. Properly discard the fixative 
and wash smears three times with ddH2O.
 3. Fill the Coplin jar with the periodic acid solution and incubate 
for 15 min at room temperature. Properly discard the acid 
solution and wash smears three times with ddH2O.
 4. Fill the Coplin jar with Schiff ’s reagent and incubate for 15 min 
at room temperature. Properly discard the Schiff ’s reagent and 
wash smears three times with ddH2O.
 5. Fill the Coplin jar with Mayer’s Hematoxylin and incubate for 
15 min at room temperature. Properly discard the stain and 
wash smears three times with ddH2O.
 6. Air-dry and mount with Cytoseal 60.
Mature neutrophils, megakaryocytes, and platelets normally stain 
intensely pink or red. Monocyte cytoplasm stains faintly pink and 
may contain fine or course granules. Myeloblasts and normal ery-
throid cells do not stain. Cytoplasmic staining increases with the 
increasing maturity of the myeloid cells.
In AML, staining is variable and largely depends on the dif-
ferentiation state of the blasts. Acute promyelocytic leukemia will 
show more intense staining of the leukemic cells than AML with 
minimal differentiation. Intense staining is also seen in acute mega-
karyoblastic leukemia. In contrast to normal erythroid precursors, 
which do not stain with PAS, large areas of PAS positivity can be 
seen in the erythroid cells of MDS and acute erythroleukemia [6]. 
Large granular staining can be seen in the cytoplasm of B lympho-
blasts (i.e., block positivity) [25].
4 Notes
 1. For the PAS stain, Schiff ’s reagent is labile and is the most 
likely reagent to cause negative results in the control reaction. 
Replacing this reagent only and testing control smears is likely 
to correct falsely negative PAS staining.
 2. This reaction is extremely light sensitive. Care must be taken to 
ensure that the smears to be stained are protected from any 
prolonged exposure to light, which may render them falsely 
negative.
 3. Whereas a positive MPO stain is sufficient for determination of 
myeloid differentiation, a negative myeloperoxidase stain 
should never be considered pathognomonic of acute nonmy-
elocytic leukemia (i.e., lymphoblastic leukemia).
3.6.1 Procedure
3.6.2 Expected Results 
(See Table 1)
Michele E. Paessler et al.
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 4. The solution should be golden brown with rim of small bub-
bles at the top.
 5. On addition of the phosphate buffer the solution will turn 
milky white; if it turns purple, properly discard and start anew.
 6. The solutions will be clear and pale gold after filtering.
 7. On addition of the phosphate buffer the solution may turn 
faintly milky white. The addition of the Fast Blue BB will make 
the mixture yellow after mixing and blue on standing after time.
 8. NSE staining is highly sensitive to reaction conditions. 
Undesired reactivity may occur if the reaction conditions are 
not followed carefully. Increasing the incubation period and 
altering the pH or temperature may give false positive results. 
Stains should be interpreted in the context of other phenotypic 
results.
 9. Solution should be amber. Formation of precipitate indicates 
reagent deterioration.
 10. Cytoseal 60 cannot be used with acid phosphatase stain.
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Chapter 3
Immunohistochemistry in Acute Myeloid Leukemia
Michael W. Cruise
Abstract
The World Health Organization’s Classification of Tumours of Haematopoietic and Lymphoid Tissues 
(Swerdlow et al. (eds) WHO Classification of tumours of haematopoietic and lymphoid tissues, 4th edn. 
WHO Press, Lyon, 2008) created a classification scheme incorporating genetic, molecular, morphologic, 
and immunophenotypic characteristics. The diagnosis of acute myeloid leukemia requires equal to or 
greater than 20% blasts (except in some cases with specific cytogenetic abnormalities or in erythroleuke-
mia). The diagnostic work up typically includes morphologic, cytochemical, and immunophenotypic fea-
tures. This generally includes evaluation of the peripheral blood, bone marrow aspirate, and bone marrow 
trephine biopsy. As stated in the WHO Classification of Tumours of Haematopoietic and Lymphoid 
Tissues, “the contribution of an adequate bone marrow biopsy cannot be over stated” (Swerdlow et al. 
(eds) WHO Classification of tumours of haematopoietic and lymphoid tissues, 4th edn. WHO Press, 
Lyon, 2008). The evaluation of the bone marrow biopsy provided the necessary material for immunohis-
tochemical studies used for both diagnosis and prognosis.
The following text will focus on the utilization of immunohistochemical studies in the classification of 
acute myeloid leukemia. Other methodologies will be discussed elsewhere in this volume.
Key words AML, Immunohistochemistry, Protocol, Classification, Bone marrow biopsy
1 Introduction
The acute leukemia/lymphomas are characterized broadly as acute 
myeloid leukemia, lymphoblastic leukemia/lymphoma, and acute 
leukemia of ambiguous lineage. Acute myeloid leukemia (AML) 
can be further subclassified into AML with recurrent genetic abnor-
malities, AML with myelodysplasia, and AML not otherwise speci-
fied. The last category, AML not otherwise specified, can be further 
subdivided by morphologic and immunophenotypic profile.
Generally the first task is determining if there are sufficient 
number/percentage of blasts. The diagnosis of acute myeloid leu-
kemia requires equal to or greater than 20% blasts (or blasts equiv-
alents). The gold standard for blast evaluation is determining the 
percentage of blasts in a 500-cell differential count of the bone 
marrow aspirate or 200-cell differential of the peripheral blood. 
paolo.fortina@jefferson.edu
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However, there are conditions in which bone marrow biopsy and 
immunohistochemical stains are required, especially when a bone 
marrow aspirate cannot be obtained or is hemodiluted. For the 
identification of blasts, the most helpful immaturity markers are 
CD34, CKIT/CD117, and Tdt. Generally these markers are 
strongest in undifferentiated cells with expression decreasing with 
maturation. In cases where the aspirate is poor or there is a dry tap, 
immunohistochemical staining of the bone marrow core biopsy 
can in fact yield an increased blast count resulting in the diagnosis 
of AML. Generally CD117 has a similar expression pattern as 
CD34 but in various specimens and diagnosis, one tends to be 
more sensitive [2, 3]. Tdt is generally useful in acute lymphoblastic 
leukemia/lymphoma (ALL), while CD117 is generally limited to 
AML (only rarely seen in T-ALL). CD34 can be seen in both AML 
and ALL but generally more limited expression, as it is only pres-
ent in approximately 50% of AML cases [4]. As such, it is usually 
beneficial to stain for multiple markers.
In addition to assessing blasts counts, immunohistochemical 
staining is useful in the classification of the lineage of the blasts 
(Table 1) and further subclassification of the process. The WHO 
classifies cytoplasmic CD3 as the lineage marker for T cells. 
However, other T-cell associated antigens can be expressed on 
AML. Specifically CD7 can be expressed on approximately 10–20% 
of AML and CD2 is often expressed in acute promyelocytic leuke-
mia [5]. The WHO classifies myeloid lineage markers as myeloper-
oxidase or evidence of monocytic differentiation with at least two 
of the following: nonspecific esterase, CD11c, CD14, CD64, or 
Table 1 
Requirements for assigning lineage to a blast
Myeloid lineage
  – Myeloperoxidase, or
  –  Monocytic differentiation (at least 2 of the following: nonspecific esterase, CD11c, CD14, CD64, 
lysozyme)
T lineage
  –  Cytoplasmic CD3 (monoclonal antibodies to CD3 epsilon chain; IHC with polyclonal anti-CD3 
antibody may react with CD3 zeta chain, which is not T cell–specific); or
  – Surface CD3 (rare in mixed phenotype acute leukemia)
B lineage (multiple antigens required)
  –  Strong CD19 with at least 1 of the following strongly expressed: CD79a, cytoplasmic CD22, 
CD10; or
  –  Weak CD19 with at least 2 of the following strongly expressed: CD79a, cytoplasmic CD22, CD10
Adapted from 2008 Tumours of Haematopoietic and Lymphoid Tissues [1]
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lysozyme. However, generally only CD14 and lysozyme are readily 
utilized by immunohistochemistry. B cell lineage is a little less spe-
cific requiring the testing of multiple antigens (CD19, CD22, 
CD79a, and CD10).
Further classification of the lesions requires determining the 
differentiation of the neoplastic cells and immunohistochemical 
stains remain a power tool for this purpose (Table 2). The typical 
markers of myeloid differentiation are myeloperoxidase, CD33, and 
CD13; however CD117, CD15, and CD56 can also suggest 
myeloid differentiation (especially in the absence of lymphoid mark-
ers). Monocytic differentiation can be highlighted by CD14, CD68 
(clones PG-M1 and KP1), lysozyme, and CD163. Additionally 
CD4 (on CD3 negative cells) can be used as a monocytic marker. 
Erythroid differentiation can be demonstrated by expression of 
Glycophorin A (CD235a) or by hemoglobin A, and megakaryo-
cytic differentiation can be highlighted by expression of CD42b, 
CD41, CD61, and von Willebrand factor (factor VIII- related Ag).
While cytogenetic and molecular findings can be entity defin-
ing, many have unique immunophenotypic findings. The typical 
immunophenotypic findings are outlined in Table 3 and some key 
findings are briefly highlighted below. Specifically here we will 
focus on acute myeloid leukemia not otherwise specified (AML 
NOS). AML with minimal differentiation is the most immature 
of the AML NOS subtypes and typically expresses only early 
antigens such as CD34 and CD117. There are no morphology 
or cytochemical features to differentiate AML with minimal dif-
ferentiation from acute lymphoblastic leukemia, thus requiring 
immunophenotyping for a diagnosis. Additionally, this subtype 
can demonstrate TdT expression in up to 20–50% of cases [6]. 
The AML with minimal differentiation is often positive for 
CD33. While it is negative for myeloperoxidase by cytochemis-
try, a subset of the blasts may be positive for myeloperoxidase by 
immunohistochemistry. Even though the blasts can be positive 
for TdT they are negative for cCD3, CD79a, PAX5, and CD22.
Table 2 
Markers of differentiation
Precursor CD34, CD117, TdT, CD10, CD3, CD19
Myeloid Myeloperoxidase, CD13, CD33, HLA-DR, 
CD117
Erythroid Glycophorin A, hemoglobin A
Megakaryocytic CD41, CD42b, CD61, von Willebrand factor 
(factor VIII-related Ag)
Monocytic CD14, CD68, CD163
Immunohistochemistry in AML
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The next category of acute myeloid leukemia without matura-
tion includes markers of myeloid differentiation including myelo-
peroxidase and often will express CD13, CD33, along with 
immaturity markers CD34 and CD117. As the name implies they 
are negative for markers of maturation including CD15, CD14, 
CD68, and CD163. They can however have aberrant expression of 
CD7 and a small percentage have been reported to express CD2, 
CD4, or CD56. Acute myeloid leukemia with maturation (FAB 
M2) expresses myeloid differentiation markers including myelo-
peroxidase, CD13, and/or CD33. Since there is maturation gen-
erally only a part of the blasts will express CD34 or CD117. 
Generally these blasts are also positive for CD15 without expres-
sion of monocytic markers CD14, CD68, CD163, or CD4. 
Additionally while CD7 can be expressed they are usually negative 
for CD2 and CD56. It should be noted that definitive differentia-
tion between AML with and without maturation can be challeng-
ing by tissue immunohistochemistry and generally is used to 
correlate with the flow cytometry results.
The next two categories under AML NOS include those with 
at least some monocytic differentiation. The acute myelomono-
cytic leukemia has two to three blast populations, one demon-
strating monocytic differentiation, another with neutrophilic 
differentiation and often a population of immature blasts. The 
immature blast population expresses CD34 and/or CD117 with 
occasional CD7 expression. The monocytic population expresses 
monocytic differentiation with one or more of the following: 
CD14, CD4, CD68, CD163, and lysozyme (muramidase). The 
myeloid or neutrophilic blasts will have expression of myeloper-
oxidase as well as CD13, CD33, or CD15. The next category, 
acute monoblastic and monocytic leukemia, is an AML in which 
greater than 80% of the blasts are of the monocytic lineage with 
only a minor neutrophilic component. As this is a more mature 
AML, the blasts are less likely to be CD34 positive but generally 
retain CD117 expression. There is generally variable expression 
of myeloid markers, myeloperoxidase, CD13, CD33, and CD15. 
The blasts also express markers of monocytic differentiation 
including CD4, CD14, CD68, CD163, and/or lysozyme.
Acute erythroid leukemia can exist either as an erythroid 
and myeloid process (greater than or equal to 50% erythroid 
precursors and greater than or equal 20% myeloblast in the non-
erythroid component) or as a pure erythroid leukemia (greater 
than or equal to 80% of the bone marrow cells). The erythroid 
and myeloid process demonstrates a population of erythroblasts 
that express markers of erythroid differentiation including 
hemoglobin-A and glycophorin- A and only have focal CD34 
expression and are generally negative for myeloperoxidase. 
Additionally, the myeloid blasts are generally immature with 
expression similar to AML with minimal differentiation.
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Acute megakaryoblastic leukemia is a leukemia with greater 
than 20% blasts in which 50% or more of the blasts demon-
strates megakaryocyte lineage. This type of leukemia can have 
extensive bone marrow fibrosis and as such there can be limited 
material collected by aspirate. As such immunohistochemistry 
on the bone marrow biopsy may be the only method to deter-
mine the immunophenotype and percentage of blasts. The 
blasts are variable positive for CD117 and CD34 and can be 
positive for CD13 and CD33. The blasts are generally negative 
for TdT and myeloperoxidase. The megakaryoblasts typical 
express CD41 and/or CD61. The mature megakaryoblasts can 
also express factor VIII and/or CD42. CD31 can be helpful 
and was once thought to be lineage specific for megakaryo-
cytes; however, CD31 can be seen on other AML and vascular 
lesions.
In cases of acute panmyelosis with myelofibrosis there is 
often a dense bone marrow fibrosis and the aspirates are gener-
ally dry (low cellularity) and insufficient for evaluation by aspi-
rate smear or by flow cytometry. Often immunohistochemical 
staining of the bone marrow biopsy is the only way to determine 
the presence of and the immunophenotypic profile of the blasts 
and confirm the diagnosis. The blast population generally 
expresses precursor markers CD34 and/or CD117 along with 
myeloid markers CD13 and CD33, and however is usually neg-
ative for myeloperoxidase. Specifically, immunohistochemistry 
is generally the only method to determine that blasts exceed the 
20% threshold needed for the diagnosis. This is a panmyelosis 
with multilineage proliferation, generally of the megakaryocytic 
(CD61, CD41, Factor VIII) and the erythroid (hemoglobin A, 
Glycophorin) lineages.
While we will not discuss in depth the immunophenotype of 
the AML with recurrent genetic abnormalities, they are listed in 
Table 3. However, we will discuss aberrant expression of 
PAX5 in AML. Specifically, PAX5 is typically a B-cell maker; 
however the expression of PAX5 in AML is correlated with the 
t(8;21) translocation [7].
There are areas of caution when utilizing certain antibodies 
by immunohistochemistry. One example would be CD15: while 
this antibody can be used to determine blast differentiation, the 
high expression in the normal granulocytes can make interpreta-
tions of the stain in tissue section very challenging. Another 
problematic antibody is HLA-DR. This antibody is extremely 
usefully by flow cytometry; however the antibody has had vari-
able success in immunohistochemical evaluation of tissue sec-
tions. As newer clones become available this marker may become 
more useful. Additionally, other myeloid markers CD13 and 
CD33 tend to be less sensitive by immunohistochemistry as com-
pared to flow cytometry [8]. Two additional markers that are not 
typically used by flow cytometry for the evaluation of AML but 
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can be utilized by immunohistochemistry are CD99 and CD43. 
Up to 95% of acute myeloid leukemia are positive for CD43, 
which can be extremely helpful, especially in extramedullary 
lesions (myeloid sarcoma) [9]. Additionally, AML/myeloid sar-
coma can be CD99 positive and as such the possibility of AML 
should be considered in cases of small round blue cell tumors 
with CD99 expression [6].
In summary, for the work up of a possible acute myeloid leu-
kemia the important first step is evaluation of the aspirate and bone 
marrow biopsy. The morphologic differential of the blast popula-
tions will dictate the panel performed. Several staining algorithms 
for working up possible AML cases have been published [8, 10]. 
Generally most panels include blast markers CD34, CD117, and 
TdT. If the blasts are immature then markers for B cell, T cell, and 
myeloid lineage are performed (as seen in the tables). Once the 
blasts have demonstrated a myeloid lineage, then differentiation 
markers can be exploited. Multiple markers must be utilized in 
order to render the correct lineage and diagnosis. Correlation with 
other ancillary studies must be performed. Below are detailed 
methodologies for both manual and automated systems.
2 Materials
 1. Sodium citrate buffer: 10 mM Sodium citrate, pH 6.0. Add 
2.94 g Tri-sodium citrate (dihydrate) to 1 L of distilled water. 
Mix to dissolve and then adjust pH to 6.0 with 1 N HCl. Store 
at room temperature for 3 months.
 2. ETDA buffer: 1 mM EDTA, adjusted to pH 8.0. Add 0.37 g 
EDTA (ethylenediaminetetraacetic acid) to 1 L of distilled 
water. Mix to dissolve and then adjust pH to 8.0 with 
NaOH. Store at room temperature for 3 months.
 3. Tris-EDTA buffer: 10 mM Tris Base (tris(hydroxymethyl)ami-
nomethane), 1 mM EDTA solution, 0.05% Tween 20, pH 9.0. 
To 1 L of distilled water add 1.21 g of Tris base and 0.37 g 
EDTA. Mix to dissolve and then adjust pH to 9.0. Finally add 
0.5 mL of Tween 20 and mix well.
 1. 10× TBS: To 900 mL of distilled water add 24 g of Tris–HCL 
(tris(hydroxymethyl)aminomethane hydrochloride), 5.6 g of 
Tris base, and 88 g NaCl. The solution is mixed until dissolved 
and then pH is adjusted to 7.6 with HCl or NaOH. Finally 
adjust volume with distilled water to a final volume of 1 L. Store 
at room temperature for 3 months.
 2. TBST: 1× Tris-buffered saline, 0.1% Tween 20. Add 100 mL 
of TBS 10× to 900 mL distilled water and mix. Then check to 
ensure pH is 7.6 and adjust if needed. Finally add 1 mL of 
Tween 20 and mix well.
2.1 Manual Antigen 
Retrieval
2.2 Manual Wash
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 1. Preferred blocking solution is 2.5% serum from the species of 
the secondary reagent. In the manual method below we utilize 
2.5% horse serum. While part of the ImmPRESS™ detection 
kits are utilized in the methods below, an alternative can be 
2.5% horse serum in TBS (2.5 mL of horse serum in 97.5 mL 
of 1× TBS) or 1% BSA in TBS blocking solution (1 g immuno-
histochemical grade bovine serum albumin (Vector laborato-
ries, Burlingame, CA, USA) with 100 mL of TBS).
2.5% serum from the species of the secondary reagent. In the man-
ual method below we utilize 2.5% horse serum in TBS. Alterative 
one could utilize 1× TBS with 0.1% immunohistochemical grade 
bovine serum albumin.
Make up fresh and add 30 mL of 30% hydrogen peroxide solution 
(Fisher Chemical, Waltham, MA, USA) to 270 mL distilled water.
Avidin/Biotin Blocking Kit (Vector laboratories, Burlingame, CA, USA).
ImmPRESS™ reagent HRP Universal Antibody (Anti-Mouse 
IgG/Anti-Rabbit IgG, Peroxidase) Polymer Detection Kit (made 
in horse) (Vector laboratories).
ImmPACT DAB Peroxidase (HRP) Substrate (Vector laboratories).
 1. Reaction Buffer (10×): Tris-based buffer (pH 7.5 ± 0.2) 
(Ventana, Tucson, AZ, USA). Make 1× reaction buffer by mix-
ing the 2 L bottle with 18 L of distilled water (1 part diluted 
with 9 parts). Check pH with a test strip, acceptable range is 
7.3–7.7.
 2. Liquid coverslip (Ventana).
 3. EZ Prep (10×): aqueous-based detergent solution with preser-
vative (Ventana). Make 1× buffer by diluting 2 L of EZ Prep 
Concentrate with 18 L of distilled water.
 4. CC1 Predilute: tris-based buffer with a slightly basic pH (8.5) 
(Ventana).
 5. CC2 Predilute: citrate buffer at a slightly acidic pH (6) 
(Ventana).
 6. Protease 2; endopeptidase containing approximately 0.1 mg/
mL alkaline protease enzyme activity (Ventana).
 7. Antibody Diluent: (0.3% protein in 0.1 M phosphate buffered 
saline pH 7.3) (Ventana).
2.3 Blocking 
Solution
2.4 Antibody Diluent
2.5 Peroxidase Block
2.6 Avidin/Biotin 
Blocking
2.7 Detection 
System
2.8 Chromogen 
Reagent
2.9 Automated 
Systems
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 8. optiView DAB IHC Detection kit: OptiView Peroxidase 
Inhibitor (3.0% hydrogen peroxide solution), OptiView HQ 
Universal Linker (cocktail of goat anti-mouse IgG and IgM, 
and goat anti-rabbit with covalently attached hapten), 
OptiView HRP Multimer (mouse monoclonal anti-hapten-
labeled HRP tertiary antibody), OptiView H2O2 (0.04% 
H2O2), OptiView DAB (0.2% of 3,3′-diaminobenzidine tetra-
hydrochloride), and OptiView Copper (copper sulfate (5 g/L) 
in an acetate buffer) (Ventana).
 9. OptiView Amplification Kit: containing OptiView Amplifier 
(tyramide with a linker containing hapten), OptiView 
Amplification Multimer (mouse anti-HQ-HRP), and OptiView 
Amplification H2O2 (0.04% H2O2) (Ventana).
 1. Xylene histology grade (Cardinal Health, Dublin, OH, USA)
 2. Reagent-grade alcohol: 100%, 95%, 80%, and 70% (Cardinal 
Health, Dublin, OH, USA).
 3. Mayer’s Hematoxylin with Lillie’s Modification (Dako, 
Carpinteria, CA, USA).
 4. Bluing Solution (Dako).
 5. Decalcification Solution: EDTA in weak hydrochloric acid 
(Thermo Fisher Scientific, Waltham, MA, USA).
 6. Zinc-formalin containers (Poly Scientific R&D Corp., Bay 
Shore, NY, USA).
 7. Cytoseal (Thermo Fisher Scientific).
 8. SUPERFROST PLUS Microscope Slide (VMR, Radnor, PA, 
USA).
3 Methods
The general method for immunohistochemical stain consists of 
sample preparation including fixation and sectioning onto charged 
slides, followed by deparaffinization of the sections. Next the anti-
gens must be retrieved, by unmasking and restoring the antigen’s 
epitope and antibody binding site. Nonspecific protein interactions 
must be blocked (generally utilizing serum from the same species 
as the secondary antibody) as well as endogenous peroxidase activ-
ity must be inhibited. Subsequently the tissue sections are incu-
bated with a primary antibody against the antigen of interest and 
then followed by incubation with a secondary antibody/detection 
system against the species of the primary antibody. Then the sec-
tions are incubated with a chromogen, typically 3,3′-diaminoben-
zidine (DAB), that creates insoluble precipitate that can be 
visualized under light microscopy.
2.10 General 
Purpose Reagents
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Typically, a bone marrow specimen consists of aspirate with smears, 
touch prep slides of bone marrow core, the bone marrow core 
biopsy, and clot formed from the aspirate.
 1. Bone marrow clot: Set aside approximately 1 cm3 of bone mar-
row aspirate and allow to clot. Next place the clot in a filter 
bag/between filter paper and place into a biopsy cassette and 
then fix the specimen in 10% formalin.
 2. The biopsies are processed per standard protocol, dehydrated 
and placed into paraffin.
 3. The biopsies are sectioned at 4 μm, placed on charged slides, 
and baked at 60 °C for 1 h.
 4. Bone marrow core biopsy: The bone marrow core biopsies are 
placed in Zinc-formalin. The biopsies are fixed for 2 h (or at 
least 30 min).
 5. The biopsies are placed in biopsy cassettes and rinsed in dis-
tilled water for 5 min.
 6. The biopsy is placed into decalcification solution (see 
Subheading 2) for 30 min followed by rinsing in distilled water 
for 30 min and placed in 10% formalin.
 7. The biopsies are processed per standard protocol, dehydrated 
and placed into paraffin.
 8. The biopsies are sectioned at 4 μm, placed on charged slides, 
and baked at 60 °C for 1 h.
 1. The formalin fixed paraffin embedded sections must be depar-
affinized and rehydrated. We typically utilize TissueTek™ slide 
racks and reagent containers (however other similar products 
could be utilized). Place slides in slide holder and move 
through slide dishes as follows: (a) Xylene—3 changes of 5 min 
each, (b) 100% Alcohol—2 changes of 3 min each; (c) 95% 
Alcohol—2 min; (d) 70% Alcohol—2 changes for 2 min each; 
(e) Distilled Water—2 changes for 2 min each.
 2. For antigen retrieval utilize the Decloaking™ chamber (Biocare 
medical, Concord, CA, USA), or similar pressure cooker system.
 3. Add 500 mL of distilled water to the reaction chamber. Move 
the slides into aluminum slide dish and fill with 250 mL anti-
gen retrieval solution (see Note 1). Place three slide-staining 
dishes (up to 72 slides) into the reaction chamber. (Always use 
three dishes; if no slides in dish then fill with 250 mL distilled 
water. This ensures consistent temperature changes and 
retrieval results.)
 4. As a quality control measure, steam monitor strips should be 
utilized as well as pH strips in order to verify that the retrieval 
solution reached the appropriate temperature and maintain the 
appropriate pH.
3.1 Special 
Consideration for Bone 
Collection 
and Processing
3.2 Manual 
Immunohistochemical 
Staining
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 5. Attach the Decloaking chamber lid and seal. Start the Decloaking 
chamber. Standard protocol increases the temperature of the 
reaction chamber up to 125 °C and then holds it for 30 s fol-
lowed by cooling to 90 °C. At this point the lid can be opened 
and the containers removed from the reactive chamber and 
allowed to cool for an additional 20 min at room temperature.
 6. Wash the slides twice with distilled water for 5 min.
 7. Place slides in freshly made 3% H2O2 solution and incubate for 
10 min at room temperature in order to block endogenous 
peroxidase.
 8. Wash the slides twice with distilled water for 5 min each, then 
wash in TBST for 5 min.
 9. Wipe slide around tissue section with Kimwipes™ (or similar 
product) and add blocking solution and incubate for 30 min at 
room temperature in a humidified chamber (see Note 2) to 
inhibit the tissue from drying out. Alternatively, the slide 
around the tissue can be marked with a hydrophobic pen. 
Optionally, if using a streptavidin biotin detection system then 
after protein block, a biotin block must be performed, which 
can be done with the Avidin/Biotin Blocking Kit (Vector labo-
ratories) (see Note 3).
 10. Drain the blocking solution and add 1–3 drops of the Avidin 
D solution to cover the tissue sections and incubate for 15 min. 
Then rinse in TBST for 5 min.
 11. Drain the blocking solution and add 1–3 drops of the biotin 
solution to cover the tissue sections and incubate for 15 min. 
Then rinse in TBST for 5 min.
 12. Drain slides and add primary antibody to tissue sections (see 
Note 4).
 13. Wash slides three times with TBST (5 min each on a shaker).
 14. Incubate the sections for 30 min with ImmPRESS™ reagent 
directed against primary antibody (secondary antibodies conju-
gated to horseradish peroxidse enzyme polymer) (see Note 5).
 15. Wash slides three times with TBST (5 min each on a shaker).
 16. Add freshly prepared ImmPACT™ DAB Peroxidase Substrate 
by adding 1 drop (approximately 30 μL) of ImmPACT™ DAB 
Chromogen concentrate to 1 mL ImmPACT™ DAB Diluent 
and mixing well. This substrate is added to the section and 
incubated until stain develops (generally 2–10 min). Optimal 
time must be determined experimentally.
 17. Rinse sections with distilled water.
 18. Stain tissue sections for 60 s with hematoxylin (Dako). Then 
rinse in water until excess reagent is removed.
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 19. Place in bluing buffer (Dako) until stain is blue (approximately 
30 s).
 20. Rinse in distilled water.
 21. Sections are dehydrated by passing racks through two changes 
of 95% alcohol and three changes of 100% alcohol, followed by 
three changes of xylene.
 22. Coverslip slides with permanent mounting media such as 
Cytoseal or similar reagent.
The protocol below represents steps utilizing the Ventana 
Benchmark™ XT (Ventana Benchmark; Ventana, Tucson, AZ, USA). 
The benchmark system utilizes a Liquid Cover Slip (LCS) solution 
during each step. The LCS consists of an inert low density, paraffinic 
hydrocarbon and mineral oil, that forms a layer over the aqueous 
solution on the slide to prevent evaporation.
 1. The slides are placed on the slide carousel and the loaded tray 
of antibodies and reagents are placed on the instrument.
 2. From the Benchmark’s main screen, start the run and follow 
the prompts until the instrument starts to scan the bar codes 
for the slides and reagents. Typical program includes the fol-
lowing steps.
 3. Removal of paraffin by combining heat, a mild detergent solu-
tion (EZ Prep) combined with vortex mixing and rinsing.
 4. Antigen retrieval utilizing Ventana’s proprietary regents for 
HIER: cell conditioning 1 (Tris containing solution, pH 8.5) 
or cell conditioning 2 (citrate buffer, pH 6.0) with standard 
antigen retrieval for 64 min at 100 °C. Alternatively Protease 2 
(endopeptidase containing approximately 0.1 mg/mL alkaline 
protease enzyme activity) applied for 4 min at 36 °C.
 5. Slides are washed with Ventana reaction buffer (Tris-based 
buffer, pH 7.5).
 6. Block endogenous peroxidase activity with OptiView 
Peroxidase Inhibitor (Ventana) and incubate for 4 min, fol-
lowed by rising with reactive buffer.
 7. Primary antibody applied and incubated (see Note 4).
 8. Slides are washed with Ventana reaction buffer (Tris-based 
buffer, pH 7.5).
 9. The antigen is detected using the OptiView DAB IHC 
Detection kit.
 10. Slides are incubated with OptiView HQ Universal Linker 
(cocktail of HQ (hapten)-labeled goat anti-mouse IgG and 
IgM, and goat anti-rabbit) for 8 min. Wash with reaction 
buffer.
3.3 Automatic 
Procedure (See Note 6)
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 11. Incubate with OptiView HRP Multimer (mouse monoclonal 
anti-HQ-labeled HRP tertiary antibody) for 8 min. Wash with 
reaction buffer.
 12. Incubate OptiView Amplifier (tyramide with a linker contain-
ing HQ hapten) and OptiView Amplification H2O2 (0.04% 
H2O2) for 8 min. Rinse with reaction buffer.
 13. Incubate OptiView Amplification Multimer (mouse anti-HQ- 
HRP) for 8 min. Rinse with reaction buffer.
 14. OptiView H2O2 (0.04% hydrogen peroxide in a phosphate 
buffer solution) and OptiView DAB for 8 min. Rinse with 
reaction buffer.
 15. OptiView Copper (contains copper sulfate in an acetate buffer) 
for 4 min, then rinse with reaction buffer.
 16. Counterstain with Hematoxylin II (Ventana) for 4 min. Rinse 
with reaction buffer.
 17. Add bluing reagent for 4 min. Rinse with reaction buffer.
 18. After the run is complete, the slides are removed from the slide 
tray and placed in a rack in warm tap water containing a mild 
dish detergent with gentle agitation to remove remaining liq-
uid coverslip.
 19. Rinse slides in running tap water until all soap is removed.
 20. Sections are dehydrated by passing racks through two changes 
of 95% alcohol and three changes of 100% alcohol, followed by 
three changes of xylene.
 21. Coverslip slides with Cytoseal or similar reagent.
All staining should be done with appropriate negative and positive 
controls run in parallel. This allows for determination of nonspe-
cific staining as well as ensuring that the immunoreactivity and 
specificity of the targeted antigen being tested. It is often advanta-
geous to have the positive control tissue and the sample on the 
same slide. All reagents should be used by their expiration dates 
and discarded if any visual contamination is seen. Data sheets and 
product inserts will generally contain information on the storage, 
dilution, and stability of the reagents.
While outside of the scope of this paper, two publications from the 
College of Pathology have evaluated and made recommendation 
on the best practices for immunohistochemical assay validation 
[11, 12]. Recently the documentation requirements by the CAP 
and CLIA for validation of immunostains have become more 
stringent.
3.4 Quality Control
3.5 Validation 
and CLIA Standards
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4 Notes
 1. The process of fixation cross-links the proteins causing methy-
lene bridges of the tissue and this process will often mask/hide 
the antigen epitopes. In order to detect the antigen this pro-
cess must be partly reversed. This is accomplished by utilizing 
two broad categories of antigen retrieval. The first utilizes 
enzymatic approaches and the second utilizes heat and various 
pH solutions. The enzymatic approach typically utilizes 
Proteinase K, Trypsin, and Pepsin. However this method gen-
erally suffers from low success rate and has the potential of 
destroying both the antigen of interest and the tissue morphol-
ogy. The heat- induced methods typical utilize one of three 
retrieval solutions, sodium citrate buffer pH 6, EDTA pH 8, or 
Tris-EDTA buffer pH 9. The slides are heated in one of these 
heat-induced epitope retrieval solutions generally using a pres-
sure cooker, a microwave, or a vegetable steamer. While these 
can be performed offline, many of the automated systems can 
perform the antigen retrieval online.
 2. Humidity chamber: In order to reduce evaporation and avoid 
drying of the tissue incubations should be carried out in a 
humidified chamber. After rehydration, drying at any stage will 
lead to nonspecific binding and high background staining. A 
humidity chamber can be created from a shallow, plastic box 
with a sealed lid and wet paper towels in the bottom. Plastic 
serologic pipettes can be cut to the length of the chamber and 
placed 4 cm apart so that the slides rest in a level position on 
the raised surface. The slides must be kept off the wet paper 
and kept level so that the reagents will not drain off.
 3. Biotin block: Many systems will utilize a strept(avidin)-biotin 
detection system in order to amplify the signal. However, possible 
endogenous strept(avidin) binding sites must be blocked. This 
can be accomplished by incubating the tissue with strept(avidin) 
to bind up the endogenous biotin, followed by strept(avidin) to 
bind up any additional strept(avidin) binding sites.
 4. Primary antibody: The selection and work up of this step is 
arguably the most important in the creation of clean crisp anti-
gen staining. The dilution of the primary antibody must be 
experimentally determined. Generally datasheets from the pri-
mary antibodies have recommended dilutions that are generally 
good starting point. Although some primary antibodies are sup-
plied in ready-to-use or prediluted formats, many are also pro-
vided in concentrated aliquots. Primary antibodies are typically 
incubated at room temperature for 30 min but can be incubated 
overnight at 4 °C. Typically when done overnight the amount of 
antibody used can be significantly reduced (higher antibody 
dilution). Table 4 lists antibodies that are often utilized in the 
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Table 4 
List of common antibodies used for AML workup. These are recommended starting points for 
straining work-up. These were determined on a Ventana automated staining platform. Each 
individual laboratory must clinically determine the protocol conditions
Antibody Catalog # Clone Vendor
Epitope 
retrieval
Antibody 
dilution
Ab 
incubation 
time (min)/
temp (°C)
CD2 MU438-UC AB75 Biogenex CC1 1:10 16/37
CD3 790–4341 2GV6 Ventana CC1 Predilute 8/37
CD4 NCL- CD4- 1F6 1F6 Leica CC1 1:10 24/37
CD5 MU430-UC 4C7 Biogenex CC1 1:10 8/RT
CD7 CM158 CK LP15 Biocare CC1 1:50 32/RT
CD10 NCL-CD10–270 56C6 Leica CC1 1:5 20/37
CD15 MU302-UC BRA4F1 Biogenex CC1 1:40 20/37
CD20 M0755 L26 Dako CC1 1:200 32/37
CD22 MS-1087S FPC1 Thermo 
Scientific
CC2 1:10 16/37
CD31 M0823 JC/70A Dako CC1 1:20 16/37
CD33 NCL- L- CD33 PWS44 Leica CC1 1:25 20/37
CD34 134 M-18 QBEnd/10 Cell Marque – Predilute 16/37
CD43 M0786 DF-T1 Dako CC1 1:25 8/37
CD45 M0701 2B11, 
PD7/26
Dako – 1:100 16/37
CD56 CD56-1B6 1B6 Leica CC1 1:100 56/RT
CD57 MU314-UC NK-1 Biogenex CC1 1:80 12/37
CD61 CD61–308 2f2 Leica CC1 1:100 16/37
CD68 790–2931 KP-1 Ventana CC1 Predilute 16/37
CD68 M0876 PG-M1 Dako CC1 1:10 16/37
CD71 NCL-CD71–309 10F11 Leica CC2 1:40 20/RT
CD79a M7050 JCB117 Dako CC1 1:20 20/37
CD99 199 M-18 H036–1.1 Cell Marque CC2 Predilute 32/42
CD117 (c-kit) A4502 polyclonal Dako CC1 1:500 16/37
CD123 554,527 7G3 BD 
Biosciences
CC1 1:250 16/37
CD163 VP-C374 10D6 Vector CC1 1:1600 16/37
Factor VIII A0082 Polyclonal Dako – 1:200 16/37
(continued)
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work up of acute myeloid leukemia cases. As a starting point 
Table 4 also includes the antigen clone/manufacture, antigen 
retrieval conditions, and time and condition for the primary 
antibody incubation. These were worked up on a Ventana 
Benchmark platform and again the best conditions will vary 
from method to method and platform to platform.
A useful reference is the Nordic immunohistochemical 
Quality Control (NordiQC)—http://www.nordiqc.org/. This 
website provides information on the performances of multiple 
antibody clones utilized over multiple staining platforms at vari-
ous institutions utilizing various antigen retrieval methods and 
antibody dilutions. This provides an excellent starting point; 
however the precise conditions must be experimentally deter-
mined for your laboratory setup.
 5. There are several secondary systems that can be utilized to detect 
the primary antibody. While a secondary antibody directly linked 
to an enzyme can be used, this often does not yield a significant 
signal and so amplification of the signal is required. This can be 
in the form of a (strept)avidin-biotin complex in which the sec-
ondary antibody is biotinylated and subsequently incubated 
with (strept)avidin-biotin complex with reporter enzyme. 
Another amplification method utilizes tyramide signal amplifica-
tion (TSA). In short, this utilizes tyramide linked biotin or hap-
ten molecules. This is added after incubation with horseradish 
peroxidase (HRP) secondary or tertiary reagent. The HRP con-
verts the tyramide into a reactive species that covalently deposits 
in the immediate area creating additional binding sites and 
amplification of the signal. Additionally, several systems utilize a 
secondary antibody linked to a polymer providing multiple 
attached enzymes or binding sites.
Table 4
(continued)
Antibody Catalog # Clone Vendor
Epitope 
retrieval
Antibody 
dilution
Ab 
incubation 
time (min)/
temp (°C)
Hemoglobin-A AR021-5R Polyclonal Biogenex – Predilute 8/RT
Muramidase A0099 Polyclonal Dako Prot 2 1:100 4/37
Myeloperoxidase 289A-78 Polyclonal Cell Marque – Predilute 8/RT
PAX-5 610,863 24 BD 
Biosciences
CC1 1:20 44/RT
TdT E19234 Polyclonal Spring 
bioscience
CC1 1:20 8/RT
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 6. Automated staining: Automated-staining platforms have greatly 
increased the efficiency and capacity of immunohistochemical 
laboratories. Many can perform all components of the proce-
dure from deparaffinization to cover slipping. There are multi-
ple platforms available and while we discuss one of Ventana’s 
platforms we do no specifically endorse this platform over oth-
ers. A recent review [13] compares the pros and cons of several 
of the available automated immunohistochemical platforms and 
may be helpful in the evaluation of the different systems.
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Chapter 4
Immunophenotyping by Multiparameter Flow Cytometry
Weina Chen and Hung S. Luu
Abstract
Multiparameter flow cytometry has become an indispensable tool for the diagnosis and classification of 
acute myeloid leukemia (AML). The basic method relies on the unique ability to detect immunopheno-
typic abnormalities on discrete subpopulations. The primary roles in the initial assessment of AML are to 
determine the immaturity of the leukemic population, define the lineage and the immunophenotypic 
aberrancies in blasts, and identify characteristic immunophenotypic features to predict important recur-
rent cytogenetic and genetic abnormalities and prognosis. The established immunophenotypic profile, a 
baseline “fingerprint,” is used for follow-up assessment of residual disease. This chapter provides an over-
view of procedures for specimen processing, staining, and immunophenotyping of AML and describes 
our strategy for data analysis supplemented with illustrative case examples.
Key words Immunophenotyping, Flow cytometry, Acute myeloid leukemia, Cytogenetics, Residual 
disease
1 Introduction
Acute myeloid leukemia (AML) is a heterogeneous group of clonal 
hematopoietic stem cell disorders characterized by a proliferation 
of immature myeloid cells (i.e., myeloid blast) showing features of 
granulocytic, monocytic, erythroid, or megakaryocytic differentia-
tion [1]. Flow cytometry (FC) immunophenotypic analysis is a 
rapid method for diagnosis and classification of AML, with results 
potentially available within just a few hours after the specimen is 
received. The principal component in the initial assessment of 
putative acute leukemia is to confirm the immaturity of the popula-
tion of interest, define lineage (myeloid or lymphoid), and charac-
terize immunophenotypic aberrancy distinct from normal myeloid 
progenitors. The established baseline immunophenotypic “finger-
print” is subsequently used for assessment of residual diseases in 
the follow-up samples [2–4].
AML is currently defined by the presence of ≥20% of myeloid 
blasts by morphologic assessment in the bone marrow (BM)  or/
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52
and peripheral blood (PB), except in cases harboring a t(15;17), 
t(8;21), or inv(16), by 2008 World Health Organization (WHO) 
classification [1]. These cases are diagnosed as AML regardless of 
the blast count. FC may be helpful in blast enumeration in PB. 
However, blast enumeration in the BM is hampered due to multi-
ple factors. These include inevitably variable degree of hemodilu-
tion, under-representation of nucleated red cells due to red cell 
lysis, loss of blasts during the specimen processing, potential impre-
cise blast gating strategy, and the instrument detection threshold 
for specimen acquisition. Therefore, morphologic evaluation in PB 
and BM is the gold standard for blast enumeration.
Myeloid blasts in various subtypes of AML may include myelo-
blasts, monoblasts, megakaryoblasts, erythroblasts, and blast 
equivalents including promyelocytes and promonocytes. Analytical 
strategies on these myeloid blasts may vary accordingly. 
Identification of myeloblasts is generally straightforward as the 
blasts typically express immature cell markers (CD34 or/and 
CD117), and frequently fall into the so-called “blast gate” [low 
CD45 and intermediate side scatter (SSC) on CD45 vs. SSC plot]. 
However, analysis on other types of myeloid blasts lacking these 
features can be challenging, in particular those blasts with mono-
cytic differentiation (promonocytes and monoblasts) in acute 
monocytic leukemia or promyelocytes in acute promyelocytic leu-
kemia. Potential pitfalls in interpretation and analytical approaches 
to the various myeloid blasts are presented.
Several composite immunophenotypic attributes can predict 
important recurrent cytogenetic abnormalities and have prognos-
tic significance. For instance, blasts in AML with t(8;21) often 
express CD19, and in some cases CD56 and Tdt [5, 6]. Blast 
equivalents/promyelocytes in acute promyelocytic leukemia with 
t(15;17) frequently lack CD34 and HLA-DR but have high SSC 
[7, 8]. These immunophenotypic features should prompt a timely 
cytogenetic study for confirmation followed by targeted treatment 
in acute promyelocytic leukemia. These two genetically defined 
AMLs have a favorable prognosis.
Furthermore, FC is able to establish the baseline immunophe-
notypic “fingerprint” that can be used for follow-up assessment of 
residual disease including minimal residual disease (MRD). This is 
based on the assumption that the panel at diagnosis is sufficiently 
broad to confidently identify immunophenotypic aberrancies in 
order to discriminate abnormal myeloid blasts from normal 
myeloid progenitors in the background of the complex mixtures of 
cell populations, particularly in BM. While debate exits as to the 
blast percentage cut-off of greatest clinical significance and the 
optimal time for MRD assessment, multiple studies have demon-
strated that MRD detected at the levels between 0.01 and 0.1% of 
white cells at either end of induction or consolidation is prognosti-
cally relevant and is associated with poorer outcome [9–15].
Weina Chen and Hung S. Luu
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The applications of FC in diagnosing AML are constantly 
changing secondary to technological advancement and employ-
ment of higher color (currently up to 10-color) FC. A variety of 
flow cytometers and analytic software are used in different labora-
tories, and therefore, the composition of antibody panels and the 
analytical approach may differ. This chapter provides an approach 
for diagnosing and classifying AML using a 4-color BD 
FACSCalibur flow cytometer with BD CellQuest Pro acquisition 
software, and describes analytical strategy for data interpretation 
using CytoPaint Classic (Leukobyte) or BD Paint-A-Gate 
software.
2 Materials
Reagents are generally used as provided by the manufacturer with 
in-house validation prior to use.
PBS/Azide/BSA (PAB) 10× Stock (1% PAB): Add 50.0 g of 
bovine serum albumin (BSA) to the 4500 mL of clinical laboratory 
reagent water (CLRW). Add 22.75 g of Sodium Azide to the mix-
ture. Add 500 mL of 10× Dulbecco’s Phosphate Buffered Saline 
(DPBS) to the mixture. Stir the mixture for at least 4 h. Adjust the 
pH of solution to 7.3 ± 0.1 using either NaOH or HCL. Filter 
sterilize the solution using the 100 mL filter system sets. Stock 
solution expiration date is 2.5 years at 2–8 °C.
PAB 1× Working solution: Add 1000 mL of 1% (10×) PAB 
solution to 8100 mL of water (CLRW). Add 900 mL of 10× DPBS 
stock solution to the mixture. Mix thoroughly. Working solution 
expiration date is 1 month at 2–8 °C.
Paraformaldehyde (PFA) 1% solution: Aliquot 100 mL of PFA 
(concentration of 10%) into a 1000 mL volumetric flask. Add 900 
mL sterile PBS to a final volume of 1000 mL. Place parafilm over 
the flask and mix thoroughly. Transfer the 1% PFA solution into 
sterile 500 mL glass bottles. Expiration date is 3 month at 2–8 °C.
Heat inactivation of the Hyclone Newborn Calf Serum: Thaw the 
serum 3–4 days before use in the refrigerator (2–8 °C), and mix 
the contents of the bottle thoroughly. Place the bottle of serum 
into a water bath containing sufficient water to immerse the bottle 
above the serum level and set it to 56 °C. Swirl the bottle every 
5 min to ensure uniform heating of the serum. Monitor the 
 temperature of the water bath and begin timing for 30 min when 
the temperature reaches 56 °C. Cool the bottle of serum in an ice 
bath immediately after removing from the 56 °C water bath. Let it 
sit for 20 min and place it in the fridge until use. Add the heat 
inactivated NCS to RPMI by aseptically pipetting 25 mL NCS into 
500 mL bottle of RPMI. Cap the bottle and mix. Expiration date 
is 1 month at 2–8 °C.
2.1 Buffers and Cell 
Staining Reagents
2.1.1 PAB Stock 
and Working Solution 
Preparation
2.2 5% Newborn Calf 
Serum (NCS) 
Preparation
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Ammonium Chloride Concentrate Solution (10×): Measure 500 mL 
of water (CLRW) into a 1000 mL volumetric flask. Add the fol-
lowing reagents into the 1000 mL flask: 80 g of NH4Cl; 10 g of 
KHCO3 (potassium bicarbonate); 3.7 g of EDTA (ethylenediami-
netetraacetic acid). Mix the solution using a magnetic stirrer and 
stir bar until reagents are dissolved. Add 500 mL of water (CLRW) 
for a total volume of 1000 mL. Adjust the pH to 7.2–7.3 using 
either NaOH or HCl. Filter sterilize using 1000 mL filter steriliza-
tion unit (0.22 μm PES filter). This results in a 10× stock that can 
be stored at 4 °C for 6 months.
Ammonium Chloride Working Solution (1×): Dilute the 
Ammonium Chloride Concentrate Solution (10×) 1:10. The fol-
lowing is a suggested volume. Add 50 mL of NH4Cl concentrate 
solution into a 500 mL bottle. Add 450 mL of water (CLRW). 
Prepare fresh working solution daily.
The antibody panels for diagnosing AML require sufficient breadth 
of markers, in a cost-effective manner, to cover a variety of lym-
phoid and myeloid antigens as well as antigens associated with cell 
immaturity. At initial diagnosis, such a panel will confidently iden-
tify abnormal myeloid blasts, rule out mixed phenotype acute leu-
kemia (MPAL), and establish an immunophenotypic profile for 
disease follow-up.
It is imperative to titer antibodies for optimal signal-to-noise 
ratio under the conditions to be used. Antibodies are preferentially 
precocktailed to ensure consistent high-quality performance 
(see Note 1). Table 1 lists our proposal of the 4-color antibody 
combination alongside the various populations assessed in each 
tube. Notably, myeloid blasts are assessed in every tube. In the 
cases where acute erythroid or megakaryoblastic leukemia is sus-
pected by virtue of CD36(+)/CD64(−) on myeloid blasts, a sub-
sequent reflex panel to add the relevant lineage-associated antigens 
(CD41, CD61, CD71, and glycophorin A) is instituted.
3 Methods
The preanalytical phase, involving specimen collection and deliv-
ery, is perhaps the most important phase of the whole process to 
ensure consistently a high-quality assay. PB and BM aspirates are 
anticoagulated with ethylenediaminetetraacetic acid (EDTA) or 
sodium heparin, transported at room temperature, and processed 
in a timely manner (i.e., ideally within 48 h of collection). The 
procedure outlined below is generic and uses up-front bulk lysis 
followed by staining (see Note 2).
It is critical to appropriately set up instrumentation including 
optimization, standardization, and compensation. These topics are 
beyond the scope of this chapter, but are essential to the success of 
2.3 Buffered 
Ammonium Chloride 
(NH4Cl) Solution
2.4 Monoclonal 
Antibody Panels
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FC analysis. Readers are referred to other resources on these topics 
[16, 17]. For routine tests, 500,000 cells are stained with appropri-
ate amounts of antibodies and 30,000–50,000 events are collected 
for analysis. For MRD tests, 1–2 million cells are stained with 
appropriate amounts of antibodies and up to approximately 
500,000 events are collected.
 1. Partially decant anticoagulated PB or BM specimen into a 
sterile 50 mL conical.
 2. If the sample is BM, add an equal amount of NH4Cl and vortex 
to break up the particles. If the sample is PB proceed to the 
next step.
 3. Dilute BM or PB sample with NH4Cl to a final 1:10 dilution.
 4. Place sample on specimen rocker for 10 min at room tempera-
ture (20–25 °C).
 5. Centrifuge for 8 min (290 relative centrifugal force, Brake 
On).
 6. Decant supernatant and vortex to resuspend the pellet.
 7. Add 50 mL of PAB Wash Buffer and mix.
 8. Centrifuge for 8 min (290 relative centrifugal force, Brake On).
 9. Decant supernatant and examine cell pellet for complete lysis.
(If predominance of red cells is observed, vortex to resuspend 
the pellet, add 20 mL NH4Cl, centrifuge for 8 min (290 rela-
tive centrifugal force), return to step 6).
 10. Vortex to resuspend the cells.
 11. Add 40 mL of PAB Wash Buffer and mix.
 12. Centrifuge for 8 min (290 relative centrifugal force, Brake On).
 13. Decant supernatant and vortex to resuspend cell pellet.
 14. Add 1 mL to 50 mL of 5% NCS based on the size of the cell 
pellet. The target concentration is about 1 × 106 cells/mL (see 
Note 3).
 15. Mix the sample well and check for visible particulate matter.
 16. Filter with nylon mesh if necessary.
 17. Perform a cell count using the Coulter AcT diff 2 Analyzer.
(Refrigerated cell suspensions are stable for up to 1 week.)
 1. Place the appropriate amount of cell suspension (500,000 cells 
for routine test) in each 12 × 75 mm tube (1–2 million cells for 
MRD test).
 2. Add 2–3 mL 1XPAB wash buffer.
 3. Centrifuge (1.9 relative centrifugal force) for 1 min and care-
fully decant.
3.1 PB and BM 
Specimen Processing 
for Immunophenotypic 
Analysis
3.2 Surface Marker 
Staining of Cell 
Suspension
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 4. Add the appropriate amount of monoclonal antibodies (e.g., 
40 μL) to each tube.
 5. Gently vortex each tube.
 6. Incubate for 20 min in the refrigerator (2–8 °C) in the dark.
 7. Add 2–3 mL 1XPAB wash buffer.
 8. Centrifuge (1.9 relative centrifugal force) for 1 min and care-
fully decant.
 9. Add 250 μL of 1% PFA to each tube.
 10. Gently vortex each tube.
 11. Run immediately on the Flow Cytometer or cap and refriger-
ate (2–8 °C) and run within 1 h.
 1. Pipette the appropriate amount (μL) of cell suspension in each 
tube.
 2. Add 2–3 mL PAB wash buffer.
 3. Centrifuge (1.9 relative centrifugal force) for 1 min and care-
fully decant.
 4. Add 100 μL of CALTAG Fix & Perm Solution A, and gently 
vortex.
 5. Incubate 15 min in the dark at room temperature (20–25 °C).
 6. Add 2–3 mL PAB wash buffer.
 7. Centrifuge (1.9 relative centrifugal force) for 1 min and care-
fully decant.
 8. Add 100 μL of CALTAG Fix & Perm Solution B.
 9. Add the appropriate amount of monoclonal antibodies/cock-
tail (e.g., 40 μL) to each tube.
 10. Gently vortex each tube.
 11. Incubate all markers, except TdT, for 20 min in the dark at 
room temperature (20–25 °C). TdT requires 30 min.
 12. Add 2–3 mL PAB wash buffer.
 13. Centrifuge (1.9 relative centrifugal force) for 1 min and care-
fully decant.
 14. Add 250 μL of 1% PFA to each tube.
 15. Gently vortex each tube.
 16. Run immediately on the Flow Cytometer or cap and refriger-
ate (2–8 °C) and run within 1 h.
It is essential to interpret FC results in the context of the clinical 
presentation, and the morphologic findings from direct smears, 
touch imprints, and/or cytocentrifuged prepared slides of the sub-
mitted tissue. This is not only for assessment of specimen quality in 
3.3 Intracellular (IC) 
Marker Staining
3.4 Data Analysis 
and Interpretation
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terms of cell viability and cellularity but also for identification of 
population(s) of interest. In some cases (especially certain mono-
cytic leukemias that lack specific immunphenotypic markers of 
immaturity), morphology may be the most important clue that a 
population of cells is indeed immature.
The initial FC assessment should focus on data quality to mini-
mize artifacts by removal of air bubble artifacts, doublets and 
aggregates, and nonviable cells. The first step is to evaluate data 
over time to exclude events corresponding to air aspirated follow-
ing exhaustion of sample (Fig. 1). The second step is to evaluate 
forward scatter area over height (FSC-A and FSC-H) to exclude 
doublets and aggregates. The third step is to evaluate forward scat-
ter area over side scatter area (FSC-A and SSC-A) to exclude very 
low forward scatter events that generally represent cellular debris 
and degenerated cells. An alternative method for removing nonvi-
able cells is the addition of a DNA-binding dye, such as 7-amino- 
actinomycin D (i.e., 7-AAD). Degenerated cells demonstrate 
characteristic light scatter and staining patterns and are excluded 
from further evaluation. However, caution must be exercised to 
ensure that such exclusion of “nonviable cells” does not entirely 
exclude the population of interest, especially in cases with highly 
proliferative neoplasms where cell degeneration is rapid.
The diagnosis of AML by FC involves identifying the myeloid blast 
population that demonstrates immaturity, myeloid lineage 
 differentiation, and immunophenotypic aberrancies [2–4]. The 
critical component is to identify the immature myeloid blasts, 
which may sometimes be a difficult endeavor. While CD34, an 
early stem cell and progenitor marker, remains a very important 
marker of immaturity, many AMLs are CD34(−), especially acute 
3.5 Analysis 
Strategy and 
Identification of Blast 
Population(s)
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Fig. 1 Assessment of data quality and minimization of artifacts. The first step is to evaluate data over time to 
exclude air aspirated following exhaustion of sample. The second step is to evaluate forward scatter area over 
height (FSC-A and FSC-H) to exclude doublets and aggregates. The third step is to evaluate forward scatter 
over side scatter (FSC-A and SSC-A) to exclude very low forward scatter events that typically represent mem-
brane damage from cellular degeneration
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promyelocytic leukemia (APL), acute monocytic leukemia, or 
megakaryocytic leukemia.
One of the commonly employed strategies to define blasts is to 
gate the population in the blast gate [low CD45 and intermediate 
side scatter (SSC) on CD45 vs. SSC plot]. The events in this pre-
selected region are subsequently analyzed for expression of various 
antigens [18, 19]. While myeloid blasts fall into this gated region 
in many cases, the gating strategy is potentially imprecise for mul-
tiple reasons. First, the commonly used blast gate may not be spe-
cific as it variably contains other marrow elements, including 
hypogranular granulocytes, atypical monocytes, hematogones, 
basophils, and plasmacytoid dendritic cells [20]. The presence of 
these contaminating populations, particularly in cases with a low 
blast count, may lead to a misinterpretation of the immunopheno-
typic profile on myeloid blasts and hamper subsequent MRD 
assessment. Second, the commonly used blast gate may not be sen-
sitive in cases where blasts show much dimmer or brighter CD45 
expression or have higher SSC than normal. In these scenarios, the 
blasts would fall outside of the “blast gate”. This is often the case 
in acute monocytic leukemia where neoplastic immature mono-
cytes have brighter expression of CD45. Furthermore, the imma-
ture monocytes frequently show a continuous pattern of 
differentiation into mature monocytes [21], creating difficulty in 
the separation of these two populations (Fig. 2a). Similarly, blasts 
that have higher SSC, such as in acute promyelocytic leukemia 
(APL), may also fall outside of typical blast region. Taken together, 
relying exclusively on traditional blast gating (low CD45 and inter-
mediate SSC) to isolate blasts may inadvertently underestimate or 
overestimate the blast population(s) or lead to inaccurate charac-
terization. Therefore, the CD45/SSC blast gate is used more 
effectively in combination with other myeloid lineage-specific and 
non-lineage-specific markers as well as CD34/CD117 to accu-
rately isolate and define the blasts.
We advocate a multiparameter cluster analysis method that 
involves identifying multiple populations in ungated data. The 
populations are defined based on cluster formation, antigen 
 expression, and the light scatter characteristics, all the available 
information in a given tube. These clusters represent distinct cell 
populations. Arbitrary colors are assigned to individual popula-
tions (“color” the populations). This allows simultaneous visual-
ization of all definable populations and assessment of their 
immunophenotypic profile for all antigens in a given tube. In such 
a system, the populations of interest can be better defined, dis-
criminated, and characterized not only from one another (Fig. 2b) 
but also from normal populations (see example Case 1 at follow-
 up). The latter provides reference levels of antigen expression on 
normal cells, which facilitates the detection of subtle shifts in the 
intensity of antigens in neoplastic myeloid cells. Therefore, the 
Multiparameter Flow Cytometry
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cluster analysis approach is very useful for analyzing complex 
immunophenotypic patterns within complex cellular mixtures par-
ticularity in bone marrow or peripheral blood, and is especially 
suitable for assessment of residual disease at follow-up.
Determination of immaturity on a population of interest is inti-
mately associated with the strategy of isolating myeloid blasts as 
explained in the above section. The following list is the proposed 
markers of immaturity or the patterns suggestive of immaturity 
(see Note 4):
3.6 Determination 
of Immaturity, Myeloid 
Lineage, and 
Immunophenotypic 
Aberrancy
B. Blasts [in red (myeloblasts) and yellow (immature monocytes)] defined by cluster analysis
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Fig. 2 Myeloid blast gating strategy: blast gate versus cluster analysis. In this example case of acute myelo-
monocytic leukemia in bone marrow, myeloid blasts are composed of two subsets, CD34(+) myeloblasts (in 
red) and CD34(−) monoblasts/promonocytes (in yellow). The immature monocytic cells have brighter CD45 
and continuously differentiate into mature monocyte (in blue). (a) The separation of myeloid blast populations 
(in red, including both myeloblasts and immature monocytes) from mature monocytes (in blue) by CD45/SSC 
blast gate is indistinct. Consequently, the characterization of the immunophenotype on the immature cells is 
compromised. (b) In contrast, cluster analysis is able to define CD34(+) myeloblasts (in red), and distinguish 
CD38(strong+)/CD14(−) immature monocytes (in yellow) from CD38(strong+)/CD14(+) mature monocytes (in 
blue). Therefore, the characterization of the immunophenotype on the immature cells is more reliable. 
Granulocytes are painted in green, lymphocytes in light blue
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Markersof immaturity: CD34(+) with or without CD117(+); 
CD117(+)/CD34(−) with high SSC (indicative of promyelo-
cytes in acute promyelocytic leukemia), or with moderate SSC.
Patterns suggestive of immaturity: CD14(− to dim+) in monocytic 
cells, suggestive of immature monocytes (monoblasts/pro-
monocytes); immature monocytes are often CD34(−) and 
variably CD117(−) [21]; Population falling into the blast gate 
(with caution, see above); CD36(+)/CD64(−) in nonery-
throid population and falling into or close to the blast gate 
region (indicative of megakaryocytic or erythroid blasts).
Myeloid lineage-associated antigens include CD11b, CD13, 
CD14, CD15, CD33, CD36, CD41, CD61, CD64, CD65, CD71 
(usually bright), CD117, glycophorin A (CD235a) (see Note 5), 
and myeloperoxidase (MPO). Commonly aberrant non-myeloid 
lineage-associated antigens include non-lineage-specific markers 
(CD38, CD45, CD123, and HLA-DR), and lymphoid lineage- 
associated markers (CD2, CD4, CD5, CD7, CD19, CD56, Tdt) 
(see Note 6).
Characterization of the immunophenotypic aberrancies on 
neoplastic myeloid blasts requires a thorough knowledge of the 
highly regular and reproducible patterns of antigen expression on 
normal myeloid progenitors, maturing myelomonocytic cells, and 
reactive or regenerative myelomonocytic populations, which is 
beyond the scope of this chapter. Briefly, normal myeloblasts 
express immature cell markers (CD34, CD117), pan-myeloid 
markers (CD13 and CD33), non-lineage-specific markers [strong 
CD38, moderate CD45 (similar to the level on granulocytes), and 
HLA-DR], and lack significant expression of later-stage mature 
myeloid markers or lymphoid markers. Immunophenotypic aber-
rancies of leukemic myeloid blasts in AML, similar to other myeloid 
stem cell neoplasms (in myelodysplastic syndrome and myelopro-
liferative neoplasm) [22, 23], typically include:
●● Abnormally increased or decreased expression of antigens nor-
mally on CD34+ myeloblasts (e.g., diminished CD38 and 
CD45; diminished to loss of CD13 or CD33).
●● Abnormally homogeneous expression of antigens that nor-
mally show coordinate variation in expression in CD34+ 
myeloblasts [e.g., abnormally homogeneous expression of 
CD38 on myeloid blasts; significant expression of MPO in 
myeloblasts].
●● Asynchronous antigen expression (e.g., expression of later 
stage of myeloid markers, CD11b, CD15, or CD64, on leuke-
mic myeloid blasts).
●● Aberrant expression of non-myeloid lineage antigens [aberrant 
expression of T-cell antigens (e.g., CD2, CD7, or CD56) or 
B-cell antigen (e.g., CD19) on leukemic myeloid blasts].
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Notably, the majority of normal myeloblasts lack expression of 
CD15 but gain expression during the later stage of maturation as 
they differentiate into promyelocytes (the subset of CD33(bright+)/
CD15(+) myeloblasts in the circle, Fig. 3). In our experience, only 
a small proportion of normal myeloblasts, approximately 20%, 
expresses MPO by FC [24]. Therefore, a significant expression of 
MPO on myeloid blasts is indicative of aberrancy.
Furthermore, background granulocytes and monocytes often 
demonstrate variable degrees of immunophenotypic abnormalities 
in AML. These include decreased SSC on granulocytes (suggestive 
of hypogranulation), altered granulocyte maturation (distorted 
pattern of antigen expression on the plots of CD13/CD16, 
CD11b/CD64, and CD11b/CD16, or lack of CD10), and 
expression of CD56 on granulocytes and monocytes.
Analytical strategies on myeloid blasts and blast equivalents may 
vary depending on the lineage differentiation, granulocytic, mono-
cytic, erythroid, or megakaryocytic differentiation. The following 
cases highlight the key points in data interpretation.
Case 1: AML with t(8;21) at Diagnosis and day 29 Follow-Up
This is a typical straightforward case of AML at diagnosis (Fig. 4a). 
Leukemic myeloblasts (in red) express CD34, CD117, fall into the 
characteristic blast gate on CD45/SSC, and express myeloid mark-
ers (CD13 and CD33), B-lymphoid marker (CD19) and CD56. 
Notably, the expression of CD19 with or without CD56 is charac-
teristically associated with t(8;21). Recognizing this association of 
aberrant CD19 in t(8;21) AML is important to avoid misclassifica-
tion as mixed phenotype acute leukemia.
3.7 Case Examples 
to Illustrate 
the Analytical Strategy
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Fig. 3 The pattern of CD15 and MPO expression on normal CD34(+) myeloblasts 
in bone marrow. A small proportion of normal myeloblasts (in red) expressing 
CD15 coupled with a bright expression of CD33 (bridging into promyelocytes, in 
the circle), and MPO. Lymphocytes are painted in light blue
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The aberrant immunophenotypic signature, CD19(+), CD33 
(dim+), CD34 (bright+), CD45(dim+), and CD56(+) and in some 
cases aberrant expression of other B-lineage markers CD79a and 
CD22, is very helpful in assessment of MRD at day 29 (Fig. 4b). 
Close examination reveals two populations of CD34(+) myeloblasts, 
one expanded subset of normal myeloblasts (in yellow) following 
granulocyte-colony stimulating growth factor treatment, and the 
other, a much smaller subset of residual neoplastic myeloblasts (in 
red) that demonstrate an aberrant immunophenotype essentially 
identical to that at diagnosis. This case illustrates that cluster analysis 
is capable of dissecting complex cellular subsets and detecting 
subtle immunophenotypic shifts using the normal myeloblasts as 
an internal control population.
Fig. 4 AML with t(8;21) at diagnosis and day 29 follow-up. (a) At diagnosis, leukemic myeloblasts (in red) in 
bone marrow express CD34, CD117, CD13, CD15(partial+), CD33, CD19, CD56, and fall into the characteristic 
blast gate on CD45/SSC. The notable immunophenotypic aberrancies are CD19(+), CD33(dim+), CD34(bright+), 
CD45(dim+), and CD56(+). (b) At day 29 follow-up in bone marrow sample, there are two populations of 
CD34(+) myeloblasts, one expanded subset of normal myeloblasts (in yellow) and the other a much smaller 
subset of residual neoplastic myeloblasts (1.4% of total events) that demonstrate an aberrant immunopheno-
type essentially identical to that at diagnosis. Granulocytes are painted in green, monocytes in dark blue, 
lymphocytes in light blue
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It is important to be aware that the leukemic blasts may 
undergo immunophenotypic shifts following treatment [25, 26]. 
Consequently, MRD detection should examine abnormal myeloid 
blasts, not only showing an identical immunophenotype to that 
described at diagnosis but also showing immunophenotypic devia-
tion from that of normal myeloid progenitors.
Case 2: Acute Promyelocytic Leukemia with t(15;17)
This case illustrates a characteristic immunophenotypic feature in 
leukemic promyelocytes in acute promyelocytic leukemia with 
t(15;17): high SSC, CD34(−), CD15(dim+), CD33(homogeneously 
and bright +), CD117(partial +), and HLA-DR(−) (Fig. 5) (see 
Note 7). Due to a high SSC that is likely related to cytoplasmic 
complexity including hypergranularity, blasts frequently fall out-
side of the typical blast gate. The diagnosis can be potentially chal-
lenging if CD117 expression is dim or negative. There needs to be 
a high level of vigilance for this entity in cases in which there is a 
large population of granulocytes lacking maturation. Expression of 
CD34 and CD2 (not in this case) is typically present in the micro-
granular variant. While these immunophenotypic attributes are 
Fig. 5 Acute promyelocytic leukemia (APL) with t(15;17). An example case of APL in bone marrow demon-
strates a characteristic immunophenotype in leukemic promyelocytes (in red): high SSC, CD15(dim+), 
CD33(homogeneously and bright +), CD34(−), CD117(partial +), and HLA-DR(−). Lack of CD11b(−) and 
CD16(−) indicates a maturation arrest. Granulocytes are painted in green, monocytes in dark blue, lympho-
cytes in light blue
Weina Chen and Hung S. Luu
paolo.fortina@jefferson.edu
65
highly suggestive of acute promyelocytic leukemia, a timely cyto-
genetic/fluorescence in situ hybridization (FISH) or molecular 
study confirmation is crucial in reaching a final diagnosis, such that 
a targeted treatment with all-trans retinoic acid (ATRA) and che-
motherapy can be initiated promptly. The consequence of delay in 
diagnosis is potentially fatal due to disseminated intravascular 
coagulopathy.
Case 3: AML with cup-like Nuclei (Lack of CD34 and HLA-DR)
AML with cup-like nuclei (the so-called fishmouth nuclei) fre-
quently has characteristic immunophenotypic features, as illus-
trated in this case (Fig. 6). The immunophenotype in these 
leukemic myeloblasts is somewhat similar to that of acute promy-
elocytic leukemia (e.g., lack of CD34 and HLA-DR). However, in 
contrast to acute promyelocytic leukemia, SSC is not increased, 
such that the blasts typically fall into the blast gate. In addition, 
these blasts tend to express CD56, which is not common in the 
conventional type of acute promyelocytic leukemia. One caveat is 
that microgranular variants occasionally show CD56 expression. If 
there is any doubt regarding the differential diagnosis of acute pro-
myelocytic leukemia versus AML with cup-like nuclei, a prompt 
Fig. 6 AML with cup-like nuclei (lack of CD34 and HLA-DR). An example case of AML with cup-like nuclei in 
peripheral blood demonstrates a characteristic immunophenotype in myeloblasts (in red): low SSC, CD15(−), 
CD33(+), CD34(−), CD117(+), and HLA-DR(−). Low SSC and CD56(+) can be helpful in distinguishing this 
entity from acute promyelocytic leukemia. Granulocytes are painted in green, lymphocytes in light blue
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evaluation for t(15;17) is required. This AML entity has unique 
genetic features, characterized by a normal karyotype and high 
incidence of FLT3, NPM1, and IDHmutations [27–29].
Case 4: Acute Myelomonocytic Leukemia
Analysis of acute myeloid leukemia with monocytic differentiation 
is generally much more challenging than typical AML, as discussed 
in the above section, due to frequent lack of specific immature 
monocytic markers and immature monocytes continuously differ-
entiating into mature monocytes, making it difficult to separate 
immature from mature monocytic cells. Nevertheless, there are 
clues to the presence of an expanded population of immature 
monocytic cells, as illustrated in this example case (Fig. 7). The 
myeloid blasts in this case are composed of two subsets: one is 
CD34(+) myeloblasts (in red), and the other is immature mono-
cytic cells (monoblasts/promonocytes, the subset of cells painted 
in blue). Immature monocytic cells often maintain the expression 
of CD15 (sometimes bright), CD33 (bright), CD36 and CD64, 
to the levels close to normal mature monocytes, but downregulate 
to completely lose CD14 [21, 30]. It is readily apparent that the 
monocytic cell population defined by the coexpression of CD15/
CD33 and CD36/CD64 is much larger than that defined by the 
Fig. 7 Acute myelomonocytic leukemia. An example case of acute myelomonocytic leukemia in bone marrow 
demonstrates a characteristic immunophenotype: the myeloid blasts composed of two subsets, one CD34(+) 
myeloblasts (in red), and the other immature monocytic cells (monoblasts/promonocytes, a subset of cells 
painted in blue). Immature monocytes maintain the expression of CD15, CD33 (bright), CD36, and CD64, to the 
levels close to normal mature monocytes, but downregulate to completely lose CD14. CD15 expression is 
increased, and CD11b and CD13 expression are decreased in the immature monocytic cells. Granulocytes are 
painted in green, lymphocytes in light blue
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expression of CD14. This discrepancy indicates the presence of an 
expanded population of CD14(−) immature monocytic cells (cells 
in circle in Fig. 7), which is confirmed through morphologic exam-
ination of the specimen.
Case 5: Acute Monoblastic Leukemia with t(9;11) (Loss of CD14)
This case illustrates one of the common features in acute mono-
blastic leukemia, significant downregulation to completely loss of 
CD14, but retention of CD15(bright), CD33, CD36, and CD64. 
This combined immunophenotype is suggestive of the presence of 
a large population of CD14(−) immature monocytic cells (Fig. 8). 
Similar to the previous case in Fig. 7, loss of CD14 and bright 
CD15 are the immunophenotypic clues to the monocytic 
immaturity.
Case 6: Acute Monoblastic Leukemia with t(8;16) (Retention of 
CD14)
This is an unusual case of acute monoblastic leukemia with t(8;16) 
in which CD14 is largely retained in immature monocytic cells 
(Fig. 9). This retention of CD14 could be a potential pitfall lead-
ing to overlooking the leukemia if this population is relatively 
small. Interestingly, CD15, similar to the previous case, is brightly 
expressed, and CD11b is underexpressed, which are potential clues 
to identifying immaturity in monocytic cells. Careful morphologic 
Fig. 8 Acute monoblastic leukemia with t(9;11) (loss of CD14). An example case of acute monoblastic leukemia 
with t(9;11) in peripheral blood demonstrates a characteristic immunophenotype, similar to previous case: 
significant downregulation to completely loss of CD14, but retention of CD15(bright), CD33, CD36, and CD64 in 
leukemic cells. Loss of CD14 and bright CD15 are the clue to the immaturity of monocytic cells. Granulocytes 
are painted in green, mature normal monocytes in dark blue, lymphocytes in light blue
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correlation and awareness of this phenomenon are essential to 
 confirm immaturity of the leukemic cells and reach the correct 
diagnosis.
Case 7: Acute Megakaryoblastic Leukemia
In this example case of adult acute megakaryoblastic leukemia with 
complex karyotypic abnormalities, myeloid blasts are composed of 
CD34(+)/CD117(+) myeloblasts (in red) and CD34(dim+)/
CD117(−) megakaryoblasts (in blue) (Fig. 10). The clue to mega-
karyocytic or erythroid differentiation is the expression of CD36 in 
the absence of CD64 in blasts that fall into the broad CD45 (dim+) 
blast region [31, 32]. A reflex study further confirms the mega-
karyocytic lineage differentiation by virtue of a typical immuno-
phenotypic profile: CD41(+), CD61(+), CD71(partial +), and 
glycophorin A(−) (see Note 8).
Case 8: Acute Pure Erythroid Leukemia
In this example case of pure erythroid leukemia, there is a pre-
dominant population of erythroblasts (>80%) with a high and 
widely variable SSC (likely related to cytoplasmic vacuolization) 
(Fig. 11). The clue to megakaryocytic or erythroid leukemia is the 
expression of CD36 in the absence of CD64 in blasts that fall into 
the CD45(−) blast region. A reflex study further confirms the ery-
throid lineage differentiation by virtue of a typical immunopheno-
typic profile: CD41(−), CD61(−), CD71(strong +), and 
Fig. 9 Acute monoblastic leukemia with t(8;16) (retention of CD14). This is an unusual case of acute monoblas-
tic leukemia with t(8;16) in peripheral blood in which CD14 is largely retained in immature monocytic cells. 
Bright CD15 expression and underexpression of CD11b may be the clue to the immaturity of monocytic cells. 
Granulocytes are painted in green, lymphocytes in light blue
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Fig. 10 Acute megakaryoblastic leukemia. An example case of acute megakaryoblastic leukemia in bone mar-
row demonstrates a characteristic immunophenotype: myeloid blasts composed of CD34(+)/CD117(+) myelo-
blasts (in red) and CD34(dim+)/CD117(−) megakaryoblasts (in blue). Megakaryoblasts are CD36(+), CD41(+), 
CD61(+), CD64(−), CD71(partial +), and glycophorin A (−). Granulocytes are painted in green, lymphocytes in 
light blue, erythroids in yellow
Fig. 11 Acute pure erythroid leukemia. An example case of pure erythroid leukemia in bone marrow demon-
strates a characteristic immunophenotype. Erythroblasts are CD36(+), CD41(−), CD61(−), CD64(−), 
CD71(strong+), and glycophorin A(+). Other markers are widely variable SSC, CD13(−), CD15(−), CD33(−), 
CD34(−), CD117(+), and HLA-DR(−). Granulocytes are painted in green, normal monocytes in dark blue, lym-
phocytes in light blue, normal erythroids in yellow
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glycophorin A (+) (see Note 9). The immunophenotype obtained 
in the reflex study is thus opposite to that in the previous case of 
megakaryocytic leukemia.
4 Notes
1.  Antibody titration and cocktail preparation: Prior to preparing a 
cocktail of antibodies, it is imperative to titer antibodies indi-
vidually for optimal signal-to-noise ratio using the final total vol-
ume of the cocktail. For example, adding sufficient PAB to give 
a total delivered reagent volume of 20–40 μL for routine 4-color 
antibody tests. For surface and intracellular antigen titration, the 
objective is to identify an amount of antibody that will provide 
the maximal intensity at the lowest background (i.e., optimal 
signal to noise ratio). Special caution should be exercised in 
titration of intracellular antigen. It may not be possible to dem-
onstrate apparent saturation, as there is a high level of nonspe-
cific binding to cytoplasmic antigens (due to complexity of the 
intracellular environment and potential abundant binding sites). 
The prepared cocktails should be tested on representative PB 
and BM cases to ensure expected antibody reactivity, to detect 
any unexpected interactions, and to determine cocktail 
stability.
2.  Specimen processing (up-front bulk lysis versus stain-lyse- wash): 
Up-front bulk lysis is better suited for samples with low nucle-
ated cell counts (such as cerebrospinal fluid (CSF) and scanty 
tissue biopsy specimens or fine-needle aspiration (FNA) sam-
ples). The additional advantage of this method is to allow for 
using a single processing protocol that is virtually suitable for all 
types of panels including surface light chain staining in lym-
phoma work- up. Moreover, this method preserves cell suspen-
sion for up to 1 week, facilitating additional staining if needed 
for an accurate diagnosis. The antibodies are fixed to the cells by 
1% paraformaldehyde after staining to stabilize antigen–anti-
body interactions and to preserve the light scatter properties. 
The drawback of the up-front lysis is the potential to lyse some 
leukocytes. Notably, many laboratories use an alternative proto-
col, staining first followed by lysis. In this so-called stain-lyse-
wash (SLW) protocol, antibodies are incubated with the cells in 
the presence of erythrocytes. The erythrocytes are lysed (using 
lysing solution with low level of fixative), and bound antibodies 
are fixed to the cells to preserve the light scatter properties. 
These two methods, up-front bulk lysis and stain-lyse-wash, are 
largely comparable.
3.  Volume of 5% NCS: Because the cell suspension’s final cell count 
is determined, the amount of 5% NCS added is not critical.
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4.  Pitfalls in interpretation of the immature cell markers: There are 
a few pitfalls in interpretation of the proposed immature cell 
markers. First, CD117 expression in isolation is not specific for 
immaturity. CD117 is normally expressed on proerythroblasts, 
promyelocytes, and mast cells (with a bright pattern) [22]. 
Second, rare acute monoblastic leukemia, especially cases with 
t(8;16), may not downregulate CD14 (as illustrated in example 
Case 6) [33]. In this scenario, the presence of a large population 
of neoplastic cells by FC and morphologic findings of blasts may 
be the most important clue to the presence of a leukemic popu-
lation. Lastly, dim to negative CD14 expression in monocytic 
cells may be a hint to the presence of unsuspected paroxysmal 
nocturnal hemoglobinuria (PNH). If clinically appropriate, this 
should trigger a specific PNH analysis by FC in PB sample for a 
confirmation.
5.  Caution in interpretation of Glycophorin A: Glycophorin A is 
expressed at a high level on erythrocytes. Therefore, it is critical 
that staining of this antigen should be performed after red cell 
lysis to avoid false positive result.
6.  CD7 expression in myeloblasts: CD7 may be expressed on normal 
myeloblasts at very early stage of maturation. In our experience, it 
tends to express on a small subset of CD13(dim+) myeloblasts.
7.  Caution in interpretation of antigen expression in acute promyelo-
cytic leukemia: Leukemic blasts in this entity tend to have a high 
level of nonspecific fluorescence resulted from nonspecific bind-
ing of antibody and autofluorescence, which is likely related to 
cytoplasmic complexity. Therefore, it is essential to carefully 
compare the level of antigen expression in leukemia cells to the 
level of fluorescence on the same leukemic population from an 
isotype control or internal negative control in order to avoid 
erroneous interpretation of antigen expression.
8.  Caution in interpretation of CD36, CD41, and CD61: Caution 
should be exercised in the interpretation of CD36, CD41, and 
CD61 in myeloid blasts due to adherence of platelets to the 
blasts. To limit this false positivity, CD36, CD41, and CD61 in 
blasts are only considered positive if the granulocytes lack posi-
tive staining. Alternatively, CD42b can assist in determining 
whether the staining is due to platelet satellitism, as CD42b is 
expressed by platelets but is absent from megakaryoblasts.
9.  Caution in assessment of erythroid leukemia: Erythroid leukemia 
blasts with less evidence of maturation may lack glycophorin 
A. Moderate CD71 expression is non-lineage specific, but bright 
CD71 expression is considered a marker for erythroid differen-
tiation [31]. The clue to erythroid leukemia is expression of 
CD36 (in the absence of CD64) and CD71 (bright) in the blast 
population.
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Chapter 5
Single-Cell Mass Cytometry of Acute Myeloid Leukemia 
and Leukemia Stem/Progenitor Cells
Zhihong Zeng, Marina Konopleva, and Michael Andreeff
Abstract
Mass cytometry time-of-flight (CyTOF) empowers us to understand acute myeloid leukemia (AML) biol-
ogy at the single-cell level. This technology, combined with advanced data-analysis methods, enables iden-
tification and characterization of the rare AML stem/progenitor cells that play key roles in drug resistance 
and AML relapse. Here we provide a protocol for AML sample preparation for CyTOF and keynotes 
emphasizing critical steps in and troubleshooting strategies for this procedure.
Key words Acute myeloid leukemia, Mass cytometry time-of-flight
1 Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease 
characterized by the uncontrolled growth of undifferentiated 
myeloid cells that originate in the bone marrow (BM) [1]. The 
prognosis for AML is poor owing to a high relapse rate and 
short overall survival, with some notable exceptions [2]. AML 
progenitor/stem cells, often called leukemic stem cells (LSCs), 
constitute a rare population of AML cells that reside in the BM 
and are responsible for AML relapse [3]. These cells can initiate 
AML development in immunodeficient NSG and NSGS mice 
(leukemia-initiating cells) [4]. The presence of more mature 
leukemic cells that can result in relapse of AML indicates that 
leukemia-initiating cells are not restricted to the most imma-
ture populations of leukemic progenitor/stem cells [5]. 
Recently, preleukemia stem cells were identified in healthy 
individuals with some acquired mutations but apparently were 
not sufficiently abundant to generate leukemia [6]. Phenotypes 
of these individuals are unknown.
LSCs and hematopoietic stem cells have several features in 
common, including low cell frequency, heterogeneity, asymmet-
rical division, and engraftment potential. However, LSCs do not 
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follow the normal differentiation pattern of hematopoiesis. 
Rather, they remain immature, appear as a subpopulation of AML 
blasts, and generate daughter LSCs [7]. Current chemotherapeu-
tic regimens are highly effective in eliminating AML blasts but 
usually not LSCs [8]. Therefore, LSCs play critical roles in leuke-
mogenesis, therapy resistance, and AML persistence. Improved 
characterization of these cells is essential for development of 
LSC-targeted therapy and higher cure rates for AML.
Over the past few decades, fluorescence flow cytometry has 
been used to characterize the phenotypes and functions of AML 
and LSCs. However, spectral overlap of fluorescent dyes limits 
the use of this technique to about 17 simultaneous measurements 
[9, 10]. Given the phenotypic complexity of AML introduced by 
the discovery of additional surface and intracellular molecules, 
the increased appreciation of AML’s phenotypic diversity, and the 
development of intracellular markers that characterize signaling 
pathways and metabolic states, fluorescence methods can no lon-
ger meet the need for a high level of multiparametric analysis of 
AML’s heterogeneity.
Mass cytometry by time-of-flight (CyTOF) is an innovative 
technology that merges single-cell flow cytometry with mass 
spectrometry [11, 12]. In this technique, transition elements are 
substituted for fluorophores to label antibodies, allowing for 
detection and measurement of up to 130 parameters in a single 
cell with minimal signal overlap. Furthermore, CyTOF uses rare 
earth elements that are not found in biological systems, thus 
minimizing the background noise from cellular signals that often 
makes analysis of fluorescence problematic. Whereas the current 
generation of CyTOF instruments (e.g., CyTOF2 and Helios; 
Fluidigm, San Francisco, CA, USA) can determine 135 simulta-
neous markers to define a cell in a single experiment, the avail-
able metal tags restrict the capacity to analyze 54 parameters.
Several computational analytic tools, including SPADE [13] 
and viSNE [14], have been developed to organize and display the 
high-dimensional data generated by CyTOF. Using unsupervised 
algorithms, these tools capture multidimensional cellular relation-
ships and compress them into two dimensions without losing 
single- cell identities. CyTOF complemented by these data-analysis 
tools provides a unique opportunity to comprehensively character-
ize AML at the single-cell level. Moreover, these computational 
tools allow for the identification of AML phenotypic and intracel-
lular alterations either transient or permanent after various treat-
ments. Most importantly, these tools empower the characterization 
of single LSCs that survive therapy, determination of the factors 
that contribute to the development of AML resistance mecha-
nisms, and, perhaps, identification of new therapeutic approaches 
to eliminating resistant AML [15–17].
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We herein present a protocol for AML sample preparation for 
CyTOF acquisition. We also provide an example of CyTOF data 
analysis using SPADE and viSNE and denote critical steps and 
potential sources of variability in CyTOF sample preparation.
2 Materials
 1. Phosphate-buffered saline (PBS).
 2. Bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO, 
USA).
 3. Fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA).
 4. MeOH (Thermo Fisher Scientific, Waltham, MA, USA).
 5. Cell-ID cisplatin (Fluidigm) or cisplatin (Sigma-Aldrich).
 6. Cell-ID Intercalator-Ir (Fluidigm).
 7. Cell-ID 127 IdU (Fluidigm; optional).
 8. Beads: EQ Four Element Calibration Beads (EQ Beads; cata-
log #201078) or CyTOF Calibration Beads (Eu Beads; catalog 
#201073) (Fluidigm).
 1. Wash buffer: 0.5% BSA in PBS.
 2. Staining buffer: 1% BSA in PBS.
 3. Quenching buffer: 10% FBS in PBS.
 4. Fixation buffer: 1.6% paraformaldehyde (PFA) in PBS (16% 
PFA catalog #15710 [Electron Microscopy Sciences, Hatfield, 
PA, USA])
 5. Permeabilization buffer: 70–80% MeOH (−20 °C; prepared 
from 100% methanol).
 6. Cisplatin staining solution:
●● 5 μM Cell-ID cisplatin (Fluidigm) in PBS;
Or
●● 25 μM cisplatin (Sigma-Aldrich) in PBS (freshly prepared 
from 10 mM working solution in PBS (10× dilution of 
100 mM stock solution in DMSO [Sigma-Aldrich] in 
PBS).
 7. IdU staining solution: 25 μM IdU in PBS (optional).
 8. Last wash solution: 0.1% BSA in Milli-Q water.
 9. Heparin stock solution: 2 mg of heparin sodium powder (Alfa 
Aesar, Haverhill, MA, USA) in 1 mL of PBS sterilized with a 
0.22 μM filter (Thermo Fisher Scientific) and stored at 4 °C.
 10. DNase I stock solution: 1 mg/mL DNase I (Roche Applied 
Sciences, Penzberg, Germany) in PBS sterilized with a 0.22 μM 
filter and stored at −20 °C.
2.1 Reagents 
and Materials
2.2 Buffers, 
Solutions, and Medium
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 11. MgSO4 stock solution: 200 mM MgSO4 (Sigma-Aldrich) in 
PBS sterilized with a 0.22 μM filter and stored at −20 °C.
 12. 20% FBS RPMI medium.
3 Methods
Separately prepare antibody cocktails for surface and intracellular 
antibodies in staining buffer. We recommend preparing the anti-
body cocktail such that the final volume for each test is 50 μL. The 
antibody cocktail can be stored for up to 24 h before staining cells. 
An example of the antibody cocktail used for the experiment dis-
played in Fig. 1 is provided in Table 1.
Freshly prepare the intercalation solution for each sample by add-
ing Cell-ID.
Intercalator-Ir to a fixation buffer for a final concentration of 
125 nM (1000× dilution of the 125 μM stock solution) and mix 
via vortexing.
Freshly prepare 10 mL of a cell-reviving solution by adding 500 μL 
of heparin stock solution, 15 μL of DNase I stock solution, and 
500 μL of MgSO4 stock solution to 20% FBS RPMI medium. The 
cell-reviving solution is used for reviving cryopreserved cells.
 1. Take a cryovial containing cells from liquid nitrogen.
 2. Place the cryovial in a 37 °C water bath.
 3. Thaw the cells in the cryovial completely.
 4. Add the cells to 10 mL of 20% FBS RPMI medium.
 5. Spin the mixture at 300 × g for 5 min.
 6. Resuspend the pellet in a cell-reviving solution; incubate for 
15–30 min in a 37 °C incubator.
 7. Filter the cells through a cell strainer to remove aggregates and 
debris.
 8. Count the viable cells and centrifuge at 300 × g for 5 min.
 9. Resuspend the pellet for further experiments.
 1. Stimulate/inhibit/treat either fresh or revived frozen cells 
according to an experimental protocol (1.0 × 106 to 
1.5 × 106 cells per sample).
 2. Wash cells with wash buffer twice and centrifuge cells at 
300 × g for 5 min.
 3. Resuspend the pellet, add 5 μM cisplatin staining solution 
(Fluidigm) (1 × 107 cell/mL) dropwise to the cells, and incubate 
3.1 Solution 
Preparation
3.1.1 Antibody Cocktails
3.1.2 Intercalation 
Solution
3.1.3 Cell-Reviving 
Solution
3.2 Reviving 
Cryopreserved Cells
3.3 CyTOF Sample 
Preparation
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Fig. 1 SPADE- and viSNE-based identification of two treatment-resistant subsets of AML samples. (a) SPADE 
tree displaying the resistant subsets (R1 and R1) and their levels of expression of CD34. (b) viSNE plot displaying 
the locations and geometric shapes of R1 and R2 in the bone marrow (BM) AML samples before (right top) and 
after (right bottom) treatment. (c) Cell frequency of resistant subsets R1 and R2 in the BM samples before and 
after treatment. (d and e) Bar graph (D) and heatmap (E) displaying the expression of surface and intracellular 
markers of R1 and R2 in treated AML cells
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them for 5 min at room temperature. Alternatively, add 25 μM 
cisplatin staining solution (Sigma-Aldrich) (2 × 106 cells/mL) 
dropwise to the cells and incubate them for 1 min at room 
temperature.
 4. Add 2 mL of quenching buffer to stop the cisplatin reaction 
and centrifuge cells at 300 × g for 5 min.
 5. Wash cells with 2 mL of wash buffer and centrifuge them at 
300 × g for 5 min.
 6. Incubate cells with 1 mL of IdU staining solution for 15 min 
at 37 °C (optional).
Table 1
CyTOF antibody panel
Surface marker panel Intracellular marker panel
Antibody Metal tag Antibody Metal tag
CD7 La139 p-4EBP1 Sm147
CD49d Pr141 p-SYK Sm149
ALDH1A1 Nd142 p-STAT5 Nd150
CD11b Nd144 p-STAT3 Sm152
HLA-E Nd145 p-AKT Tb159
CD8a Nd146 p-mTOR Dy164
CD34 Nd148 p-ERK Er167
CD123_beads1 Eu151 p-S6 Yb172
CD133_beads2 Eu153
CD45 Sm154
TIM-3 Gd156
CD33 Gd158
CD69 Dy162
CD99 Ho165
CD44 Er166
CD38 Er168
CD143 Tm169
CD47 Er170
CD66 Yb171
CLL-1 Yb174
CXCR4 Lu175
CD56 Yb176
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 7. Add 1.5 mL of wash buffer to the cells and centrifuge them at 
300 × g for 5 min.
 8. Wash cells with 2 mL of a wash buffer twice and centrifuge 
them at 300 × g for 5 min.
 9. Surface staining: the surface antibody cocktail in the staining 
buffer added should be made at a 4× to 5× stock concentration 
(so that 12.5 or 10.0 μL of the antibody cocktail can be added). 
Cells should be stained in a total volume of 50 μL (exactly). 
The volume of residual liquid and cell pellet should be deter-
mined with a pipette and enough staining buffer added to 
make the total volume of the solution 50 μL minus the anti-
body cocktail volume. Thus, adding the staining buffer will 
bring the total volume to 50 μL and ensure that the antibody 
concentration is equivalent in all samples. Incubate cells for 
30 min at room temperature.
 10. Add 2 mL of wash buffer to the cells and centrifuge them at 
300 × g for 5 min.; repeat twice.
 11. Add 0.5 mL of fixation buffer to cells and fix cells for 10 min 
at room temperature (in the dark); add 1.5 mL of wash buffer 
to cells and centrifuge them at 1000 × g for 10 min.
 12. Wash cells with 2 mL of wash buffer and centrifuge them at 
1000 × g for 10 min; repeat once.
 13. Add 1 mL of permeabilization buffer (−20 °C) dropwise to 
cells, vortex the mixture to resuspend the cells, permeabilize 
cells for 10 min on ice, and store them at −20 °C overnight.
 14. Add 1.5 mL of wash buffer to cells and centrifuge them at 
1000 × g for 10 min.
 15. Wash cells with 2 mL of wash buffer and centrifuge them at 
1000 × g for 10 min; repeat once.
 16. Intracellular staining: the intracellular antibody cocktail in 
staining buffer added should be made at a 4× to 5× stock con-
centration (so that 12.5 or 10.0 μL of the antibody cocktail 
can be added). Cells should be stained in a total volume of 
50 μL (exactly). The volume of residual liquid and cell pellet 
should be determined with a pipette and enough staining buf-
fer added to make the total volume of the solution 50 μL 
minus the antibody cocktail volume. Thus, adding the staining 
buffer will bring the total volume to 50 μL and ensure that the 
antibody concentration is equivalent in all samples. Incubate 
the cells for 1 h at room temperature.
 17. Add 2 mL of wash buffer to cells and centrifuge them at 
1000 × g for 10 min; repeat twice.
 18. Add 0.5 mL of fixation buffer to cells and fix cells for 10 min 
at room temperature (in the dark). Then add 1.5 mL of wash 
buffer to cells and centrifuge them at 1000 × g for 10 min.
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 19. Wash cells with 2 mL of wash buffer and centrifuge cells at 
1000 × g for 10 min; repeat once.
 20. Add 0.5 mL of intercalation solution to cells and incubate the 
mixture for 20 min at room temperature (in the dark).
 21. Add 1.5 mL of wash buffer to cells and centrifuge them at 
1000 × g for 10 min.
 22. Wash cells with 2 mL of wash buffer and centrifuge them at 
1000 × g for 10 min; repeat once.
 23. Resuspend cells in 1 mL of the last wash solution, filter the 
cells through a cell strainer into a new tube, and count the cells 
(see Subheading 4.1.5 below).
 24. Centrifuge cells at 1000 × g for 10 min.
 25. Save the pellet for use in a CyTOF machine.
 26. Before CyTOF, resuspend the pellet in deionized water at 
concentration of 0.5 × 106 cells/50 μL, and add 50 μL 
beads (final concentration ~30,000 beads/mL) (see 
Subheading 4.1.5 below).
We provide here an example of CyTOF data analysis that we used 
to identify treatment-resistant subsets in primary AML samples.
CyTOF data were normalized using a MATLAB-based soft-
ware program called bead normalization [18]. Normalized data 
were analyzed using FlowJo software (version 10) to generate 
clean data by eliminating beads, cisplatin-positive events, back-
ground noise, and doubles. The clean data were then exported to 
SPADE to build a tree of 100 nodes using surface markers clus-
tered by the k-mean clustering algorithm and branched by the 
minimal spanning tree algorithm. The subsets of AML identified 
using SPADE were confirmed using viSNE. Results of the analysis 
are displayed in Fig. 1.
4 Notes
Signal overlap from metal tags into other channels generates back-
ground signals in CyTOF. However, signal overlap in mass cytometry 
is much smaller than that in fluorescence flow cytometry. Potential 
sources for generation of background signals are oxides in mass+16 
channels, metal isotope impurities, and sample and/or reagent con-
tamination. Most of these can be minimized or prevented.
 1. The isotopes lanthanum, cerium, praseodymium, and neo-
dymium, which have strong oxides, produce a background sig-
nals in mass+16 channels. This background noise cannot be 
prevented but can be reduced by optimizing the plasma tem-
perature, which is part of the CyTOF instrument-tuning 
procedure.
3.4 CyTOF Data 
Analysis
4.1 Critical Steps 
and Troubleshooting 
Strategies
4.1.1 Background Signal
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 2. Isotope impurities cause signal overlap in the mass+1 and 
mass-1 channels, and some signal overlap may not be strictly in 
mass proximity. This is often seen with the isotopes neodym-
ium- 144, neodymium-145, and neodymium-146 and lantha-
num- 139. The purity of each isotope is determined at the time 
of its production. This signal overlap can be reduced or pre-
vented by using markers of mutually exclusive lineages such as 
T-cell markers followed by B-cell markers or dumping the 
channels that contain the most contaminated isotopes.
 3. Environmental contamination causes CyTOF background 
noise in mass channels.
(a) Reagents: PFA, MeOH, and argon gas impurities cause 
background noise with the isotopes of samarium.
(b) Primary samples generate background noise with isotopes 
of iodine and platinum.
(c) Dish soap, detergents, and syringes may generate back-
ground noise with isotopes of barium and lead.
Background noise can be detected in iridium (Ir)-only samples 
(unstained samples: cells not stained with any antibodies) and 
need to be gated out before further analysis. Reagent contami-
nation can be avoided by using different product lots.
Staining of fresh live cells that are 95% viable is always ideal for 
CyTOF assays. Frozen cells should be revived using a cell-reviving 
solution (described above) to prevent cell aggregation and death. 
In experiments in which frozen cells need to be stimulated or 
inhibited, revived cells should be counted to determine cell viabil-
ity and number before performing experiments.
The concentrations of fixation and permeabilization reagents vary in 
CyTOF assays and depend on the surface and intracellular molecules 
detected in the cells. Certain cell-surface epitopes can be damaged 
by high concentrations of fixation and permeabilization solutions. 
On the other hand, certain intracellular molecules, such as the STAT 
protein family, need to be permeabilized twice or at high concentra-
tions for better detection. Therefore, it is necessary to titrate the 
concentrations of fixation and permeabilization  solutions once the 
panel of antibodies is selected. Optimized concentrations are effec-
tive for intracellular molecular staining with minimal damage of cell-
surface epitopes. Alternatively, replacement of methanol with a 
gentle detergent such as saponin or Triton X-100 as the permeabili-
zation solution may be considered to preserve surface epitopes.
The number of cells lost after the fixation/permeabilization and wash 
steps in CyTOF sample preparation can be reduced by adding BSA to 
1× PBS wash buffer at concentrations ranging from 0.1 to 2.0% 
4.1.2 Cell Quality
4.1.3 Fixation/
Permeabilization 
of Reagent Concentrations
4.1.4 Loss of Cells 
during CyTOF Sample 
Preparation
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(w/v), increasing the centrifuge speed to 1000 × g and centrifuge 
time or reducing wash steps.
To minimize buildup of salt residue in the CyTOF instrument, the 
final wash in CyTOF sample preparation should be performed 
with the last wash solution (0.1% BSA in Milli-Q water [Subheading 
3.3, step 23]) and filtered through a cell strainer to remove aggre-
gates, and the cells should be counted before centrifugation at 
1000 × g for 10 min. The cell pellet then should be resuspended 
in deionized water at a concentration of 0.5 × 106/50 μL (See 
Subheading 3.3 step 26).
The purpose of adding beads in all cell samples in CyTOF is 
normalization of signal strength decay when acquisition of mul-
tiple samples in an experiment. Fluidigm produces two types of 
beads: (1) EQ Four Element Calibration Beads (EQ Beads; cata-
log #201078), which contain a natural abundance of cerium 
(140/142), europium-151/153 (151Eu/153Eu), holmium-165, 
and lutetium-175/176, and (2) CyTOF Calibration Beads (Eu 
Beads; catalog #201073), which have a natural abundance of 
151Eu/153Eu. EQ Beads contain multiple elements, including 
cerium, an element that is not available in CyTOF antibody 
panel design. This ensures that such beads are readily discrimi-
nated from the cells in samples. In using Eu beads, all samples 
must be labeled with iridium (Ir), which enables discrimination 
of Ir-Eu+ beads from Ir+Eu- cells in samples.
Currently, two methods using different algorithms can be employed 
to normalize data for signal decay in CyTOF assays. First, the 
Fluidigm method requires CyTOF software version 6.0.626 and 
above. This method normalizes data according to a global stan-
dard that is determined by each lot of manufactured EQ Beads. 
Second, the MATLAB-based method, developed by Finck and col-
leagues [18], requires a software program available from a Stanford 
University website (http://www.cytobank.org/nolanlab). In this 
method, data is normalized to the median bead intensity deter-
mined by the experimental data file. This method requires collec-
tion of the Ir channel even if the sample is not stained with Ir.
The use of a blocking antibody is optional in CyTOF sample stain-
ing, but one should be included if cells have high levels expression of 
Fc receptors, which will contribute to nonspecific antibody binding. 
This can be prevented by adding 100 μL of Fc block to each sample 
of cells before surface marker staining (Fc block diluted in a staining 
buffer; final concentration between 0.5 μg and 1 μg/106 cells), incu-
bating the mixture on ice for 20 min, centrifuging at 300 × g for 
5 min at 4 °C, and discarding the supernatant.
4.1.5 Filtering Samples 
in the Last Step of CyTOF 
Sample Preparation
4.1.6 Signal Decay 
and Adding Beads 
in Samples
4.1.7 Bead- 
Normalization Methods
4.1.8 Blocking Antibody
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When using customer-conjugated antibodies in a CyTOF assay, 
the optimal staining concentration for each antibody should be 
determined in a titration experiment with an appropriate posi-
tive and negative control (e.g., cells with and without the 
expression of the antibody-target epitopes). If conjugation is 
performed using Maxpar labeling kits (Fluidigm), the testing 
concentrations should range from 250 to 8000 ng/mL. Also, 
the five steps of a threefold serial dilution of the antibody con-
centration are recommended.
Biological knowledge is often used to set the cutoffs for posi-
tive and negative expressions of surface and intracellular mole-
cules in CyTOF sample analysis. However, some stained samples 
have higher background noise on all channels (even samples of 
cells biologically negative for expression of certain molecules) 
than do unstained samples. In such cases, an unstained sample 
(control) is not ideal for setting the background. A metal-
minus-one (MMO) or metal-minus-multiple (MMM) 
channel(s) is a better control for setting up the cutoff for the 
background. Another strategy for identifying expression of a 
molecule in CyTOF sample analysis is to identify a stained cell 
population (within the sample or another sample being tested) 
that is biologically known to be negative for expression of the 
relevant molecule and set the cutoff so that the sample is clearly 
negative and then count anything above the cutoff as being 
positive for expression of the molecule. In addition, the mass+1 
and mass+16 spillover from very bright channels results in 
false-positive populations. This can be corrected by using dim-
mer antibodies in these channels.
Recently, Nolan’s group [19, 20] and later Fluidigm developed 
palladium-based cell barcoding methods for CyTOF assays. 
Barcoded samples can be combined and then stained and exam-
ined as one multiplexed sample to prevent sample-specific staining 
and data-collection variation. Both methods include debarcoding 
software programs that facilitate sample deconvolution and debar-
coding for downstream analysis of the individual component 
 samples. Also, Fluidigm produces a barcoding kit for CyTOF 
assays (Cell-ID 20-Plex Pd Barcoding Kit [catalog #201060]).
In addition to SPADE and viSNE, Wanderlust [21] and 
PhenoGraph [17] are advanced analytical programs for high- 
dimensional CyTOF data analysis. Also, Cytobank (http://www.
cytobank.org) is a web-based analytical tool for flow and mass 
cytometry data analysis. The premium and enterprise versions of 
Cytobank feature SPADE and viSNE and other software.
4.1.9 Titrating Antibodies
4.1.10 Determination 
of the Cutoff to Define 
Positive and Negative 
Expressions of Surface or 
Intracellular Molecules
4.2 A Newly 
Developed Barcoding 
Method for CyTOF 
Assay and the CyTOF 
Analytic Program
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Live cells cannot be recovered for sorting and further experimenta-
tion in CyTOF. Additionally, CyTOF requires the presence of puri-
fied metal isotopes to detect cells. Therefore, a metal-chelating DNA 
intercalator must be used to ensure detection of all cells. Also, 
CyTOF has low transmission efficiency (25%). A large starting num-
ber of cells are often required to detect rare cell populations. CyTOF 
also has a slow maximum cell-acquisition rate (~1000 cells/s). 
Therefore, each sample takes longer to run using CyTOF than it 
would to run a comparable flow cytometry experiment.
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Chapter 6
Design and Application of Multiplex PCR Seq 
for the Detection of Somatic Mutations Associated 
with Myeloid Malignancies
Naomi Park and George Vassiliou
Abstract
Targeted sequencing, in which only a selected set of genomic loci are sequenced, enables a much higher 
coverage of each target than what is obtained using whole genome or exome sequencing. Multiplex PCR 
offers a simple and affordable technique for specific capture of target regions and can be easily adapted to 
generate next-generation sequencing (NGS)-ready amplicons. Here we describe a multiplex PCR 
(MxPCR) approach for capturing 13 leukemia-associated mutation hotspots followed by MiSeq sequenc-
ing that enables robust detection of mutations with a variant allele fraction (VAF) as low as 0.8% (0.008) 
in blood DNA.
Key words Clonal hemopoiesis, Leukemia, Multiplex PCR, Targeted sequencing
1 Introduction
There is an ever-increasing range of commercial options available 
for the targeted capture of genomic regions for analysis by NGS, 
particularly for whole exome and for disease panels [1]. Although 
highly suited and cost-effective for genome-scale applications, 
these approaches are prohibitively expensive and slow for re- 
sequencing of small numbers of hotspot locations as are required 
for molecular diagnostic applications. Additionally, genome-scale 
approaches deliver lower sequence coverage depths of hotspot 
regions leading to reduced power for the detection of low sub- 
clonal variants. By contrast, MxPCR is capable of simultaneously 
capturing multiple target regions in a single reaction whilst also 
incorporating adaptor sequences to generate NGS-ready ampli-
cons [2] without the need for expensive equipment and with the 
ability to tackle large numbers of samples rapidly and at low cost.
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88
In this chapter, we describe a multiplex PCR protocol for the 
amplification and sequencing of regions known to be recurrently 
mutated in myeloid malignancies, but the same approach can be 
applied to any set of target loci. Amplicons included in the two- 
step PCR protocol described below were designed to capture a 
narrow size range (190–250 bp) to complement the sequencing 
length of the MiSeq instrument (Illumina San Diego, CA). The 
protocol has been validated using the KAPA HiFi HotStart high- 
fidelity polymerase selected for its capability of amplifying inserts of 
a wide range of GC compositions [3], but other polymerases with 
similar characteristics can be tried instead. The first PCR reaction 
involves a limited number of PCR cycles during which genomic 
primer annealing takes place during a stepwise reduction in tem-
perature. This enables the gene-specific primers, containing com-
mon forward and reverse 5′-tail sequences, to simultaneously 
anneal every PCR cycle, whilst limited cycle number minimises 
amplification bias between the different amplicons [2]. The second 
PCR step involves no additional reagents or cleanup after the first 
PCR, aside from the addition of a single primer pair that anneals to 
and extends from the common tails introduced by the first-round 
PCR primers. During the 19 cycles of second-round PCR, unique 
sample barcodes are incorporated into the amplicon sequence to 
enable up to 384-level multiplexing of the sequencing run [4]. A 
schematic overview of multiplex PCR seq is presented in Fig. 1. 
The multiplex PCR described in this chapter was designed using 
the Hiplex and mprimer primer design tools [2, 5]. The first ver-
sion of the multiplex was designed using Hiplex, but due to 
mprimer’s more sophisticated design algorithms, additional 
hotspot primers were designed using mprimer and the final multi-
plex evaluated with MFEprimer. MFEprimer is a program for 
checking the specificity of PCR primers against the background 
DNA [6]. All further in-house MxPCR designs utilised mprimer 
and MFEprimer alone. Primers were synthesised to include a single 
2′-O-Methyl base substitution, one base from the 3′-end to reduce 
primer dimer formation. Primer dimers forming in the first round 
of PCR are particularly problematic if not adequately removed 
prior to Illumina sequencing, due to the preferential clustering of 
short fragments containing the sequencing motifs. Here we pres-
ent the methodology for interrogating 13 leukemia-associated 
mutation hotspots using multiplex PCR, an approach that was 
used to detect clonal haemopoiesis in people aged 17–98 years old 
[7]. Hematological malignancies develop through the serial acqui-
sition of somatic mutations in a process that can take many years or 
even decades [8–10]. Also, it is clear that the presence of hemopoi-
etic cells carrying leukemia-associated mutations is only followed 
by the onset of hematological malignancies in a minority of cases 
[11–15]. In order to understand the incidence and clonal dynam-
ics of pre-leukemic clonal hemopoiesis, we applied the described 
methodology to ultra-deep sequencing of each hotspot [7].
1.1 Protocol Outline
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2 Materials
The use of a high-fidelity polymerase capable of amplification of 
a range of GC contents is important in order to generate ade-
quate coverage of all target hotspots at a representative allele frac-
tion. In order to avoid false variant calls due to PCR product 
contamination of starting material, it is vital to have dedicated 
laboratory areas for each processing step, ideally as physically sep-
arate locations with their own dedicated equipment for DNA 
sample preparation, pre-PCR and post-PCR handling steps. All 
reagents and laboratory equipment associated with each step 
should be dedicated to a single area and not transferred between 
areas, other than in the workflow direction (i.e. sample prep to 
pre-PCR to post-PCR).
 1. Oligonucleotides: Oligonucleotides used in the MxPCR are 
listed in Table 1. Note that many manufacturers only offer the 
2′-O-Methyl modification for synthesis scales of 100 nmole or 
greater (see Note 1). No further purification above standard 
desalting is necessary. Centrifuge and resuspend freeze-dried oli-
gonucleotides to 500 μM in T0.1E buffer (10 mM Tris, 0.1 mM 
EDTA, pH 8.0) or similar. When not in use, primers should be 
stored at −20 °C. Before use, primers should be defrosted, pulse 
centrifuged and gently vortexed.
2.1 Oligonucleotides
a) Multiple primers simultaneously amplify gDNA sites flanking hotspot regions in a 6-cycle PCR. Each forward and 
reverse primer has a common non-priming tail sequence.  
b) A pair of PCR primers complementary to the common tailed sequence further amplify the multiplexed targets (19 cycles 
PCR) whilst incorporating sample barcodes and sequencing motifs. (Red = Illumina P5 sequence, yellow = Illumina P7 
sequence and purple = barcode sequence.  
Barcode
c) Uniquely barcoded multiplexed amplicon library ready for sequencing
Fig. 1 Multiplex PCR sequencing-ready library workflow
Design and Application of Multiplex PCR Seq for the Detection of Somatic Mutations…
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 2. Oligonucleotide pool: Pipette volumes of each primer according 
to Table 1 into a 1.5 mL Eppendorf to generate a pool con-
taining an effective concentration of 14.48 μM of each primer. 
Briefly vortex and pulse centrifuge. Combine 10 μL of this 
pool with 351.9 μL EB (10 mM Tris–Cl, pH 8.5) for a work-
ing concentration of 0.4 μM of each primer. Store at −20 °C 
in aliquots to reduce the event of multiple freeze-thaw cycles.
 1. Oligonucleotide pool (see Subheading 2.1).
 2. T0.1E buffer (10 mM Tris, 0.1 mM EDTA, pH 8.0).
 3. Elution buffer (10 mM Tris–Cl, pH 8.5) (Qiagen).
 4. gDNA normalised to 10 μL at 20 ng/μL (see Note 2).
 5. 96-well skirted PCR plate, 0.2 mL polypropylene or 0.2 mL 
PCR tubes.
 6. KAPA HiFi HotStart ReadyMix 2X (Kapa Biosystems).
 7. Nuclease-free water.
 8. Reagent reservoir.
 9. Adhesive PCR Plate Seals (such as Thermo Fisher AB-0558).
 10. Vortexer.
 11. Plate centrifuge: Ideally with a refrigeration capability.
 12. PCR thermocycler with heated lid capability.
 13. Second round PCR primers and PE1.0: Dispense 1 μL (at 10 
μM) of each into a PCR plate. Make multiple copies of single 
use plates, seal and store at −20 °C. (see Note 3 and ref. 16).
 14. Multichannel pipette (8 or 12 channels).
 1. Agencourt AMPure XP (Beckman Coulter, Inc).
 2. Dynal magnetic rack suitable for 1.5 mL Eppendorf tubes.
 3. 80% Ethanol: Combine 80 mL of absolute ethanol with 20 mL 
of water (see Note 4).
 4. Elution buffer (10 mM Tris–Cl, pH 8.5) (Qiagen).
 5. Agilent 2100 Bioanalyzer System (see Note 5).
 6. Agilent DNA 1000 Kit.
 7. Agilent High Sensitivity DNA Kit.
 8. qPCR Instrument such as StepOne™ Real-Time PCR Systems 
(Applied Biosystems).
 9. Kapa Library Quantification Kit for Illumina platforms.
 10. Multichannel pipette (8 or 12 channels).
 1. MiSeq Reagent Kit v2 (500 cycle).
 2. Freshly diluted 0.2 N NaOH.
2.2 PCR Components
2.3 PCR Product QC 
and Cleanup
2.4 Illumina Miseq 
Sequencing
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 3. Long-reach pipette tip 100/200 μL
 4. iPCRtag sequencing primer (PAGE purified):
AAGAGCGGTTCAGCAGGAATGCCGAGACCGATCTC
3 Methods
Defrost all components at room temperature and place on ice prior 
to use.
 1. Dispense 10 μL of gDNA (20 ng/μL) to 96-well PCR 
plate(s).
 2. Prepare a PCR master mix sufficient for the number of samples 
(N) plus a 10% excess. Combine:
1.1 × N × 12.5 μL KAPA HiFi HotStart ReadyMix.
1.1 × N × 0.5 μL AML pool (0.4 μM).
Vortex, pulse centrifuge and transfer to a reagent reservoir. 
Keep on ice until ready for use. With a multichannel P20 
pipette, dispense 13 μL of master mix to each PCR plate well 
containing DNA. Apply an adhesive plate seal, taking care to 
apply sufficient pressure to seal all wells. Gently vortex and 
centrifuge at 1200 g for 1 min. If possible, set the centrifuge to 
4 °C for step 4.
 3. Transfer to a thermocycler and run the following program (with 
heated lid set to a constant 100 °C): 95 °C for 3 min, (98 °C for 
20 s, 65 °C for 60 s, 60 °C for 60 s, 55 °C for 60 s, 50 °C for 
60 s, 70 °C for 60 s) × 6 cycles. Hold at 4 °C.
 4. Centrifuge at 1200 g for 1 min (ideally at 4 °C) and place on 
ice. Defrost and spin down a prealiquoted plate containing 
indexing primers and PE1.0 primers as prepared in Subheading 
2.2, step 11. Place on ice.
 5. Carefully remove seals from both plates, taking extra care not 
to splash any liquid—temporarily remove plates from the ice to 
facilitate the ease of this. Using a multichannel pipette and 
fresh tips for each sample, transfer the entire volume of PCR 
products, one row at a time, to the plate containing the second 
round primers. Keep both plates on ice throughout the trans-
fer step (see Note 6).
 6. Seal with a plate seal, taking care to apply sufficient pressure to 
ensure every well is sealed. Centrifuge at 1200 g for 1 min 
(ideally at 4 °C).
 7. On ice, transfer the plate to a dedicated post-PCR thermocy-
cler and run the following program (with heated lid set to a 
constant 100 °C): (98 °C for 20 s, 62 °C for 15 s, 72 °C for 30 
s) × 19 cycles and 72 °C 60 s. Hold at 4 °C.
3.1 PCR
Naomi Park and George Vassiliou
paolo.fortina@jefferson.edu
95
 1. Assess the PCR products by directly running a 12 sample subset 
on an Agilent Bioanalyzer using an Agilent DNA 1000 Kit 
(Fig. 2) (see Note 7).
 2. Using a P10 multichannel pipette and fresh tips for each sam-
ple, take a 5 μL aliquot of each row, dispensing into a reagent 
reservoir in-between rows. Up to 384 samples may be pooled, 
each having a different barcode incorporated during the sec-
ond PCR. With a single-channel P200 pipette set to 200 μL, 
thoroughly mix the pooled samples by aspirating and dispens-
ing across the reservoir. Transfer pooled sample to a fresh 1.5 
mL Eppendorf.
 3. Alternatively, if only a few samples require pooling, combine in 
a 1.5 mL Eppendorf with a single-channel pipette.
 4. Using a P100, accurately transfer 100 μL of pooled PCR sam-
ple into a labelled fresh 1.5 mL Eppendorf. If there is less than 
100 μL of pooled amplicon, make up to volume with EB. Add 
exactly 55 μL of room temperature SPRI beads, briefly vortex 
to mix and pulse centrifuge to collect all liquid at the bottom 
of the tube without disturbing the bead suspension.
 5. Incubate at room temperature for 5 min before transferring to 
a magnetic rack. Wait until supernatant is clear and all beads are 
collected at the side of the magnet before collecting ~155 μL 
3.2 PCR Product QC, 
Pooling and Cleanup
Fig. 2 A typical profile obtained of an AML MxPCR runs directly (without any Ampure SPRI purification) on an 
Agilent Bioanalyzer DNA1000 chip. Peaks <170 bp are due to unincorporated primers and primer dimers, 
peaks 300–400 bp are from on target products and a larger peak at ~950 bp is due to amplification across 
two adjacent products
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supernatant and transferring to a labelled fresh 1.5 mL 
Eppendorf tube. (see Note 8).
 6. Using a P20, add a further 20 μL of room temperature SPRI 
beads to the supernatant from step 4, vortex and pulse 
centrifuge.
 7. Incubate at room temperature for 5 min before transferring to 
a magnetic rack. Once the supernatant is clear and all beads are 
captured on the side of the magnet, remove and discard the 
supernatant (see Note 9).
 8. Wash by adding 700 μL of 80% ethanol, being careful not to 
disturb the beads captured on the magnet. After 30 s, remove 
and discard the ethanol. Repeat for a total of two washes.
 9. Pulse centrifuge to draw residual ethanol to the bottom of the 
tube and remove with a P10 pipette. Air dry at room tempera-
ture for approximately 2 min, until beads have a “wet paint” 
appearance (see Note 10).
 10. With a P20 pipette, re-suspend beads in 20 μl of EB and incu-
bate off the magnet for 5 min to release the target product into 
solution.
 11. Transfer to the magnetic rack. Once the supernatant is clear and 
beads are captured on the magnet, transfer supernatant con-
taining the purified pool to a labelled fresh Eppendorf tube.
 12. Make a 1 in 10 dilution of 1 μL of the purified pool for analysis 
with an Agilent Bioanalyzer High Sensitivity DNA Kit (Fig. 3) 
(see Note 11).
 13. For accurate quantification, required to enable optimal cluster 
density during MiSeq sequencing, use a KAPA SYBR FAST 
qPCR complete kit or similar compatible with your qPCR 
instrument. Dilute library to 4 nM with EB, ready for Miseq 
sequencing.
 1. Prepare 8 pM denatured libraries for loading onto the 500- 
cycle MiSeq cartridge according to “Preparing Libraries for 
Sequencing on the MiSeq®” (Illumina Part number 15039740).
 2. Sequence as a 250, 11, 250 paired-end single-index read 
according to “MiSeq® System Guide” (Document number 
15027617 v01) using default chemistry, with the following 
exception: Pierce the foil seal at port 13 and, using a P100 with a 
long-reach pipette tip, remove 100 μL. Transfer to a clean 1.5 mL 
Eppendorf tube and spike in 3.5 μL of iPCRtag (100 μM). Briefly 
pipette mix and transfer the entire contents back into port 13. The 
addition of the custom index sequencing primer into the default 
index sequencing primer cartridge location enables the stan-
dard “default” chemistry option to be selected on the MiSeq 
3.3 Illumina Miseq 
Sequencing
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sample sheet. Only the complementary custom index primer 
will successfully anneal and extend during the index read.
A number of different approaches can be used for data analysis, 
depending on the required sensitivity for variant allele detection. 
The method described here was used by McKerrell et al. [7] to 
reliably detect variant alleles with VAFs as low as 0.8% (0.008): 
Sequencing data are aligned to the human reference genome 
(hg19) using BWA. Subsequently, the SAMTOOLS pileup com-
mand is used to generate pileup files from the generated bam files 
(version 0.1.8; http://samtools.sourceforge.net [17]). The flexi-
ble in-house Perl script MIDAS generated by our group [18] was 
modified in order to interrogate only the hotspot nucleotide posi-
tions of interest on the pileup file, considering only those reads 
with a sequence quality higher than 25 and a mapping quality 
higher than 15. For each sample, the numbers of reads reporting 
the reference and variant alleles at each position were extracted. 
VAFs were derived by dividing the number of reads reporting the 
most frequent variant nucleotide to the total. In order to detect 
NPM1 mutations with high sensitivity, the bespoke tool described 
by McKerrell et al. can be used [7].
3.4 Data Analysis
Fig. 3 A typical profile obtained of an Ampure SPRI size selected AML MxPCR, run on an Agilent Bioanalyzer 
High Sensitivity DNA chip. Note remaining peak at ~160 bp, a result of primer dimers between first-round 
genomic PCR primers. Due to their size, these will preferentially cluster during sequencing and result in data 
loss. Aim to remove all peak of this size by repeating a X0.75 SPRI until not visible by bioanalyzer analysis. A 
remaining peak at ~950 bp is not of concern
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4 Notes
 1. A single 2′-O-Methyl group placed one base upstream of the 
3′-end minimises primer dimers caused by 3′-hetero comple-
mentarity between primers.
 2. Using input DNA of the same concentration, quantity and 
quality will likely generate similar library yields across the plate. 
This enables equivolume pooling of final libraries prior to size 
selection and purification, reducing manual handling steps and 
resulting in more even sequencing coverage for each sample. 
Less DNA may be used without problem, i.e. 100 ng; how-
ever, lower amounts may result in reduced sensitivity of cap-
ture for rare allele frequencies.
 3. Dispensing second-round primers into stocks of single-use 
plates before the commencement of any PCR eliminates the 
possibility of contaminating stocks with amplicons from the 
first PCR step. It also simplifies combining first-round prod-
ucts with second-round primers, reducing the potential for 
mispipetting and sample to sample mix-ups.
 4. 80% ethanol is hygroscopic. When opened, overtime the etha-
nol will both evaporate and absorb water. Despite the % etha-
nol decreasing, the solution remains usable for at least 2 weeks, 
as 70% ethanol is also suitable for washing DNA-bound SPRI 
beads. Note that because of miscibility of ethanol with water, 
measuring 80 mL ethanol and 20 mL water separately, and 
then combining them will generate ~95 mL of 80% ethanol. 
Do not top up to 100 mL.
 5. Alternative methods for evaluating the size range of amplicons 
may be used, such as agarose gel electrophoresis.
 6. KAPA HiFi HotStart DNA Polymerase was activated in the 
first PCR and therefore should be kept on ice to inhibit any 
undesirable polymerase and exonuclease activity prior to the 
second round PCR.
 7. Peaks between ~300 and 400 bp represent the desired (on- 
target) Illumina sequencing-ready amplicons. A larger peak 
at ~921 bp is the amplification across two adjacent products 
and does not require absolute removal prior to sequencing. 
Peaks around ~150 bp are a result of primer dimers formed 
in the first PCR cycles and must be removed prior to sequenc-
ing. These shorter products will preferentially cluster during 
MiSeq sequencing and may result in reduced sequencing 
quality and yield.
 8. During the X0.55 Ampure SPRI incubation, a large propor-
tion of products >500 bp will precipitate onto the magnetic 
beads, leaving smaller fragments in solution. By retaining the 
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supernatant for the addition of further Ampure SPRI beads, an 
upper size selection is performed in this step.
 9. Adding an additional 20 μL of beads to the supernatant (~155 
μL) from the previous step is equivalent to a X0.75 Ampure 
SPRI. Small primer dimers and unincorporated primers <170 
bp will remain in the supernatant whilst desired amplicons pre-
cipitate onto the beads.
 10. Excessive drying of beads at room temperature or on a heat 
block will make the DNA difficult to resuspend into elution 
buffer which may result in a reduced yield.
 11. For optimal sequencing results, repeat X0.75 Ampure SPRI if 
a peak remains at ~160 bp.
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Chapter 7
AMLprofiler: A Diagnostic and Prognostic Microarray 
for Acute Myeloid Leukemia
Marco Alessandrini, Sharon S. Kappala, and Michael S. Pepper
Abstract
Acute myeloid leukemia is characterized by the proliferation and accumulation of immature hematopoietic 
cells of the myeloid lineage in the bone marrow. The disease is typified by diverse genetic abnormalities and 
marked heterogeneity both with regard to response to treatment and survival. The AMLprofiler is a quali-
tative in vitro diagnostic microarray developed by SkylineDx for use with Affymetrix technology. The 
AMLprofiler makes use of RNA chemistry and incorporates seven separate assays based on three different 
technologies—cytogenetics, mutation, and expression analysis—to predict post-therapy survival rates in 
patients with acute myeloid leukemia. The assay has been validated for processing of bone marrow samples 
from which RNA is isolated within 48 h. The samples are subsequently processed using Affymetrix 
GeneChip reagent kits and analyzed on the Affymetrix GeneChip 3000Dx v2 system. The scanned 
AMLprofiler data is sent to a centralized server of SkylineDx via a secured Internet connection, and a 
diagnostic report is generated within 15 min. We have performed several AMLprofiler assays in our labora-
tory and found the data generated via this assay to be consistent with standard modalities.
Key words Acute myeloid leukemia, AMLprofiler, SkylineDx, Microarray
1 Introduction
In the United States of America alone, over 20,000 diagnoses and 
10,000 deaths occur due to acute myeloid leukemia (AML) annu-
ally [1]. The disease is characterized by the proliferation and accu-
mulation in the bone marrow of immature hematopoietic cells of 
myeloid lineage. AML is further typified by diverse genetic abnor-
malities and marked heterogeneity both with regard to response to 
treatment and survival.
Laboratory diagnosis of AML requires a multidisciplinary and 
often time-consuming approach, which encompasses a range of 
tests based on cell morphology, immunophenotyping, and specific 
genetic markers. The AMLprofiler is a microarray-based assay that 
utilizes RNA chemistry to detect specific chromosomal aberra-
tions, mutations, and gene expression patterns relevant to the 
diagnosis and prognosis of AML. More specifically, the AMLprofiler 
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replaces seven separate assays that are routinely used for the detection 
of favorable prognostic markers, including t(16;16)/inv.(16), 
t(8;21), t(15;17), CEBPA double mutations, NPM1 type A/B/D 
mutations, “low BAALC” expression, and expression of the “very 
poor” prognostic marker, EVI1.
The AMLprofiler assay is performed on the Affymetrix 
GeneChip 3000Dx v.2 system and is hence designed for in vitro 
diagnostic use. Following scanning of the AMLprofiler chip, data 
generated in the laboratory setting is automatically sent via a 
secured Internet connection to the centralized server of SkylineDx, 
and the diagnostic report is generated in under 15 min, thus mak-
ing it a valuable and efficient tool for diagnostic purposes. The 
AMLprofiler workflow and methodology [2], as described in this 
chapter, are outlined broadly in Fig. 1.
2 Materials
 1. Affymetrix GeneChip 3000Dx v2 Instrument system, which 
includes an Affymetrix FS450Dx v2 Fluidics Station, Affymetrix 
GeneChip 3000Dx v2 Scanner, Affymetrix GeneChip 
Hybridization Oven 645, and an Affymetrix GeneChip 
3000Dx v2 workstation with AMDS operating software.
2.1 Equipment
Wash, stain and scan of AMLprofiler Data analysis and reporting
Da
y 
3
Bone marrow collection
and isolation of
mononuclear cells
RNA purification cDNA synthesis
In vitro transcription
(overnight)
Da
y 
1
Store at -80°C
RNA
quality assessment
Hybridization of AMLprofiler
(overnight) cRNA fragmentation
cRNA purification and
quantification
Da
y 
2
Store at -80°CStore at -80°C
cRNA
quality assessment
Fragmented cRNA
quality assessment
Fig. 1 Overview of methodology used for AMLprofiler analysis. Visual representation of the day-to-day 
processing of AMLprofiler microarrays. Adapted from [2]
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 2. Thermocycler (e.g., GeneAmp PCR System 9700, Thermo 
Fisher Scientific, USA).
 3. Thermoblock (e.g., AccuBlock Digital Dry Bath, Labnet 
International, USA).
 4. Vacuum concentrator (e.g., Savant SpeedVac, Thermo Fisher 
Scientific, USA).
 5. Micro-centrifuge (for 0.2, 0.5, 0.6, and 1.5 mL tubes), capa-
ble of reaching 15,000 × g (e.g., Sorvall Legend Microcentrifuge, 
Thermo Fisher Scientific, USA).
 6. Brayer or soft rubber microplate sealer (e.g., Mylar Plate Sealer, 
Thermo Fisher Scientific, USA).
 7. Centrifuge with rotors/swing buckets for 15 mL tubes and 
96-well plates (e.g., Heraeus Multifuge, Thermo Fisher 
Scientific, USA).
 8. Vortex (e.g., Vortex Genie 2, Scientific Industries, USA).
 9. Compression pad for thermocycling with 96-well PCR plates 
(e.g., Axygen, USA).
 10. Benchtop cooler (−20 °C) (Thermo Fisher Scientific, USA).
 11. Plastic rack for 96-well PCR plates.
 12. Pipettes for volumes between 1 μL and 1000 μL.
 13. Magnetic stand for 96-well plates.
 14. Electrophoresis system for RNA/cRNA quality control (e.g., 
TapeStation 2200, Agilent Technologies, USA).
 15. Spectrophotometric system for RNA/cRNA quality control 
(e.g., NanoDrop, Thermo Fisher Scientific, USA).
 1. Histopaque-1077 (Sigma-Aldrich, USA).
 2. RNA isolation kit (AllPrep DNA/RNA Mini Kit, Qiagen, 
Germany).
 3. Affymetrix GeneChip reagent kits (see Table 1).
 1. 96-well PCR plates (compatible for use with the sealing film 
and compression pad).
 2. Aluminum adhesive foil for PCR or cold storage (in case PCR 
plates are used).
 3. 96-well U-bottom plate compatible with the magnetic stand.
 4. 0.2 mL, 0.5 mL, or 0.6 mL thin-walled PCR tubes.
 5. Powder-free gloves.
 6. Nuclease-free 1.5 mL nonstick tubes, without lid.
 7. Nuclease-free 15 mL nonstick tubes.
 8. Pipette tips with aerosol-resistant filters, RNase-free.
2.2 Reagents
2.3 Consumables
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Table 1 
Affymetrix reagent kits required for AMLprofiler analysis
Affymetrix kit Components
GeneChip® 3′ IVT PLUS Reagent Kit  
(P/N 902416)
3′ IVT PLUS Amplification Kit—Module 1
  1. 3′ first-strand enzyme
  2. 3′ first-strand buffer
  3. 3′ second-strand enzyme
  4. 3′ second-strand buffer
  5. 3′ IVT enzyme
  6. 3′ IVT buffer
  7. 3′ IVT biotin label
  8. Nuclease-free water
3′ IVT PLUS Amplification Kit—Module 2
  9. Purification beads
  10. 3′ fragmentation buffer
GeneChip® Hybridization Control Kit
  11. 20× hybridization controls
  12. 3 nM control Oligo B2
GeneChip® Hybridization, Wash, and Stain  
Kit (P/N 900720 Kit)
Hybridization module
  13. Pre- hybridization mix
  14. 2× hybridization mix
  15. DMSO
  16. Nuclease-free water
Stain module
  17. Stain cocktail 1
  18. Stain cocktail 2
  19. Array holding buffer
Wash buffers
  20. Wash buffer A
  21. Wash buffer B
 9. Crushed ice.
 10. Tough-spots (3/8 in.).
 11. RNase-free micro-centrifuge tubes (sterile, amber, 1.5 mL).
 12. RNase-free micro-centrifuge tubes (sterile, 1.5 mL).
 1. Deionized water.
 2. Certified nuclease-free water.
 3. 100% ethanol for molecular biology.
3 Methods
The AMLprofiler workflow includes many steps and typically takes 
place over a period of 3 days (Fig. 1). Please refer to Notes 1–4 for 
general principles to adhere to throughout the workflow. Each step 
is described in detail in the subsections to follow.
2.4 Chemicals
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It is recommended that a minimum of 1 mL bone marrow aspirate 
is collected in either an EDTA (ethylenediaminetetraacetic acid) or 
heparin tube. This is sampled by the clinician according to stan-
dard operating procedures used for diagnostics and transported to 
the laboratory at ambient temperature, i.e., the collected sample 
should not be refrigerated, frozen, or exposed to temperatures 
exceeding 37 °C (see Note 5).
Isolation of mononuclear cells from collected bone marrow 
samples should be performed within 48 h of collection in order to 
allow for enrichment of the blast cells. The number of white blood 
cells is usually determined prior to RNA isolation. It is recom-
mended that a WBC count of at least 5 × 106 is required to pro-
ceed to further processing.
Several approaches can be used for the enrichment of blasts, 
but the most commonly used method is a manual protocol involv-
ing a Ficoll-based separation, which is included as a gold standard 
in many diagnostic laboratories. The step-by-step protocol fol-
lowed in our laboratory is described below:
 1. Add 2 mL of Histopaque-1077 to a 15 mL conical centrifuge 
tube, and allow for up to 30 min to settle at room temperature 
(see Note 6).
 2. Dilute the 1 mL of bone marrow aspirate with 3 mL of 
phosphate- buffered saline (PBS).
 3. Gently layer the above 4 mL of diluted bone marrow on top of 
the Histopaque-1077.
 4. Centrifuge for 20 min at 300 × g at room temperature.
 5. Carefully remove the white intermediate layer containing the 
enriched blasts with a pipette, and transfer it to a new 15 mL 
conical centrifuge tube.
 6. Wash the cells by filling the tube to 15 mL with PBS, resus-
pend gently, and centrifuge for 5 min at 300 × g.
 7. Remove the PBS without disturbing the pellet at the bottom 
of the tube, and resuspend the washed pellet in 1 mL PBS 
before transferring to a 1.5 mL microfuge tube.
Isolate mRNA (messenger RNA) from the enriched blast cells 
according to the laboratory’s current procedure. MicroRNA 
extraction procedures should not be used.
Once isolated, the RNA should be assessed for both concentration 
and integrity/quality. The former should be performed via a spec-
trophotometric method. RNA concentration (in ng/μL) should 
be determined by 260 nm absorbance. The purity of the RNA is 
determined by the 260 nm (A260) and 280 nm (A280) ratio 
(A260/A280). The RNA purity should preferably be between 
ratios of 1.6 and 2.0.
3.1 Bone Marrow 
Collection and 
Isolation of 
Mononuclear Cells
3.2 RNA Purification 
and Quality 
Assessment
3.2.1 Quality Assessment 
of Purified mRNA
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RNA quality is an important parameter to be assessed in any 
microarray protocol. This is typically determined via an electro-
phoretic method. For the AMLprofiler assay, quality analysis is per-
formed at three definitive points during the protocol, namely, (1) 
after RNA isolation from mononuclear cells, (2) after the 
in vitro transcription reaction, and (3) after fragmentation of 
cRNA (see Fig. 1).
To prepare RNA samples for analysis, the recommended pro-
tocol provided by the manufacturer is usually followed depending 
on the type of instrument used. A molecular ladder that allows for 
fragments of between 200 and 4000 nucleotides to be viewed 
should be included in every assay run. Once completed, and con-
firmation is obtained that the assay was adequately performed (i.e., 
the ladder is comparable to its specifications, and the markers indi-
cate completeness of electrophoresis), the quality of the isolated 
mRNA can be assessed according to the expected electrophoretic 
profile illustrated in Fig. 2.
It is critical that only good quality RNA be used for the 
AMLprofiler analysis, which will avoid any downstream complica-
tions and also possible failure of the assay. One must proceed to 
cDNA synthesis only when the recommended criteria are met for 
RNA concentration, purity, and integrity.
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Fig. 2 Expected electrophoretic profile for isolated RNA. RNA purified from mononuclear cells, demonstrating 
the presence of 18S and 28S ribosomal RNA (rRNA) fragments, as generated in our laboratory using the 
TapeStation 2200 (Agilent Technologies). Electrophoretic peaks of 28S fragments should be at least 1.9 times 
that of the 18S peak. This is also reflected in the RNA integrity number (RIN) which is greater than 8.0 and 
hence indicative of good quality RNA. The “lower” fragment at 25 nucleotides is included in every assay for 
alignment purposes
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The synthesis of complementary DNA (cDNA) is performed in 
two reactions, namely, first-strand and second-strand cDNA syn-
theses. If more than one sample is assayed at a time, reactions can 
be performed in a 96-well PCR plate or in individual nuclease-free 
PCR tubes.
The starting RNA concentration required for the cDNA syn-
thesis reaction is 100 ng/μL, which is to be prepared to a final 
volume of 6 μL. An algorithm illustrating a simplified approach to 
achieve this is presented in Fig. 3.
Reagents for the first-strand cDNA synthesis reaction should be 
prepared on ice, and if more than one sample is being analyzed at 
a time, it is recommended that a master mix be prepared in a 
nuclease- free nonstick tube. Reaction contents and reagent vol-
umes for the first-strand cDNA synthesis are listed in Table 2.
 1. Once thawed, mix the first-strand buffer by vortexing briefly, 
and then pulse-spin to collect the contents at the bottom of 
the tube.
 2. Pulse-spin the first-strand enzyme and place in a benchtop 
cooler (or on ice).
 3. Prepare the master mix (Mix1) according to the number of 
samples being assayed. As a general rule, volumes of 1.1 times 
of each reagent listed in Table 2 should be added for the mas-
ter mix.
 4. Resuspend the final master mix and pulse-spin to collect con-
tents at the bottom of the tube.
 5. Immediately transfer 5 μL of Mix1 to the bottom of the appro-
priate wells of the 96-well PCR plate or PCR tubes, and keep 
on ice.
3.3 cDNA Synthesis
3.3.1 First-Strand cDNA 
Synthesis
Concentration of RNA
(ng/µL)
Determine volume
for 500 ng
If < 0.4 µL
If 0.5 – 5.0 µL
If > 5.0 µL
Make 1/10 dilution
Vacuum concentrate*
Prepare 600 ng in 6 µL volume
(100 ng/µL)
Fig. 3 Algorithm for preparation of RNA concentration for cDNA synthesis. (asterisk) Vacuum concentrate at 
30 °C, while regularly checking the volume, evaporate to approximately 7 μL. In case the sample is (or 
becomes) <7 μL, add nuclease-free water to a total volume of 7 μL. Check the RNA concentration (ng/μL) and 
the purity again using a spectrophotometric method. The undiluted RNA concentration should be ≥100 
ng/μL. The RNA purity should preferably be between 1.6 and 2.0
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 6. While keeping on ice, add 5 μL (500 ng) of the RNA sample 
to the 5 μL of Mix1 in the appropriate wells of the 96-well 
plate or nuclease-free PCR tubes. Gently mix by resuspending 
three times.
 7. Close the tubes or seal the PCR plate with aluminum adhesive 
foil using a brayer.
 8. Pulse-spin the final reaction contents if using PCR tubes. If 
using 96-well PCR plates, centrifuge 300 × g in a centrifuge 
with buckets for 96-well plates for no more than 10 s at room 
temperature to collect the solution at the bottom of the wells.
 9. Place the PCR tubes or 96-well PCR plate in a thermocycler 
and run the “first-strand” program provided in Table 3. 
Perform reaction with the lid of the thermocycler closed 
(105 °C if it can be programmed), and enter a total volume of 
10 μL if required for the thermocycler.
 10. To prepare for the second-strand synthesis reaction, remove 
the second-strand buffer from its storage location, and place 
on ice to allow it to thaw.
 11. Remove the PCR tubes or 96-well plate from the thermocycler 
after at least 2 min but within 10 min of completion of the 
42 °C incubation.
 12. Pulse-spin the PCR tubes or centrifuge the 96-well PCR plates 
for no more than 10 s at 300 × g to collect the contents at the 
bottom of the wells.
 13. Immediately place on ice and proceed to the second-strand 
cDNA synthesis.
Table 2 
Reagents and volumes for the first-strand synthesis
Pipetting sequence Reagent
Volume per 
reaction (μL)
1 First-strand buffer 4
2 First-strand enzyme 1
Total volume 5
If preparing a master mix, use 1.1 times the reagent volumes listed in the table
Table 3 
Temperature cycling for the first-strand cDNA synthesis
Method and program name Temperatures and duration
First-strand cDNA synthesis—
“first strand”
42 °C for 2 h, followed by 4 °C for 10 
min, and 4 °C hold
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The second-strand synthesis reaction should be initiated imme-
diately, since holding the first-strand cDNA synthesis reaction 
for longer than 10 min may significantly reduce copy RNA 
(cRNA) yield.
 1. Pre-cool the thermocycler block to 16 °C.
 2. Briefly vortex and pulse-spin the second-strand buffer and 
keep on ice.
 3. Pulse-spin the second-strand enzyme and place in a benchtop 
cooler (or on ice).
 4. If assaying more than one sample at a time, prepare the second- 
strand master mix (Mix2) according to contents listed in 
Table 4.
 5. Vortex the reaction or master mix thoroughly and pulse-spin 
to collect the contents at the bottom of the tube.
 6. Ensure that the PCR tubes or 96-well PCR plate have been 
cooled on ice for at least 2 min before adding Mix2.
 7. Transfer 20 μL of Mix2 to the side wall of each PCR tube or 
appropriate wells of the 96-well plate containing the 10 μL of 
first-strand reaction. Mix by resuspending three times.
 8. Close the PCR tubes properly or cover the 96-well plate with 
a new aluminum foil cover and carefully seal with a brayer.
 9. Pulse-spin the final reaction contents if using PCR tubes. If 
using 96-well PCR plates, centrifuge 300 × g in a centrifuge 
with buckets for 96-well plates for no more than 10 s at room 
temperature to collect the solution at the bottom of the wells.
 10. Place the PCR tubes or 96-well PCR plate in a thermocycler 
and run the “second-strand” program provided in Table 5. 
Perform reaction without closing the lid of the thermocycler, 
and enter a total volume of 30 μL if required for the 
thermocycler.
3.3.2 Second-Strand 
cDNA Synthesis
Table 4 
Reagents and volumes for the second-strand synthesis
Pipetting sequence Reagent
Volume per 
reaction (μL)
1 Nuclease-free water 13
2 Second-strand buffer 5
3 Second-strand enzyme 2
Total volume 20
If preparing a master mix, use 1.1 times the reagent volumes listed in the table
AMLprofiler: A Diagnostic and Prognostic Microarray for Acute Myeloid Leukemia
paolo.fortina@jefferson.edu
110
 11. To prepare for the in vitro transcription (IVT) reaction, place 
the IVT buffer on ice and the RNA biotin label at room 
temperature.
 12. Remove the plate from the thermocycler following the 65 °C 
incubation, after at least 2 min and within 10 min at 4 °C.
 13. Pulse-spin the PCR tubes or centrifuge the 96-well PCR plates 
for no more than 10 s at 300 × g to collect the contents at the 
bottom of the wells.
 14. Proceed immediately to the in vitro transcription reaction.
In the in vitro transcription reaction, biotinylated cRNA is 
synthesized.
 1. Remove the IVT enzyme from its storage location and place in 
a benchtop cooler (or on ice).
 2. Once the IVT buffer is thawed completely on ice, place it at 
room temperature for at least 10 min before proceeding with 
the reaction. Vortex briefly and pulse-spin to collect the buffer 
at the bottom of the tube.
 3. Prepare the IVT reaction at room temperature, and if assaying 
more than one sample at a time, prepare the IVT master mix 
(Mix3) according to the contents listed in Table 6.
 4. Vortex thoroughly and collect the reagents or Mix3 at the bot-
tom by pulse-spinning.
 5. After at least 5 min at room temperature, open the PCR tube(s) 
or carefully remove the aluminum adhesive foil from the PCR 
plate containing the cDNA, and add 30 μL of Mix3 to the side 
walls. Mix directly by pipetting up and down three times.
 6. Close the PCR tubes properly or cover the 96-well plate with 
a new aluminum foil cover and carefully seal with a brayer.
 7. Pulse-spin the final reaction contents if using PCR tubes. If 
using 96-well PCR plates, centrifuge at 300 × g in a centrifuge 
with buckets for 96-well plates for no more than 10 s at room 
temperature to collect the solution at the bottom of the wells.
 8. Place in a thermocycler and run the “IVT” program provided 
in Table 7. Perform reaction with the lid of the thermocycler 
3.4 In Vitro 
Transcription
Table 5 
Temperature cycling for the second-strand cDNA synthesis
Method and program name Temperatures and duration
Second-strand cDNA synthesis—
“second strand”
16 °C for 1 h, followed by 65 °C for 
10 min, 4 °C for 10 min, and 4 
°C hold
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closed (105 °C if it can be programmed), and enter a total 
volume of 60 μL if required for the thermocycler.
 9. After no longer than 20 h from starting the IVT reaction, 
remove the PCR tubes or 96-well PCR plate from the 
thermocycler.
 10. Pulse-spin the PCR tubes or centrifuge the 96-well PCR plates 
for no more 10 s at 300 × g to collect the contents at the bot-
tom of the wells.
 11. Place on ice and proceed to purification of the labeled cRNA.
Purification of cRNA is performed by means of a magnetic bead 
separation technique, following which the purified cRNA is quan-
tified to determine the total amount. A detailed outline of the pro-
cedure is provided below, which is performed at room 
temperature.
 1. Aliquot 50 μL per sample of nuclease-free water into a nuclease- 
free 1.5 mL tube.
 2. Preheat the nuclease-free water at 65 °C for at least 10 min in 
a heating block or incubator.
 3. Prepare fresh dilutions of 80% ethanol wash solution each time 
from 100% ethanol (molecular biology grade or equivalent) 
and nuclease-free water. A total of 650 μL for each reaction 
should be prepared.
3.5 cRNA 
Purification 
and Quantification
3.5.1 cRNA Purification
Table 6 
Reagents and volumes for in vitro transcription
Pipetting sequence Reagent
Volume per 
reaction (μL)
1 IVT biotin label 4
2 IVT buffer 20
3 IVT enzyme 6
Total volume 30
If preparing a master mix, use 1.1 times the reagent volumes listed in the table
Table 7 
Temperature cycling for in vitro transcription
Method and program name Temperatures and duration
In vitro transcription—“IVT” 40 °C for 4 h, followed by a 4 °C hold
Program can run overnight and samples removed within 20 h of starting the IVT 
reaction
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 4. Open the PCR tubes or remove the aluminum foil from the 
96-well plate containing the cRNA.
 5. Mix the purification beads container by briefly vortexing.
 6. Pipette the magnetic bead suspension up and down three 
times, and then add 100 μL into each 60 μL IVT reaction mix-
ture. Resuspend gently and transfer the samples to a U-bottom 
96-well plate.
 7. Mix well by pipetting up and down ten times, and incubate for 
10 min at room temperature.
 8. Place the U-bottom plate on a magnetic stand to capture the 
purification beads, and allow the beads to pellet for 5–10 min 
until the solution is clear (see Note 7).
 9. Keep the plate on the magnetic stand, and carefully aspirate 
and discard the supernatant without disturbing the beads.
 10. Mix the 80% ethanol wash solution by inversion, and while 
keeping the plate on the magnetic stand, wash each sample 
with 80% ethanol two times as follows:
(a) Take 200 μL of 80% ethanol wash solution and add to the 
side wall of each sample well without disturbing the beads. 
Incubate for 30–50 s at room temperature.
(b) Slowly aspirate and discard the supernatant without 
disturbing the beads.
 11. Repeat these wash steps twice for a total of three washes. For 
the last wash, ensure that all the supernatant is removed with-
out disturbing the beads.
 12. Air-dry the plate for approximately 5 min while keeping the 
plate on the magnetic stand until no liquid is visible and the 
pellet appears shiny. Do not cover the plate and do not over 
dry the beads. An overdried pellet is recognizable by a dull 
appearance and apparent “surface cracks.” This will reduce 
elution efficiency.
 13. Remove the plate from the magnetic stand.
 14. Remove the nuclease-free water from the 65 °C heat block. 
Aspirate 27 μL and discard. Aspirate 27 μL per sample and add 
to each sample well. Do not use the last 27 μL of the nuclease- 
free water.
 15. Incubate for 1 min on the lab bench at room temperature, and 
then mix well by pipetting up and down approximately ten 
times.
 16. Check that the pellet of beads is fully dispersed. If the pellet is 
not fully dispersed, pipette up and down ten times to fully dis-
rupt the pellet.
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 17. Move the plate to the magnetic stand again and allow beads to 
settle for approximately 5 min. The solution must be clear and 
all the beads pelleted against the magnet.
 18. Only once the solution is transparent and the beads have set-
tled, very carefully remove the supernatant without disturbing 
the pellet. Transfer the supernatant containing the eluted 
cRNA to a new 96-well plate or individual tubes while measur-
ing the elution volumes for each sample. This can be performed 
easily by aspirating decreasing volumes until the elution 
volume is established.
 19. Immediately proceed to measure the cRNA concentration.
 1. Make a 1/10 dilution of the cRNA with nuclease-free water in 
a new PCR tube.
 2. Determine the concentration in ng/μL using a spectrophoto-
metric method.
 3. The A260/A280 ratio is also to be recorded in order to deter-
mine the purity of the cRNA product. This ratio should prefer-
ably be between 2.03 and 2.07.
 4. Calculate the cRNA yield from the concentration based on the 
following equation:
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“x” is derived from the volume of eluted cRNA collected in 
Subheading 3.5.1.
 5. The cRNA yield should be ≥12.7 μg. If less, do not proceed 
further with sample processing (see Note 8).
 6. An aliquot of 1.3 μL of the diluted cRNA sample(s) should be 
stored for quality analysis by means of an electrophoretic 
method (see Note 8).
 7. Proceed immediately to cRNA fragmentation or store the 
cRNA sample at −20 °C for intermediate storage or −80 °C 
for long-term storage.
Fragmentation of the cRNA is the final step in preparing the sample 
for hybridization to the AMLprofiler microarrays. Efficient frag-
mentation (and confirmation thereof) is an important aspect that 
contributes to the success of hybridization.
 1. Calculate the Volume of Undiluted cRNA Sample that 
Contains 7.5 μg cRNA According to the Following Equation
3.5.2 cRNA 
Quantification
3.6 cRNA 
Fragmentation 
and Quality 
Assessment
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“x” is the volume of eluted cRNA collected in Subsection 
3.5.1, while “y” represents the volume required to obtain 7.5 
μg cRNA.
 2. Prepare the fragmentation reaction for each sample in a 0.5 
mL PCR tube, and label each tube with the respective sample 
ID.
 3. Prepare the fragmentation reaction on ice and according to the 
contents in Table 8.
 4. Mix each tube thoroughly by vortexing, and pulse-spin to col-
lect the fragmentation reaction at the bottom of the tube.
 5. Place in a thermocycler and run the “Fragmentation” program 
provided in Table 9. Perform reaction with the lid of the ther-
mocycler closed (105 °C if it can be programmed), and enter a 
total volume of 20 μL if required for the thermocycler.
 6. Remove the plate from the thermocycler after at least 2 min at 
4 °C, but within 10 min of completion of the 94 °C 
incubation.
 7. Pulse-spin the fragmented cRNA to collect the contents at the 
bottom of the tube, and place the samples on ice.
Table 8 
Reagents and volumes for cRNA fragmentation
Pipetting sequence Reagent
Volume per 
reaction (μL)
1 cRNA (7.5 μg) y
2 Nuclease-free water 16-y
3 3′ fragmentation buffer 4
Total volume 20
If preparing a master mix, use 1.1 times the reagent volumes listed in the table
Table 9 
Temperature cycling for cRNA fragmentation
Method and program name Temperatures and duration
cRNA fragmentation— 
“Fragmentation”
94 °C for 35 min, followed by 4 
°C for 10 min and a 4 °C hold
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 8. Aliquot 1.3 μL of the fragmented cRNA sample(s) into sepa-
rate PCR tubes or a 96-well plate, and proceed to quality anal-
ysis by means of an electrophoretic method.
 9. The fragmented cRNA can be stored at −20 °C (intermediate 
storage) or at −80 °C for long term.
Quality assessment of intact and fragmented cRNA is performed 
via an electrophoretic method. Following the recommended 
 procedures and confirming that the assay was adequately performed 
(i.e., the ladder is comparable to its specifications, and the markers 
indicate completeness of electrophoresis), the quality of the RNA 
can be assessed according to the expected electrophoretic profile 
illustrated in Fig. 4.
3.6.1 Quality Assessment 
of cRNA and Fragmented 
cRNA
N
uc
le
ot
 id
es
La
dd
er
cR
N
A
A.
Size
(nt)
25 50
0
20
0
1,
00
0
2,
00
0
4,
00
0
6,
00
0
Sa
m
pl
e 
in
te
ns
ity
 [F
U
]
6,000
4,000
2,000
1,000
500
200
25
5,000
4,000
3,000
2,000
1,000
0
6,000
7,000
8,000
9,000
N
uc
le
ot
 id
es
La
dd
er
Fr
ag
m
en
te
d 
cR
N
AB.
6,000
4,000
2,000
1,000
500
200
25
Sa
m
pl
e 
in
te
ns
ity
 [F
U
]
5,000
4,000
3,000
2,000
1,000
0
Fig. 4 Expected electrophoretic results for intact and fragmented cRNA. (a) Electrophoretic profile expected 
after cDNA synthesis and in vitro transcription, as generated in our laboratory using the TapeStation 2200 
(Agilent Technologies). The gel smear reflects a broad range of cDNA amplification and conversion to 
cRNA. Occasionally distinct fragments are visible around 1000 nucleotides. This has no impact as long as a 
“smear” between 200 and 4000 nucleotides is still present. (b) Fragmented cRNA is typically observed as an 
intense range of fragments between 50 and 150 nucleotides
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If the cRNA and fragmented cRNA meet the expected quality 
criteria and reflect similar electrophoretic profiles as demonstrated 
in Fig. 4, then proceed to hybridization of the AMLprofiler.
The most important step in the processing of the AMLprofiler 
involves hybridization of the fragmented cRNA to the AMLprofiler 
chips. In the hybridization steps of the protocol, the fragmented 
cRNA is hybridized to the AMLprofiler microarrays. Details for 
preparation of the hybridization cocktail, pre-hybridization of 
AMLprofilers, and hybridization of the arrays are described below.
 1. Remove the AMLprofiler microarray from the refrigerator, 
verify that the pouch is still intact (otherwise take a new array), 
and allow it to equilibrate (unopened) to room temperature 
for at least 30 min. This is very important as the rubber septa 
may be prone to cracking, and hence leaking might occur if 
used cold.
 2. Remove the Oligo B2, 20× hybridization control, 2× hybrid-
ization mix, DMSO, and pre-hybridization buffer from their 
respective storage conditions, and allow them to thaw at room 
temperature.
 3. Turn on the hybridization oven, set the temperature to 45 °C, 
and set the rotation speed to 60 rpm.
 4. Once the AMLprofiler array(s) have equilibrated to room tem-
perature (after 30 min), remove them from the pouch and 
label each with the sample numbers to be assayed.
 5. Turn on the Affymetrix computer and login.
 6. Click on the Active Worklist button on the left panel and then 
on Create to create a new test request. Enter a Specimen ID 
and select the AMLprofiler Assay Name for each sample to be 
assayed, and click on Submit.
 7. Navigate to the Registration page (button on the left panel). 
Click on the hyperlinked specimen ID, and enter the sample 
particulars in the pop-up screen. Save and Close and scan the 
corresponding AMLprofiler microarray barcode with the 
Affymetrix barcode scanner. Repeat this for each sample to be 
assayed, and click on the Complete Step button.
 8. Proceed to pre-hybridization.
 1. Insert a pipette tip (generally a 20 μL tip) gently into the upper 
right septum of the array until you feel it penetrate the rubber 
septum (see Fig. 5). This allows for venting of the array.
 2. Hold the array up vertically in the orientation shown in Fig. 5.
 3. Wet the array with 80 μL of pre-hybridization mix by filling it 
through the bottom left septum of the array. Also gently pen-
etrate the rubber septum first before dispensing the pre- 
hybridization mix.
3.7 Hybridization 
of AMLprofiler 
Microarrays
3.7.1 Preparation 
for Hybridization
3.7.2 Pre-hybridization
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 4. Remove the pipette tip from the upper right septum of the 
array, and incubate the array in the hybridization oven for 
10–30 min at 45 °C and 60 rpm rotation.
 1. Once all reagents are thawed to room temperature, vortex 
briefly (2 s at 80 × g), and pulse-spin to collect them at the 
bottom of their respective tubes.
 2. Preheat an aliquot of 5.6 μL per microarray of the 20× hybrid-
ization control at 65 °C for 5 min on a thermocycler according 
to the program in Table 10.
 3. Prepare the hybridization reaction mix at room temperature 
according to the reagents listed in Table 11, and if multiple 
samples are being assayed at the same time, prepare a master 
mix (Mix4) in a nuclease-free 1.5 mL microfuge tube.
 4. Mix thoroughly by vortexing (2 s at 80 × g), and pulse-spin to 
collect the contents at the bottom of the tube(s).
 5. Aliquot 13.3 μL of the fragmented cRNA sample(s) into new 
nuclease-free PCR tube(s).
3.7.3 Hybridization
B
A
Pipette tip
Pipette tip
Fig. 5 Adding and removing fluids to the AMLprofiler microarray. Image adapted 
from [2]
Table 10 
Preheating of 20× hybridization control
Method and program name
Temperatures and 
duration
Pre-hybridization—“Pre-hyb” 65 °C for 5 min
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 6. Add 86.7 μL of the hybridization reaction mix (Mix4) to the 
fragmented cRNA to prepare the hybridization cocktail (see 
Table 12).
 7. Mix thoroughly by vortexing (2 s at 80 × g), and pulse-spin to 
collect the contents at the bottom of the tube.
 8. Place the hybridization cocktail in the thermocycler and run 
the “hybcocktail” program provided in Table 13.
 9. Centrifuge the hybridization cocktail at 13,000 × g for 5 min 
at room temperature.
Table 12 
Reagents and volumes for preparation of the hybridization cocktail
Pipetting sequence Reagent Volume per reaction (μL)
1 Fragmented cRNA (5 μg)* 13.3
5 Hybridization mix (Mix4) 86.7
Total volume 100
*cRNA is labeled and the equivalent of 5 μg is used, based on the standardization per-
formed under Subheading 3.6
Table 11 
Reagents and volumes for preparation of the hybridization reaction (Mix4)
Pipetting sequence Reagent Volume per reaction (μL)
1 Oligonucleotide B2 1.7
2 20× hybridization controls 5
3 2× hybridization mix 50
4 DMSO 10
5 Nuclease-free water 20
Total volume 86.7
If preparing a master mix, use 1.1 times the reagent volumes listed in the table
Table 13 
Heating of the hybridization cocktail
Method and program name Temperatures and duration
Hybridization cocktail—“hybcocktail” 99 °C for 5 min, followed by 45 
°C for 5 min
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 10. Remove the pre-hybridized AMLprofiler array(s) from the 
hybridization oven.
 11. Insert a pipette tip into the upper right septum to vent the 
array (Fig. 5).
 12. Hold the array up vertically and remove the pre-hybridization 
mix with a 200 μL pipette tip via the bottom left septum and 
discard it.
 13. Fill the AMLprofiler array(s) with 80 μL (all but the insoluble 
matter on the bottom) of the matching hybridization 
cocktail(s).
 14. Store the remainder of the cocktail (~20 μL) at −20 °C for 
intermediate (overnight) storage or at −80 °C for long-term 
storage.
 15. Close both of the septa of the AMLprofiler array with tough- 
spot stickers, and place the AMLprofiler arrays(s) back into the 
hybridization oven.
 16. Login to the Affymetrix computer and navigate to the 
Hybridization Oven menu (on left-hand side panel). 
Highlight the sample(s) to be hybridized and click on Start.
 17. Hybridization of the AMLprofilers will initiate, and the pro-
gram will run overnight for 17 ± 1 h at 45 °C and 60 rpm in 
the hybridization oven.
Prior to initiating the following steps, ensure that the Affymetrix 
Fluidics Station is in good order and adequately cleaned (see Note 9).
 1. Remove buffer A and buffer B from the refrigerator and allow 
them to equilibrate to room temperature (approximately 1 h 
or the previous evening).
 2. Connect bottles with at least 250 mL of buffers A and B, and 
deionized (DI) water to the Fluidics Station, as indicated on 
the right-hand side of the instrument.
 3. Load three empty 1.5 mL microfuge tubes in the sample hold-
ers of each module to be primed.
 4. Login on the Affymetrix computer and click on the Fluidics 
icon button on the left panel.
 5. Click on the Station Setup button.
 6. Select the Station #, the Assay, and the Modules to be primed 
(i.e., only those to be used in the AMLprofiler processing that 
follows).
 7. Click the Prime button and follow the instructions provided 
on the digital display of the Fluidics Station.
3.8 Washing, 
Staining, and Scanning 
AMLprofiler Arrays
3.8.1 Priming 
of the Affymetrix Fluidics 
Station
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 8. The Fluidics Station will enter into the priming protocol, 
which will continue for approximately 15–20 min.
 9. Once completed, a “Priming Done” message will appear on 
the display of each of the modules primed.
 10. Click on the Close Station Setup button to return to the 
Fluidics screen.
 1. Remove the AMLprofiler(s) from the hybridization oven after 
approximately 17 h of hybridization in the oven.
 2. Click on the Complete Step button in the Hybridization 
Oven tab, and continue to scanning of the AMLprofiler(s).
 3. Remove the tough-spot stickers from the AMLprofiler and 
vent the array by inserting a clean pipette tip into the upper 
right septum (Fig. 5). Extract the hybridization cocktail with 
the pipette through the lower left septum of the AMLprofiler 
array while holding it in a vertical orientation.
 4. Add the hybridization cocktail back to the sample tube con-
taining the remainder of the hybridization cocktail, and store 
at −20 °C for intermediate (overnight) storage or at −80 °C 
for long-term storage.
 5. Fill the AMLprofiler array entirely (>100 μL) with buffer A.
 6. If any AMLprofiler arrays are not to be processed immediately 
on the Fluidics Station, these can be stored in the refrigerator 
(5 ± 3 °C) for up to 24 h.
 7. Prepare and aliquot the staining reagents for each AMLprofiler 
array, as indicated in Table 14 below.
 8. Pulse-spin all tubes to remove any air bubbles.
 9. For each module on the Fluidics Station to be used:
(a) Place stain cocktail 1 tube in sample holder 1 of the 
Fluidics Station.
(b) Place stain cocktail 2 tube in sample holder 2 of the 
Fluidics Station.
(c) Place array holding buffer tube in sample holder 3 of the 
Fluidics Station.
3.8.2 Washing 
and Staining 
the AMLprofiler Arrays
Table 14 
Preparation of stain reagents for each AMLprofiler array
Stain reagent Volume and tube
Stain cocktail 1 (light sensitive) 600 μL in amber 1.5 mL microfuge tube
Stain cocktail 2 600 μL in clear 1.5 mL microfuge tube
Array holding buffer 800 μL in clear 1.5 mL microfuge tube
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 10. Place the AMLprofiler arrays to be processed in each of the 
allocated modules of the Fluidics Station (without lowering 
the needle lever yet).
 11. Login on the AMLprofiler computer and click on the Fluidics 
button on the left-hand side panel.
 12. Click Start and allow the wash and stain program to run, 
which takes approximately 1 h and 15 min to complete.
 13. Once completed, the “Eject and Inspect Cartridge” message 
will be displayed on each module of the Fluidics Station.
 14. Check the glass window on the front of the AMLprofiler and 
verify that no large air bubble(s) are present. If there are any, 
then vent the upper septum (Fig. 5), remove all the liquid 
from the array, and fill it completely with fresh array holding 
buffer (>105 μL).
 15. Clean any excess fluid from around the septa and seal them 
with tough-spots.
 16. Login on the Affymetrix computer and click on the Complete 
Step button in the Fluidics tab, and proceed immediately to 
scanning of the AMLprofiler(s).
 1. Switch on the Affymetrix GeneChip Scanner 3000 and allow it 
to warm up (approximately 15 min before scanning).
 2. When the scanner status is reflected as ready, insert the 
AMLprofiler arrays randomly into the scanning tray. The 
autoloader functionality will read the barcodes and auto-
matically assign the microarrays to the corresponding spec-
imen IDs.
 3. Login to the Affymetrix computer and navigate to the Scanner 
tab on the left panel.
 4. Highlight the arrays to be scanned and click Start.
 5. Each array will be scanned, and when completed, click 
Complete Step.
Once the scanning of AMLprofilers is completed, the data is sent 
via a secured Internet connection to SkylineDx for analysis and 
reporting. A test result report is generated for each array and 
returned to the DX2 Affymetrix system automatically within 
15 min. This report displays the two QC parameters of the assay: 
% Present and R2 for the hybridization controls, as well as the 
AMLprofiler marker results. If these QC criteria are not met, 
INVALID comments are automatically returned.
3.8.3 Scanning 
the AMLprofiler Arrays
3.9 Data Analysis 
and Reporting
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4 Notes
In our experience, we have found that the aspects listed below are 
critical for successful processing of the AMLprofiler microarrays. 
Even the slightest deviation in timing, temperature, and storage 
conditions might result in the failure of the assay or give intermedi-
ate products of low yield and quality. An excellent and detailed 
protocol is provided by SkylineDx, which is to be followed at all 
times throughout the processing of samples.
 1. Time management for processing of reagents: Please ensure to 
maintain the exact time interval between the subsequent reac-
tions throughout the processing of AMLprofiler microarrays. 
The protocol provided by the manufacturer should be strictly 
followed for setting up reactions to maintain the same recom-
mended time conditions. This includes the time intervals 
between each reaction, the time required to take out the final 
product from the thermocycler, and also the time at which the 
next reaction should be started.
 2. Temperature maintenance for setting up each reaction: Please 
ensure to maintain the reactions at the exact recommended 
temperatures in the thermocycler for the required period of 
time. In the detailed protocol provided by the manufacturer, 
there are stages where the thermocycler should also be set to a 
certain temperature prior to placing the reaction tubes inside.
 3. Temperature maintenance for storage of reagents: Please ensure 
that the AMLprofiler reagents are stored at the right tempera-
tures, including 4 °C, 20 °C, and −80 °C, as recommended by 
the manufacturer.
 4. Storage of intermediate products: Throughout the processing of 
AMLprofiler, the intermediate products can be stored at cer-
tain temperatures in order to continue the processing at a later 
stage. Please maintain these intermediate products at the rec-
ommended temperatures in order to prevent the total failure 
of the reaction, low yield, and low quality of products.
 5. Sample collection (Subheading 3.1): Most people tend to place 
the bone marrow sample on ice or at 4 °C prior to isolation of 
the mononuclear cells. This should be avoided, and the sample 
should be maintained at room temperature.
 6. Isolation of mononuclear cells (Subheading 3.1): Be sure to 
equilibrate the Histopaque®-1077 to room temperature prior 
to isolation of the mononuclear cells. In addition, the entire 
isolation protocol should be performed at room temperature, 
including the centrifugation steps. The tendency is often to 
keep the sample chilled or at 4 °C.
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 7. cRNA purification (Subheading 3.5.1): One should be highly 
attentive during the purification of cRNA while using the mag-
netic plate for separation of cRNA using the magnetic beads 
solution. Wait until the solution is totally clear after separation 
and don’t leave the wells to dry longer than recommended.
 8. cRNA yield and quality assessment (Subheading 3.5.2): The 
processing of AMLprofiler cannot be continued if the yield 
and the quality of cRNA does not meet the requirements of 
the manufacturer’s protocol.
 9. Bleach protocol and replacement of tubingin the Affymetrix 
Fluidics System (Subheading 3.8): The Affymetrix Fluidics 
Station requires regular cleaning via a bleach protocol (weekly) 
and changing of the peristaltic silicone tubing (monthly). 
Ensure that these aspects are attended to regularly (according 
to the Affymetrix guidelines) and hence that the Fluidics 
Station is free from contamination prior to proceeding with 
the processing of the AMLprofiler arrays. This can take up to 
3 h and one should bear this in mind when preparing for the 
final day of AMLprofiler processing.
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Chapter 8
Microsphere-Based Assessment of DNA Methylation 
for AML Prognosis
Gerald B.W. Wertheim, Marlise R. Luskin, Martin Carroll, 
and Stephen R. Master
Abstract
Epigenetic dysregulation, including aberrant methylation of cytosine residues in DNA, is a hallmark of 
cancer and clearly results in oncogenic cellular alterations such as transcriptional attenuation of tumor sup-
pressors and genomic instability. A number of studies have examined DNA methylation alterations in 
patients with acute myeloid leukemia (AML) and have shown that analysis of multilocus methylation pat-
terns can identify biologically distinct AML subclasses and can predict patient prognosis. In order to utilize 
the prognostic capability of methylation analysis in a clinical setting, we have developed a microsphere- 
based HpaII tiny fragment enrichment by ligation-mediated PCR (xMELP) assay to interrogate the meth-
ylation state of genomic multiple loci along with a random forest-based classification algorithm that 
correlates DNA methylation status with patient prognosis. These tools can be easily implemented in a clini-
cal molecular pathology laboratory and can be utilized for more accurate risk stratification of AML patients.
Key words Methylation, Help, xMELP, Acute myeloid leukemia, M-score, Random forest
1 Introduction
Aberrant cytosine methylation at CpG dinucleotides is a recurrent 
feature of many tumors, including acute myeloid leukemia (AML) 
[1–3]. The importance of cytosine methylation in AML pathogen-
esis is highlighted by the fact that multiple recurrent mutations in 
AML are within genes that regulate methylation, and mice that 
harbor targeted mutations in these genes can develop AML [4–7]. 
A number of studies have analyzed the global pattern of DNA 
methylation in AML [2–8]. Not only have these demonstrated that 
patterns in AML are distinct from normal hematopoietic precur-
sors, but they have shown that AML can be subclassified into bio-
logically and clinically relevant categories simply by their cytosine 
methylation profiles. Additionally, patient outcomes can be pre-
dicted from the methylation profiles. Indeed, we and others have 
shown that analysis of DNA methylation at a restricted number of 
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loci can stratify patients with AML into significantly distinct risk 
groups, and that this stratification is independent of other com-
monly used markers of AML prognosis [2, 8–10]. Thus, clinical 
assessment of multilocus or even global DNA methylation allows 
for proper patient classification and can aid with therapeutic 
decisions.
Many methods to assess DNA methylation on a global level 
have been developed. These include enzymatic methods that uti-
lize the differential sensitivity of restriction enzymes to cytosine 
methylation, DNA pull down assays that use antibodies or proteins 
to bind and precipitate methylated DNA, and bisulfite treatment 
methodologies that convert unmethylated cytosine to uracil [11, 
12]. Analysis of the digested, precipitated, or bisulfite converted 
DNA can then be performed on various platforms such as array 
hybridization, mass spectrometry, and next generation sequencing. 
Of note, although each technique assesses cytosine methylation, 
they are distinct and can yield distinct patterns of methylation. Thus, 
comparing global methylation results across platforms should be 
done with extreme caution.
One of the initial techniques used to assess global DNA meth-
ylation in AML samples was the HpaII tiny fragment enrichment 
by ligation-mediated PCR (HELP) assay [13]. This method relies 
on the differential sensitivity of the restriction enzyme isos-
chizomers HpaII and MspI—both of which recognize and digest 
the tetranucleotide CCGG sequence after the first C—to cytosine 
methylation. HpaII does not digest methylated sequences, whereas 
MspI retains activity regardless of methylation status. Thus, after 
isolation, genomic DNA is divided into two aliquots and digested 
with either MspI or HpaII. Using the CG overhang for annealing 
specificity, oligonucleotide linkers are ligated to the digested DNA 
and linker-specific PCR with Taq polymerase is performed. Since 
Taq polymerase inefficiently amplifies fragments >2 kb, only rela-
tively small fragments will be amplified. Analysis of the relative 
amounts of amplified regions, which in the original HELP assay is 
done by hybridization of fluorescently labeled products to custom- 
made solid oligonucleotide arrays, reflects the level of methylation 
of the flanking cytosines (Fig. 1). Using this technique, Figueroa 
et al. demonstrated that the DNA methylation pattern of 18 loci 
could predict outcome of AML patients independently of known 
prognostic factors such as patient age, cytogenetics, and recurrent 
mutations in FLT3 and NPM1 [2].
Since HELP-derived DNA methylation data predicted out-
come of patients with AML, and since the laboratory techniques 
used for HELP (i.e., restriction enzyme digestion, ligation, and 
PCR) are commonplace in clinical molecular pathology laborato-
ries, we developed a revised version of the HELP assay (termed 
xMELP for expedited microsphere HELP) with the specific intent 
of multilocus methylation profiling in a clinical setting [9, 10]. For 
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Fig. 1 Schematic diagram of HELP (A) and xMELP (B). Genomic DNA is shown 
with either unmethylated (open circles) or methylated (circles with M) regions. 
The DNA is digested with either MspI or HpaII into fragments shown. Linkers are 
ligated, and PCR with linker-specific primers is carried out. Small fragments are 
preferentially amplified. For HELP (A), after labeling and hybridization to solid 
phase microarrays, the relative signals of amplicons from MspI and HpaII reac-
tions reflect levels of methylation. For xMELP (B), amplicon identity is determined 
by hybridization to oligonucleotide-coupled fluorescent microspheres. As with 
HELP, the ratio of amplicon signal from MspI and HpaII reactions reflect level of 
methylation (figure originally published in [9], used by permission)
DNA Methylation for AML Prognosis
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the most part, xMELP is identical to HELP, yet differs in at least 
two important ways. First, the linker primers for xMELP have been 
modified from the original HELP assay and allow digestion and 
ligation to be performed simultaneously. Second, xMELP detec-
tion of methylated regions is through a branched DNA hybridiza-
tion of products onto fluorescent microspheres rather than onto 
custom-made solid arrays. This modification allows the assay to be 
done in a highly reproducible and cost-effective manner, as many 
clinical laboratories currently possess the instrumentation to per-
form xMELP.
In the course of assay modification, we also identified addi-
tional prognostic loci and developed a more robust algorithm for 
methylation-based risk assessment than was originally utilized by 
Figueroa et al. [2]. Specifically, we used a random forest machine 
learning algorithm (based on building an ensemble of decision 
trees) that predicts AML survival using variations in methylation at 
17 loci that have been normalized to 3 loci previously shown to 
exhibit constant methylation across a wide set of AML samples [9, 
10]. These 17 normalized loci are combined into a single score 
that predicts risk (low score corresponds to low risk/favorable 
prognosis, while high score corresponds to high risk/unfavorable 
prognosis), and we have designed this the M-Score (methylation 
score). We have previously published the data and software neces-
sary to perform the M-Score calculation, and a standalone script 
for the R statistical program is available [14]. Additionally, we have 
created a web-accessible application that allows investigators to 
determine the M-Score based on their own data [14].
Here we describe both our laboratory method of xMELP, as 
well as the analytic algorithm we use to assess the methylation data 
obtained by xMELP in relation to patient prognosis.
2 Materials
 1. Qiagen Gentra Puregene Blood DNA isolation kit (Qiagen, 
Hilden, Germany).
 2. Primer JHpa12xxxx (HPLC purified), 5′-CGCCTGTTCA 
TG- 3, resuspend at 12 OD/mL. The first two bases (under-
lined) in this primer hybridize to the genomic DNA to allow 
for specific ligation. The third base (in bold) is modified from 
the original JHpa12 primer to remove the MspI/HpaII site in 
the ligated product to allow for simultaneous ligation.
 3. Primer JHpa24xxxx (HPLC purified), 5′-CGACGTCGACTA 
TCCATGAACAGG- 3′, resuspend at 6 OD/mL. The last base 
(in bold) is modified from the original JHpa12 primer to 
remove the MspI/HpaII site in the ligated product to allow 
for simultaneous ligation.
2.1 Genomic DNA 
Extraction, Digestion/
Ligation, 
and Amplification 
of Tiny Fragments
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 4. Preannealed primers. Mix equal volumes of JHpa12xxxx and 
JHpa24xxxx. Place in heat block at 98 °C. Remove block from 
heat source and let cool on bench. Annealed linkers can be 
stored at −20 °C.
 5. HpaII restriction enzyme, supplied with 10× CutSmart buffer 
(NEB, Ipswich, MA).
 6. MspI restriction enzyme, supplied with 10× CutSmart buffer 
(NEB).
 7. 100 mM ATP, pH 7 (Roche, Basel, Switzerland).
 8. T4 DNA ligase (Thermo Fisher Scientific, Waltham, MA, USA).
 9. dNTP mix, 10 mM each (Thermo Fisher Scientific).
 10. Native Taq polymerase (Thermo Fisher Scientific), supplied 
with 10× Buffer and 50 mM magnesium chloride.
 11. Thermocycler.
 1. Luminex FlexMAP 3D system with xPONENT software (see 
Note 1).
 2. Hand-held magnetic plate for 96-well plate (Affymetrix #EPX- 
55555- 000) (see Note 2).
 3. VorTemp 56 shaker incubator (see Note 3).
 4. Tabletop centrifuge with plate adaptors.
 5. QuantigenePlex 2.0 Microsphere Assay (see Note 4).
 6. QuantigenePlex DNA Assay Kit (Affymetrix #QPD1010). Kit 
contains Pre-Amplifier probe and diluent, amplifier probe, 
label probe and diluent, streptavidin-PE (SAPE), wash buffer 
components, SAPE wash, blocking reagent, Proteinase K, 
Lysis mixture, Neutralization buffer, 96-well plates (hybridiza-
tion and magnetic separation), plate seals.
 7. 1 N sodium hydroxide.
3 Methods
Since both HELP and xMELP rely on differential Taq amplifica-
tion of large and small fragments, intact genomic DNA must be 
isolated and digested to completion. We recommend evaluation 
of extracted DNA by gel electrophoresis (or equivalent method) 
and overnight digestion. Additionally, we advise against use of 
FFPE samples (e.g., aspirate clot sections) as DNA undergoes 
 fragmentation with sample processing. We also recommend evalu-
ation of PCR amplicons by electrophoresis prior to microsphere 
hybridization. To control for genomic integrity, the restriction 
enzyme can be eliminated from the digestion/ligation reaction.
2.2 Amplicon 
Hybridization 
to Microspheres 
and Fluorescence 
Detection
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 1. Pellet 1–3 million cells at room temperature in a 15 mL conical 
at 300 × g for 5 min. Remove supernatant, resuspend in 5 mL 
of PBS, and pellet again at 300 × g.
 2. Extract DNA using Qiagen Gentra Puregene kit (see Note 5). 
Resuspend the cell pellet in 200 μL of 10 mM Tris pH 8.0. This 
may require overnight incubation at room temperature or an 
increase in the resuspension volume for large quantities of DNA.
 3. Quantitate DNA and run 1–5 μL on a 0.8% agarose gel to 
check quality. Unsheared genomic DNA should run at >10 kb.
 4. Prepare the digestion/ligation mix as follows (see Notes 6–8):
(a) 250–500 ng of genomic DNA.
(b) 5 μL 10x NEB CutSmart buffer (supplied with restriction 
enzymes).
(c) 7.5 μL Annealed JHpa12xxxx and JHpa24xxxx 
oligonucleotides.
(d) 0.5 μL 100 mM ATP.
(e) 2 μL HpaII or MspI.
(f) 2 μL T4 DNA ligase.
(g) ddH2O to 50 μL total reaction volume.
 5. Incubate reaction mixture in thermocycler set at 25 °C for at 
least 12 h (see Note 9).
 6. Add 450 μL of ddH2O to the reaction mixture.
 7. Prepare PCR mix as follows
(a) 10 μL diluted digested/ligated DNA.
(b) 1 μL dNTPs.
(c) 1.5 μL MgCl2.
(d) 5 μL 10× PCR buffer.
(e) 1 μL JHpa24xxxx primer.
(f) 0.5 μL Taq polymerase.
(g) 31 μL ddH2O.
 8. Run PCR cycling as follows (see Notes 9 and 10):
(a) 72 °C for 5 min.
(b) 20 cycles of
●● 95 °C for 30 s.
●● 72 °C for 3 min.
(c) 72 °C for 10 min.
(d) 4 °C hold.
 9. Run 5 μL of the PCR products on a 1.5% gel to assess amplifi-
cation. Most products should appear between 100 bp and 2 kb. 
If the products are appropriate, proceed to the hybridization 
steps.
3.1 Extraction 
and Amplification
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 1. Prewarm lysis mixture buffer to 37 °C. Then mix the following 
reagents (see Note 12)
(a) 8 μL PCR product.
(b) 18 μL Lysis mixture buffer.
(c) 12.5 μL 1 N sodium hydroxide.
(d) 5 μL probeset.
(e) 24.5 μL ddH2O.
 2. Incubate the mixture at room temperature for 30 min.
 3. During this incubation, prepare the microsphere mix by mix-
ing (see Note 12)
(a) 15 μL.
(b) 0.2 μL Proteinase K.
(c) 2 μL blocking reagent.
(d) 1 μL beadset.
(e) 1.8 μL ddH2O.
 4. If a master mix was made, aliquot 20 μL of this latter mix into 
wells of the hybridization plate.
 5. After incubation of the probeset mix, add 12 μL of neutraliza-
tion buffer to the probeset mix, pipette up and down, and add 
the entire 80 μL to the beadset mix in the hybridization plate.
 6. Seal the plate with the pressure seal, place in the VorTemp 
incubator, and incubate for at least 12 h at 54 °C with shaking 
at 600 rpm (see Note 13).
 7. Place amplifier diluent in 37 °C water bath.
 8. Make enough wash buffer with wash buffer components 
(amount sufficient for remaining steps). Wash buffer compo-
nents are included in DNA assay kit. To make buffer mix
(a) 100 μL wash buffer component 1.
(b) 1.6 mL wash buffer component 2.
(c) 31.6 ddH2O.
 9. After incubation, spin plate for 30 s in the tabletop centrifuge 
to collect the liquid in each well. Transfer reactions to the mag-
netic separation plate.
 10. Place the magnetic separation plate on the magnetic washer 
and let stand for 1 min. Invert the plate on a paper towel to 
remove liquid. Wash three times with 100 μL wash buffer per 
well, inverting plate on paper towel each time to remove 
liquid.
 11. Dilute 6 μL preamplifier in 1.9 mL prewarmed amplifier dilu-
ent (see Note 14). Mix well. Add 100 μL to each well with 
magnetic microspheres. Seal the plate with the plate sealer, 
3.2 Amplicon 
Hybridization 
to Microspheres 
and Fluorescence 
Detection (See  
Note 11)
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place in the VorTemp incubator, and incubate 1 h at 50 °C 
with shaking at 600 rpm.
 12. Place the magnetic separation plate on the magnetic washer 
and let stand for 1 min. Invert the plate on a paper towel to 
remove liquid. Wash three times with 100 μL wash buffer per 
well, inverting plate on paper towel each time to remove 
liquid.
 13. Dilute 6 μL amplifier in 1.9 mL amplifier diluent. Mix well. 
Add 100 μL to each well with magnetic microspheres. Seal the 
plate with the plate sealer, place in the VorTemp incubator, and 
incubate 1 h at 50 °C with shaking at 600 rpm.
 14. Place the magnetic separation plate on the magnetic washer and 
let stand for 1 min. Invert the plate on a paper towel to remove 
liquid. Wash three times with 100 μL wash buffer per well, 
inverting plate on paper towel each time to remove liquid.
 15. Dilute 6 μL label probe in 1.9 mL label probe diluent. Mix 
well. Add 100 μL to each well with magnetic microspheres. 
Seal the plate with the plate sealer, place in the VorTemp incu-
bator, and incubate 1 h at 50 °C with shaking at 600 rpm.
 16. Place the magnetic separation plate on the magnetic washer and 
let stand for 1 min. Invert the plate on a paper towel to remove 
liquid. Wash three times with 100 μL wash buffer per well, 
inverting plate on paper towel each time to remove liquid.
 17. Turn the VorTemp to 25 °C and place a bag of ice in the 
VorTemp (see Note 15).
 18. Dilute 6 μL SAPE in 1.9 mL SAPE diluent. Mix well. Add 100 
μL to each well with magnetic microspheres. Seal the plate 
with the plate sealer, place in the VorTemp incubator, and 
incubate 30 min at 25 °C with shaking at 600 `.
 19. Place the magnetic separation plate on the magnetic washer 
and let stand for 1 min. Invert the plate on a paper towel to 
remove liquid. Wash three times with 100 μL SAPE wash 
 buffer per well, inverting plate on paper towel each time to 
remove liquid.
 20. Add 100 μL SAPE wash buffer to each well.
 21. Analyze microspheres from each well on FlexMAP 3D instru-
ment running XPONENT software (see Notes 16 and 17).
 1. To utilize xMELP for AML prognosis, detection reagents for 
the 17 test loci and 3 control loci previously described must 
first be obtained from the manufacturer.
 2. In order to use the standalone software available electronically 
in the supplementary materials, the R statistical software pro-
gram (www.r-project.org) must first be installed along with 
appropriate libraries (including the randomForestSRC package 
3.3 Data Processing 
and M-Score 
Calculation
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version 1.4). Because of the additional technical challenges 
associated with this installation, a web-accessible program is 
also available at https://labapps.shinyapps.io/MScore/.
 3. To correctly use the provided software or web-accessible appli-
cation to calculate M-Score, samples should be named with a 
unique identifier that is preceded by “H” (HpaII digests) or 
“M” (MspI digests). For example, for material processed from 
subject 1234, the respective samples should be named H1234 
and M1234 in order to allow the software to automatically pair 
these samples. The individual probes (listed as separate col-
umns) may occur in any order, but they should match the pre-
viously published locus names (e.g., “MSPI0406S00011246”).
 4. Data files from the FlexMAP 3D instrument should be saved 
in CSV (comma-separated values) format.
 5. Using the web application, the CSV file may be loaded into the 
M-score calculator. Upon loading, the full file is shown along 
with a subset representing median count data (to manually 
ensure that the data file has been correctly interpreted). 
Selecting the “Process” function will calculate M-Scores for all 
matched (HpaII and MspI both present) samples.
 6. A quality control cutoff (which may be altered in the web 
application or by editing the source code of the standalone 
program) is provided as a minimum value for the median 
counts. Previously published work has established 100 as a rea-
sonable default [10]. Samples that do not reach the necessary 
level of signal are omitted from the results. Low signal of a 
single enzyme (HpaII or MspI) sample suggests an amplifica-
tion failure, while low signal in both samples suggests an issue 
with DNA quality.
4 Notes
 1. Alternative instruments, such as the significantly less expen-
sive Luminex 100/200 systems with associated software, can 
be used.
 2. Numerous magnetic plates that are compatible with 96-well 
pates are available. We use the one listed since it has clamps 
that prevent the 96-well plate from dislodging from the mag-
net when inverted. We have found that placing a strip of mag-
netic tape on the underside of the 96-well plate also prevents 
dislodging. Automatic magnetic plate washers may also be 
used.
 3. As communicated by Affymetrix, optimal mixing occurs in the 
VorTemp 56 incubator. We have not attempted the assay in 
other shaker incubators.
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 4. The assay employing the 17 prognostic loci and 3 control loci 
is listed as Affymetrix # 411816–120. The list loci used in the 
AML xMELP assay can be found in Wertheim et al. [15]. 
Custom- made microsphere assays are available from Affymetrix.
 5. We use the Qiagen Gentra Puregene kit as this was recom-
mended by Figueroa et al. [13] and we were specifically advised 
to avoid silica column binding (ME Figueroa, personal com-
munication). However, we have successfully performed 
xMELP on purified DNA from other investigators who have 
used alternative methods of DNA extraction, including silica 
adsorption. IMPORTANTLY, in at least one case we have 
identified a Puregene kit that resulted in uniformly poor HpaII 
digestion in all samples and artifactually high M-scores. DNA 
“cleanup” methods on this DNA do NOT correct the inap-
propriate M-scores. We suggest, therefore, multiple samples 
with known M-scores should be re-extracted as a quality con-
trol each time a new Puregene kit is used.
 6. Master mixes can be used for this reaction and the following 
PCR step. For these mixes, we calculate amounts for at least 
one additional reaction in order to account for pipetting error.
 7. The ligation reaction requires ATP, not dATP.
 8. These reactions can proceed at room temperature on the 
benchtop; however, temperature standardization in a water 
bath or thermocycler is recommended.
 9. Given large number of amplifiable fragments in the starting 
DNA pool, the PCR reaches saturation between 10 and 20 
cycles. Increasing the number of cycles beyond 20 does not 
increase the assay sensitivity.
 10. The first extension prior to the cycling is critical. The ligation 
only ligates the JHpa24xxxx primer to the genomic DNA 
through the 5′ phosphate retained on the genomic DNA. The 
JHpa12xxxx primer does not ligate since it lacks a 5′ phos-
phate. The initial 72 °C incubation allows extension of 
sequence that is complementary to JHpa24xxxx and is required 
for the subsequent PCR cycles to proceed.
 11. The method used was developed by Affymetrix and additional 
details can be found at http://cdn.panomics.com/down-
loads/UM17353_QGP_DNAMagSep_UserManual_
RevA_091105.pdf.
 12. Master mixes can be used for the probeset mix and the micro-
sphere mix. For these mixes, we calculate amounts for at least 
one additional reaction in order to account for pipetting error. 
For large sample numbers, we generally calculate amounts for 
two or three additional reactions. For larger numbers of sam-
ples, n + 2 or even n + 3 reactions should be made.
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 13. The proper plate and seal combination must be used to 
ensure that the seal remains intact during the incubation. 
Improper sealing can result in sample contamination and 
evaporation.
 14. This is essentially a master mix. Reagent amounts needed for 
this and subsequent hybridization steps can be calculated using 
the 6 μL reagent to 1.9 mL diluent ratio.
 15. The VorTemp incubator will not start if the temperature is too 
high. We place a bag of ice in the incubator while performing 
the previous washes in order to cool rapidly. If the SAPE reac-
tion is prepared prior to incubator cooling, it can be kept at 
room temperature wrapped in aluminum foil.
 16. As indicated in the description of equipment, the alternative 
instruments and software can be used to analyze the micro-
spheres. All Luminex instruments require calibration and vali-
dation microspheres, and instructions for use of the instrument 
should be consulted prior to performing experiments. 
Microsphere regions for PE analysis (i.e., Luminex bead num-
bers) are provided with the probeset order. These should be 
entered into the analysis software prior to performing the 
experiment. Other instrument parameters are provided by 
Affymetrix.
 17. During instrument setup, the plate should remain shaking to 
prevent microsphere clumping. If we are running more than 
48 samples, we will pause the analysis half way through the 
run, shake for 2 min, and resume the analysis.
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Chapter 9
Genome-Wide Analysis of DNA Methylation 
in Hematopoietic Cells: DNA Methylation Analysis by WGBS
Mira Jeong, Anna G. Guzman, and Margaret A. Goodell
Abstract
DNA methylation is a major epigenetic modification that regulates gene expression, genome imprinting, 
and development and has a role in diseases including cancer. There are various methods for whole-genome 
methylation profiling that differ in cost and resolution. Recent advances in high-throughput sequencing 
technologies coupled with bisulfite treatment enable absolute DNA methylation quantification and 
genome-wide single-nucleotide resolution analysis. In this chapter, we provide detailed protocols for 
whole-genome bisulfite sequencing (WGBS), which captures the complete methylome. Using WGBS, we 
are able to generate a reference DNA methylome for normal or malignant hematopoietic cells.
Key words DNA methylation, CpG islands, Whole-genome bisulfite sequencing, High-throughput 
sequencing
1 Introduction
DNA methylation is a well-studied, heritable, and reversible epi-
genetic modification essential for diverse cellular processes. 
Specifically, DNA methylation is achieved via an enzymatic mecha-
nism in which a methyl group is added to the five-position of cyto-
sine, usually in the context of a CpG dinucleotide (Fig. 1a). CpG 
is almost invariably methylated, except when CpGs are at high den-
sity, in which case methylation tends to be lower or absent alto-
gether. While methylation patterns are fairly stable across cell types, 
some regions of the genome, such as enhancers, are variable in 
methylation levels among different cell and tissue types. Aberrant 
DNA methylation patterns are associated with a number of human 
diseases such as cancer and neurodevelopmental diseases. While 
DNA methylation in promoters and enhancers generally is corre-
lated with repression of gene expression, DNA methylation in gene 
bodies is positively correlated with active transcription. 
Comprehensive genome-wide DNA methylation maps may shed 
light on the role of DNA in normal development and diseases. 
paolo.fortina@jefferson.edu
138
Therefore, genome-wide mapping of DNA methylation is of great 
interest for epigenetic studies.
The development of high-throughput sequencing technology 
has facilitated genome-wide measurement of DNA methylation. 
Currently, several methods falling into three major assay types are 
utilized to study DNA methylation [1]. Bisulfite conversion-based 
methods, such as whole-genome bisulfite sequencing (WGBS) [2, 3] 
and reduced representation bisulfite sequencing, (RRBS) are 
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Fig. 1 (a) Methylation of cytosine to 5-methylcytosine by DNA methyltransferase. 
(b) Deamination of cytosine by sodium bisulfite conversion. Unmethylated cyto-
sines are converted to uracil. (c) DNA sequences following bisulfite conversion 
and PCR amplification. Unmethylated cytosine will be detected as thymine
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currently the most standard methods [4, 5], but methylation arrays 
and affinity capture methods are also used to assay methylation 
differences, particularly in human cells.
In bisulfite sequencing methods, sodium bisulfite is used to 
convert cytosines into uracils (Fig. 1b), which are then detected as 
thymines in subsequent PCR and sequencing [6]. In contrast, 
methylated cytosines and hydroxymethylated cytosines are left 
unmodified and identified as cytosines during DNA sequencing 
(Fig. 1c). The bisulfite conversion method has become a very 
effective approach for detecting genome-wide DNA methylation 
differences at a single-nucleotide resolution.
Affinity capture-based methods, such as methylated DNA 
immunoprecipitation sequencing (MeDIP-seq) [7, 8] and hydroxy-
methylated DNA immunoprecipitation sequencing (hMeDIP- seq) 
[9], use antibodies that recognize methylcytosines and hydroxy-
methylcytosines, respectively, to pull down methylated and hydroxy-
methylated genomic regions. Cytosine 5- methylenesulfonate 
sequencing (CMS-seq) utilizes both bisulfate conversion and affin-
ity capture methods for 5hmC detection [10] using CMS-specific 
antiserum. The last approach utilizes enrichment-based methods 
such as methylation-sensitive restriction enzyme digestion sequenc-
ing (MRE-seq) [11].
Affinity capture- and enrichment-based methods are cost- 
effective and simple; however, they provide lower resolution than 
bisulfite conversion. Bisulfite conversion-based methods, especially 
WGBS, provide high resolution and accurate data and are better at 
detecting differentially methylated regions, particularly with high 
sequencing coverage. The drawback to these approaches is that 
they are expensive and have bioinformatic challenges. For example, 
bisulfite conversion can vary in efficiency and challenges in aligning 
bisulfite-converted sequences to the reference genome due to the 
conversion of the many unmethylated Cs to Ts. Each method has 
its own advantages and disadvantages; therefore, it is important to 
choose the right method based on the question to be addressed. 
Here, we provide detailed experimental protocols for WGBS on 
the Illumina platform.
While we focus below on sample preparation (Fig. 2), sequenc-
ing depth should also be considered, as this is a significant factor in 
the total cost of the procedure. We recommend a minimum aver-
age coverage of 10–15-fold. This translates to approximately 200 
million reads using the current Illumina HiSeq protocols. However, 
better resolution and power to detect minor methylation differ-
ences can be attained with higher coverage.
Finally, the discovery of 5-hydroxymethylcystosine (5hmC) as a 
type of DNA methylation with potentially different properties from 
5mC has increased interest in detecting this mark. Importantly, 
bisulfite sequencing methods cannot distinguish between 5mC and 
5hmC, as cytosine modified with either mark are protected from 
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bisulfite. Therefore, bioinformatics analysis and interpretation must 
take this into account. Alternative methods such as oxidative bisul-
fite sequencing (OxBS-seq) [12] or Tet-assisted bisulfite sequencing 
(TAB-seq) [13] can be used to detect the 5hmC if desired.
2 Materials
 1. PureLink Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, 
USA).
 2. Quant-iT dsDNA Assay Kit, high sensitive (Invitrogen, 
Carlsbad, CA, USA).
 3. Snap-Cap MicroTUBE vials (Covaris, Woburn, MA, USA).
 4. 4–20% Criterion™ TBE Gel (Bio-Rad, Hercules, CA, USA).
 5. Low-binding DNAse-/RNAse-free microtubes (Ambion, 
Waltham, MA, USA).
2.1 Reagents
Genomic DNA  isolat ion
DNA fragmentat ion
End-repairing, A tailing
Adapter ligat ion
Bisulfite conversion
PCR amplificat ion
Quality control
Sequencing
A
T
T
A
Ready for sequencing
Fig. 2 Overview of the WGBS protocol. Isolated genomic DNA is fragmented to 
average 350 bp size. Repair the 3′ and 5′ overhangs into blunt ends and add 
single “A” to the 3′ end of the blunt fragment. After A-tailing, ligate methylated 
adapters to the A-tailed fragment, and treat with sodium bisulfite. Perform final 
amplification PCR and check library quality
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 6. TBE buffer, 10×, Molecular Biology Grade (Promega, 
Madison, WI, USA).
 7. Sybr Gold (Invitrogen, Waltham, MA, USA).
 8. TruSeq Nano DNA Sample Prep Kit (Illumina, San Diego, 
CA, USA).
 9. EpiTect Bisulfite Kit (Qiagen, Hilden, Germany).
 10. AMPure XP beads (Beckman Coulter, Brea, CA, USA).
 11. PfuTurbo Cx hotstart DNA polymerase (Agilent Technologies, 
Santa Clara, CA, USA).
 12. 100 mM dNTP mix (25 mM of each dNTP; Agilent 
Technologies, Santa Clara, CA, USA).
 13. EvaGreen (Biotium, Fremont, CA, USA).
 14. 100% ethanol.
 15. 10× PBS (GenDepot, Katy, TX, USA).
 16. Ultrapure DNAse-/RNAse-free water (Thermo Fisher, 
Waltham, MA, USA).
 17. 100 bp DNA Ladder (GenDepot, Katy, TX, USA).
 18. 6× DNA loading dye (Promega, Madison, WI, USA).
 19. High Sensitivity DNA Kit (Agilent, Santa Clara, CA, USA).
 1. Covaris S2 system (Covaris, Woburn, MA, USA).
 2. MicroTube holder (Covaris, Woburn, MA, USA).
 3. Dark Reader transilluminator (Clare Chemical Research, 
Dolores, CO, USA).
 4. Qubit fluorometer (Invitrogen, Carlsbad, CA, USA).
 5. DynaMag-2 magnet (Invitrogen, Carlsbad, CA, USA).
 6. Bio-Rad Thermal cycler (Bio-Rad, CFX96 Touch, Hercules, 
CA, USA).
 7. Real-time PCR cycler (Bio-Rad, C1000, Hercules, CA, USA).
 8. Criterion cell system (Bio-Rad, Hercules, CA, USA).
 9. Heat blocks.
 10. Vortex mixer.
 11. Bioanalyzer (Santa Clara, CA, USA).
 12. Illumina HiSeq 2500 (San Diego, CA, USA).
3 Methods
 1. Resuspend cells into 200 μL of PBS, add 20 μL of proteinase 
K and 20 μL of RNase from the PureLink Genomic DNA iso-
lation kit, mix thoroughly, and incubate for 2 min at room 
temperature (see Notes 1–3).
2.2 Equipment
3.1 Genomic DNA 
Isolation
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 2. Add 200 μL PureLink Genomic lysis/binding buffer and mix 
well by vortexing.
 3. Incubate at 55 °C for 3 h to overnight (see Note 4).
 4. Add 200 μL of 96–100% ethanol to the lysate. Mix well by 
vortexing to yield a homogenous solution.
 5. Proceed immediately to isolating DNA using a spin column 
from the PureLink Genomic DNA Kit.
 6. Place spin column in a provided collection tube. Transfer 640 
μL of reaction mix to the spin column and centrifuge for 30 s 
at full speed.
 7. Wash column with 500 μL of washing buffer and centrifuge for 
30 s at full speed.
 8. Centrifuge column in the same collection tube for an addi-
tional 30 s at full speed to remove remaining buffer.
 9. Place column into a clean PCR tube and elute genomic DNA 
with 50 μL of warm elution buffer from the kit. Perform a 
second elution to recover more DNA using an additional 50 
μL of warm elution buffer.
 10. Measure the DNA concentration using Qubit dsDNA HS 
assay kit according to the manufacturer’s instructions.
 11. Quantify 100 ng–1 μg of DNA in up to 100 μL of volume. If 
the DNA volume is <100 μL, add EB buffer to make total 
volume equal to 100 μL.
 1. Fill the Covaris water bath with deionized water up to the level 
indicated on the tank. Turn on the cooling system connected 
to the Covaris to maintain the bath temperature between 6 
and 8 °C, and degas the water bath for 30 min prior to use.
 2. Set the Covaris at the appropriate operating condition. Covaris 
conditions for a 350 bp size fragmentation are as follows:
Duty cycle 10%
Intensity 4
Cycle/burst 200
Time 40 s
 3. Transfer 100 μL of genomic DNA into the microtube through 
the presplit septa by slowly releasing sample along the wall of 
the microtube. Make sure to keep the cap on the tube and 
avoid the introduction of bubbles.
 4. Load the microtube inside the Covaris holder.
 5. Start run process (see Note 5).
3.2 DNA 
Fragmentation 
and Cleanup 
Fragmented DNA
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 6. After process, remove holder and transfer the processed sample 
to a new 1.5 mL tube.
 7. Let AMPure XP beads come to room temperature, and vortex 
for at least 1 min to ensure even distribution. Add 1.6× 
AMPure XP beads to sample and pipette entire volume ten 
times to homogenize.
 8. Incubate at room temperature for 5 min.
 9. Place sample on a magnetic rack at room temperature for 
5 min or until the liquid is clear.
 10. Carefully remove and discard all supernatant from the tubes 
without disturbing the beads.
 11. With tubes on magnetic rack, rinse twice with 200 μL of freshly 
made 80% EtOH.
 12. Air-dry the bead pellet on the magnetic stand for 5 min.
 13. Resuspend beads with 62.5 μL of resuspension buffer and mix 
well by pipetting entire volume ten times. Incubate homoge-
nized sample for 2 min at room temperature.
 14. Place tubes back on magnetic rack for 5 min.
 15. Transfer 60 μL of clear supernatant into a new PCR tube.
 16. Quantify DNA concentration by using Qubit dsDNA HS assay 
kit.
 1. Use 100 ng–1 μg of fragmented DNA in up to 60 μL of 
volume. Add resuspension buffer to bring the total volume 
to 60 μL.
 2. Add 40 μL end-repair mix for a total volume of 100 μL, mix 
well by pipetting entire volume ten times, and centrifuge for 
30 s at full speed.
 3. Incubate at 30 °C for 30 min, and then place the samples on 
ice (see Note 6).
 4. Vortex the sample purification beads from the kit to ensure 
even distribution. Warm beads to room temperature before 
use.
 5. Dilute 95 μL of sample purification beads in 65 μL nuclease- 
free water.
 6. Add 160 μL of diluted sample purification beads to the end- 
repair reaction mixture. Pipette the entire volume ten times 
and incubate at room temperature for 5 min.
 7. Place the tubes on a magnetic stand for 5 min.
 8. Transfer 250 μL of the supernatant, containing the DNA of 
interest, from each tube to a new PCR tube. Discard tubes 
containing beads.
3.3 End-Repair, 
Poly-a Tailing, 
and Adaptor Ligation 
(Illumina Nano DNA 
Sample Prep kit)
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 9. Vortex sample purification beads for at least 1 min. Add 30 μL 
of room temperature undiluted sample purification beads to 
each sample containing 250 μL of the supernatant with 
DNA. Pipette the entire volume ten times.
 10. Incubate at room temperature for 5 min.
 11. Place sample on a magnetic rack at room temperature for 
5 min or until liquid is clear.
 12. Carefully remove and discard all supernatant from the tubes 
without disturbing the beads.
 13. With tubes on the magnetic rack, rinse twice with 200 μL of 
freshly made 80% EtOH.
 14. Air-dry the bead pellet on the magnetic stand for 5 min.
 15. Resuspend beads with 20 μL of resuspension buffer and mix 
well by pipetting the entire volume ten times. Incubate for 
2 min at room temperature.
 16. Place tubes on magnetic rack for 5 min.
 17. Transfer 17.5 μL of clear supernatant into a new PCR tube.
 18. Add 12.5 μL A-tailing mix to 17.5 μL supernatant, and pipette 
the entire volume of the reaction mixture ten times.
 19. Incubate at 37 °C for 30 min and 70 °C for 5 min and hold at 
4 °C (see Note 7).
 20. When the thermal cycler temperature has been at 4 °C for 5 
min, remove tubes from it. Briefly centrifuge and keep on ice 
then proceed to the next ligation step.
 21. Add 2.5 μL of resuspension buffer, 2.5 μL of Ligation Mix, 
and 2.5 μL of DNA adaptor index to the reaction mixture.
 22. Pipette the entire volume ten times and centrifuge briefly.
 23. Incubate at 30 °C for 10 min, and then place on ice.
 24. Add 5 μL of Stop Ligation Buffer to the mix and pipette to mix.
 25. Add 42.5 μL well-mixed sample purification beads, pipette ten 
times, and incubate 5 min at room temperature.
 26. Place the tubes on a magnetic rack for 5 min.
 27. Carefully remove and discard 80 μL of the supernatant with-
out disturbing beads.
 28. Wash the beads twice with 200 μL freshly made 80% ethanol. 
Allow to air-dry at room temperature for 5 min.
 29. Remove tubes from the magnetic rack and resuspend the beads 
in 52.5 μL of resuspension buffer by pipetting ten times. 
Incubate for 2 min at room temperature.
 30. Place tubes on the magnetic rack for 5 min at room temperature.
 31. Transfer 50 μL of supernatant to a new PCR tube.
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 32. Add 50 μL of well-mixed sample purification beads, pipette ten 
times, and incubate 5 min at room temperature.
 33. Carefully remove and discard 100 μL of the supernatant with-
out disturbing beads.
 34. Wash the beads twice with 200 μL freshly made 80% ethanol. 
Allow to air-dry at room temperature for 5 min.
 35. Remove tubes from the magnetic rack and resuspend the beads 
in 27.5 μL resuspension buffer by pipetting ten times. Incubate 
for 2 min at room temperature.
 36. Place tubes on the magnetic rack for 5 min at room 
temperature.
 37. Transfer 25 μL of supernatant to a new PCR tube.
 38. Proceed to bisulfite conversion.
 1. Set up a bisulfite conversion per the manufacturer’s recom-
mendations (EpiTect Bisulfite Kit, Qiagen).
Bisulfite conversion reaction mix:
Reagents
Volume per  
reaction (μL)
Ligated DNA library  20
Bisulfite mix (dissolved)  85
DNA protect buffer  35
Total volume 140
 2. Perform bisulfite conversion as per manufacturer’s recommen-
dations to avoid template degradation and DNA loss during 
treatment and cleanup, while achieving high bisulfite  conversion 
rates of the DNA. Two consecutive rounds of bisulfite conver-
sion help to achieve ≥99% conversion ratio.
 3. PCR conditions.
Stage Temperature and time
Denaturation 95 °C for 5 min
Incubation 60 °C for 25 min
Denaturation 95 °C for 5 min
Incubation 60 °C for 85 min
Denaturation 99 °C for 5 min
Incubation 60 °C for 175 min
Hold 20 °C forever
 4. Once the bisulfite conversion is complete, briefly centrifuge 
PCR tubes and transfer the complete bisulfite reactions to 
3.4 Bisulfite 
Conversion
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clean 1.5 mL tubes (any precipitants in the solution will not 
affect the performance or yield of the reaction).
 5. Make a master mix of 310 μL of freshly prepared buffer BL + 
10 μg/mL carrier RNA. Mix the master mix solution by vortex 
and centrifuge briefly. Add 310 μL of the master mix to each 
sample.
 6. Add 250 μL ethanol, vortex for 15 s, and centrifuge briefly to 
remove any drops from inside the lid.
 7. Place an EpiTect spin column and collection tube in a suitable 
rack. Transfer the solution from step 3 into the EpiTect spin 
column, and centrifuge the column at maximum speed for 
30 s. Run the flow-through once more through the column and 
centrifuge at maximum speed for 1 min. Discard flow-through.
 8. Add 500 μL of Buffer BW (wash buffer) to the spin column, 
and centrifuge at maximum speed for 1 min. Discard flow- 
through, and place the spin column back into the collection 
tube.
 9. Add 500 μL of Buffer BD (desulfonation buffer) to the spin 
column and incubate for 15 min at room temperature. 
Centrifuge column at maximum speed for 1 min, and discard 
flow-through.
 10. Add 500 μL of Buffer BW. Centrifuge at maximum speed for 
1 min. Discard flow-through.
 11. Repeat step 7.
 12. Place the spin column into a clean 1.5 mL microcentrifuge 
tube. Add 20 μL of warm Buffer EB to the center of the col-
umn. Elute the purified DNA by centrifugation for 1 min at 
15,000 × g (12,000 rpm).
 13. Add an additional 20 μL of warm Buffer EB to the center of the 
column, and centrifuge for 1 min at 15,000 × g (12,000 rpm) 
(see Notes 8 and 9).
 1. Prepare a PCR master mix.
Component Amount (μL)
PfuTurbo Cx DNA polymerase buffer (10×) 10
dNTP (25 mM each, 100 mM)  1
DNA template 20
Primer cocktail 10
Pfu Turbo Cx DNA polymerase  2
EvaGreen  5
Water 57
3.5 Library PCR 
Amplification 
and Bead Purification
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Add the PCR master mix to each 20 μL bisulfite-converted 
library. Mix well and divide the reaction into two tubes with 50 μL 
each (see Note 10).
 2. Amplify the Reaction in Real-Time PCR Cycle.
Stage Temperature (°C) Time Cycles
Denaturation 95 3 min 1
Library amplification 98 20 s 5–15
60 15 s
72 30 s
 4 Hold 1
 3. To minimize the bias caused by PCR, monitor the amplifica-
tion cycles. The optimal PCR cycle is the midpoint of the lin-
ear phase of the amplification curves. The red line marks the 
midpoint of the linear phase of the amplification curves and is 
used to determine the optimal numbers of amplification cycles 
(Fig. 3a, see Note 11).
 4. When the PCR is finished, combine each reaction set and 
purify PCR products using 1× AMPure XP bead.
 5. Elute into 20 μL of resuspension buffer.
 1. Quantify libraries using Qubit fluorometer. Expected DNA 
concentration is 10–30 ng/μL.
 2. Check the library size distribution by running 1 μL of the final 
library using Bioanalyzer High Sensitivity DNA Kit. Expected 
average size of distribution is 300–500 bp (Fig. 3b).
4 Notes
 1. Bench, pipettes, and racks used should be thoroughly cleaned 
with DNA decontamination solution.
 2. Use low DNA-binding DNAse-/RNAse-free plastic tubes and 
filter tips.
 3. We recommend starting with a minimum of 50,000 cells for 
best results. The yield of genomic DNA per hematopoietic cell 
is around 5–10 pg on average.
 4. Avoid DNA degradation and remove cellular RNA and pro-
teins completely. Remaining RNA will affect DNA quantifica-
tion, and DNA-binding proteins will affect downstream 
enzyme reactions as well as bisulfate conversion. Intact genomic 
DNA without degradation and without protein and RNA con-
tamination is important.
3.6 Library Quality 
Control
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 5. Covaris shearing generates dsDNA fragment with 3′ or 5′ 
overhangs.
 6. If the thermocycler cannot hold 100 μL volume, divide reaction 
mix into two tubes or use water bath. In this step, DNA frag-
ments with overhangs are converted to blunt-ended fragments.
 7. A single “A” nucleotide is added to the 3′ ends of the blunt 
fragments to prevent them from ligating to each other during 
the adapter ligation reaction. A corresponding single “T” 
nucleotide on the 3′ end of the adapter provides a complemen-
tary overhang for ligating the adapter to the fragment. This 
strategy ensures a low rate of chimera (concatenated template) 
formation.
 8. Bisulfite-converted DNA can be stored at −80 °C for about 6 
months. The major sources of sequencing bias and measure-
ment error come from incomplete bisulfite conversion. 
Confirm bisulfite conversion rate is >99% (Bisulfite conver-
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Fig. 3 WGBS library QC. (a) Example of real-time analysis of final PCR amplification with fluorescent dye 
EvaGreen in it. Results were obtained using CFX96 Touch Real-Time PCR Detection systems (Bio-Rad). 
(b) Example for a size distribution of final library analyzed on a Bioanalyzer (Agilent)
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sion rate = Total number of C conversions in non-CpG 
context divided by total number of Cs in non-CpG context).
 9. Bisulfite conversion defects include fC, caC detected as unmeth-
ylated C, and 5mC and 5hmC detected as methylated C.
 10. PfuTurbo Cx DNA polymerase is a proofreading PCR enzyme 
that does not stall when it encounters uracil, the product of the 
bisulfite reaction. Differential PCR efficiency for methylated 
versus unmethylated sequence is one of the potential sources 
of biased results.
 11. The WGBS method is accurate and reproducible compared 
with other methods. The major sources of bias and  measurement 
error stem from incomplete bisulfite conversion and differen-
tial PCR efficiency for methylated versus unmethylated ver-
sions of the sequences.
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Chapter 10
Detection and Quantification of Acute Myeloid  
Leukemia- Associated Fusion Transcripts
Jonathan Schumacher, Philippe Szankasi, and Todd W. Kelley
Abstract
Real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR)-based detection of 
abnormal fusion transcripts is an important strategy for the diagnosis and monitoring of patients with 
acute myeloid leukemia (AML) with t(8;21)(q22;q22); RUNX1-RUNX1T1, inv(16)(p13.1;q22); 
CBFB- MYH11 or t(15;17)(q22;q12); PML-RARA. In RT-qPCR assays, patient-derived cDNA is sub-
jected to amplification using PCR primers directed against the fusion transcript of interest as well as a 
reference gene for normalization. Quantification is typically performed by constructing standard curves 
for each PCR run using a series of plasmid standards of known concentration that harbor the same 
fusion transcript or the same reference gene of interest. Fusion transcripts and reference gene copy 
numbers are then calculated in patient samples using these standard curves. The process of construct-
ing standard curves is laborious and consumes additional reagents. In this chapter, we give the method 
details for a multiplex RT-qPCR strategy to detect and quantify the acute myeloid leukemia (AML)-
associated fusion transcripts PML-RARA in patients with t(15;17) without the need for standard 
curves. This general method can also be applied to other AML-associated fusion transcripts such as 
CBFB-MYH11 and RUNX1-RUNX1T1.
Key words Acute myeloid leukemia, PML-RARA, RT-qPCR, Normalized copy number, Minimal 
residual disease
1 Introduction
Acute myeloid leukemia (AML) is a genetically heterogeneous 
group of hematologic malignancies that arise due to acquired 
chromosomal rearrangements and mutations. Common, recur-
rent translocations include t(8;21)(q22;q22), t(15;17)
(q22;q21), and inv(16)(p13.1;q22) generating RUNX1-
RUNX1T1, PML- RARA, and CBFB-MYH11 fusion tran-
scripts, respectively [1, 2]. The identification of cytogenetic 
abnormalities is important for risk stratification and for thera-
peutic decisions [3, 4].
Expression of PML-RARA fusion transcripts is a hallmark of 
acute promyelocytic leukemia (APL) [5]. This cytogenetic 
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abnormality confers a favorable prognosis. Patients are treated 
with a regimen unique to APL utilizing all-trans-retinoic acid 
(ATRA) and arsenic trioxide (ATO) [6]. Despite the high rate of 
complete remission, up to 30% of patients eventually relapse [7].
Three PML-RARA isoforms exist and differ in the location of 
the PML breakpoint (see Fig. 1) [8]. The bcr1 PML breakpoint is 
intronic and forms fusion transcripts between PML exon 6 and 
RARA exon 6. The bcr2 breakpoint occurs in variable regions 
within PML exon 6 and fuses to RARA exon 6. The bcr3 PML 
breakpoint is also intronic and forms fusion transcripts between 
PML exon 3 and RARA exon 6. Other PML-RARA isoforms 
have been described but occur rarely [9].
Real-time reverse transcription quantitative PCR 
(RT-qPCR) analysis of PML-RARA fusion transcripts can be 
an important component in the monitoring of patients owing 
to its simplicity and sensitivity. This method also allows for 
detection of minimal residual disease (MRD) and early relapse 
[10, 11]. It is possible to target both bcr1 and bcr2 forms with 
the same primer and hydrolysis probe set because of their simi-
lar breakpoints (see Fig. 1). The bcr3 forms can be detected 
with a second primer set and a reference gene with a third. The 
most common method of quantitation is amplifying a series of 
plasmid standards of known concentration to generate standard 
curves. The crossing point (Cp), or point at which fluorescence 
rises above background during a PCR reaction in patient speci-
mens, is determined for each reaction and used to calculate 
copy number (CN) by extrapolating from the standard curves. 
A normalized copy number (NCN) is then generated reflecting 
the ratio of fusion transcripts to reference transcripts. The 
NCN value is monitored in follow-up specimens to assess treat-
ment response.
The use of plasmid standards for quantitation has several dis-
advantages. First, the large number of required plasmid standards 
increases assay complexity. Second, the plasmid standards are 
laborious to create or purchase and add to assay costs. Here we 
describe the method details for a strategy to quantitate 
Fig. 1 Illustration of three PML-RARA isoforms and involved exons
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PML-RARA fusion transcripts that does not require the genera-
tion of standard curves. The NCN of each fusion and reference is 
calculated relative to a single plasmid calibrator that contains one 
copy of the bcr1 or bcr3 cDNA fusion and one copy of the ABL1 
reference on the same plasmid molecule representing a 1:1 ratio 
of fusion and reference (see Fig. 2). The plasmid calibrator is 
amplified at a single concentration, and the NCN in patient speci-
mens on the same run is calculated by extrapolation using the 
ΔΔCp method [12–14].
2 Materials
 1. Two plasmid calibrators are synthesized. The bcr1/ABL1 plas-
mid consists of a PML exon 6-RARA exon 3 fusion and a 
 fragment of ABL1 exons 3–4. The bcr3/ABL1 plasmid con-
sists of a PML exon 3-RARA exon 3 fusion and a fragment of 
ABL1 exons 3–4. The PML-RARA bcr1/ABL1 or bcr3/ABL1 
plasmid calibrators were designed using the following refer-
ence sequences: PML-NM_033238.2, RARA-NM_000964.3, 
and ABL1-NM_005157.5. The bcr1 calibrator was synthe-
sized with the following elements: EcoRI restriction site, PML 
nt positions 1539–1797, RARA nt positions 657–805, 
HindIII restriction site, ABL1 nt positions 426–793, and 
BglII restriction site. The bcr3 calibrator links the following 
2.1 PML-RARA bcr1/
ABL1 and PML-RARA 
bcr3/ABL1 Plasmid 
Calibrators (Integrated 
DNA Technologies, 
Coralville, IA)
Fig. 2 Design strategy for PML-RARA bcr1/ABL1 (a) and bcr3/ABL1 (b) plasmid 
calibrators
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fragments: EcoRI restriction site, PML nt positions 1050–
1323, RARA nt positions 657–805, HindIII restriction site, 
ABL1 nt positions 426–793, and BglII restriction site (see 
Fig. 3). Both fragments were cloned into pIDTSMART 
(Integrated DNA Technologies) (see Note 1).
 2. 10 mM Tris–HCl, 0.5 mM EDTA, pH = 8.0.
 1. Hematology analyzer (see Note 2).
 2. RNA-dedicated biocontainment hood.
 3. Maxwell® instrument (Promega, Madison, WI) (see Note 3).
 4. Maxwell 16® LEV simplyRNA Purification Kit (Promega).
 5. Centrifuge and vortex.
 6. Sterile 15 mL conical tubes.
 1. Ipsogen RT Kit (Qiagen, Valencia, CA) (see Note 4).
 2. Thermocycler.
 3. Nuclease-free PCR strip tubes and caps.
 4. Nuclease-free water.
 1. LightCycler® 480 real-time PCR instrument (Roche, Basel, 
Switzerland) (see Note 5).
 2. LightCycler® 480 Multiwell Plate 96 (Roche).
 3. LightCycler® 480 Multiwell Plate 96 Sealing films (Roche).
 5. PerfeCta® Multiplex qPCR ToughMix® (no ROX) (Quanta 
Biosciences, Gaithersburg, MD).
 6. PCR primers and probes (Integrated DNA Technologies) 
(see Table 1 and Note 6).
 7. PCR primer and probe resuspension calculator (available at 
http://www.idtdna.com/Calc/resuspension/).
2.2 RNA Isolation
2.3 Reverse 
Transcription
2.4 RT-qPCR
Fig. 3 Illustration of PML-RARA bcr1/ABL1 (a) and bcr3/ABL1 (b) target regions included in plasmid 
calibrators
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3 Methods
Carry out all steps in a dedicated clean laboratory devoid of PCR 
amplicon and plasmid, unless otherwise specified. Wear gloves and 
laboratory coat at all times and change gloves often during RNA 
isolation and reverse transcription or when working with plasmids. 
Plasmids should be diluted individually to reduce the likelihood of 
cross-contamination. Maintain all reagents at recommended 
temperatures.
 1. If lyophilized, centrifuge plasmids at 6000 × g for 1 min. 
Reconstitute plasmids to 50 ng/μL with Tris–EDTA, pH = 8.0. 
Aliquot plasmids into multiple tubes can be stored at −20 °C 
for long term.
 2. Dilute plasmids to a 1:10,000 working stock in Tris–EDTA, 
pH = 8.0, and store at −20 °C.
 1. Prepare homogenization solution by adding 20 μL of 
1- thioglycerol per 1 mL of homogenization solution. Store on 
ice or at 2–10 °C.
3.1 Plasmid 
Calibrator Preparation
3.2 Total RNA 
Isolation from Patient 
Specimens
Table 1 
Primer and probe sequences
Oligonucleotide Sequence (5′ – 3′)
Target 
exon(s) Target positions
PML-RARA:
PML bcr1/2 F ACCTGGATGGACCGCCTAG 6 1702 − 1720
PML bcr3 F CCGATGGCTTCGACGAGTT 3 1258 − 1276
RARA R GCTTGTAGATGCGGGGTAGAG 6 737 − 717
RARA P 6-FAM AACTGCTGC/ZEN/
TCTGGGTCTCAATGGa
6 680 − 657
ABL1:
ABL1 F GCAATGCCGCTGAGTATC 3 593 − 610
ABL1 R GGGACACACCATAGACAGTG 4 880 − 861
ABL1 P Cy5 ACACTGCTTCTGATGGCAAGCTCTb 3–4 722 − 745
Primers and probes designed based upon the following reference sequences:
PML: NM_033238.2, RARA: NM_000964.3, and ABL1: NM_005157.5
F forward, R reverse, and P probe
aThe RARA probe is labeled with a 5′ 6-FAM dye and is double-quenched with ZEN™ internal and 3′ Iowa Black® FQ
bThe ABL1 probe is labeled with a 5′ Cy5 dye and is single-quenched with 3′ Iowa Black® RQ-SP
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 2. Prepare DNase I solution by adding 275 μL of nuclease-free 
water to lyophilized vial of DNase I. Invert to rinse residual 
DNase I off cap and swirl to mix. Add 5 μL of blue dye to 
resuspended DNase I as a visual cue for pipetting. Aliquot 
DNase I into 11 μL single-use aliquots and store at −20 °C.
 3. Using a hematology analyzer, count the number of white 
blood cells (WBCs) from EDTA whole blood or bone marrow 
(see Note 7).
 4. Transfer a specimen volume corresponding to 1 × 107 WBCs 
into a sterile 15 mL conical tube, and add 7.5 mL of cell lysis 
solution (see Note 8). Invert 5–6 times to mix.
 5. Incubate at room temperature for 10 min. Invert to mix twice 
during incubation to facilitate lysis.
 6. Centrifuge tube at 3000 × g for 10 min.
 7. Remove and discard supernatant without disturbing WBC pel-
let. Briefly centrifuge tube, and remove and discard residual 
supernatant with a pipette without disturbing WBC pellet.
 8. Add 200 μL chilled 1-thioglycerol/homogenization solution to 
WBC pellet and mix by vortexing or pipetting to resuspend.
 9. Add 200 μL lysis buffer and 25 μL proteinase K to the resus-
pended pellet. Vortex for 20 s to thoroughly resuspend.
 10. Incubate at room temperature for 10 min and prepare the sim-
plyRNA Blood Cartridge during incubation. Remove one vial 
of DNase I solution per specimen from freezer and thaw on 
ice. Add 10 μL DNase I solution to well #4 of the simplyRNA 
Blood Cartridge.
 11. Following incubation, add lysate to well #1 of the simplyRNA 
Blood Cartridge.
 12. Place cartridge in Maxwell® 16 LEV Cartridge Rack with the 
label side facing away from the Elution Tubes. Press cartridge 
down to snap into position. Gently peel back seal and discard.
 13. Place an LEV Plunger in well #8 of each cartridge.
 14. Place a 0.5 mL Elution Tube in the front of the Maxwell® 16 
LEV Cartridge Rack, and add 50 μL nuclease-free water to the 
bottom of the elution tube.
 15. Place rack in Maxwell® instrument and close door.
 16. Run the simplyRNA Blood protocol.
 17. When run is complete, transfer RNA to an RNase-free 1.5 mL 
tube and store at −80 °C (see Note 9).
 1. Thaw RNA on ice and add 10 μL of total RNA to 0.2 mL PCR 
tube (see Note 10). Incubate at 65 °C for 5 min.
 2. Place tube on ice for 5 min.
3.3 Reverse 
Transcription
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 3. Pulse spin tube and replace on ice.
 4. Prepare a reverse transcription mastermix by combining all 
reagents (see Table 2).
 5. Add 15 μL reverse transcription mastermix to RNA and pipette 
to mix. Centrifuge briefly.
 6. Run the following program in a thermocycler: 25 °C for 
10 min followed by 50 °C for 60 min followed by 85 °C for 
5 min and 4 °C for 5 min.
 7. Store cDNA at −20 °C.
 1. Resuspend PCR primers (see Table 1) to 100 μM in 10 mM 
Tris–HCl, 0.5 mM EDTA, pH = 8.0 using a PCR primer, 
and probe resuspension calculator. Store at −20 °C long 
term.
 1. Thaw patient cDNA on ice and in dedicated amplicon labora-
tory; thaw working stock plasmid calibrators on ice.
 2. Prepare a 96-well plate layout reflecting the analysis of each 
patient specimen and plasmid calibrator in duplicate and water 
control in singlet (see Fig. 4).
 3. Prepare PML-RARA bcr1/2-ABL1 and bcr1/ABL1 master-
mixes following Table 3. Add 1–2 dead volumes.
 4. Gently vortex PML-RARA bcr1/2-ABL1 and bcr3-ABL1 
mastermixes and briefly centrifuge.
 5. Pipette 20 μL of PML-RARA bcr1/2-ABL1 mastermix into 
wells dedicated for bcr1/2 reactions and 20 μL of bcr3-ABL1 
mastermix into wells dedicated for bcr3 reactions (see Fig. 4).
3.4 Preparation 
of Multiplex 
and Individual PCR 
Primer and Probe 
Mixes
3.5 Real-Time 
Quantitative PCR 
(RT-qPCR)
Table 2 
Reverse transcription mastermix reagents
Reagent Volume (μL)
Final 
concentration
Reverse transcriptase buffer 5.0 1×
dNTP mix (10 mM each) 2.0 0.8 μM
Random nonamers (100 μM) 5.25 21 μM
RNase inhibitor (40 U/μL) 0.5 0.8 U/μL
Reverse transcriptase (200 U/μL) 1.0 8 U/μL
DTT 1.25
Final volume 15.0
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 6. Pipette 5 μL of patient cDNA into the two wells correspond-
ing to PML-RARA bcr1/2-ABL1 and 2 wells corresponding 
to PML-RARA bcr3-ABL1.
 7. Transition plate to dedicated amplicon laboratory and pipette 
5 μL of plasmid calibrator into each designated well.
 8. With a multichannel pipette set to 20 μL, mix each well 5×.
 9. Cover plate with optical sealing film.
 10. Centrifuge at 550 × g for 1 min.
 11. Place plate in LightCycler® 480 real-time PCR instrument and 
program the following conditions:
Table 3 
25× primer-probe mastermix reagents
Component Volume (μL)
Final concentration 
volume (μM)
PML bcr1/2 OR bcr3 F 12.5 5.0
RARA R 12.5 5.0
RARA P 2.5 1.0
ABL1 F 5.0 2.0
ABL1 R 5.0 2.0
ABL1 P 2.5 1.0
Water 160.0
Final volume 200.0
F forward, R reverse, and P probe
Fig. 4 Illustration of PCR plate setup for multiplex amplification of PML-RARA and 
ABL1. Patient specimens and controls are amplified in duplicate for both bcr1/2- 
ABL1 and bcr3-ABL1
Jonathan Schumacher et al.
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●● Under Setup:
 – Select Multi Color Hydrolysis Probe then Customize. Select 
Cyan 500 and FAM as active Filter Combinations and OK.
 – Change Reaction Volume to 25 μL.
●● Under Program:
 – Add two Programs. The first, Hot Start, should consist of 
1 cycle and None under Analysis Mode, and the second, 
Amplification, should consist of 45 cycles and Quantification 
under Analysis Mode.
●● Under Temperature targets:
 – Select Hot Start from Program Name. Target temperature 
is 95 °C, Acquisition Mode of None, Hold for 2:00, and 0 
for Set Target, Step Size, and Step Delay.
 – Select Amplification from Program Name. Target temper-
ature is 95 °C, Acquisition Mode of None, Hold for 15 s, 
Ramp Rate of 4.4, and 0 for Set Target, Step Size, and 
Step Delay.
 – Add a second step with Target temperature of 60 °C, 
Acquisition Mode of Single, Hold for 60s, Ramp Rate of 
4.4, and 0 for Set Target, Step Size, and Step Delay.
 12. Start Run.
 13. When the run is complete, open Subset Editor, and create 2 
subsets: bcr1/2-ABL1 and bcr3-ABL1. Select the specimens 
corresponding to each subset and Apply.
 14. Open Sample Editor.
●● Under Step 1: Select Workflow, and select Rel Quant.
●● Under Step 2: Select Samples, and use the dropdown arrow 
to select the bcr1/2- ABL1 subset.
●● In the right box, define replicate specimens and type specimen 
name. Identify patient specimen wells with the Filter 
Combination of FAM as bcr1/2 and designate as Target 
Unknown. Identify patient specimen wells with the Filter 
Combination of Cyan 500 as ABL1 and designated as Reference 
Unknown. The bcr1/2 plasmid calibrator wells should be des-
ignated as Target PosCalibrator and Reference PosCalibrator, 
respectively. Water control should be designated as Target 
Negative and Reference Negative, respectively.
●● Under Step 2: Select Samples, and use the dropdown arrow 
to select the bcr3- ABL1 subset.
●● In the right box, define replicate specimens and type specimen 
name. Identify patient specimen wells with the Filter 
Combination of FAM as bcr3 and designate as Target Unknown. 
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Identify patient specimen wells with the Filter Combination of 
Cyan 500 as ABL1 and designated as Reference Unknown. The 
bcr3 plasmid calibrator wells should be designated as Target 
PosCalibrator and Reference PosCalibrator, respectively. Water 
control should be designated as Target Negative and Reference 
Negative, respectively.
 15. Select Analysis using the Advanced Relative Quantification 
method for bcr1/2-ABL1 subset and select Calculate. Under 
the Results tab, the NCN or ratio of bcr1/2 to ABL1 will 
appear. Raw data may be viewed under the Sample View tab.
 16. Select Add Item and under Analysis Type, select Advanced Relative 
Quantification method for bcr3-ABL1 subset and select Calculate. 
Under the Results tab, the NCN or ratio of bcr3-ABL1 will appear. 
Raw data may be viewed under the Sample View tab.
 17. Specimens with amplification of PML-RARA bcr1/2 often 
exhibit amplification in the bcr3 reaction, whereas specimens 
with amplification in the bcr3 reaction should not exhibit 
amplification in the bcr1/2 reaction (see Note 11).
 18. QC indicators should be validated per institution reflecting 
WBC input, RNA isolation and reverse transcription method, 
and real-time PCR instrumentation. No template (water) con-
trols should not amplify, and patient specimens should amplify 
in duplicate with minimal validated Cp differences (ex: <1.0) 
between replicates.
4 Notes
 1. Restriction sites were included in the event that individual 
fragments require cloning.
 2. A hematology analyzer is used to enumerate WBCs for stan-
dardized cell input in RNA isolation.
 3. Other validated RNA isolation methods may be used.
 4. Other validated reverse transcription methods may be used.
 5. Other validated real-time PCR instrumentation may be used 
but ensure that probe fluorescent dyes are compatible.
 6. PCR primers probes may be ordered salt-free. HPLC purifies 
fluorescent probes to ensure highest purity.
 7. RNA isolation must occur within 48 h of collection to ensure 
RNA integrity. Ethylenediaminetetraacetic acid (EDTA) is the 
recommended anticoagulant as heparin and citrate may con-
tain PCR inhibitors.
 8. A standard 1 × 107 WBCs generates lower ABL1 Cps and 
greater assay sensitivity. If 1 × 107 WBCs are not possible, use 
highest blood volume possible (up to 2.5 mL).
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 9. RNA is highly labile, and freeze-thaw cycles should be kept to a 
minimal to reduce degradation. Reverse transcription should be 
performed immediately upon completion of RNA isolation.
 10. RNA solution may be discolored from bead carry-over during 
isolation, but beads should not impact assay performance.
 11. Specimens expressing the bcr1 or 2 isoform retain PML exons 
3–6. As a result, these cases will amplify in the bcr3 reaction, 
but because the PML region includes three exons, the product 
is longer and will yield higher Cp values due to relatively inef-
ficient amplification. Specimens expressing the bcr3 isoform 
lack PML exon 6 and will not amplify in the bcr1/2 reaction.
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Chapter 11
Targeted Next-Generation Sequencing of Acute Leukemia
Eric Konnick, Christina M. Lockwood, and David Wu
Abstract
Mutation profiling of acute leukemias is a valuable tool for identifying genetic mutations with prognostic, 
predictive, therapeutic, and diagnostic utility. Technological advances, such as massively parallel sequenc-
ing, have allowed laboratories to assess for variation across dozens or hundreds of genes simultaneously 
with relatively low cost per target.
Here, we describe a procedure for designing and using a TruSeq Custom Amplicon assay targeting 
genes involved in acute leukemias. This method is a fully customizable, amplicon-based assay for targeted 
resequencing, allowing interrogation of selected genomic regions of interest. The most readily available 
form of the assay allows sequencing of up to 1536 amplicons in a single reaction using a straightforward 
workflow. The ability to multiplex up to 1536 amplicons per reaction allows coverage of up to 650 kb of 
cumulative sequence and supports up to 96 samples per batch, depending on library size and desired 
sequencing depth.
Key words Next-generation sequencing, TruSeq, Amplicon, Leukemia, Illumina
1 Introduction
Acute leukemias are generally defined as the presence of greater 
than 20% abnormal blasts in the peripheral blood or bone marrow 
and can often be classified based on the hematopoietic cell of ori-
gin. Approximately two-thirds of cases arise from myeloid lineage 
cells (acute myeloid leukemias [AML]), and one-third originate 
from lymphoid lineage cells (acute lymphoid leukemia [ALL]) [1]. 
There are numerous differences in the mutational spectrum of dif-
ferent types of acute leukemias that have been elucidated, many of 
which are recurrent in a given classification. Some genetic aberra-
tions appear to be limited to a specific spectrum of entities, while 
other mutations are observed in a wider range of neoplasia.
In the context of AML, numerous mutations and structural 
alterations have been described, with some mutations, such as the 
PML-RARA translocation having diagnostic and therapeutic 
implications, while other mutations have a prognostic role in other 
AML subtypes. For example, internal tandem duplications of a 
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portion of the fms-related tyrosine kinase 3 (FLT3) gene (FLT3- 
ITD) have been associated with poor prognosis [2], while CEBPA 
and NPM1 mutations have been associated with favorable progno-
sis [3, 4]. Other mutated genes that have been associated with 
poor prognosis include KIT [5], DNMT3A [6], RUNX1 [7], and 
TET2 [8]. Additional mutations have been identified that are asso-
ciated with resistance to targeted therapies [9, 10], and other genes 
have been identified that offer prognostic information. A subset of 
the known clinically relevant genes and structural rearrangements 
known to be important in AML are presented in Table 1.
Similar to AML, genetic mutations have been discovered to 
have a meaningful impact on prognosis in ALL. Mutations in spe-
cific genes have been associated with poor prognosis in ALL, 
including FBXW7 [11] and IL7R [12]. Other genes have also 
been observed to have mutations in a fraction of ALL cases, includ-
ing in genes that may be amenable to therapeutic intervention, 
such as JAK1 [13]. As scientific and medical knowledge expand, 
additional genes are likely to be identified that will have prognos-
tic, diagnostic, and/or predictive utility [15]. A subset of the 
known clinically relevant genes and structural rearrangements 
known to be important in ALL are presented in Table 1.
Although many genes with mutations appear to be limited to 
distinct subsets of AML and ALL, the overall frequency of many of 
the meaningful variants may be low. With the advent of massively 
parallel sequencing (also known as next-generation sequencing 
[NGS]), large numbers of clinically relevant genes can be simulta-
neously evaluated in a single assay [14]. This technology allows for 
rapid, cost-efficient, and tissue-sparing identification of relevant 
mutations for a specific disease population that is especially useful 
when the spectrum of mutated genes and mutations is wide.
Table 1 
Examples of molecular or cytogenetic aberrations in tumors useful for pathologic classification, 
prognostication, or clinical targeting
Molecular/cytogenetic aberrations
Acute myeloid leukemia CBFB-MYH11, DEK-NUP214, PML-RARA, inv. [16], 
RUNX1/RUNX1T1, FLT3, IDH1, IDH2, KIT, MLL- 
MLLT3, NPM1, CEBPA, KIT, DNMT3A, TP53, WT1, 
RPN1- EVI1, RBM15-MKL1, PTEN, PHF6, TP53, TET2, 
RAS, ASXL1, GATA2
Acute lymphoid leukemia BCR-ABL, MLL, CRLF2, JAK2, JAK1, JAK3, IL7R, IKZF1, 
NOTCH1, FBXW7, IDH2, DNMT3A, ETV6, NF1
Given the rapidity of change in this field, this represents at, best, an incomplete list of known and recently discovered 
molecular genetic aberrations present in the listed neoplasms
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The TruSeq amplicon-based NGS method uses oligonucle-
otide probes to hybridize to targeted regions of interest on 
non- fragmented genomic sample DNA. In a subsequent extension-
ligation step, a DNA polymerase extends from the upstream oligo-
nucleotide through the targeted region followed by ligation to the 
5′ end of the downstream oligonucleotide using a DNA ligase. 
The extension-ligation products are separated from genomic DNA 
in a wash step and subsequently amplified using primers that incor-
porate multiplexing index sequences as well as adapters required 
for cluster generation. Following the amplification and an indexing 
step, samples are purified and normalized with bead-based nor-
malization. Pooled libraries are diluted and heat denatured prior to 
loading on the Illumina instrument for sequencing. Data analysis 
can be accomplished using onboard informatics, or raw data can be 
exported for analysis and annotation using a commercial or custom 
pipeline.
2 Materials
Prepare reagents as indicated in the methods. Freshly prepared 
solutions and reagents will result in optimal method performance.
 1. Adjustable micropipettes with aerosol-resistant disposable 
pipette tips.
 2. Microcentrifuge tubes—various sizes.
 3. PCR eight-tube strips.
 4. Microcentrifuges.
 5. Thermal cycler.
 6. 96-well skirted PCR plate, 0.2 mL, polypropylene.
 7. Reagent and waste troughs.
 8. 10 N NaOH.
 9. Ethanol, 200 proof for molecular biology.
 10. TruSeq Index Plate Fixture Kit (Illumina).
 11. TruSeq Custom Amplicon Filter Plate (Illumina).
 12. TruSeq Index Plate Fixture and Collar Kit (Illumina).
 13. 96-well storage plates, 0.8 mL (MIDI plates) (Fisher Scientific).
 14. Agencourt AMPureXP kit (Beckman Coulter).
 15. Adhesive aluminum foil seal (Beckman Coulter).
 16. Microseal “B” adhesive seals (Bio-Rad).
 17. Agarose gel or Bioanalyzer system for quality assessment of 
PCR product.
 18. Ice bucket.
Targeted Next-Generation Sequencing of Acute Leukemia
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 19. 37° incubator.
 20. Heat block for 1.5 mL centrifuge tubes (96 °C).
 21. Hybex Microsample Incubator for PCR plate, 96-well (Scigene).
 22. Tabletop centrifuge (plate centrifuge that can achieve 2400 × g).
 23. Magnetic Stand-96 Side Skirted (Invitrogen).
 24. BioShake iQ High-Speed Thermal Mixer (Q instruments).
 25. Thermal cycler with heated lid.
 26. Custom or manufacturer distributed TruSeq oligonucleotides 
targeting regions of interest (see Notes 1 and 2, Illumina).
 27. TruSeq reagents (included with TruSeq oligonucleotides): 
OHS2, ACD1, ACP1, ELM4, SW1, UB1, ELM4, PMM2, i5 
primers, i7 primers, TDP1, EBT, LNA1, LNB1, LNW1, 
LNS2, and HT1 (Illumina).
 28. MiSeq reagent cartridge and kit (Illumina).
 29. MiSeq instrument (Illumina).
3 Methods
DNA can be isolated using numerous methods. An important con-
sideration is the source of the specimen (fresh, frozen, blood, 
plasma, formalin-fixed paraffin-embedded tissue, etc.) as specimens 
with more manipulation (i.e., FFPE) generally yield poorer-quality 
DNA. Numerous commercial kits are available for DNA extrac-
tion, or DNA can be extracted with a laboratory-developed proce-
dure. We have had success using DNA extraction kits from Qiagen 
for FFPE, blood, plasma, and bone marrow applications.
During this step, a custom pool containing upstream and down-
stream oligonucleotide probes specific to the targeted regions of 
interest is hybridized to genomic DNA extracted from the samples 
(Table 2).
 1. Remove the reagents (CAT, ACD1, ACP1, OHS2) and 
genomic DNA from −15 to −25 °C storage and thaw at room 
temperature. The OHS2 reagent may require more time to 
thaw than the other reagents.
 2. Set the Hybex 96-well heat block to 95 °C (see Note 3).
 3. Preheat an incubator to 37 °C to prepare for the extension- 
ligation step.
 4. Mix all reagents well by vortexing and quick spin using a table-
top centrifuge prior to use.
 5. Label a new 96-well hybridization plate with the date, run 
identifier, and wells in use.
3.1 DNA Isolation
3.2 Hybridization 
of Oligonucleotide 
Pool
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 6. Pipette 5 μL of custom amplicon oligonucleotide tube (CAT) 
to the sample wells and 5 μL of Amplicon Control Oligo Pool 
1 (ACP1) to the ACD1 control well (if used).
 7. Add 250 ng (up to 10 μL) of genomic or FFPE DNA to each 
sample well of the hybridization plate to be used in the assay. 
For more dilute samples (<25 ng/μL), up to 15 μL of DNA 
can be used.
 8. If used, add 5 μL of Amplicon Control DNA (ACD1) and 5 
μL of water the ACD1 control well in the hybridization plate 
for the assay control. ACD1 is a pool of known amplicons that 
will be amplified by ACP1 primers and can be included to 
assess the assay performance. The generated data are primarily 
used by Illumina technical support for troubleshooting. Note 
that the targets and primers used for these reagents do not 
overlap with the genomes that can be used in the online assay 
design software.
 9. If samples are not positioned at the bottom of the well, seal the 
hybridization plate with adhesive aluminum foil and centrifuge 
to 1000 × g at 20 °C for 1 min.
 10. After ensuring that any crystals or precipitate in the OHS2 
reagent have dissolved, use a single channel pipette to pipette 
35 μL of OHS2 to each sample in the hybridization plate. 
Change tips after each sample to avoid cross-contamination. 
When finished, gently pipette up and down 3–5 times to mix 
with a multichannel pipette.
 11. Seal the hybridization plate securely with plastic optical 
Polyolefin Sealing Film and centrifuge to 1000 × g at 20 °C for 
1 min.
Table 2 
Reagents and consumables required for hybridization of oligonucleotide pool
Item Quantity Storage (°C) Supplied
Custom amplicon oligonucleotide tube (CAT) 1 tube −15 to −25 Illumina
OHS2 (Oligo Hybridization for Sequencing 2) 1 tube −15 to −25 Illumina
Amplicon Control DNA (ACD1) 1 tube −15 to −25 Illumina
Amplicon Control Oligo Pool 1 (ACP1) 1 tube −15 to −25 Illumina
Genomic DNA As needed −15 to −25 User
96-well skirted PCR plate 1 plate Room temperature User
Adhesive aluminum foil seal 2 seals Room temperature User
Troughs As needed Room temperature User
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 12. Place the hybridization plate in the preheated Hybex block at 
95 °C and incubate for 1 min (see Note 3).
 13. While the plate remains on the preheated block, set the tem-
perature to 40 °C and continue incubating for 80 min.
 14. It is helpful to return 20–30 min before the end of the incuba-
tion to prepare for the next steps of the procedure.
Unbound oligonucleotide probes are removed from template 
DNA using a size selection filter and two washes with a stringent 
wash solution (SW1). A final wash using a buffered solution (UB1) 
removes the residual wash solution and prepares samples for the 
extension-ligation reaction (Table 3).
 1. Remove ELM4 from −15 to −25 °C storage and thaw at room 
temperature. This reagent will be used for the subsequent 
extension-ligation reaction.
 2. Remove stringent wash solution (SW1) and Universal Buffer 1 
solution (UB1) from 2 to 8 °C storage and set aside at room 
temperature.
 3. Assemble the filter plate assembly unit (FPAU) in the order 
from top to bottom: lid, filter plate, adapter collar, and 96-well 
storage plates (0.8 mL).
 4. Mix all reagents well by vortexing and quick spin prior to use.
 5. Prewash the FPAU plate membrane as follows: Using a multi-
channel pipette, add 45 μL of SW1 to each well; cover the 
FPAU plate with the filter plate lid and keep it covered during 
each centrifugation step; and centrifuge the FPAU at 2400 × g 
at 20 °C for 10 min.
3.3 Removal 
of Unbound 
Oligonucleotide 
Probes
Table 3 
Reagents and consumables required for removal of unbound oligonucleotide probes
Item Quantity Storage (°C) Supplied
ELM4 (thawed in preparation for 
extension-ligation)
1 tube −15 to −25 Illumina
SW1 (Stringent Wash 1) contains formamide 1 tube 2–8 Illumina
UB1 (Universal Buffer 1) 1 tube 2–8 Illumina
Filter plate with lid 1 plate Room temperature Illumina
Adapter collar (reusable) 1 plate Room temperature Illumina
96-well storage plates, 0.8 mL (MIDI plates) 1 plate Room temperature User
Troughs As needed Room temperature User
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 6. Inspect the filter plate: if there is >15 μL/well of residual buf-
fer in ≥10 wells/plate, discard the current plate and repeat the 
above process with a fresh filter plate.
 7. After the 80-min incubation of the sample DNA and probe 
oligonucleotides, confirm that the heat block has cooled to 
40 °C. Do not proceed until the heat block has cooled to 
40 °C.
 8. While the HYB plate is still in the heat block, reinforce the seal 
using a rubber roller or sealing wedge (see Note 4).
 9. Remove the HYB plate from the heat block and centrifuge to 
1000 × g at 20 °C for 1 min to collect condensation.
 10. Using a multichannel pipette set to 65 μL, using aerosol bar-
rier pipette tips, transfer the entire volume (50 μL) of each 
sample onto the center of the corresponding prewashed wells 
of the FPAU plate. Change tips after each column to avoid 
cross-contamination.
 11. Cover the FPAU plate with the filter plate lid and centrifuge 
the FPAU at 2400 × g at 20 °C for 2 min.
 12. Wash the FPAU plate as follows: Using a multichannel pipette, 
add 45 μL of SW1 to each sample well (see Note 5); cover the 
FPAU plate with the filter plate lid and centrifuge the FPAU at 
2400 × g for 2 min; and inspect the FPAU. If there is residual 
SW1 reagent present in the filter plate, centrifuge the plate at 
2400 × g for 2 min for up to 10 min (see Note 6); repeat the 
wash procedure one more time.
 13. Using a pipette, discard all the flow-through (containing for-
mamide waste and unbound oligonucleotides) collected up to 
this point in a biohazard waste container, and then reassemble 
the FPAU. The same MIDI plate can be reused for the remain-
ing pre-amplification steps.
 14. Using a multichannel pipette, add 45 μL of Universal Buffer 1 
(UB1) to each sample well.
 15. Cover the FPAU plate with the filter plate lid and centrifuge 
the FPAU at 2400 × g for 2 min.
At the end of the previous wash step, sample DNA and bound 
oligonucleotide probes specific for the targets of interest are present 
in the membrane of the filter plate, with unbound oligonucleotides 
washed away. This step will ligate the hybridized upstream and 
downstream oligonucleotide probes (oligos) via an enzymatic reaction. 
A DNA polymerase is used to extend from the upstream oligo through 
the targeted region, followed by ligation to the 5′ end of the 
downstream oligo using a DNA ligase. The extension- ligation 
results in the formation of products containing the targeted regions 
3.4 Extension- 
Ligation of Bound 
Oligonucleotides
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of interest flanked by sequences on both the 5′ and 3′ ends that 
facilitate amplification using indexed PCR primers in the next step 
(Table 4).
 1. Using a multichannel pipette, add 45 μL of Extension-
Ligation Mix 4 (ELM4) to each sample well of the FPAU 
plate (see Note 7).
 2. Seal the FPAU plate with adhesive aluminum foil, and then 
cover with the lid to secure the foil during incubation.
 3. Incubate the entire FPAU assembly in the preheated 37 °C 
incubator for 45 min.
 4. While the FPAU plate is incubating, prepare the Indexed 
Amplification Plate (IAP) as described in the following 
Subheading.
Once the oligonucleotide probes flanking the targeted regions of 
DNA have been extended and ligated, each oligonucleotide probe 
contains nontarget genome primer binding sites that will allow the 
extension-ligation products to be amplified using primers that add 
sample multiplexing index sequences (i5 and i7) as well as com-
mon adapters required for sequencing cluster generation (P5 and 
P7). Common adapters allow the amplified products to hybridize 
to the sequencing instrument flow cell, and the incorporation of 
unique index sequences allows multiple samples to be multiplexed 
on the same flow cell (Table 5).
 1. Determine the index primers to be used in the assay and record 
index primer positions for downstream use in the bioinformat-
ics pipeline.
 2. Remove PCR Master Mix 2 (PMM2) and the index primers 
(i5 and i7) from −15 to −25 °C storage and thaw on a bench 
at room temperature. Vortex each tube to mix and briefly cen-
trifuge the tubes in a microcentrifuge.
 3. Arrange i5 primer tubes (white-green caps, clear solution) ver-
tically in a rack, aligned with rows A through H.
3.5 Polymerase 
Chain Reaction 
Amplification
Table 4 
Reagents and consumables required for extension-ligation of bound oligonucleotides step
Item Quantity Storage (°C) Supplied
ELM4 (Extension- Ligation Mix 4) 1 tube −15 to −25 Illumina
Adhesive aluminum foil seal 1 seal Room temperature User
Troughs As needed Room temperature User
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 4. Arrange i7 primer tubes (orange caps, yellow solution) hori-
zontally in a rack, aligned with columns 1 through 12.
 5. Prepare fresh 50 mM NaOH (1:200 dilution of 10 N NaOH). 
For example, for 16 samples, use 7 μL 10 N NaOH diluted 
into 1393 μL Molecular Grade water (see Note 8).
 6. Combine TruSeq DNA Polymerase 1 (TDP1) and PCR Master 
Mix 2 (PMM2) for the number of samples in your run, plus 
two additional samples to account for volume loss, as follows:
# of samples × 22 μL = Volume of PMM2 needed.
Volume of PMM2 ÷ 50 = Volume of TDP1 needed.
 7. Mix all reagents well to create the PMM2/TDP1 PCR master 
mix and quick spin prior to use.
 8. When the 45-min extension-ligation reaction is complete, 
remove the FPAU from the incubator. Remove the aluminum 
foil seal and replace with the filter plate lid.
 9. Centrifuge the FPAU at 2400 × g for 2 min.
 10. Using a multichannel pipette, add 25 μL of 50 mM NaOH to 
each sample well on the FPAU plate to denature the double- 
stranded DNA product. Ensuring that pipette tips come in contact 
with the membrane, pipette the NaOH up and down 5–6 times. 
Tips must be changed after each column (see Note 9).
 11. Incubate the FPAU plate at room temperature for 5 min.
 12. While the FPAU plate is incubating, use a multichannel pipette 
to transfer 22 μL of the PMM2/TDP1 PCR master mix to each 
well of the Indexed Amplification Plate (IAP) (see Note 10).
Table 5 
Reagents and consumables required for polymerase chain reaction amplification
Item Quantity Storage (°C) Supplied
PMM2 (PCR Master Mix 2) 1 tube −15 to −25 Illumina
i5 primers (A5XX) 1 tube per primer −15 to −25 Illumina
i7 primers (A7XX) 1 tube per primer −15 to −25 Illumina
TDP1 (TruSeq DNA  
Polymerase 1)
1 tube −15 to −25 Illumina
Microseal “B” adhesive film 1 Room temperature User
50 mM NaOH  
(fresh; prepared  
from 10 N NaOH)
3.5 mL for 96 samples,  
25 μL/sample  
10 N to 50 mM
1:200 dilution
Room temperature User
96-well skirted PCR plate 1 plate Room temperature User
Troughs As needed Room temperature User
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 13. Using a multichannel pipette, add 4 μL of i5 primers (clear 
solution) to each column of the IAP plate.
 14. To avoid index cross-contamination, discard the original white 
caps and apply new white-green caps provided in the TruSeq 
Custom Amplicon Index Kit (see Note 11).
 15. Using a multichannel pipette, add 4 μL of i7 primers (yellow 
solution) to each row of the IAP plate. Tips must be changed 
after each row to avoid index cross-contamination (see Note 9).
 16. To avoid index cross-contamination, discard the original 
orange caps and apply new orange caps provided in the TruSeq 
Custom Amplicon Index Kit (see Note 9).
 17. Transfer samples eluted from the FPAU plate to the IAP plate. 
Set a multichannel P20 pipette to 20 μL. Using fine tips, 
pipette the NaOH in the first column of the FPAU plate up 
and down 5–6 times. Then transfer 20 μL from the FPAU 
plate to the corresponding column of the IAP plate. Gently 
pipette up and down 5–6 times to combine the DNA with the 
PCR master mix (see Note 12). Transfer the samples from the 
remaining columns from the FPAU plate to the IAP plate in a 
similar manner. Tips must be changed after each column to 
avoid index and sample cross-contamination.
 18. After all the samples have been transferred, the waste collection 
MIDI plate of the FPAU can be discarded. Put the metal 
adapter collar away for future use. If only a partial FPAU plate 
is used, clearly mark which wells have been used. Store the 
FPAU plate and lid in a sealed plastic bag to avoid contamina-
tion of the filter membrane.
 19. Cover the IAP plate with Microseal “B” film and seal with a 
rubber roller.
 20. Centrifuge to 1000 × g at 20 °C for 1 min.
 21. Transfer the IAP plate to the post-amplification area.
 22. Perform PCR on a thermal cycler using the following program:
95 °C for 3 min.
24 cycles of:
95 °C for 30 s.
66 °C for 30 s.
72 °C for 60 s.
72 °C for 5 min.
Hold at 10 °C.
 23. Immediately proceed to PCR cleanup or store PCR product 
(see Note 13).
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Unbound primers and unused PCR reagents are removed from 
dual indexed, double-stranded PCR product using AMPure XP 
beads (Table 6).
 1. Turn on a heat block suitable for 1.5 mL centrifuge tubes to 
96 °C and allow to preheat for step 8.
 2. Bring the AMPure XP beads to room temperature and mix 
prior to use (see Note 14).
 3. Prepare fresh 80% ethanol from absolute ethanol. 400 μL will 
be required for each sample (see Note 15).
 4. Label a new 0.8 mL 96-well storage plate (MIDI plate) for use 
during the PCR cleanup and normalization procedures.
 5. Centrifuge the IAP plate at 1000 × g at 20 °C for 1 min to col-
lect condensation.
 6. To confirm that the library successfully amplified, run an ali-
quot of the control and selected test samples on a 4% agarose 
(5 μL) or on a Bioanalyzer (1 μL). The expected PCR product 
size depends on the design parameters (e.g., 175 bp design 
should have a ~310 bp band).
 7. Using a multichannel pipette, add 60 μL of AMPure XP beads 
to each well of the cleanup plate.
 8. Using a multichannel pipette set to 60 μL, transfer the entire 
PCR product from the IAP plate to the 96-well skirted PCR 
plate, 0.2 mL (CLP) plate. Change tips between samples.
 9. Seal the CLP plate with a foil adhesive seal.
 10. Shake the CLP plate on a microplate shaker at 1800 rpm for 
2 min.
 11. Incubate at room temperature without shaking for 10 min.
 12. Place the plate on an appropriate magnetic stand for 2 min or 
until the supernatant has cleared.
3.6 PCR Cleanup
Table 6 
Reagents and consumables required for PCR cleanup
Item Quantity Storage (°C) Supplied
EBT (Elution Buffer with Tris) 1 tube Room temperature Illumina
AMPure XP beads As needed 2–8 User
Freshly prepared 80% ethanol 400 μL per sample Room temperature User
96-well storage plates, 0.8 mL  
(MIDI plates)
2 Room temperature User
Foil adhesive seal As needed Room temperature User
Troughs As needed Room temperature User
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 13. Using a multichannel pipette set to 100 μL and with the CLP 
plate on the magnetic stand, carefully remove and discard the 
supernatant. Change tips between samples.
 14. With the CLP plate on the magnetic stand, wash the beads 
with freshly prepared 80% ethanol. Using a multichannel 
pipette, add 200 μL of freshly prepared 80% ethanol to each 
sample well (see Note 16). Incubate the plate on the magnetic 
stand for 30 s or until the supernatant appears clear. Carefully 
remove and discard the supernatant. Repeat the 80% ethanol 
wash described in the previous step. After repeating the etha-
nol wash, use a P20 multichannel pipette set to 20 μL to 
remove any remaining excess ethanol.
 15. Remove the CLP plate from the magnetic stand and allow the 
beads to air-dry for 10 min or until cracks form (see Note 17).
 16. Using a multichannel pipette, add 30 μL of EBT to each well 
of the CLP plate (see Note 15).
 17. Seal the CLP plate with foil seal and shake on a microplate 
shaker at 1800 rpm for 2 min. After shaking, if any samples are 
not resuspended, gently pipette up and down or lightly tap the 
plate on the bench to mix, and then repeat this step.
 18. Incubate at room temperature without shaking for 2 min.
 19. Place the plate on the magnetic stand for 2 min or until the 
supernatant has cleared.
 20. Carefully transfer 20 μL of the supernatant from the CLP plate 
to the bottom of the wells of a new MIDI plate (Library 
Normalization Plate [LNP]). Alternatively, an unused set of wells 
on the CLP plate can be used. Change tips between samples.
In order to multiplex samples on a single flow cell, the relative 
amounts of sequencing library for each sample must be similar to 
ensure approximately equal library representation in the final 
pooled sample. This step uses a bead-based procedure to normal-
ize the libraries of the samples prior to combining and sequencing 
(Table 7).
 1. Prepare fresh 0.1 N NaOH (see Note 18).
 2. Set a heat block suitable for 1.5 mL centrifuge tubes to 96 °C 
and allow to preheat for step 3.8.
 3. Remove Library Normalization Additives 1 (LNA1) and 
Library Normalization Storage Buffer 2 (LNS2) from −15 to 
−25 °C storage and bring to room temperature. When at room 
temperature, vortex vigorously and make sure that all precipi-
tates have dissolved.
 4. Remove Library Normalization Beads 1(LNB1) and Library 
Normalization Wash 1 (LNW1) from 2 to 8 °C storage and 
bring to room temperature.
3.7 Library 
Normalization
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 5. Vigorously vortex LNB1 for at least 1 min with intermittent 
inversion until the beads are well resuspended, and no pellet is 
found at the bottom of the tube when the tube is inverted.
 6. Use a P1000 pipette set to 1000 μL to resuspend LNB1 thor-
oughly by pipetting up and down 15–20 times, until the bead 
pellet at the bottom is resuspended (see Note 19).
 7. Calculate the volume of LNA1 and LNB1 needed to prepare 
enough of the LNA1/LNB1 solution for the number of sam-
ples being processed as follows, being sure to prepare extra for 
volume loss during pipetting:
Volume LNA1 per sample = 45 μL.
Volume LNB1 per sample = 8.2 μL.
 8. Immediately after LNB1 is thoroughly resuspended, use a 
P1000 pipette transfer LNB1 to the tube containing LNA1. 
Mix well by inverting the tube 15–20 times.
 9. Add 45 μL of the combined LNA1/LNB1 mixture to each 
well of the LNP plate containing the individual sequencing 
libraries (see Note 20).
 10. Seal the LNP plate with a foil adhesive seal and shake on a 
microplate shaker at 1800 rpm for 30 min (see Note 21).
 11. Place the plate on a magnetic stand for 2 min or until the 
supernatant has cleared.
Table 7 
Reagents and consumables required for library normalization
Item Quantity Storage (°C) Supplied
LNA1 (Library Normalization  
Additives 1)
1 tube −15 to −25 Illumina
LNB1 (Library Normalization  
Beads 1)
1 tube 2–8 Illumina
LNW1 (Library Normalization  
Wash 1)
2 tubes 2–8 Illumina
LNS2 (Library Normalization  
Storage Buffer 2)
1 tube Room temperature Illumina
0.1 N NaOH (fresh) 30 μL per sample Room temperature User
96-well skirted PCR plate 1 plate Room temperature User
15 mL conical tube 1 tube Room temperature User
Foil adhesive film As needed Room temperature User
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 12. With the LNP plate on the magnetic stand, use a multichannel 
pipette set to 80 μL to remove the supernatant and then dis-
card in the normalization biohazard waste container.
 13. Remove the LNP plate from the magnetic stand and wash the 
beads with LNW1. Using a multichannel pipette, add 45 μL of 
LNW1 to each sample well. Seal the LNP plate with a foil 
adhesive seal. Shake the LNP plate on a microplate shaker at 
1800 rpm for 5 min. Place the plate on the magnetic stand for 
2 min or until the supernatant has cleared. Carefully remove 
and discard the supernatant in normalization biohazard waste 
container. Use a P20 multichannel pipette to remove excess 
LNW1 (see Note 22). Repeat the LNW1 wash.
 14. Remove the LNP plate from the magnetic stand and add 30 μL 
of fresh 0.1 N NaOH to each well to elute the sample.
 15. Seal the LNP plate with a foil adhesive seal and shake on a 
microplate shaker at 1800 rpm for 5 min (see Note 8).
 16. During the 5-min elution, designate clean wells of the 96-well 
plate as storage plate (SGP) or prepare a separate storage plate.
 17. Add 30 μL LNS2 to each well to be used in the SGP plate.
 18. After the 5-min elution, make sure that all samples in the LNP 
plate are resuspended completely. If the samples are not resus-
pended, gently pipette up and down or lightly tap the plate on 
the bench to resuspend the beads. Then shake for another 
5 min.
 19. Place the LNP plate on the magnetic stand for 2 min or until 
the liquid is clear.
 20. Using a multichannel pipette set to 30 μL, transfer the super-
natant containing the released sequencing libraries from the 
LNP plate to the SGP plate wells containing LNS2. Change 
tips between samples to avoid cross-contamination.
 21. If stopping is not avoidable, seal the SGP plate with foil seal 
and then centrifuge to 1000 × g for 1 min. Store at −20 °C for 
a maximum of 2 h (see Note 23).
Equal volumes of normalized library are combined, diluted in 
hybridization buffer, and heat denatured in preparation for cluster 
generation and sequencing (Table 8).
 1. Set a heat block suitable for 1.5 mL centrifuge tubes to 96 °C, 
as indicated in steps 3.6 and 3.7.
 2. Remove a MiSeq reagent cartridge from −15 to −25 °C stor-
age and thaw at room temperature.
 3. In an ice bucket, prepare an ice-water bath by combining three 
parts ice and one part water.
3.8 Library Pooling 
and MiSeq Sample 
Loading
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 4. If stored, centrifuge the SGP plate at 1000 × g at 20 °C for 
1 min to collect condensation.
 5. Label a clean 1.5 mL low retention Eppendorf tube with the 
name and date of your run and Pooled Amplicon Library (PAL).
 6. Determine the samples to be pooled for sequencing.
 7. Using a P20 multichannel pipette, transfer 5 μL of each library 
to be sequenced from the SGP plate, column by column, to a 
single unused column. Change tips after each column to avoid 
cross-contamination.
 8. Combine and transfer the contents of the combined sample 
column into the PAL tube. Mix PAL well. Seal the SGP plate 
and store the sealed plate at −15 to −25 °C.
 9. Label two new 1.5 mL low retention Eppendorf tubes with 
the date, name of run, and “DAL-1” and “DAL-2” (Dilute 
Amplicon Library).
 10. Create DAL-1 by combining 590 μL of HT1 and 10 μL 
PAL. Upon transferring PAL, using the same tip, pipette up 
and down 3–5 times to rinse the tip and ensure complete trans-
fer. Close cap tightly (see Note 24).
 11. Do the same for DAL-2 using 15 μL of PAL and 585 μL HT1. 
This will be stored in case of low cluster density of DAL-1 
(see Note 24).
 12. Mix DALs by vortexing the tube at top speed. Continue to the 
next step with DAL-1 (see Note 25) and place the PAL and 
DAL-2 at −15 to −25 °C after sealing the containers.
 13. Using a heat block, incubate the DAL-1 tube at 96 °C for 
2 min.
 14. After the incubation, invert DAL 1–2 times to mix and imme-
diately place in the ice-water bath.
 15. Keep the DAL-1 tube in the ice-water bath for a minimum of 
5 min.
Table 8 
Reagents and consumables required for library pooling and MiSeq sample loading
Item Quantity Storage (°C) Supplied
HT1 (hybridization buffer) 1 tube −15 to −25 Illumina
1.5 mL Eppendorf tubes  
(screw-cap recommended)
2 tubes Room temperature User
PCR eight-tube strip 1 Room temperature User
2.5 L ice bucket 1 Room temperature User
Ice As needed Room temperature User
Water As needed Room temperature User
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 1. Remove one MiSeq reagent cartridge (MiSeq Reagent Kit v2, 
300 cycles box 1 of 2) from the freezer and thaw in room tem-
perature water. Remove one MiSeq Reagent Kit v2 (box 2 of 2) 
from the refrigerator immediately prior to loading.
 2. After the reagent cartridge has thawed, invert the cartridge 
gently 5–10 times to mix the reagents. Visually confirm that 
the reagents are completely thawed in all reagent trays and that 
reagents are well mixed.
 3. After a minimum of 5-min ice-water incubation, transfer the 
600 μL contents of the DAL to the designated sample position 
on the Illumina cartridge.
 4. Follow the manufacturer’s instructions for MiSeq and run 
setup. Components of setting up the system are as follows: 
Load the PR2 fluid and waste bottle, remove the wash car-
tridge, load the prepared sample cartridge, and identify the 
samples being tested.
 5. Prepare flow cell. Remove flow cell from the vial with clean 
forceps. Only touch the plastic casing. Hold it over a beaker 
and rinse thoroughly with Molecular Grade water. Make sure 
all traces of buffer are washed off. Using a Kimwipe, carefully 
dry all surfaces. Make sure the flow cell glass surface is free of 
smudges, lint, moisture, or other foreign material. Hold it up 
against the light to visually double check. Following the 
prompt on MiSeq, remove the used flow cell from the instru-
ment and insert the new flow cell (see Note 26). Close the 
outer door of the MiSeq.
 6. After the MiSeq has passed the internal self-check routine, start 
the sequencing run.
After completion of sequencing, the data must be manipulated, 
aligned to a reference genome, and variants called before analysis 
by qualified professionals. Numerous options exist for this process 
that include software packaged with the instrumentation, separate 
third-party packages, cloud-computing platforms, or custom in- 
house developed bioinformatics pipelines. All approaches have the 
following common processes:
 1. Demultiplexing (DEMUX), base calling, and quality assess-
ment of raw sequence data of the individual sequencing data to 
generate FASTQ files.
 2. Mapping sequencing reads from a given sample to a reference 
genome sequence to generate BAM and/or Sequence 
Alignment/Map format (SAM) file.
 3. Variant calling and annotation programs to generate a Variant 
Call File (VCF).
3.9 Loading 
the MiSeq
3.10 Data Analysis
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Additional software packages can be used to identify structural 
changes that are larger than can be reliably identified using many 
of the common variant calling programs (e.g., VarScan, GATK). 
These programs often have unique output files.
The analysis methods chosen by the laboratory to perform the 
above tasks are highly dependent on the specific experimental 
application, the expertise of the laboratory, the availability of bio-
informatics and computational resources, and the time available to 
assemble vs. purchase bioinformatics pipelines. Our laboratory 
uses a modification of the custom pipeline previously described 
pipeline [16] that includes the PINDEL [17] package, but excludes 
Breakdancer [18], CREST [19], and CONTRA [20].
Basic quality metric information for a given MiSeq run can be 
obtained as follows:
 1. Open the Sequence Analysis Viewer program from the com-
puter desktop of the MiSeq personal computer (PC).
 2. Click the “Browse” icon and locate the data file in the MiSeq 
Data folder in the pop-up window. Select ok.
 3. Click the “Refresh” icon on Sequence Analysis Viewer.
(a) Select the summary tab and record the following run metrics 
on the run worksheet: cluster density (k/mm2), clusters 
passing filter %, final yield (GB), and final Q score %.
4 Notes
 1. The design of the custom TruSeq Custom Amplicon assay can 
be accomplished using the design studio application available 
from Illumina (http://designstudio.illumina.com). This 
design method allows the user to customize amplicon-based 
assays for a total target size up to 650 kilobases (kb) and 
sequence up to 1536 amplicons in a single reaction using the 
Illumina MiSeq or NextSeq instruments. The software allows 
the user to select several parameters that are used to create the 
oligonucleotides for the design. The software allows the user 
to use either DBSNP 138 or 1000 genomes project data to 
avoid probes being placed over variable sites, which would 
potentially alter annealing and ligation in a subset of subjects. 
The software also allows the user to select amplicons of varying 
sizes. In general, shorter amplicon sizes should be used in 
applications where use of DNA from formalin-fixed paraffin- 
embedded tissues (FFPE) is anticipated. Since the design 
restrictions are greater with designs using 150 base pair (bp) 
amplicons, it is suggested to use 175 bp amplicons as the mini-
mum design size, if possible. Larger design sizes offer the 
ability to interrogate regions with small stretches of repetitive 
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or complex sequence but require higher-quality DNA input, 
such as fresh tissue, frozen tissue, blood, or bone marrow, and 
longer sequencing protocols. Two versions of assay are avail-
able, the TruSeq Custom Amplicon (TSCA) 1.5 and the TSCA 
low input. The TSCA 1.5 requires 50 ng or more of input 
DNA, can accommodate amplicon designs ranging from 150–
425 bp, and can use read lengths up to 2 × 300 bp. The TSCA 
low input is designed for lower-quality DNA and can accept 
down to 10 ng of input DNA but is limited to 150–250 bp 
designs and only 2 × 150 bp reads. The assay used as the basis 
of the described method uses a 175-bp amplicon design incor-
porating all or part of the following genes: ABL1, ASXL1, 
CALR, CBL, CEBPA, CSFR3, DNMT3A, EZH2, FLT3-ITD/
FLT3-TKD, IDH1, IDH2, JAK2, KIT, MLL, MPL, NPM1, 
PHF6, RB1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, 
WT1, and ZRSR2.
 2. Gene targets can be added by HG19 coordinates or by specify-
ing the gene of interest and either the coding region (CDS), 
exons, or entire gene. Selecting CDS restricts the design spe-
cifically to coding regions and will not include probes for exon 
sequence that does not result in protein as well as the 3′ and 5′ 
untranslated regions (UTR). Selecting exons includes all cod-
ing and noncoding exons as well as the 3′ and 5′ untranslated 
regions. Selecting the whole region will target all coding and 
noncoding regions, including introns. There is an option to 
include additional bases upstream and downstream of the 
selected region, which could allow detection of splice site 
changes. While these options are convenient, the algorithm 
used to design oligonucleotide probes may design probes to 
off-target regions with homology to the region of interest 
when these choices are employed. These off-target oligonucle-
otides will consume reagents, flow cell space, and sequencing 
capacity; so to reduce the possibility of such interferences, we 
recommend that the user select specific target regions, includ-
ing additional bases up- and downstream of the desired region. 
The manufacturer also offers services to aid laboratories in the 
design process for a fee. Once the design is created and ordered, 
synthesis can take up to 8–10 weeks. The end product of the 
synthesis is a pool of oligonucleotides, so individual targets 
cannot be excluded after synthesis but will require a repeat 
synthesis.
 3. The 96-well heat block used for annealing the oligonucleotide 
probes to the target DNA sequence is critically important. The 
specified Hybex block has a heated lid that does not contact 
the sealed 96-well plate and has a heat ramp feature that 
decreases the lid temperature as the block cools. Heat blocks 
without a heated lid will allow condensation on the sealing 
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material, which results in decreased annealing and ligation 
efficiency. The use of a thermocycler with a heated lid is not 
recommended because the heated lid for most thermocyclers 
will be in contact with the sealant and typically is maintained at 
a high temperature. This situation results in heat transfer to the 
plate and reagents, which decreases the annealing and ligation 
efficiency of the oligonucleotide probes, which will result in 
suboptimal sequencing coverage. Gradual cooling is critical for 
proper hybridization; therefore, PCR thermal cyclers with 
active cooling must not be used for this process. A standard 
heat block is not recommended because they typically lack 
heated lids. The heated lid on the specified Hybex incubator 
prevents large amounts of condensation from collecting on the 
underside of the 96-well plate seal. Large amounts of conden-
sation will cause uneven heating and negatively affect uniform 
hybridization.
 4. Reinforcing the plate seal before removing the 0.8 mL MIDI 
block from the Hybex heat block is important to help decrease 
cross-contamination between samples. Any cross- 
contamination or splash-over at this stage may result in false- 
positive results because sample indices have not been uniquely 
added to the sample DNA.
 5. When adding wash solutions, changing pipette tips between 
columns is not necessarily required if care is used to avoid con-
tact with the surfaces of the destination plate, and do not 
observe splashing or splattering of reagents as they are dis-
pensed from the pipette. However, having a low threshold to 
change pipette tips will help avoid cross-contamination.
 6. The presence of residual SW1 after the centrifugation steps will 
compromise target enrichment specificity.
 7. The Extension-Ligation Mix 4 (ELM4) reagent generally has 
a short shelf life, and optimum performance is critical to 
achieve optimum target amplification. Do not use this reagent 
after the expiration date and pay careful attention to assay per-
formance as the expiration date approaches.
 8. Always prepare fresh 0.1 N NaOH. After the addition of 
NaOH, the DNA is single-stranded (ssDNA). As such, it is 
more fragile and will shear if vortexed too vigorously.
 9. Adequate rinsing of the filter plate with 50 mM NaOH during 
the elution following the ELM4 incubation is important for 
ensuring good yield from the PCR step.
 10. Tilting the filter plate when aspirating and transferring the 
extension-ligation product aids in transferring the product 
volume.
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 11. Contamination of index reagents will cause incorrect sequence 
data to be assigned to incorrect specimens.
 12. Slightly tilting the FPAU plate will ensure complete aspiration 
of the targeted DNA and will help avoid air bubbles.
 13. If you do not plan to proceed to PCR cleanup immediately, the 
plate can remain on the thermal cycler overnight or can be 
stored at 2–8 °C up to 2 days.
 14. Always allow the AMPure XP beads to come to room tempera-
ture (30 min is recommended) and mix well so that the beads 
are completely resuspended and form a homogenous 
solution.
 15. Always prepare fresh 80% ethanol from absolute ethanol. 
Eighty percent ethanol is hygroscopic and will become dilute 
over time. Using the improper alcohol dilution will decrease 
DNA yield.
 16. Do not touch the side of the reaction tube or the beads that 
are attracted to the side of the tube. Changing tips is not 
required at this stage if you use care to avoid cross- 
contamination. The beads do not need to be resuspended at 
the time of pipetting.
 17. After the second 80% ethanol wash, allow the beads to air-dry 
only until visible cracks form in the bead pellet. Waiting the full 
10 min may result in overdrying and will make resuspension of 
sequencing libraries more difficult. If overdrying occurs, after 
addition of EBT (elution buffer), pipette up and down and 
mix on the microplate shaker until all beads are resuspended 
regardless of the time it takes (potentially up to 30 min).
 18. Always prepare fresh 0.1 N NaOH and have a low tolerance for 
using a fresh stock reagent since the concentration of NaOH 
can dramatically impact the quality of sequence data gener-
ated. In cases where a high concentration of NaOH is used, 
troubleshooting will reveal that increasing the amount of DNA 
presented to the flow cell will result in a similar low cluster 
density and low-quality sequencing data.
 19. It is critical to completely resuspend the LNB1 bead pellet at 
the bottom of the tube. The use of a P1000 ensures that the 
beads are homogeneously resuspended and that there is no 
bead mass at the bottom of the tube. Resuspension is essential 
for achieving consistent cluster density on the flow cell. If you 
do not plan to use full tubes for 96 samples, a P1000 set to 
1000 μL is required to resuspend the beads completely. Mix 
only the required amounts of LNA1 and LNB1 for the current 
experiment. Do not use a P200 pipette to handle LNB1. Store 
the remaining LNA1 and LNB1 separately at their respective 
recommended temperatures. To preserve stability, never freeze 
LNB1 beads or mix with LNA1 if not used immediately.
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 20. Do not use a reagent trough for this step; the total volume of 
reagent needed for samples and dead volume is insufficient.
 21. The foil seal can be reused during the cleanup procedure if care is 
taken not to cross-contaminate sample wells. If the foil is reused, 
a low tolerance for using a fresh seal is imperative. If there is any 
possibility of contamination, a fresh seal should be used.
 22. Using a P20 multichannel to remove residual LNW1 is impor-
tant to avoid reagent carryover into the storage buffer and to 
reduce volume variability, which would affect library 
normalization.
 23. Post normalization and resuspension in NaOH, proceed 
directly to pooling and sequencing on the MiSeq or NextSeq 
instrument. Post-library normalization is NOT A SAFE 
STOPPING POINT because ssDNA will adhere to the sides 
of plastic tubes/wells if stored more than a few hours. This will 
negatively affect uniform sample pooling and result in lower 
cluster densities. If stopping is unavoidable, proceed to cre-
ation of Pooled Amplicon Library (PAL) and sequence as soon 
as possible (preferably next day, within 1 week max). In addi-
tion, on the day of sequencing, before diluting PAL to Diluted 
Amplicon Library (DAL), heat the 1.5 mL PAL tube at 96 °C 
for 2 min, and then invert PAL tube to mix well and immedi-
ately cool in ice bath (this helps releases ssDNA from the sides 
of the PAL tube). Dilute PAL to DAL immediately and heat 
DAL at 96 °C for 2 min.
 24. Volumes for diluting PAL with HT1 were established using 
recommended equipment (e.g., plate shaker calibrated for 
shaking speed) and typical laboratory conditions (e.g., 20–25 °C) 
during the normalization procedure. If cluster density is too 
high or too low, adjustment of the dilution ratio may be neces-
sary to accommodate the equipment and conditions in the 
testing laboratory.
 25. Make sure that the diluted library DAL is freshly prepared and 
used immediately for MiSeq loading. Storage of the DAL 
results in a significant reduction of cluster density.
 26. After removal of the spent flow cell, make sure the platform is 
free of debris. Gently wipe the flow cell platform with a moist 
Kimwipe followed with ethanol-moistened Kimwipe (do not 
squirt water or ethanol directly onto the platform). Gently 
place the new flow cell on the platform. The flow cell will only 
fit in one direction (use the arrow on the flow cell as a guide). 
Make sure the position of the flow cell is correctly aligned and 
flat on the platform. Gently close the lid. Do not force the lid. 
It should close easily with a “click.”
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Chapter 12
Bioinformatics Data Analysis of Next-Generation 
Sequencing Data from Heterogeneous Tumor Samples
Sean R. Landman and Tae Hyun Hwang
Abstract
Tumor heterogeneity is a major challenge when it comes to treating cancer and also complicates research 
aimed at determining genetic sources for tumorigenesis. Leveraging high-throughput sequencing technol-
ogy has been an effective approach for advancing our understanding of genetic diseases, and this type of 
data can also be used to better understand and make inferences about tumor heterogeneity. Here we 
describe the basics of genomics data analysis, as well as analysis pipelines for investigating tumor heteroge-
neity with next-generation sequencing data.
Key words Tumor heterogeneity, Subclone, Subpopulation, Structural variation, Bioinformatics, 
Genomics, Next-generation sequencing
1 Introduction
The aggressive cell growth characteristic in tumor tissue often leads 
to an accumulation of many new mutations in genomes of the rap-
idly dividing cells. Some of these mutations will establish a selective 
advantage for certain tumor cells over neighboring cells, resulting 
in an evolutionary battle between different genetic subpopulations 
within a tumor, also known as tumor subclones. This phenomenon 
is known as intra-tumor heterogeneity, and it is a complicating fac-
tor in the study of cancer genetics for a number of reasons. When 
treating a tumor, such as via drug therapy or chemotherapy, a 
treatment may be affective against some, but not all, subclones 
within the tumor. As a result, treatment may appear to be success-
ful in abolishing the tumor, though this could be due to effectivity 
against only the primary subclones. Smaller subclones harboring 
resistive traits may yet rise up to take their place, resulting in the 
reemergence of the tumor. Additionally, the heterogeneous mix of 
genetic material present in a tumor tissue sample makes it difficult 
to adequately predict the most relevant causal mutations that drove 
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the initial tumor growth. Thus, it is important to account for 
tumor heterogeneity when studying DNA from tumor tissue.
Next-generation sequencing has become the prevailing 
approach for collecting DNA data due to its rising throughput and 
efficiency coupled with its increasingly affordable cost. Sequencing 
data consists of many short DNA sequences (called reads) frag-
mented from amplified copies of the original genetic sequence(s) 
of interest. The first step in any sequencing data analysis is often to 
align these reads against a reference genome in order to determine 
which section of the genome they each originated from. Inferences 
can be made from this data by detecting clusters of abnormally 
aligned reads. For example, regions of the genome that have far 
fewer reads aligned to it than expected might be indicative of a 
deletion that is present in that sample.
Recently there have been a number of algorithms and software 
developed that utilize this discordant alignment information to 
make inferences related to tumor heterogeneity. One such pro-
gram is sample heterogeneity estimation and assembly by reference 
(SHEAR) [1], which predicts structural variations (SVs) while also 
estimating the portion of the sequencing sample that each SV 
occurs in. SHEAR works by predicting SVs via a split-read approach 
in which single reads are partially mapped to two different regions 
of the genome, indicating a novel fusion event. The heterogeneity 
estimation for each SV is then calculated using information about 
the number of spanning and soft-clipped reads at each SV break-
point. Another complementary program for helping to understand 
tumor heterogeneity in a tumor tissue sample is tumor heterogene-
ity analysis (THetA) [2, 3]. Rather than estimating heterogeneity 
frequencies variant by variant, THetA estimates the number of 
subclones present as well as the integer copy numbers for different 
regions of the genome for each subclone. Unlike SHEAR, THetA 
does not deal with copy-neutral SVs, such as inversions or translo-
cations, but does group variants together into their respective sub-
clones. Thus, the two can be complementary to one another in a 
tumor heterogeneity analysis pipeline.
Here we describe a simple workflow for analyzing next- 
generation sequencing data and making inferences about intra- 
tumor heterogeneity from tumor tissue samples. This description is 
far from comprehensive, but is instead designed to get a beginner 
user comfortable working with next-generation sequencing data 
and to help familiarize the user with some of the capabilities avail-
able through next-generation sequencing data analysis.
2 Materials
Next-generation sequencing data analysis typically begins with 
FASTQ files, which contain the read sequences along with their 
quality strings (i.e., the quality score of each base in each read). We 
Sean R. Landman and Tae Hyun Hwang
paolo.fortina@jefferson.edu
187
will not describe the process of sequencing itself, nor the low-level 
analysis that results in the generation of FASTQ files, but we will 
instead focus on the downstream bioinformatics analysis of next- 
generation sequencing data. In the methods described, we will 
assume that we are working with Illumina data, as that is typically 
most common.
All steps of the Subheading 3 describe commands to be entered 
at the command line of a UNIX/Linux operating system. We 
assume that users are familiar with this style of operating system, as 
well as comfortable working with command line programs.
 1. Trimmomatic (http://www.usadellab.org/cms/?page= 
trimmomatic).
 2. Burrows-Wheeler Aligner (BWA: https://sourceforge.net/
projects/bio-bwa/).
 3. Picard Tools (https://github.com/broadinstitute/picard/
releases/tag/2.6.0).
 4. SAMtools (http://www.htslib.org/download/).
 5. Genome Analysis ToolKit (GATK: https://software.broadin-
stitute.org/gatk/download/).
 6. DELLY (https://github.com/tobiasrausch/delly).
 7. SHEAR (http://vk.cs.umn.edu/SHEAR/).
 8. THetA (http://compbio.cs.brown.edu/projects/theta/).
3 Methods
Each step explains one component of the data analysis pipeline by 
describing what is being done, giving the command to perform the 
step, and then explaining aspects of the command itself and/or the 
meaning behind different output files from the command. This 
assumes all required programs are already installed on the user’s 
system. Generic file paths (e.g., <path to trimmomatic.jar>) 
should be replaced with the proper paths on the user’s specific 
system.
 1. Trim and filter read sequences for quality control using 
Trimmomatic [4]. This will trim low-quality ends of reads 
(quality often drops off toward the end of a read) and remove 
reads that fall below a certain threshold length as a result of 
trimming.
java -jar <path to trimmomatic.jar> PE reads-1.fq 
reads-2.fq \
filtered-reads-1.fq filtered- reads- unpaired-1.fq \
filtered-reads-2.fq filtered- reads- unpaired-2.fq \
LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:36
2.1 Software 
Applications 
(Publically Available 
for Download)
3.1 Data Preparation
Bioinformatics Data Analysis of Next-Generation Sequencing Data…
paolo.fortina@jefferson.edu
188
This command applies filters to remove leading and trailing 
bases marked as “low quality” by Illumina (LEADING:3 and 
TRAILING:3), examines the average quality across the read 
using a 4 bp sliding window and trims the read at the point 
where that average quality drops below 15 
(SLIDINGWINDOW:4:15), and removes reads that are smaller 
than 36 bp after trimming (MINLEN:36) (see Note 1). The 
relevant output files are filtered-reads-1.fq and fil-
tered-reads-2.fq, which contain the trimmed reads that 
are still paired after filtering.
 2. Align reads against the reference genome using BWA [5]. This 
creates an alignment file in SAM/BAM format [6] (see Note 2), 
which contains the read sequences along with additional infor-
mation about where and how each read aligns to the reference 
genome.
bwa mem -R ‘@RG\tID:sample\tSM:sample’ <path to ref-
erence.fa> \ filtered-reads-1.fq filtered-reads-2.fq > 
alignment.sam
You can replace ‘sample’ with relevant read group information, 
if desired (see Note 3). This assumes that a BWA index is avail-
able for the hg19.fa reference genome (see Note 4).
 3. Correct potential formatting errors in the alignment file and 
sort the alignment using Picard Tools [7]. This will ensure that 
downstream analyses work correctly (see Note 5).
java –jar <path to picard.jar> CleanSam 
I=alignment.sam \ O=alignment.cleaned.bam
java –jar <path to picard.jar> FixMateInformation \ 
 I=alignment.cleaned.bam O=alignment.final.bam 
SO=coordinate
The CleanSam command will fix various common SAM format 
problems, as well as automatically convert from SAM to BAM 
(see Note 6). The FixMateInformation command will ensure 
that read pair information is consistent while also sorting the 
alignment, which is required for indexing (next step).
 4. Index the Alignment Using SAMtools [6].
samtools index alignment.final.bam
This creates a new file, alignment.final.bam.bai, which contains 
the index and will be used by any programs that process the 
alignment file.
 1. Predict SNPs and small Indels using GATK HaplotypeCaller 
[8] (see Note 7). SNPs and small Indels are predicted by deter-
mining areas in the alignment where aligned reads consistently 
contain the same sequence differences relative to the reference 
sequence.
3.2 Variant 
Prediction
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java –jar <path to GenomeAnalysisTK.jar> -T 
HaplotypeCaller \           –R <path to reference.
fa> –I alignment.final.bam –o snps_indels.vcf
This will produce a VCF file [9] (snps_indels.vcf) that contains 
the predicted SNPs and small Indels for your sample 
(see Note 8).
 2. Predict structural variations (SVs) using DELLY [10] 
(see Note 9). This program predicts SVs by locating regions in 
the alignment where read pairs align in a consistent but discor-
dant way (i.e., many read pairs align in an unexpected way, but 
all do so in the same way, thus supporting evidence of a large-
scale SV) and other read pairs align partially to two different 
regions of the reference sequence (to identify the SV 
breakpoints).
delly –t DEL –o sv-predictions.del.vcf –f <path to 
reference.fa> \ alignment.final.bam
delly –t DUP –o sv-predictions.dup.vcf –f <path to 
reference.fa> \ alignment.final.bam
delly –t INV –o sv-predictions.inv.vcf –f <path to 
reference.fa> \ alignment.final.bam
delly –t TRA –o sv-predictions.tra.vcf –f <path to 
reference.fa> \ alignment.final.bam
This set of commands produces several VCF files (sv- 
predictions.*.vcf), one for each SV type, that con-
tain the predicted SVs of that type.
 1. Predict variants, along with their estimated heterogeneity per-
centage, using SHEAR [1]. SHEAR works by estimating vari-
ants using external programs (usually DELLY [10] and 
GATK’s HaplotypeCaller [8]), refining the variant predictions 
using an iterative local realignment at SV breakpoint regions, 
and finally estimating the heterogeneity percentage of each 
variant separately using the counts of clipped and spanning 
reads at each SV breakpoint.
java –jar <path to SHEAR.jar> sv –p shear-results \ 
–b alignment.final.bam –f <path to reference.fa>
The shear-results.report file contains the main SHEAR results, 
which includes final variant calls and their associated heteroge-
neity percentage estimations (see Note 10).
 2. Predict tumor subclones and their respective integer copy 
number intervals using THetA [2, 3]. THetA works by taking 
a DNA segmentation and predicting the most likely collection 
of subclones to support the data using a maximum likelihood 
 estimation for a multinomial distribution. The input to THetA 
is an interval count file, which contains information about the 
numbers of reads from tumor and normal tissue samples align-
ing in different segments of the genome (see Note 11).
3.3 Tumor 
Heterogeneity 
Estimation
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RunTHetA –OUTPUT_PREFIX theta- results interval_
count_file
The theta-results.BEST.results output file contains the optimal 
solution to the heterogeneity estimation for the sample. This 
file contains information about the copy number of each inter-
val segment in each normal and tumor subclone for the opti-
mal solution. A more detailed description of this output file is 
provided in the official documentation that comes bundled 
with THetA.
At the end of this process, there will be results from several analyses 
(HaplotypeCaller, DELLY, SHEAR, and THetA) that can then be 
examined in detail in order to better understand the underlying 
genetic background of the tumor sample. The results from 
HaplotypeCaller and DELLY will contain SNPs/Indels and SVs, 
respectively, that are predicted to be present without taking tumor 
heterogeneity into account. SHEAR’s results will contain variant 
predictions (which may or may not overlap with those predictions 
from HaplotypeCaller and DELLY) along with the estimated per-
centage of the sample that each is present in. Finally, THetA’s 
results will contain the estimated copy number for different regions 
of the genome for different tumor subclones.
All of these programs and algorithms have their respective 
strengths and weaknesses. Thus, running different analyses con-
currently allows for complementary approaches and can strengthen 
supporting evidence for findings. This is just a small sampling of 
the types of analyses that are available, but it should hopefully 
begin to demonstrate the many possibilities of next-generation 
sequencing data analysis.
4 Notes
 1. The necessary level of quality control will differ for every data 
set. For additional available options, please refer to the 
Trimmomatic manual (http://www.usadellab.org/cms/
u p l o a d s / s u p p l e m e n t a r y / T r i m m o m a t i c /
TrimmomaticManual_V0.32.pdf). It may also be informative 
to examine the overall quality trends of your sequencing data 
using a tool such as FastQC [11].
 2. Detailed information about the SAM/BAM file format specifi-
cation can be found at http://samtools.github.io/hts- specs/
SAMv1.pdf.
 3. Whether or not accurate read group is specified, the read group 
headers are required to be present for many downstream analy-
ses (such as GATK), so specifying read groups via the “-R” flag 
should be done regardless.
3.4 Discussion
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 4. See the BWA manual (http://bio-bwa.sourceforge.net/bwa.
shtml) for information about creating a BWA index, as well as 
information about additional BWA options.
 5. Most modern alignment programs sufficiently conform to 
proper file format standards. However, it is still generally 
good practice to use programs such as Picard Tools’ CleanSam 
and FixMateInformation to ensure valid formatting, espe-
cially for alignment files that were processed or prepared by 
other parties.
 6. BAM is a more condensed version of the SAM file format. 
BAM files should be used for all downstream analyses, as well 
as for storage space considerations.
 7. For more information about running HaplotypeCaller, see the 
GATK Best Practices guide on the subject (http://www.
broadinstitute.org/gatk/guide/article?id=2803).
 8. VCF is a file format used for storing information about vari-
ants. Detailed information about the VCF file format can be 
found at http://www.broadinstitute.org/gatk/guide/
article?id=1268, and it may also be informative to refer to the 
GATK Best Practices guide on the subject (http://www.
broadinstitute.org/gatk/guide/article?id=1268).
 9. DELLY is used here as just one example, but there are numer-
ous other programs and algorithms available that can be used 
for predicting SVs. It is generally good practice to predict SVs 
using a variety of programs and then select consistently pre-
dicted variants for downstream analyses.
 10. The heterogeneity estimations produced by SHEAR reflect the 
total portion of the DNA mass that contains the particular 
variant. Thus, a 50% heterogeneity estimation could be due to 
a heterozygous variant present in 100% of the tumor subclones 
in a diploid case, a homozygous variant present in 50% of the 
tumor subclones, or other possibilities in situations involving 
aneuploidy in tumor subclone(s).
 11. The expected format for the interval count file is provided in 
the official documentation that comes bundled with 
THetA. There are many ways to prepare this file, though it is 
recommended to use a DNA segmentation program called 
BIC-Seq [12] and to then post-process the BIC-Seq results 
using the runBICSeqToTHetA.jar utility program that comes 
bundled with THetA. This is beyond the scope of this chapter, 
but instructions for how to do this can be found in the official 
THetA documentation.
Bioinformatics Data Analysis of Next-Generation Sequencing Data…
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Chapter 13
A Zebrafish Model for Evaluating the Function of Human 
Leukemic Gene IDH1 and Its Mutation
Alvin C.H. Ma, Xiangguo Shi, Bai-Liang He, Yuhan Guo, 
and Anskar Y.H. Leung
Abstract
The recent advent of next-generation sequencing (NGS) has greatly accelerated identification of gene 
mutations in myeloid malignancies at unprecedented speed that will soon outpace their functional valida-
tion by conventional laboratory techniques and animal models. A high-throughput whole-organism 
model is useful for the functional validation of new mutations. We recently reported the use of zebrafish 
to evaluate the hematopoietic function of isocitrate dehydrogenase 1 (IDH1) and the effects of express-
ing human IDH1-R132H that is frequently identified in human acute myeloid leukemia (AML), in 
myelopoiesis, with a view to develop zebrafish as a model of AML. Here, we use IDH1 as an example to 
describe a comprehensive approach to evaluate hematopoietic gene function and the effects of mutations 
using zebrafish as a model.
Key words Zebrafish, Hematopoiesis, Myelopoiesis, Myeloid malignancy, Mutation, Transient 
expression
1 Introduction
The recent advent of next-generation sequencing (NGS) has led to 
the identification of novel gene mutations with hitherto unknown 
pathogenetic role in myeloid malignancies [1–4]. This new infor-
mation has resolved mechanisms of pathogenesis as well as poten-
tial therapeutic strategies for myeloid malignancies. However, with 
the expected decrease in cost and increased availability of NGS 
technologies, the emergence of new genetic information has out-
paced our ability to perform functional validation by conventional 
laboratory techniques and animal models. Therefore, a novel and 
clinically relevant animal model with high-throughput capacity is 
needed. Zebrafish (Danio rerio) exhibits unique features and has 
emerged as an ideal model for the study of life processes and human 
diseases. In particular, the cellular and molecular features of 
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 embryonic hematopoiesis are remarkably similar to those in human. 
Technically, the embryos are externally fertilized and optically 
transparent and are highly amendable to pharmacological and 
genetic manipulations [5–8]. The small size of adult animals and 
their high fecundity have also made it an affordable and cost- 
effective model organism that can be exploited for the functional 
validation of gene mutations discovered by NGS.
Isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) are key met-
abolic enzymes that convert isocitrate to α-ketoglutarate (α-KG) in 
the citric acid cycle (TCA cycle). In particular, arginine substitu-
tion at IDH1 R132 or IDH2 R140/R172 confers novel substrate 
specificity to the mutant enzymes by which α-KG is converted to 
the oncogenic metabolite 2-hydroxyglutarate (2-HG). Increase in 
2-HG results in an aberrant epigenetic landscape and contributes 
to leukemic transformation [9–12]. In mice, IDH1 R132H knock-
 in has been shown to expand the hematopoietic progenitor popu-
lation [13]. However, the role of IDH1 in hematopoiesis and its 
pathogenetic link with human leukemia remain unclear. We previ-
ously reported the use of zebrafish model in the study of IDH1 
and its mutations in hematopoiesis [14] and herein describe the 
protocols of the study.
2 Materials
 1. TRIzol reagent (Life Technologies, Grand Island, NY).
 2. SuperScript First-Strand Synthesis System (Life Technologies).
 3. 293T cell line (ATCC, Manassas, VA).
 4. Wild-type (WT) zebrafish embryos at 24-h post-fertilization 
(hpf).
 5. Primers for cloning human IDH1 into pCS2+ expression vec-
tor (pCS2-IDH1): pCS2-IDH1-BamHI-F (CGG GAT CCT 
CAG AAG CGG AGG CA) and pCS2-IDH1-XbaI-R (GCG 
CGC TCT AGA CAA AGG TGG CAA TAA CT).
 6. Primers for cloning zebrafish idh1-egfp fusion construct (pidh1-
egfp): zidh1-HindIII-F (GGG CCC AAG CTT CTC CTC 
CTT ACT GCT AAA ATA G) and zidh1-BamHI-R (GTC 
GCG GAT CCA AGT TTG GGT TGG CTT GAT AG).
 7. Primers for subcloning zebrafish idh1-egfp fusion into pCS2+ 
expression vector (pCS2-idh1-egfp): pCS2-zidh1-egfp-ClaI-F 
(CCA TCG ATC TCC TCC TTA CTG CTA AAA TAG) and 
pCS2-zidh1-egfp-EcoRI-R (CGG AAT TCT CTA CAA AAT 
GTG GTA TGG C).
 8. Primers for TA cloning of zebrafish idh1 with mutated (see 
Note 1) MO targeting sequence (pGEMT-idh1): zidh1- 
rescue- F (CGT GAT TTG AGA ACA TGG ATT CCT CAC 
2.1 Molecular 
Cloning
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GAA AC) and zidh1-rescue-R (CAT TTG TGG TAA AGT 
GAC AGA CCG TAA TGA GTG TG).
 9. Primers for TA cloning of zebrafish idh1 partial sequence (412 
b.p.) for antisense probe synthesis (pGEMT-idh1P): zidh1- 
probe- F (AAC AGT TGA GGC AGC AGA A) and zidh1- 
probe- R (AGC AAA GTC CCG GAT TGA C).
 10. Standard agarose gel electrophoresis setup.
 11. Restriction enzymes: BamHI, ClaI, EcoRI, HindIII, XbaI 
(New England Biolabs, Ipswich, MA).
 12. T4 DNA ligase (400,000 units/mL, New England Biolabs).
 13. pGEM-T Easy Vector Systems (Promega, Fitchburg, WI).
 14. Heat-shock competent DH5α E. coli cell.
 15. QIAprep Spin Miniprep Kit (Qiagen, Valencia, CA).
 16. QIAquick Gel Extraction Kit (Qiagen).
 17. Sequencing Primers: CMV (CGC AAA TGG GCG GTA GGC 
GTG), SP6 (ATT TAG GTG ACA CTA TAG), T3 (GCA ATT 
AAC CCT CAC TAA AGG), and T7 (TAA TAC GAC TCA 
CTA TAG GG).
 1. Primers for human IDH1 R132H site-directed mutagenesis: 
IDH1-R132H-F (GTA AAA CCT ATC ATC ATA GGT CAT 
CAT GCT TAT GGG GAT CAA TAC) and IDH1-R132H-R 
(GTA TTG ATC CCC ATA AGC ATG ATG ACC TAT GAT 
GAT AGG TTT TAC).
 2. Primers for zebrafish idh1 R146H site-directed mutagenesis: 
zidh1-R146H-F (GTA CTG GTC CCC ATG TGC ATG ATG 
GCC GAT AAT TAT AGG CTT GAT) and zidh1-R146H-R 
(ATC AAG CCT ATA ATT ATC GGC CAT CAT GCA CAT 
GGG GAC CAG TAC).
 3. Platinum Pfx DNA polymerase (Life Technologies).
 4. DpnI (New England Biolabs).
 5. QIAquick PCR Purification Kit (Qiagen).
 6. T4 DNA ligase (400,000 units/mL, New England Biolabs).
 1. E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 
0.33 mM MgSO4).
 2. 0.003% PTU (1-phenyl-2-thiourea) (Sigma-Aldrich, St. Louis, MO).
 3. 4% paraformaldehyde (PFA).
 4. 25% (in PBS), 50% (in PBS), 75% (in deionized water), and 
100% ethanol.
 5. 0.016% tricaine methanesulfonate (MS-222, Sigma-Aldrich) in 
E3 medium.
 6. 3% methylcellulose (Sigma-Aldrich).
2.2 Site-Directed 
Mutagenesis
2.3 Zebrafish 
Embryo Husbandry
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 1. MO targeting start codon of idh1 (TCT GTT TCT TGA AGA 
GTC CAT ATG C) (Gene Tools, LLC, Philomath, OR).
 2. Standard control MO (CCT CTT ACC TCA GTT ACA ATT 
TAT A) (Gene Tools, LLC).
 3. Danieau’s solution (17.4 mM NaCl, 0.21 mM KCl, 0.12 mM 
MgSO4, 0.18 mM Ca(NO3)2, 1.5 mM HEPES, pH 7.2).
 4. pidh1-egfp (MO efficiency testing).
 5. pGEMT-idh1 (in vitro transcription of WT idh1 mRNA for 
rescue experiment).
 6. Ambion mMESSAGE mMACHINE Transcription Kit (Life 
Technologies).
 7. Ambion Poly(A) Tailing Kit (Life Technologies).
 8. SalI (20,000 units/mL, New England Biolabs).
 1. 10× MOPS buffer (0.2 M MOPS, 10 mM sodium acetate, pH 
5.0, 10 mM EDTA, pH 8.0).
 2. Formaldehyde gel-loading buffer (For 100 μL: 62.5 μL for-
mamide, 9.3 μL 37% formaldehyde, 12.5 μL 10× MOPS, 1 μL 
1% bromophenol blue, 5 μL 1 mg/mL ethidium bromide, 9.7 
μL deionized water).
 3. 0.5–10 Kb RNA Ladder (Life Technologies).
 1. Golden Gate TALEN and TAL Effector Kit 2.0 (Addgene Kit 
#1000000024, Cambridge, MA).
 2. RCIscript-GoldyTALEN backbone (Addgene #38142).
 3. T4 DNA ligase (2,000,000 units/mL, New England Biolabs).
 4. BsaI (New England Biolabs).
 5. Plasmid-Safe ATP-Dependent DNase (Epicentre 
Biotechnologies, Madison, WI).
 6. 10 mM ATP.
 7. Esp3I (Thermo Fisher Scientific, Waltham, MA).
 8. SacI (New England Biolabs).
 9. Heat-shock competent E. coli cell.
 10. LB medium and agar plate with spectinomycin (100 μg/mL).
 11. LB medium and agar plate with ampicillin (100 μg/mL).
 12. X-Gal (5-bromo-4-chloro-3-indolyl-β-d-galactoside) (20 mg/
mL).
 13. IPTG (isopropylthio-β-galactoside) (0.1 M).
 14. Primers (colony PCR and sequencing): pCR8_F1 (TTG ATG 
CCT GGC AGT TCC CT), pCR8_R1 (CGA ACC GAA CAG 
GCT TAT GT), TAL_F1 (TTG GCG TCG GCA AAC AGT 
GG), and TAL_R2 (GGC GAC GAG GTG GTC GTT GG) [15].
2.4 Morpholino (MO) 
Knockdown 
of Zebrafish idh1
2.5 Denaturing 
Formaldehyde RNA Gel 
Electrophoresis
2.6 Transcription 
Activator-like Effector 
Nuclease (TALEN) 
Synthesis
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 15. QIAquick PCR Purification Kit (Qiagen).
 16. Ambion T3 mMESSAGE mMACHINE Transcription Kit 
(Life Technologies).
 17. Lithium chloride precipitate solution (7.5 M LiCl, 50 mM 
EDTA, pH 8.0).
 18. 70% ethanol.
 1. Genomic DNA (gDNA) extraction buffer (10 mM Tris-HCl, 
pH 8.3, 50 mM KCl).
 2. 10% Tween 20.
 3. 10% NP-40.
 4. Proteinase K solution (recombinant, PCR grade, 14–22 mg/
mL in 10 mM Tris–HCl, pH 7.5, Roche Life Science, 
Indianapolis, IN).
 5. Primers for genotyping idh1 Exon-1: zidh1-E1-gF (CAA ACT 
GCT CGT TTT CAT G) and zidh1-E1-gR (TTT CCA CTC 
ACC TTT ATC G).
 6. BsmI (New England Biolabs).
 7. pGEM-T Easy Vector Systems (Promega).
 1. pCS2-IDH1 and pCS2-IDH1R132H.
 2. pCS2-idh1-egpf and pCS2-idh1R146H-egfp.
 3. NotI-HF (20,000 units/mL, New England Biolabs).
 4. QIAquick PCR Purification Kit (Qiagen).
 5. Ambion mMESSAGE mMACHINE SP6 Transcription Kit 
(Life Technologies).
 6. Ambion Poly(A) Tailing Kit (Life Technologies).
 7. Lithium chloride precipitate solution (7.5 M LiCl, 50 mM 
EDTA, pH 8.0).
 8. 70% ethanol.
 1. DMSO
 2. IDH1 R132H-specific inhibitor, AGI-5198 (10 mM in 
DMSO, Xcess Biosciences, San Diego, CA).
 1. pGEMT-idh1P.
 2. SacII (20,000 units/mL, New England Biolabs).
 3. QIAquick PCR Purification Kit (Qiagen).
 4. SP6 DIG RNA Labeling Kit (Roche Life Science).
 5. Lithium chloride precipitate solution (7.5 M LiCl, 50 mM 
EDTA, pH 8.0).
 6. 70% ethanol.
2.7 Zebrafish 
Embryo/Adult 
Genotyping and RFLP 
Assay for TALEN 
Mutagenic Activity
2.8 Overexpression 
of Human IDH1 R132H 
and Zebrafish idh1 
R146H
2.9 Pharmacological 
Treatment of Zebrafish 
Embryos
2.10 Generation 
of Antisense RNA 
Probe
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 1. Phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM 
KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.3).
 2. PBST (PBS with 0.2% Tween 20).
 3. 25% (in PBS), 50% (in PBS), 75% (in deionized water), and 
100% ethanol.
 4. Proteinase K solution (1:1000 diluted in PBST, Roche Life 
Science).
 5. 4% PFA.
 6. 20× SSC buffer (3 M NaCl, 0.3 M sodium citrate, pH 7.0).
 7. Pre-hybridization buffer (PHB) (50% formamide, 5× SSC, 50 
μg/mL heparin, 500 μg/mL yeast rRNA, 5 mM EDTA, 0.1% 
Tween 20, 9.2 μL/mL 1 M citric acid).
 8. DIG-labeled RNA probes for zebrafish idh1, scl, lmo2, pu.1, 
l-plastin, mpo, mpeg1, gata1, gata2, ahe1, cebpa, c-myb, rag1, 
runx1, efnb2a, and flt4 [14, 16–22].
 9. Anti-digoxigenin-AP, Fab fragments (Roche Life Science).
 10. Alkaline phosphatase (AP) buffer (100 mM NaCl, 50 mM 
MgCl2, 100 mM Tris–HCl, pH 9.5, 0.1% Tween 20).
 11. Lamb serum (Life Technologies).
 12. NBT/BCIP stock solution (Roche Life Science).
 1. Acetone (ice cold).
 2. PBS with 1% Triton X-100 (PBSTX).
 3. 25% (in PBS), 50% (in PBS), 75% (in deionized water), and 
100% ethanol.
 4. Blocking solution (10% FBS in PBSTX).
 5. Primary antibody (1:500 dilution): rabbit anti-spi1 antibody 
[23] and rabbit anti-phospho-histone H3 (Ser10) (Upstate, 
Lake Placid, NY).
 6. Secondary antibody (1:1000 dilution): goat anti-rabbit IgG 
Alexa Fluor 488 (Life Technologies) and goat anti-rabbit IgG 
Alexa Fluor 594 (Life Technologies).
 1. TRIzol reagent (Life Technologies).
 2. SuperScript First-Strand Synthesis System (Life Technologies).
 3. Power SYBR Green PCR master mix (Life Technologies).
 4. StepOnePlus Real-Time PCR System (Life Technologies).
 5. MicroAmp Optical 96-Well Reaction Plate (0.1 mL, Life 
Technologies).
 6. MicroAmp Optical Adhesive Film (Life Technologies).
 7. Primer sequences:
2.11 Whole-Mount 
In Situ Hybridization 
(WISH)
2.12 Whole-Mount 
Fluorescent 
Immunostaining
2.13 Quantitative 
PCR
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β-actin-F TTC CTT CCT GGG TAT GGA ATC
β-actin-R GCA CTG TGT TGG CAT ACA GG
scl-F CTA TTA ACC GTG GTT TTG CTG G
scl-R CCA TCG TTG ATT TCA ACC TCA T
lmo2-F GGA CGC AGG CTT TAC TAC AAA C
lmo2-R CCG GAT CCT CTT TTC ACA GGA A
gata1-F AAG ATG GGA CAG GCC ACT AC
gata1-R TGC TGA CAA TCA GCC TCT TTT
αhe1-F TGC TCT CTC CAG GAT GTT GA
αhe1-R TCA CAG TCT TGC CGT GTT TC
βhe1-F AGG CTC TGG CAA GGT GTC TCA
βhe1-R CAT TGG GTT TCC CAG GAT
pu.1-F GGG CAG TTT TAA CCA AAG ATC A
pu.1-R CCC AAG AGT GAT CGT TCT GAC
l-plastin-F GAA GCT CTG ATC GCT CTG CT
l-plastin-R GTT GTT GAT TTT GGG GCA TC
mpeg1-F CCC ACC AAG TGA AAG AGG
mpeg1-R GTG TTT GAT TGT TTT CAA TGG
mpo-F GGG GCA GAA GAA GAA AGT CC
mpo-R CCC TTG CTA AAC TCT CAT CTC G
 1. 10 mM BrdU.
 2. E3 medium.
 3. 4% PFA.
 4. PBST.
 5. 25% (in PBS), 50% (in PBS), 75% (in deionized water), and 
100% ethanol.
 6. Proteinase K solution (1:1000 diluted in PBST, Roche Life 
Science).
 7. 2 N HCl.
 8. Blocking solution (1% BSA in PBST).
 9. PE-conjugated anti-mouse BrdU antibody (1:500 dilution) 
(BD Biosciences, San Jose, CA).
 1. ApopTag Fluorescein Direct In Situ Apoptosis Detection Kit 
(equilibration buffer, reaction buffer, TdT enzyme, and stop/
wash buffer included; Millipore, Billerica, MA).
2.14 Whole-Mount 
BrdU Incorporation 
Assay
2.15 Whole-Mount 
TUNEL Assay
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 2. 4% PFA.
 3. Proteinase K solution (1:1000 diluted in PBST, Roche Life 
Science).
 4. PBST.
 1. Transgenic zebrafish line Tg(mpo:gfp) [24] (ZIRC).
 2. Trypsin-EDTA (0.05%), phenol red (Life Technologies).
 3. 100 mM CaCl2.
 4. 40 μm cell strainer (BD Biosciences).
 5. 0.9× PBS with 2% FBS.
 6. Cytocentrifuge.
 7. Wright-Giemsa stain (Sigma-Aldrich).
 1. CelLytic MT Cell Lysis Reagent (Sigma-Aldrich).
 2. Protease and phosphatase inhibitor cocktail (100×, Thermo 
Fisher Scientific).
 3. 5× loading buffer (0.25% bromophenol blue, 0.5 M dithioth-
reitol (DTT), 50% glycerol, 10% sodium dodecyl sulfate 
(SDS)).
 4. Standard SDS-PAGE (polyacrylamide gel electrophoresis) 
system.
 5. 12% resolving Tris-glycine polyacrylamide gel.
 6. Protran Nitrocellulose Transfer Membranes (PerkinElmer, 
Waltham, MA).
 7. TBST (20 mM Tris, pH 7.5, 500 mM NaCl, 0.1% Tween 20).
 8. Blocking buffer: 5% (Wt/Vol) milk in TBST.
 9. Primary antibody: mouse anti-β-actin (1:5000 dilution) 
(Sigma-Aldrich) and rabbit anti-idh1 (1:3000) (GeneTex, 
Irvine, CA).
 10. Secondary antibody (1:5000 dilution): sheep anti-mouse IgG- 
HRP antibody (GE Healthcare Life Sciences, Pittsburgh, PA) and 
goat anti-rabbit IgG-HRP antibody (Thermo Fisher Scientific).
 11. Luminata Forte Western HRP substrate (Millipore).
 1. Adult idh1 mutants and WT siblings.
 2. 5 mL syringe with 18G needle.
 3. 40 μm cell strainer (BD Biosciences).
 4. 0.9× PBS with 5% FBS.
 5. Cytocentrifuge.
 6. Wright-Giemsa stain (Sigma-Aldrich).
2.16 Flow Cytometry 
Quantification and Cell 
Sorting from 
Fluorescent 
Transgenic Embryo
2.17 Western Blot
2.18 Adult Zebrafish 
Kidney Marrow 
Analysis
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 1. 80% methanol (in deionized water).
 2. Ultrasonic Processor (Cole-Parmer, Vernon Hills, IL).
 3. N-methyl-N-ter tbutyldimethylsilyltrifluoroacetamide 
(MTBSTFA) (Regis Technologies, Morton Grove, IL).
 4. 450-GC system (Bruker).
 5. VF-5 ms inert capillary column (30 m length × 0.25 mm inner 
diameter with 0.25 μM film thickness) (Varian, Palo Alto, CA).
 6. 320-MS triple quadrupole mass spectrometer (Bruker, 
Billerica, MA).
 7. 2-HG standard (Sigma-Aldrich).
 1. QIAamp DNA Mini Kit (Qiagen).
 2. Quest 5-hmC DNA ELISA Kit (Zymo Research, Irvine, CA).
 3. Standard microplate reader.
3 Methods
 1. To clone human and zebrafish Idh1, total RNA is prepared 
using TRIzol reagent from 293FT cell line and WT zebrafish 
embryos at 24 hpf (hours post-fertilization).
 2. Synthesize first-strand complementary DNA (cDNA) from 
total RNA using SuperScript First-Strand Synthesis System fol-
lowing manufacturer’s recommendations.
 3. To subclone human IDH1 into pCS2+ expression vector 
(pCS2-IDH1), full coding sequence is PCR amplified with 
primer pair pCS2-IDH1-BamHI-F and pCS2-IDH1-XbaI-R 
with the following PCR program (see Note 2):
 (a) 95 °C, 5 min.
 (b) 95 °C, 30 s; 58 °C, 30 s; and 72 °C, 2 min → 35 cycles.
 (c) 72 °C, 7 min.
 (d) 4 °C and hold.
 4. Check PCR product size and purity by agarose gel 
electrophoresis.
 5. Digest PCR product and pCS2+ vector with BamHI and XbaI 
at 37 °C for 2 h.
 6. Resolve digested products with agarose gel electrophoresis and 
purify them by QIAquick Gel Extraction Kit following manu-
facturer’s recommendations.
 7. Set up ligation reaction and incubate the reaction product at 
room temperature (RT) for 2 h or at 16 °C overnight:
2.19 GC-Mass 
Spectrometry of 2-HG
2.20 ELISA Assay for 
5-Hydroxy 
methylcytosine
3.1 Molecular 
Cloning of Human 
and Zebrafish Idh1
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Reagents Standard reaction Background control
10× T4 DNA ligase 
reaction buffer
1 μL 1 μL
T4 DNA ligase 0.5 μL 0.5 μL
Digested vector 25 ng 25 ng
Digested PCR product 75 ng –
Deionized water to a 
total volume of
10 μL 10 μL
 8. Transform 5 μL of the ligation reaction into DH5α competent 
cells by heat shock.
 9. Pick and grow 3–5 colonies at 37 °C overnight and purify plas-
mid DNA from bacterial culture using QIAprep Spin Miniprep 
Kit.
 10. To clone the zebrafish idh1-egfp fusion gene (pidh1-egfp), 
PCR amplify the full coding sequence without stop codon with 
primer pair zidh1-HindIII-F and zidh1-BamHI-R following 
steps 3–9. Digest PCR products with HindIII/BamHI fol-
lowed by ligation into pEGFP-N3 vector in frame between the 
HindIII and BamHI sites.
 11. To subcloneidh1-egfp fusion gene into pCS2+ expression vec-
tor (pCS2-idh1-egfp), PCR amplify the fusion construct idh1- 
egfp with primer pair pCS2-zidh1-egfp-ClaI-F and 
pCS2-zidh1-egfp-EcoRI-R from pidh1-egfp following steps 
3–9. PCR product was then restriction digested with ClaI/
EcoRI and ligated into pCS2+ vector between the ClaI and 
EcoRI sites.
 12. To clone WT zebrafish idh1 (pGEMT-idh1) for in vitro mRNA 
transcription, PCR amplify full coding sequence with primer 
pair zidh1-rescue-F and zidh1-rescue-R (see Note 1) with the 
following PCR program:
 (a) 95 °C, 5 min.
 (b) 95 °C, 30 s; 55 °C, 30 s; and 72 °C, 2 min → 35 cycles.
 (c) 72 °C, 7 min.
 (d) 4 °C hold
And the PCR product is TA-cloned into pGEM-T Easy Vector 
following manufacturer’s recommendations.
 13. To clone zebrafish idh1 partial sequence (pGEMT-idh1P) for 
antisense RNA probe synthesis, PCR amplify full coding 
sequence with primer pair zidh1-probe-F and zidh1-probe-R 
with the following PCR program:
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 (a) 95 °C, 5 min.
 (b) 95 °C, 30 s; 64 °C, 30 s and 72 °C, 2 min → 35 cycles.
 (c) 72 °C, 7 min.
 (d) 4 °C hold.
And the PCR product is TA-cloned into pGEM-T Easy Vector 
following manufacturer’s recommendations.
 14. All the subcloned constructs are confirmed by bidirectional 
sequencing using appropriate sequencing primers:
pCS2+: CMV, T3.
pEGFP-N3: CMV, EGFP-N.
pGEM-T Easy: T7, SP6.
 1. Design primer pair for site-directed mutagenesis with Agilent 
QuikChange Primer Design software (http://www.genomics.
agilent.com/primerDesignProgram.jsp), as shown in 
Subheading 2.2, Primers for site-directed mutagenesis.
 2. For generating human IDH1 R132H mutation (pCS2- 
IDH1R132H), set up the following PCR reaction with primer 
pair IDH1-R132H-F and IDH1-R132H-R:
Reagents
Volume 
(μL)
10× Pfx amplification buffer 5
10 mM dNTP mixture 1.5
50 mM MgSO4 1
Forward primer (10 μM ) 1
Reverse primer (10 μM ) 1
Platinum Pfx DNA polymerase 0.5
pCS2-IDH1 DNA template (60 ng)
Deionized water to a total volume of 50
 3. PCR with the following program:
 (a) 95 °C, 1 min.
 (b) 95 °C, 50 s; 60 °C, 50 s; and 68 °C, 6 min → 17 cycles.
 (c) 68 °C, 7 min.
 (d) 4 °C hold.
 4. Check PCR product size and purity by agarose gel electropho-
resis (see Note 3).
 5. Eliminate plasmid DNA template by DpnI digestion at 37 °C 
for 2 h:
3.2 Site-Directed 
Mutagenesis 
of Human 
and Zebrafish Idh1
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Reagents Volume (μL)
10× NEB CutSmart buffer 5
PCR product 40
DpnI (20,000 units/mL) 1
Deionized water to a total volume of 50
 6. Purify the reaction with QIAquick Gel Extraction Kit and 
ligate the purified PCR product with T4 DNA ligase by over-
night at 16 °C.
Reagents Standard reaction (μL)
10× T4 DNA ligase reaction 
buffer
5
T4 DNA ligase 1
Purified PCR product 44
 7. Transform 5 μL of the ligation reaction with DH5α competent 
cells by heat shock.
 8. Pick and grow 3–5 colonies at 37 °C overnight and purify plas-
mid DNA from bacterial culture using QIAprep Spin Miniprep 
Kit.
 9. Confirm sequence by bidirectional sequencing using primers 
CMV and T3.
 10. To generate zebrafish idh1 R146H mutation (pCS2- 
idh1R146H- egfp), repeat steps 2–9 with primer pair 
zidh1-R146H-F and zidh1-R146H-R using pCS2-idh1-egfp 
construct as PCR template.
 1. All embryos are raised in E3 medium at 28.5 °C.
 2. For whole-mount in situ hybridization, whole-mount immu-
nostaining, or whole-embryo fluorescence microscopy, 
embryos are treated from 6 hpf onward with 0.003% PTU in 
E3 medium to suppress pigmentation.
 3. Embryos at appropriate stages are dechorionated, fixed with 
4% PFA at RT for 4 h (or at 4 °C overnight), and dehydrated 
stepwise from 25%, 50%, and 75% to 100% ethanol. Dehydrated 
embryos are stored at −20 °C in 100% ethanol until subse-
quent analysis.
 4. For whole-mount imaging, live or fixed zebrafish embryos are 
mounted in 3% methylcellulose. Live embryos are anesthetized 
with 0.016% MS-222 prior to mounting.
3.3 Zebrafish 
Embryo Handling
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 1. Dilute MOs to appropriate working concentration with 
Danieau’s solution.
 2. Determine optimal MO dosage by microinjecting MO into 1- 
to 4-cell stage zebrafish embryos at different doses ranging 
from 1 to 9 ng. Approximately 90% of the embryos should 
tolerate up to 6 ng of idh1 MO without obvious toxicity and 
lethality, and the maximum tolerable dose should be chosen 
for subsequent experiments.
 3. The same amount of standard control MO is injected to sibling 
embryos as control.
 4. To test the efficiency of idh1 MO, pidh1-egfp construct is 
injected into 1-cell stage embryos with or without idh1 MO. A 
quenching of mosaic egfp expression in co-injected embryos 
demonstrated the molecular targeting of idh1 MO (Fig. 1a).
3.4 Morpholino 
Knockdown 
of Zebrafish idh1
Fig. 1 Morpholino-mediated knockdown and TALEN-mediated knockout of idh1. (a) Mosaic fluorescent pattern 
(white arrows) in embryos injected with pidh1-egfp was almost completely abolished (lower panel) byidh1 MO 
co-injection. (b) Target site of idh1 TALEN. Cyan: binding sequence for the TALEN pair (indicated by “left” and 
“right”); yellow: BsmI site; bold: The start codon of idh1; E: exon. (c) RFLP assay with BsmI digestion from 
pooled gDNA of five embryos injected with idh1 TALEN in three separate experiments. Cleaved and uncleaved 
PCR products are indicated by arrows. (d) Representative sequences of mutated idh1 locus. These figures 
were originally published in Blood. Shi X, He BL, Ma AC, Guo Y, Chi Y et al. Functions of idh1 and its mutation 
in the regulation of developmental hematopoiesis in zebrafish. Blood. 2015; 125(19): 2974-2984. © the 
American Society of Hematology
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 5. For rescue experiment, capped WT idh1 mRNA not targetable 
by idh1 MO (see Note 1) is in vitro transcribed from pGEMT- 
idh1 linearized with SalI using Ambion mMESSAGE mMA-
CHINE T7 Transcription Kit (see Note 4).
 6. Polyadenylate freshly synthesized mRNA using Ambion 
Poly(A) Tailing Kit.
 7. Purify and quantify in vitro-transcribed mRNA:
 (a)  Add 100 μL LiCl precipitation solution to each transcrip-
tion reaction.
 (b) Precipitate at −20 °C ≥ 1 h.
 (c) Centrifuge at 4 °C, 12,000 × g for 15 min.
 (d) Remove supernatant and wash with 70% ethanol.
 (e) Centrifuge at 4 °C, 12,000 × g for 5 min.
 (f) Remove supernatant and air-dry pellet.
 (g)  Resuspend mRNA pellet in 50 μL deionized water and 
quantify mRNA.
 8. Check size and integrity of in vitro-transcribed mRNA by 
denaturing formaldehyde RNA gel electrophoresis, briefly:
 (a) 1% denaturing agarose RNA gel.
 – Dissolve 1.5 g agarose in 72 mL water and cool down 
to 55 °C.
 – Mix with 10 mL 10× MOPS buffer and 18 mL 37% form-
aldehyde (both pre- warmed to 55 °C) and cast the gel.
 (b) Denaturing RNA sample.
 – Mix RNA sample (up to ~200 ng) with formaldehyde 
gel-loading buffer-loading dye at 1:8 (Vol/Vol) ratio.
 – Incubate RNA samples at 70 °C for 15 min.
 – Chill on ice.
 – Resolve on RNA gel in 1× MOPS buffer at 4–5 V/cm.
 9. Optimal or maximum tolerable mRNA dosage for rescue 
experiment is determined. In the published experiments, 100 
pg idh1 mRNA was injected into 1-cell stage embryos with and 
without idh1 MO.
 1. To induce loss-of-function idh1 mutation, TALEN targeting 
idh1 is designed based on the following parameters described 
previously [25] (Fig. 1b) (see Note 5):
 (a) Length of TAL-binding domain with 15 RVDs.
 (b) Spacer length between 14 and 18 b.p.
 (c)  Unique restriction site within the spacer for RFLP assay of 
NHEJ-mediated mutagenesis.
3.5 TALEN-Mediated 
Mutagenesis 
of Zebrafish idh1
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 (d)  T nucleotide upstream of both TAL-binding domains.
 2. TALEN pair in GoldyTALEN scaffold [25] is assembled 
through Golden Gate method with the Golden Gate TALEN 
and TAL Effector Kit 2.0 as described [15] (see Note 6).
 3. Linearize the TALEN constructs with SacI and purify the 
digested plasmids with QIAquick PCR Purification Kit.
 4. Synthesize capped mRNA encoding the TALEN pairs with 
Ambion T3 mMESSAGE mMACHINE Transcription Kit 
(see Note 7).
 5. Purify and quantify in vitro-transcribed mRNA as in Subheading 
3.4, step 7.
 6. Check mRNA size and integrity as in Subheading 3.4, step 8.
 7. Mix and dilute mRNA pair to working concentration for 
microinjection (final concentration 50 ng/μL of each TALEN 
mRNA).
 8. Microinject 3 nl of working mRNA solution (150 pg of each 
TALEN arm; see Note 8) into the yolk of 1-cell stage embryos.
 1. Extract gDNA from zebrafish embryos or adult fin tissue:
 (a)  Prepare working extraction buffer (freshly add 30 μL 10% 
Tween 20, 30 μL 10% NP-40, and 10 μL proteinase K solution 
to 930 μL gDNA extraction buffer 1 mL working buffer).
 (b)  Transfer embryo or fin tissue to PCR tube and remove 
excess water carryover.
 (c)  Add working extraction buffer (50 μL per embryo, 100 μL 
per fin tissue).
 (d)  Incubate at 55 °C with shaking ≥4 h until complete diges-
tion of embryo or fin tissue followed by 10 min at 98 °C 
to inactivate proteinase K.
 (e)  gDNA can be stored at −20 °C until PCR (5 μL of extracted 
gDNA are typically used in 25 μL PCR reaction).
 2. PCR amplify idh1 Exon-1 locus with primers zidh1-E1-gF and 
zidh1-E1-gR (see Note 9) with the following program:
 (a) 95 °C, 5 min.
 (b) 95 °C, 30 s; 58 °C, 30 s and 72 °C, 2 min → 35 cycles.
 (c) 72 °C, 7 min.
 (d) 4 °C hold.
 3. Digest 10 μL PCR product directly with BsmI at 37 °C for 2 h 
(Fig. 1c).
 4. Resolve digested PCR product on 1.5% agarose gel and quan-
tify mutagenic activity by Image Analysis software (e.g., Image 
J, http://imagej.nih.gov/ij/).
3.6 Genotyping 
Targeted Genomic 
Locus
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 5. To confirm small indels introduced in target locus, TA-clone 
the remaining undigested PCR product with pGEM-T Easy 
Vector Systems and sequence ~10 colonies per sample bidirec-
tionally with sequencing primer T7 and SP6 (Fig. 1d).
 1. Linearize expression construct with NotI-HF and purify the 
digested plasmids with QIAquick PCR Purification Kit.
 2. Synthesize capped mRNA encoding WT or mutant IDH1 
(idh1) with Ambion SP6 mMESSAGE mMACHINE 
Transcription Kit.
 3. Polyadenylate freshly synthesized mRNA using Ambion 
Poly(A) Tailing Kit.
 4. Purify and quantify in vitro-transcribed mRNA as in Subheading 
3.4, step 7.
 5. Check mRNA size and integrity as in Subheading 3.4, step 8.
 6. Dilute mRNA working concentration and microinjecting 100 
pg of either WT or mutant IDH1 (idh1) encoded mRNA (see 
Note 8) into the yolk of 1-cell stage sibling embryos.
 1. Plate 30–50 embryos overexpressing human WT or IDH1 
R132H as in Subheading 3.7 into 6-well plate.
 2. Treat the embryos with AGI-5198 at 10 μM from 6 hpf 
onward. Treat the vehicle control embryos with equivolume 
amount of DMSO.
 3. Collect the embryos at appropriate time points for further 
analysis.
 1. Linearize 2 μg of pGEMT-idh1P with SacII at 37 °C for 2 h.
 2. Purify the linearized plasmid with QIAquick PCR Purification 
Kit.
 3. Setup the following SP6 in vitro transcription reaction and 
incubate at 37 °C for 2 h:
Reagents Volume
Linearized pGEMT-idh1P 0.6–1 μg
10× transcription buffer 2 μL
10× DIG-UTP labeling mix 2 μL
RNAse inhibitor (20 units/μL) 1 μL
SP6 RNA polymerase (20 units/μL) 2 μL
Deionized water to a total volume of 20 μL
 4. Remove plasmid template by adding 1 μL DNase I (10 units/
μL) and incubate at 37 °C for 15 min.
3.7 Overexpression 
of Human IDH1 R132H 
and Zebrafish idh1 
R146H
3.8 Pharmacological 
Inhibition 
of IDH R132H
3.9 Generation 
of Antisense RNA 
Probe 
Against Zebrafish idh1
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 5. Purify RNA probe by LiCl solution as in Subheading 3.4, step 7.
 6. Check size and integrity of RNA probe as in Subheading 3.4, 
step 8.
 1. Rehydrate the fixed and dehydrated embryos stepwise (5 min 
each) from 100, 75, 50, and 25% ethanol to PBST.
 2. Embryos beyond 24 hpf are further permeabilized with work-
ing proteinase K solution at RT (see Note 10), refixed with 4% 
PFA for 30 min (RT), and then washed with PBST four times 
(5 min).
 3. Wash in PHB for 5 min and then pre-hybridize in PHB at 65 
°C for 4–6 h.
 4. Hybridize embryos in DIG-labeled RNA probe diluted in 
PHB (0.5 ng/μL) at 65 °C overnight.
 5. Wash sequentially with the 100% PHB; 75% PHB, 0.5× SSC; 
50% PHB, 1× SSC; and 25% PHB, 1.5× SSC and 2× SSC at 65 
°C, 15 min each.
 6. Wash twice with 0.2× SSC for 30 min at RT.
 7. Wash sequentially with the 0.15× SSC, 25% PBST; 0.1× SSC, 
50% PBST; and 0.05× SSC, 75% PBST at RT, 5 min each.
 8. Wash twice with PBST at RT, 5 min each.
 9. Incubate with alkaline phosphatase-conjugated anti-DIG anti-
body (diluted 1:5000 in PBST) with 5% lamb serum at 4 °C 
overnight with constant shaking.
 10. Wash four times with PBST at RT, 30 min each.
 11. Wash three times with AP buffer at RT, 5 min each.
 12. Develop staining with 0.01× NBT/BCIP stock solution 
(diluted in AP buffer) with inspections at regular interval to 
avoid overstaining (see Note 11).
 13. Stop staining by washing in PBST and dehydrate embryos 
stepwise from 25, 50, and 75 to 100% ethanol to remove back-
ground staining. Embryos can be stored in 100% ethanol until 
imaging.
 14. Rehydrate embryos stepwise from 100% ethanol to PBST 
before imaging (Fig. 2).
 1. Rehydrate fixed and dehydrated embryos stepwise (5 min 
each) from 100, 75, 50, and 25% ethanol to PBST.
 2. Permeabilize embryos with ice-cold acetone for 5 min.
 3. Wash four times in PBST at RT, 5 min each.
 4. Incubate with blocking solution for 1 h at RT with constant 
shaking.
3.10 Whole-Mount 
in Situ Hybridization
3.11 Whole-Mount 
Fluorescent 
Immunostaining
A Zebrafish Model for Evaluating the Function of Human Leukemic Gene IDH1…
paolo.fortina@jefferson.edu
210
 5. Incubate with primary antibody at 4 °C overnight with con-
stant shaking.
 6. Wash four times in blocking solution at RT, 30 min each.
 7. Incubate with secondary antibody at 4 °C overnight in the 
dark with constant shaking.
 8. Wash four times in PBSTX at 4 °C in the dark, 30 min each.
 9. Mount embryos in 3% methylcellulose for fluorescent microscopy 
(Fig. 3a). Stained embryos should be kept in 4 °C in the dark.
Fig. 2 WISH showing expression pattern of idh1 and genes associated with myeloid lineages in zebrafish 
embryos. (a) Left panel: spatial expression pattern of idh1 at 36 hpf. Dashed line indicates the level of the 
histological paraffin section in right panel showing idh1 expression around the ventral wall of the dorsal aorta 
(DA). (b) WISH showing the expression of early myeloid progenitor marker pu.1 and late myelomonocytic dif-
ferentiation markers l-plastin, mpo, and mpeg1 at 24 hpf in embryos injected with pCS2-IDH1 (IDH1-WT) or 
pCS2-IDH1R132H (IDH1-R123H), with or without AGI-5198 (10 mM) treatment starting from bud stage. Red 
arrows indicate myeloid cells on the yolk sac. These figures were originally published in Blood. Shi X, He BL, 
Ma AC, Guo Y, Chi Y et al. Functions of idh1 and its mutation in the regulation of developmental hematopoiesis 
in zebrafish. Blood. 2015; 125(19): 2974-2984. © the American Society of Hematology
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 1. Extract total RNA from control or treated embryos at 18 hpf 
(at least 30 embryos were pooled for each sample) using 
TRIzol reagent according to the manufacturer’s 
recommendations.
 2. Synthesize cDNA from total RNA using SuperScript First- Strand 
Synthesis System following manufacturer’s recommendations.
 3. Setup the following reaction in 96-well plate with triplicates:
Reagents
Volume 
(μL)
2× SYBR Green PCR master mix 6.5
Forward primer 0.26
Reverse primer 0.26
cDNA (0.01×, see Note 12) 1
Deionized water to a total volume of 13
 4. Run the following program with StepOnePlus Real-Time PCR 
System:
 (a) 95 °C, 10 min.
 (b) 95 °C, 15 s; 60 °C, 1 min → 40 cycles.
 5. Analyze gene expression using comparative CT method with 
β-actin as the housekeeping gene.
 1. Incubate the dechorionated embryos at 24 hpf with BrdU (10 
mM) in 1× E3 for 1 h at 28 °C.
 2. Fix and dehydrate embryo as in Subheading 3.3, step 3.
 3. Rehydrate embryos stepwise (5 min each) from 100, 75, 50, 
and 25% ethanol to PBST.
 4. Digest with proteinase K for 20 min at RT.
 5. Refix with 4% PFA at RT for 20 min.
 6. Incubate with 2 N HCl for 1 h at RT.
 7. Incubate with blocking solution for 2 h at RT.
 8. Incubate with PE-conjugated anti-BrdU antibody at 4 °C 
overnight.
 9. Wash three times with PBST at RT, 5 min each.
 10. Mount embryos in 3% methylcellulose for fluorescent micros-
copy (Fig. 3b).
 1. Rehydrate fixed and dehydrated embryos stepwise (5 min 
each) from 100, 75, 50, and 25% ethanol to PBST.
 2. Digest with proteinase K for 5 min at RT.
3.12 Quantitative 
PCR
3.13 Whole-Mount 
BrdU Incorporation 
Assay
3.14 Whole-Mount 
TUNEL Assay
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 3. Wash three times with PBST at RT, 5 min each.
 4. Incubate in 50 μL equilibration buffer for 1 h at RT.
 5. Incubate with 50 μL of working strength TdT solution (35 μL 
reaction buffer and 15 μL TdT enzyme) at 37 °C for 1 h.
 6. Wash four times with working strength stop/wash buffer (1:34 
Vol/Vol diluted in deionized water) at RT, 5 min each.
 7. Mount embryos in 3% methylcellulose for fluorescent micros-
copy (Fig. 3c).
 1. Dechorionate Tg(mpo:gfp) transgenic embryos (and wild-type 
as negative control) at 36 hpf.
 2. Rinse embryos in E3 medium and digest with 0.05% trypsin- 
EDTA solution for 15 min at 28.5 °C.
 3. Completely dissociate embryos into single-cell suspension by 
pipetting up and down.
 4. Add CaCl2 (final concentration 2 mM) to inactivate trypsin 
digestion.
 5. Filter cell suspension through 40 μm cell strainer to remove 
debris and cell clumps.
 6. Centrifuge cell suspension at 1200 rpm for 5 min at RT and resus-
pend cell pellet in 0.9× PBS (with 2% FBS) and keep it on ice.
3.15 Flow Cytometry 
Quantification 
and Sorting 
of Neutrophils 
in Transgenic Embryos
Fig. 3 Fluorescent immuno- and biochemical staining to examine proliferation and apoptosis in zebrafish 
embryos. (a) Tg(mpo:gfp) embryo at the caudal hematopoietic tissue (CHT) region stained for phospho-histone 
H3 (pH 3) at 28 hpf injected with control or idh1 MO. Arrows indicate pH 3 and mpo double-positive proliferat-
ing myeloid cells. (b) BrdU incorporation assay showing cellular proliferation (white arrows) embryos injected 
with pCS2-IDH1 (IDH1-WT) or pCS2-IDH1R132H (IDH1-R132H) at 24 hpf. (c) Whole-mount TUNEL assay show-
ing apoptosis cells along the CHT in embryo at 48 hpf injected with control or idh1 MO. These figures were 
originally published in Blood. Shi X, He BL, Ma AC, Guo Y, Chi Y et al. Functions of idh1 and its mutation in the 
regulation of developmental hematopoiesis in zebrafish. Blood. 2015; 125(19): 2974-2984. © the American 
Society of Hematology
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 7. Enumerate percentage of GFP+ cell population with flow 
cytometer (acquired >10,000 total cells) or isolate GFP+ cell 
population by fluorescence-activated cell sorting (FACS) 
(Fig. 4a)
 8. To examine morphology of sorted neutrophils, centrifuge cells 
at 300 rpm using standard cytocentrifuge, then stain cytospin 
with Wright-Giemsa stain, and observe under microscope 
(Fig. 4b).
 1. Homogenize 30 dechorionated zebrafish embryos in 100 μL 
CelLytic MT Cell Lysis Reagent with 1× protease and phos-
phatase inhibitor cocktail (~2–5 μL lysis buffer per embryo).
 2. Centrifuge lysate at top speed for 15 min at 4 °C and collect 
supernatant.
 3. Add 25 μL 5× loading buffer.
 4. Boil the protein lysate for 10 min.
 5. Resolve protein sample with SDS-PAGE on 12% resolving 
polyacrylamide gel.
 6. Electro-transfer resolved protein onto nitrocellulose 
membranes.
 7. Incubate membrane in blocking buffer at RT for 1 h with con-
stant shaking.
 8. Incubate with primary antibody at 4 °C overnight with con-
stant shaking.
 9. Wash four times with TBST at RT, 15 min each with constant 
shaking.
 10. Incubate with secondary antibody for 2 h at RT.
 11. Wash four times with TBST at RT, 15 min each with constant 
shaking.
 12. Detect target protein by chemiluminescence with Luminata 
Forte Western HRP substrate according to manufacturer’s 
recommendations.
 1. Euthanize 3 months old idh1 mutants and their WT siblings 
on ice.
 2. Dissect kidney marrow from euthanized fish and rinse it in ice 
cold 0.9× PBS with 5% FBS.
 3. Dissociate kidney marrow by trituration using pipette and then 
syringe with 18G needle.
 4. Filter cell suspension through 40 μm cell strainer to remove 
debris and cell clumps.
 5. Centrifuge cell suspension at 1200 rpm for 5 min at RT and resus-
pend cell pellet in 0.9× PBS (with 5% FBS) and keep it on ice.
3.16 Western Blot
3.17 Adult Zebrafish 
Kidney Marrow 
Analysis
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 6. Analyze and enumerate different hematopoietic populations in 
the kidney marrow by flow cytometry as described [26, 27] 
(Fig. 4c).
 7. Particular population can be isolated through cell sorting to 
examine cell morphology through cytospin as in Subheading 
3.15, step 8 (Fig. 4d).
 1. Sonicate embryos at 24 hpf in 1 mL 80% methanol (ice cold) 
on ice at 3 s on and 3 s off cycle for 5 min.
 2. Incubate methanol extract at −80 °C for 30 min.
 3. Centrifuge extract at top speed for 30 min at 4 °C to remove 
precipitated protein and cellular debris.
3.18 GC-Mass 
Spectrometry of 2-HG
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Fig. 4 Examination of hematopoietic lineages at cellular level in embryonic and adult zebrafish with flow 
cytometry and cytospins. (a) Flow cytometry result quantifying percentage of gfp-positive cells in Tg(mpo:gfp) 
embryos at 36 hpf. (b) Morphology of FACS-sorted gfp-positive cells in dissociated Tg(mpo:gfp) embryos. (c) 
Contour plot of flow cytometry showing myelomonocytic (red), precursor (green), lymphocytic (blue), and ery-
throid lineages (purple) from dissociated adult kidney marrow. (d) Morphology of hematopoietic cells from 
kidney marrow of idh1 TALEN-injected adult zebrafish. Red arrows, erythrocytes; black arrows, precursor cells; 
arrowheads, myelomonocytes; asterisks, lymphocytes. These figures were originally published in Blood. Shi X, 
He BL, Ma AC, Guo Y, Chi Y et al. Functions of idh1 and its mutation in the regulation of developmental hema-
topoiesis in zebrafish. Blood. 2015; 125(19): 2974-2984. © the American Society of Hematology
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 4. Evaporate the aqueous metabolites in the supernatant layer to 
dryness under nitrogen gas (stored at −80 °C until GC/MS 
analysis).
 5. Resuspend dried extract with 1:1 (Vol/Vol) acetonitrile and 
MTBSTFA mixture.
 6. Heat the mixture at 70 °C for 75 min.
 7. Inject 1 μL of derivatized materials into 450-GC system 
equipped with a VF-5 ms capillary column and connected to a 
320-MS triple quadruple mass spectrometer in a splitless model 
with the following setting:
(a) Injection, interface, and ion source temperatures at 310 
°C, 250 °C, and 200 °C, respectively.
(b) Initial GC oven temperature at 100 °C for 3 min, then 
raise to 230 °C at 4 °C/min (hold for 4 min) and maintain 
at 300 °C for 5 min.
Measure with electronic ionization (70 eV) in the full-scan 
mode (m/z: 50–550 amu) and detector voltage at 1200 V
 8. Confirm 2-HG peak with standard.
 9. Quantify 2-HG and glutamate signal intensity by integration 
of peak areas and determine relative 2-HG level with the ratio 
of 2-HG to glutamate normalized by number of embryos.
 1. Extract gDNA from embryos with QIAamp DNA Mini Kit.
 2. Quantify 5-hmC DNA by using Quest 5-hmC DNA ELISA 
Kit briefly:
(a) Coat reaction wells with anti-5-hmC polyclonal antibody 
(1 ng/μL in coating buffer, 100 μL/well) with 1 h incuba-
tion at 37 °C.
(b) Wash three times with 1× ELISA buffer at RT, 5 min each.
(c) Incubate with 200 μL 1× ELISA buffer at 37 °C for 
30 min.
(d) Denature sample and control DNA at 98 °C for 5 min, and 
then cool on ice for 10 min.
(e) Remove all liquid from wells, add 100 μL denatured sam-
ple or control DNA (1 ng/μL in 1× ELISA buffer) to each 
well, and incubate at 37 °C for 1 h.
(f) Wash three times with 200 μL 1× ELISA buffer at RT, 
5 min each.
(g) Incubate with 100 μL anti-DNA HRP antibody (1:100 
diluted in 1× ELISA buffer) at 37 °C for 1 h.
(h) Wash three times with 200 μL 1× ELISA buffer at RT, 
5 min each.
3.19 ELISA Assay 
for5- Hydroxy 
methylcytosine in 
Zebrafish Genome
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(i) Incubate with 100 μL 1× Developer at RT for 30 min.
(j) Measure absorbance at 405 nm by microplate reader.
 3. Generate standard curve using absorbance from control DNAs 
and quantify percentage of 5-hmC in each sample with the 
standard curve.
4 Notes
 1. To generate idh1 mRNA that is not targetable by idh1 MO 
during rescue experiment, silent mutations (5 b.p. mismatch) 
should be introduced into the MO-binding sequence through 
primer zidh1-rescue-F.
 2. PCR program can be modified to suit different PCR systems or 
DNA polymerases. All the PCR reactions described in the pro-
tocol are based on AmpliTaq Gold 360 (Life Technologies) 
unless otherwise stated.
 3. Although a band with a size corresponding to the plasmid is 
usually seen in electrophoresis, procedures can be carried on 
and correct mutant clone may be obtained even if initial PCR 
fail to produce any visible band. However, PCR conditions 
should be optimized if multiple bands are observed.
 4. For pGEMT-idh1 and pGEMT-idh1P, orientation during TA 
cloning is random and should be confirmed by sequencing. 
The construct should be linearized with appropriate enzyme 
and in vitro transcribed with correct RNA polymerase. Briefly, 
to synthesize mRNA, construct should be linearized at 3′ end 
and RNA polymerase at 5′ end should be chosen, while for 
antisense RNA probe, construct should be linearized at 5′ end 
and RNA polymerase at 3′ end should be chosen.
 5. To generate loss-of-function mutation, TALEN should be 
designed to target early exons after the start codon (or alter-
nate start codon) or particular functional domain. TALEN will 
potentially introduce frame-shifting small indels at target site 
through nonhomologous end joining (NHEJ). Recent devel-
opment in microhomology-mediated end joining (MMEJ) 
prediction algorithm [28] greatly enhanced the possibility of 
out-of-frame mutation and should be taken into consideration 
during TALEN design. Zebrafish line or colonies in use should 
be genotyped to avoid polymorphism that will otherwise affect 
TALEN activity. Online software Mojo Hand (www.talende-
sign.org) is available to facilitate TALEN design [29].
 6. A new version of Golden Gate TALEN assembling system 
(FusX) has been developed recently. It has streamlined the 
original Golden Gate system to a single reaction with higher 
efficiency. Corresponding plasmid libraries may soon be avail-
able through Addgene.
Alvin C.H. Ma et al.
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 7. A half (10 μL) in vitro transcription reaction will produce suf-
ficient mRNA for TALEN applications.
 8. Optimum dose of mRNA should be determined by dose- 
response trials. Typically, the highest dose compatible with 
normal development in more than 50% embryos is chosen.
 9. Although any PCR reagent can be use, ready-to-use PCR mas-
ter mix will facilitate large-scale genotyping.
 10. Proteinase K digestion time depends on the developmental 
stage of embryos as well as the specific batch of proteinase K 
solution. Typically, embryos at 36, 48, 72, and 96 hpf are 
digested for 5, 10, 15, and 20 min, respectively.
 11. If embryo is subjected to paraffin sectioning after whole- mount 
in situ hybridization (Fig. 2a), significant overstaining is 
needed to ensure adequate staining on individual section.
 12. cDNA sample synthesized from a standard 20 μL reaction with 
the SuperScript First-Strand Synthesis System is usually diluted 
100-fold to use as template for quantitative PCR.
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Chapter 14
Measurement of Oncometabolites d-2-Hydroxyglutaric Acid 
and l-2-Hydroxyglutaric Acid
Patricia M. Jones, Richard Boriack, Eduard A. Struys, 
and Dinesh Rakheja
Abstract
We describe a liquid chromatography-tandem mass spectrometry assay for measurement of d-2- 
hydroxyglutaric acid and l-2-hydroxyglutaric acid. These metabolites are increased in specific inborn 
errors of metabolism and are now recognized as oncometabolites. The measurement of  d-2- hydroxyglutarate 
in peripheral blood may be used as a biomarker for screening and follow-up of patients with IDH-mutated 
acute myeloid leukemia.
Key words 2-Hydroxyglutaric acid, 2HG, Biomarker, d-2-Hydroxyglutaric acid, d-2HG, l-2- 
Hydroxyglutaric acid, l-2HG, Liquid chromatography-tandem mass spectrometry, LC-MS/MS, 
Oncometabolite
1 Introduction
2-Hydroxyglutaric acid (2HG) is a 5-carbon dicarboxylic acid 
with a hydroxyl group at the second or alpha carbon 
(2- hydroxypentanedioic acid). The second carbon is thus a chiral 
or asymmetric carbon, resulting in two stereoisomers: d-2HG (or 
R-2HG or [+]-2HG) and l-2HG (or S-2HG or [−]-2HG). The 
stereoisomers have identical physical properties. However, they 
have different three-dimensional spatial configurations and are 
therefore recognized by different enzymes (Fig. 1), whose defi-
ciencies lead to distinct inborn errors of metabolism. l-2HG is 
thought to be formed by the oxidation of alpha-ketoglutarate 
(2KG) by l-malate dehydrogenase (and by lactate dehydrogenase 
A under hypoxic conditions) and is converted back to 2KG by 
l-2-hydroxyglutarate dehydrogenase (L2HGDH) [1–5]. An 
inherited, autosomal recessive, deficiency of L2HGDH, caused by 
mutations in L2HGDH, results in the metabolic disorder 
 l-2- hydroxyglutaric aciduria (OMIM #236792) [6–8]. d-2HG is 
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formed by the oxidation of 2KG by hydroxyacid-oxoacid transhy-
drogenase (which simultaneously catalyzes the conversion of 
γ-hydroxybutyrate to succinate semialdehyde) and converted back 
to 2KG by d-2-hydroxyglutarate dehydrogenase (d-2HGDH) [9]. 
An inherited, autosomal recessive, deficiency of D2HGDH, caused 
by mutations in D2HGDH, produces the metabolic disorder 
d-2-hydroxyglutaric aciduria-1 (OMIM #600721) [9–12]. An 
inherited, autosomal recessive, deficiency of mitochondrial citrate 
carrier, caused by mutations in SLC25A1, produces the metabolic 
disorder combined d- and l-2-hydroxyglutaric aciduria (OMIM 
#615182) [13]. Interestingly, R140 mutations in IDH2 (that 
encodes mitochondrial isocitrate dehydrogenase 2 [IDH2]) give 
rise to the autosomal dominant d-2-hydroxyglutaric aciduria-2 
(OMIM #613657) [14]. Somatic R140 or R172 mutations in 
IDH2 and R132 mutations in IDH1 (that encodes cytoplasmic 
isocitrate dehydrogenase 1 [IDH1]) have been reported in multi-
ple cancers including glioma [15, 16], acute myeloid leukemia 
[17–20], intrahepatic cholangiocarcinoma [21, 22], and central 
chondrosarcoma [23]. The mutant IDH1 and IDH2 acquire a 
new enzymatic activity of reduction of 2KG to d-2HG (in prefer-
ence to oxidation of isocitrate to 2KG) resulting in high levels of 
d-2HG in tumors with IDH mutations [24–27]. Even before the 
discovery of somatic IDH1 and IDH2 mutations in cancer, there 
was a known association of l-2-hydroxyglutaric aciduria with brain 
tumors [28–30]. Recently, increased levels of l-2-hydroxyglutaric 
acid have been described in renal cell carcinoma [31]. Thus, both 
Fig. 1 Metabolic pathway. TCA tricarboxylic acid, IDH isocitrate dehydrogenase, 
HOT hydroxyacid-oxoacid transhydrogenase, d2HGDH d-2-hydroxyglutarate 
dehydrogenase, l2HGDH l-2-hydroxyglutarate dehydrogenase, MDH malate 
dehydrogenase, LDH-A lactate dehydrogenase A
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d-2HG and l-2HG are oncometabolites predicted to effect epi-
genetic changes resulting in hypermethylation phenotype in 
affected cancer cells [31–36]. In addition, they can serve as sensi-
tive and specific biomarkers for IDH-mutated cancers [27, 
37–45].
Here, we describe a liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) assay for measurement of d-2HG and l- 
2HG [20, 31, 46, 47]. The method is an adaptation of the method 
by Struys [48, 49]. This method utilizes (+)-Di-O-acetyl-l-tartaric 
anhydride (DATAN), a chiral derivatizing agent, to modify the d- 
and l-stereoisomers of 2HG, allowing separation and quantifica-
tion by LC-MS/MS. Deuterated stable-isotope internal standard, 
d,l-[3,3,4,4-2H4)-2-hydroxyglutaric acid, is made from 
2- ketopentanedioic acid-[2H6] and used in the quantification of 
the d- and l-2HG. The internal standard is added to the samples 
which are then vortexed. Plasma and homogenized tissue and cell 
pellets are extracted (urine requires no extraction), and the extract 
is dried under a gentle stream of nitrogen. The dried residue is 
then derivatized with DATAN, dried under nitrogen again, dis-
solved in water, and injected onto the LC-MS/MS system. The 
samples are injected onto a C18 column to separate the d- and 
l-stereoisomers and then introduced into the tandem mass spec-
trometer where the compounds are identified, and their abun-
dances reported and quantified using a standard curve.
2 Materials
 1. Serum, anti-coagulated plasma (heparin or EDTA) from 
peripheral blood or bone marrow, and urine are acceptable.
 2. Samples of cell culture media, cultured cells, and tissues are 
also acceptable.
 3. Serum and plasma samples should be centrifuged, separated 
from the cells, and frozen as soon after collection as possible. 
All other sample types should be frozen as soon as possible. 
Samples are stable for 1 year if frozen at <−10 °C. Samples are 
shipped frozen.
Native d-2HG (Sigma-Aldrich, St. Louis, MO, ≥95.0%) stock 
solution is made to 10 mmol/L in Optima® LC/MS grade water 
(Fisher Scientific, Pittsburgh, PA). 1 mmol/L native d-2HG is 
then made by diluting the 10 mmol/L stock solution in Optima® 
LC/MS grade water. Both stock solutions are stable for 1 year 
below −10 °C.
Native l-2HG (Sigma-Aldrich, St. Louis, MO, ≥98.0%) stock 
solution is made to 10 mmol/L in Optima® LC/MS grade water. 
1 mmol/L native l-2HG is made by diluting the 10 mmol/L stock 
2.1 Samples
2.2 Native 
and Stable-Isotope 
d- and l-2- 
Hydroxyglutaric Acids
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solution in Optima® LC/MS grade water. Both stock solutions are 
stable for 1 year below −10 °C.
Deuterated stable-isotope mixed d,l-[3,3,4,4-2H4] internal 
standard (d,l-IS) is made as follows:
 1. 0.12 g of zinc powder (Riedel-de-Haën, Seelze, Germany (Sigma-
Aldrich now owns)) is added to 1 mL of ice-cold, Optima® LC/
MS grade water in a 16 × 100 mm glass screw cap tube and stirred 
using a flea (tiny magnetic stirrer) and a magnetic stir plate. The 
tube is kept on ice with stirring throughout.
 2. Completely dissolve 0.15 g of 2-ketopentanedioic acid-[2H6] 
(Isotec, now also Sigma-Aldrich) in 0.5 mL of ice-cold, 
Optima® LC/MS grade water in a second glass screw cap tube. 
Vortex to ensure completely dissolved.
 3. Slowly add the 0.5 mL of dissolved 2-ketopentanedioic acid-
[2H6] to the stirring zinc solution and continue stirring for 
30 min after addition is complete.
 4. Centrifuge the sample at 750 × g for 2 min at room tempera-
ture to precipitate the excess zinc.
 5. Remove the supernatant with a Pasteur pipette and save in a 
third glass tube held on ice.
 6. Wash the zinc pellet two times with 1 mL ice-cold Optima® 
LC/MS grade water each time, centrifuging after each wash 
and combining the supernatants with the original supernatant. 
The total volume of saved supernatants should be approxi-
mately 3.5 mL.
 7. Add three volumes (approximately 10.5 mL) of acetone to the 
saved supernatant mixture to precipitate the d,l-2- 
hydroxyglutaric acid-[2H4]-Zn salt. Note: The terminal deute-
rium ions are lost during this process of converting the 
keto-groups to OH-groups, resulting in a 2H4 product from 
the 2H6 starting compound (Fig. 2).
Fig. 2 2-Ketopentandioc acid conversion to 2-hydroxyglutaric acid
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 8. Centrifuge for 5 min at 2200 × g.
 9. Remove the supernatant by Pasteur pipette and discard it.
 10. Wash the pellet two times with 10 mL acetone each time, 
resuspending the pellet and then recentrifuging at 2200 × g for 
5 min each time (see Notes 1 and 2).
 11. Dry the resulting pellet under a very gentle stream of nitrogen, 
under the chemical hood at room temperature to avoid loss of 
product, and store below −10 °C until use. The d,l-IS is stable 
for 1 year below −10 °C (see Note 3).
 12. Reaction yield is approximately 150 mg. Determine reaction 
success by dissolving 1.5 mg of product into 10 mL reagent 
grade water (making 1 mmol/L). Transfer 20 μL to a screw 
cap tube, dry down, and derivatize with DATAN as described 
in Subheading 3.2. After derivatization, dry down and dissolve 
in 1 mL Optima® LC/MS grade water. Infuse on the LC-MS/
MS along with a previous batch of d,l-IS, monitoring the base 
ions. First infuse the previous batch of d,l-IS, monitoring the 
367.2 and 151.14 base ions in negative mode. Repeat the pro-
cess with the new batch of d,l-IS and compare the abundances. 
The 151.14 abundance represents the unreacted 2-ketopen-
tanedioic acid, and the 367.2 abundance represents the 
DATAN-derivatized d,l-[3,3,4,4,-2H6]-2HG (see Note 4).
 13. 10 mM deuterated d,l-IS stock solution is made by weighing 
10.9 mg and diluting to 5 mL in Optima® LC/MS grade 
water. This solution is frozen at ≤−10 °C and is stable for 1 
year at this temperature.
 14. d,l-IS is used at a concentration of 40 μM. This is made by 
diluting 40 μL of the 10 mM d,l-IS stock solution into 10 mL 
of methanol. This solution is stable for 1 year at ≤−10 °C.
A five-point calibration curve is run with every assay. The calibra-
tors are made as follows:
 1. Label 16 × 100 mm glass screw cap tubes as 1 mM, 100 μM, 
10 μM, 1 μM, and 100 nM.
 2. For 1 mM add 100 μL of 10 mM l-2HG stock solution and 
100 μL of 10 mM d-2HG stock solution to 800 μL of Optima® 
LC/MS grade water. Vortex and dilute for the other calibra-
tors as follows:
 3. For 100 μM, add 100 μL of the 1 mM mixture in Subheading 
2.3, step 2 to 900 μL Optima® LC/MS grade water. Vortex.
 4. For 10 μM, add 100 μL of the 100 μM mixture in Subheading 
2.3, step 3 to 900 μL Optima® LC/MS grade water. Vortex.
 5. For 1 μM, add 100 μL of the 10 μM mixture in Subheading 
2.3, step 4 to 900 μL Optima® LC/MS grade water. Vortex.
2.3 Calibrators 
and Quality Controls
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 6. For 100 nM, add 100 μL of the 1 μM mixture in Subheading 
2.3, step 5 to 900 μL Optima® LC/MS grade water. Vortex.
 7. These calibrators are stable for 2 years if frozen at ≤−10 °C 
(see Note 5).
 8. Transfer 10 μL of each calibrator into a separate, labeled screw 
cap tube. Add 25 μL of 40 μM d,l-IS to each tube, mix, and 
dry down at 37 °C under a gentle stream of nitrogen. The cali-
brator concentrations correspond to 1481 ng (10 nmol), 
148 ng (1 nmol), 14.8 ng (100 pmol), 1.48 ng (10 pmol), and 
0.15 ng (1 pmol) l- and d-2HG.
 9. Once dried, the calibrators are ready to be derivatized with the 
rest of the samples as described below.
Two concentrations of controls that are assayed along with 
clinical patient samples are made from the d-2HG and l-2HG 
stock solutions as follows:
 1. For serum/plasma controls, obtain expired fresh frozen plasma 
(FFP) from transfusion services.
 2. Serum/plasma quality control (QC) level 1 (~19,000 ng/mL 
l-2HG and ~100 ng/mL d-2HG) (see Notes 6 and 7). To 20 
mL of FFP, add 200 μL of 10 mmol/L l-2HG stock solution 
and 10 μL of 1 mmol/L d-2HG stock solution. Vortex well to 
mix, aliquot into labeled tubes, and store frozen at ≤−70 °C. 
Stable for 5 years at ≤−70 °C.
 3. Serum/plasma quality control (QC) level 2 (~100 ng/mL l- 
2HG and ~19,000 ng/mL d-2HG): To 20 mL of FFP, add 10 
μL of 1 mmol/L l-2HG stock solution and 200 μL of 10 
mmol/L d-2HG stock solution. Vortex well to mix, aliquot 
into labeled tubes, and store frozen at ≤−70 °C. Stable for 5 
years at ≤−70 °C.
 4. For each level of control to be analyzed in the run, transfer 100 
μL into a separate, labeled 1.5 mL microfuge tube. Treat these 
QC samples as serum/plasma samples and extract and deriva-
tize with them as described below.
 1. 6.0 M hydrochloric acid (HCl) (Ricca Chemical, Arlington, 
TX).
 2. 0.1 M hydrochloric acid (HCl): Add 0.5 mL of 6.0 M HCl to 
29.5 mL Optima® LC/MS grade water. Stable for 1 year at 
room temperature.
 3. Optima® LC/MS grade methanol (Fisher Scientific, 
Pittsburgh, PA).
 4. Methanol/water (80:20): Mix 200 mL of Optima® LC/MS 
grade methanol with 50 mL of Optima® LC/MS grade water. 
Stable for 1 year at room temperature.
2.4 Extraction 
and Derivatization 
Reagents
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 5. Methylene chloride (Optima® grade, Fisher Scientific).
 6. Acetic acid, J. T. Baker (VWR International, Radnor, PA).
 7. Formic acid, Fluka (Sigma-Aldrich, St. Louis, MO).
 8. 10 M ammonium formate (Sigma-Aldrich, St. Louis, MO).
 9. Oasis HLB solid phase extraction (SPE) reverse phase columns 
(Waters Corp. Milford, MA).
 10. Derivatizing agent: DATAN ((+)-Di-O-acetyl-l-tartaric anhy-
dride) (Sigma-Aldrich, St. Louis, MO) 20 mg/mL in methy-
lene chloride/acetic acid (80:20). This is made under a hood 
immediately before use. Only as much as is needed to deriva-
tize the current set of samples in the run is made. DATAN is 
weighed on an analytical balance and placed into a 16 × 
100 mm glass screw cap tube, into which methylene chloride 
and acetic acid is added as shown below:
Number  
of samples
Methylene 
chloride (μL)
Acetic  
acid (μL)
DATAN 
(mg)
1–15 800 200 20
16–35 1600 400 40
36–55 2400 600 60
If exactly 20, 40, or 60 mg of DATAN is not weighed, the 
amount of methylene chloride and acetic acid to be used can 
be calculated using the following formulas:
mg of DATAN weighed ÷ 20 × 800 = μL of methylene 
chloride to add.
mg of DATAN weighed ÷ 20 × 200 = μL of acetic acid to 
add.
 1. Buffer A: 125 mg/L ammonium formate, pH 3.6. Dilute 400 
μL of 10 M ammonium formate in 2 L Optima® LC/MS grade 
water. Adjust pH to 3.6 using concentrated formic acid and a 
pH meter. Stable for 2 weeks at room temperature.
 2. Buffer B: Acetonitrile (Optima® LC/MS grade, Fisher 
Scientific). Stable for 3 months at room temperature.
 1. Dulbecco’s Modified Eagle Medium (DMEM) (Gibco/BRL, 
Bethesda, MD) is used for all cell culture with 10% fetal bovine 
serum (FBS) (Gibco/BRL, Bethesda, MD) added.
2.5 Liquid 
Chromatography 
Buffers
2.6 Cell 
Culture Media
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3 Methods
The method is calibrated, and the linearity, precision, and lower 
limit of detection are established using the prepared native stock 
solutions. The assay is linear from 1.5 to 15,000 ng/mL and has a 
lower limit of detection of 1.5 ng/mL. Precision ranged from 1 to 
31% across the range of concentrations (see Notes 8 and 9). Once 
validated, the assay can be used for testing various sample types 
including serum, plasma, urine, tissue, cultured cells, and culture 
media from cell culture.
Clinical patient samples of serum or plasma are pipetted into 
test tubes, into which is added internal standard and methanol/
water (80:20) for extraction of the d,l-2HG. After extraction, the 
samples are centrifuged and dried down under nitrogen and then 
derivatized with DATAN. The derivatized samples are dried down 
under nitrogen again and then diluted in water, centrifuged, and 
transferred to autosampler vials to be run on the LC-MS/MS.
The LC-MS/MS method separates the d- and l-2HG isomers 
on a C18 column in a 30-min run using a slight gradient of 125 
mg/L ammonium formate and acetonitrile. After separation on 
the column, the sample is introduced into the tandem MS using 
electrospray ionization, and transitions are monitored at m/z − 
363.2 → m/z − 147.1 and m/z − 367.2 → m/z − 151.1 for the 
native 2HGs and the stable-isotope standard, respectively. 
Quantification is done using the abundances of the product ions of 
the transitions. The amount of native d- or l-2HG is calculated 
using a standard curve which is assayed with each run. The ratio of 
native to isotope abundances are calculated and then plotted 
against the standard to isotope concentration to create the stan-
dard curve. In the patient samples, the ratio of native abundance to 
isotope abundance is calculated and the 2HG concentration is 
derived from the standard curve equation.
 1. Pipette 100 μL of each serum, plasma, or QC sample into an 
appropriately labeled, 1.5 mL polypropylene microfuge tube.
 2. Add 25 μL of 40 μmol/L d,l-IS to each tube.
 3. Add 1 mL methanol/water (80:20) which has been precooled 
in the −80 °C freezer to each tube.
 4. Cap tightly and vortex vigorously for 30 s.
 5. Incubate the tubes in the −80 °C freezer for 30 min.
 6. Remove tubes from freezer and centrifuge on high (16,100 × g) 
for 5 min in the microfuge at room temperature.
 7. Transfer 500 μL of the supernatant from each tube to its 
respective, properly labeled 16 × 100 mm glass screw cap tube.
 8. Dry samples down at 37 °C under a gentle stream of nitrogen.
 9. Derivatize samples with DATAN as described in Subheading 
3.2.
3.1 Sample 
Extraction
3.1.1 Serum/Plasma 
Extraction
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 1. Pipette 20 μL of each duplicate urine sample into an appropri-
ately labeled, 16 × 100 mm glass screw cap tube.
 2. Add 25 μL of 40 μmol/L d,l-IS to each tube.
 3. Vortex vigorously for 30 s.
 4. Dry samples down at 37 °C under a gentle stream of 
nitrogen.
 5. Derivatize samples with DATAN as described in Subheading 
3.2.
 1. Prepare a cell culture pellet by centrifuging 2 × 106 to 10 × 106 
cultured cells at 500 × g for 7 min at room temperature. 
Carefully aspirate off the medium or buffer.
 2. The cell pellet or 50 mg of frozen tissue is placed into an 
appropriately labeled, 50 mL polypropylene conical centrifuge 
tube.
 3. Add 25 μL of 40 μmol/L d,l-IS to each tube.
 4. Add 1 mL methanol/water (80:20) which has been precooled 
on ice.
 5. Homogenize the sample on ice for 30 s using the appropriate 
plastic omni tip (Omni International, Kennesaw, GA). 
Alternatively, the tissue may be sonicated on ice.
 6. Incubate samples in the −80 °C freezer for 30 min.
 7. Two 5 μL aliquots of each homogenate are transferred to 
labeled 1.5 mL microfuge tubes and dried by placing open 
under the hood for 30–60 min until dry. These are used to 
determine protein concentration as previously described [50].
 8. The remaining homogenates are each transferred to labeled 
1.5 mL microfuge tubes and centrifuged at 16,100 × g for 
5 min in a microfuge at room temperature.
 9. Transfer 500 μL of the supernatant from each tube to its 
respective, properly labeled 16 × 100 mm glass screw cap tube.
 10. Dry samples down at 37 °C under a gentle stream of 
nitrogen.
 11. Derivatize samples with DATAN as described in Subheading 
3.2.
 1. Oasis HLB columns are conditioned by placing a column for 
each sample in a labeled 16 × 125 mm glass tube. A 750 μL of 
Optima® LC/MS grade methanol is added to each column 
and let drain through. A 750 μL of 0.1 M HCl is then added 
and let drain through.
 2. Pipette 1 mL of each media sample into a labeled 1.5 mL 
microfuge tube and acidify to a pH of <1 by adding 30 μL of 
6 M HCl.
3.1.2 Urine Extraction
3.1.3 Tissue or Cell 
Culture Pellet Extraction
3.1.4 Cell Culture/Cell 
Culture Medium Extraction
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 3. Add 25 μL of 40 μM d,l-IS to each sample and vortex for 
30 s.
 4. Using a transfer pipette, transfer each sample onto its appropri-
ately labeled, conditioned column.
 5. After the samples drain through the columns, wash the col-
umns with 750 μL of 0.1 M HCl.
 6. Let drain and then make sure all wash fluid is through the col-
umn by applying pressure to the column with a pipette bulb or 
by applying a vacuum using a manifold.
 7. Transfer the columns to a second, clean, labeled 16 × 100 mm 
glass tube.
 8. Elute the samples from the columns by adding 850 μL of 
Optima® LC/MS grade methanol to each column.
 9. Dry samples down at 37 °C under a gentle stream of 
nitrogen.
 10. Derivatize samples with DATAN as described in Subheading 
3.2.
 1. Pipette 50 μL of DATAN solution, prepared as described in 
Subheading 2.4, step 10, into each tube to be derivatized, 
including calibrators, controls, and samples.
 2. Cap each tube and heat to 75 °C for 30 min in a heat block to 
derivatize samples.
 3. Cool tubes to room temperature and dry down under a gentle 
stream of nitrogen.
 4. Add 0.5 mL of Optima® LC/MS grade water to each sample 
residue and vortex to dissolve.
 5. Transfer all samples to labeled microfuge tubes and centrifuge 
in the microfuge for 5 min at 16,100 × g.
 6. Transfer all samples to labeled autosampler vials and cap (see-
Note 10).
 7. Transfer vials to the Perkin-Elmer autosampler and analyze via 
LC-MS/MS.
 1. Perform liquid chromatography-tandem mass spectrometry 
analysis using C18 reverse phase separation for the liquid chro-
matography and multiple reaction monitoring (MRM) in the 
tandem mass spectrometer at the specified transitions.
 2. Prior to analyzing samples, perform the following functions: 
(a) Turn on the Turbo Ionspray Gas to 7000–7500 mL/min. 
(b) Equilibrate the column for at least ten column volumes 
(see Note 11).
 3. The LC-MS/MS method uses the Perkin-Elmer autosampler 
to inject 20 μL of sample onto the 150 × 3.9 mm (i.d.) C18 
column with a 5 μm bead size, at a flow rate of 0.5 mL/min. 
3.2 Sample 
Derivatization
3.3 LC-MS/MS 
Analysis
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The 2HG isomers are separated on the column utilizing a 
mobile phase gradient that starts at 100% buffer A and drops 
to 96.5% buffer A and 3.5% buffer B at 3.5 min. This is held 
for 20 min and then ramps back to 100% buffer A by 23 min, 
followed by a 7-min re-equilibration at 100% buffer A. This 
results in a 30-min run time. After passing through the col-
umn, half of the column eluent is diverted to waste before the 
sample is introduced directly into the AB Sciex-3000 tandem 
MS via an electrospray ionization nebulizer and analyzed in the 
tandem mass spectrometer.
 4. The MS/MS-run parameters for this method are given in 
Table 1.
 5. After the analysis is finished, quantification of the results is per-
formed. Each sample file is examined to ensure that the 
 instrument has properly identified the peaks. l-2HG is always 
the first peak and d-2HG is the second peak. The quantifica-
tion transition for both isomers is m/z − 363.2 > m/z − 147.1 
and the qualifier transition is m/z − 363.2 > m/z − 129.1. 
The quantifier transition for the internal standard is m/z − 
367.2 > m/z − 151.1 and a qualifier is not used. All three 
transition peaks must be present in order for the sample to be 
quantitated. Figure 3 depicts a chromatograph with elevated 
concentrations of d-2-hydroxyglutaric acid and normal con-
centrations of l-2- hydroxyglutaric acid.
The concentration calculations are performed as follows: Calibrator 
concentrations/IS concentrations are graphed on the x-axis. 
Table 1 
AB Sciex-3000 instrument parameters
Parameter Setting
Nebulizer gas (NEB) 4
Curtain gas (CUR) 10
Collision gas (CAD) 4
IonSpray voltage (IS) −4500 V
Temperature (TEM) 500 °C
Declustering potential (DP) −22
Focusing potential (FP) −115
Entrance potential (EP) −11
Collision energy (CE) −15 (147.1, 151.05); 
−34 (129.1)
Collision cell exit potential (CXP) −10
2-Hydroxyglutaric Acid
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Calibrator abundance counts/IS abundance counts are 
graphed on the y-axis; the equation for the resulting line is 
used by the instrument software to calculate the concentra-
tions of the QCs and samples. The results are divided by the 
sample volume in mL (0.1) to give 2HG results in ng/
mL. Finally, results are reported as numerical data for l-2HG, 
d-2HG, total 2HG, and the ratio of d,/l-2HG, with the 
appropriate reference intervals and accompanied by an inter-
pretive comment as shown in Table 2 (see Note 12).
4 Notes
 1. Sonication (VirSonic 50, VirTis Co., Inc., Gardiner, NY) at 
setting 5 (using a microprobe) for 10–20 s facilitates resus-
pending the pellet.
 2. Discard the acetone washes by evaporating under a hood.
 3. All evaporations and dry-down steps must be done under a 
chemical fume hood.
0.0
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Fig. 3 Representative chromatograph demonstrating elevated d-2-hydroxyglutaric acid. A = [d4]-l-2- 
hydroxyglutaric acid internal standard, B = [d4]-d-2-hydroxyglutaric acid internal standard, C = l-2- 
hydroxyglutaric acid, D = d-2-hydroxyglutaric acid
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 4. While the contaminating substance will not affect the assay or 
results, it will cause the weighed concentration of IS to be less 
than expected when diluted. Additionally, one can compare 
the abundances of the m/z − 367.2 and m/z − 363.2 base 
ions and the m/z − 367.2 > m/z − 151.1 and 363.2 > m/z 
− 147.1 transitions in MRM mode. This will tell you if your 
DATAN derivatization went to completion. If the reaction is 
incomplete, more DATAN, higher derivatization tempera-
tures, and/or longer derivatization times may be employed.
 5. If using pre-prepared calibrators that have been frozen, bring 
them to room temperature prior to use.
 6. The concentrations are approximate because they are the theo-
retical concentrations the controls are made to be. Actual mea-
sured concentrations are determined by repeated assays.
 7. The concentrations for both QCs were chosen because the 
high values are close to the highest plasma values normally 
Table 2 
Reference intervals and interpretations for human peripheral blood 
plasma and bone marrow plasma samples
Reference intervals
l-2HG 6–147 ng/mL
d-2HG 18–263 ng/mL
Total 2HG 24–410 ng/mL
Ratio d-/l-2HG 0.2–3.8
Result Interpretation
l-, d-, and total 2HG  
fall within reference 
intervals
Normal concentrations of l- and 
d-2-hydroxyglutarate
l-2HG and total 2HG  
are elevated; d-2HG is 
normal. Ratio is low
Markedly increased levels of l-2-
hydroxyglutarate suggestive of mutations 
in L2HGDH (l-2- hydroxyglutarate 
dehydrogenase)
L-2HG is normal.  
d-2HG, total 2HG,  
and ratio are elevated
Markedly increased levels of d-2-
hydroxyglutarate suggestive of mutations 
in IDH1 (isocitrate dehydrogenase 1), 
IDH2 (isocitrate dehydrogenase 2), or 
D2HGDH (d-2- hydroxyglutarate 
dehydrogenase)
Other combinations Free text interpretation
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seen in affected individuals. The low values are both in the 
normal range.
 8. Linearity and lower limit of detection were determined by 
repeatedly assaying calibration curves using the calibration 
standards as described above. The ratio of native to isotopic 
compound abundance was obtained for each calibrator, and 
the ratios were then plotted against ratio of the known native 
to the known isotope concentration (ng). It was determined 
that best linearity was achieved between 1.5 and 15,000 ng/
mL, with 1.5 ng/mL being the lowest concentration that 
could be reliably reproduced.
 9. Precisions were determined from repeated analyses at the bot-
tom, middle, and top of the range, and coefficient of variation 
(CV) was found to range from 0.8 to 31% across the range, 
with CVs between 0.8 and 1.0% at the high end of the range 
and CVs of 26–31% at the low end of the concentration range.
 10. At this point, the samples are stable for 2 weeks or more if 
stored in the refrigerator.
 11. This equilibration is roughly 70 min which is most easily 
accomplished by equilibrating for 10 min with buffer A and 
then running two 30 min water blanks at the start of the run.
 12. Total 2HG is calculated by adding l-2HG and d-2HG together. 
The ratio is calculated by dividing d-2HG results by l-2HG 
results.
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Chapter 15
Nanofluidic Allele-Specific Digital PCR Method 
for Quantifying IDH1 and IDH2 Mutation Burden in Acute 
Myeloid Leukemia
Daniel H. Wiseman and Tim C.P. Somervaille
Abstract
Precise quantitation of allelic burden for a pathogenic mutation has diverse clinical and research applica-
tions but can be difficult to achieve with conventional qPCR-based techniques, especially at lower mutant 
allele frequencies. Digital PCR overcomes many of the limitations of qPCR and can be highly quantitative 
even for single-nucleotide variants, with distinct advantages over next-generation sequencing approaches. 
Here we describe a method combining the principles of TaqMan®-chemistry SNP genotyping with micro-
fluidic digital PCR to generate a highly sensitive, quantitative allele-specific digital PCR assay for the six 
most common IDH1 and IDH2 mutations encountered in myeloid malignancy. The concept and approach 
could easily be applied to other suitable SNVs.
Key words Digital PCR, Allelic discrimination, Mutant allele frequency, Acute myeloid leukemia, 
Isocitrate dehydrogenase
1 Introduction
The metabolic enzymes IDH1 and IDH2 are each mutated in 
~10% of patients with acute myeloid leukemia (AML) [1]. Virtually 
all are single-nucleotide variants (SNVs) involving the arginine 
hotspots R132 in IDH1 or R140 or R172 in IDH2. Sanger 
sequencing remains the gold-standard method for detection but is 
nonquantitative and has limited sensitivity (~10–15%) for the vari-
ant allele. The ability to sensitively quantify mutant allele frequency 
(MAF) in AML can have diverse clinical and research applications. 
For example, the allelic burden of some mutations may be prog-
nostic [2], and others are validated markers of minimal residual 
disease (MRD) [3]. Quantitation further enables the researcher to 
track individual mutations longitudinally and to study the sub- 
clonal architecture of malignancy.
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Whereas qPCR has high sensitivity for oncogenic fusions and 
NPM1 (four base pair) insertional mutations [4], designing qPCR 
assays to quantitate SNVs against a backdrop of wild-type DNA is 
more challenging. Such assays tend to have lower specificity because, 
for any mix of wild-type and mutant DNA, the alternate (i.e., major-
ity wild type) sequence will usually also be detected, albeit at much 
lower (~5%) detection efficiency than for the variant sequence [5]. 
Various allele-specific qPCR methods for quantifying SNVs have 
been developed based on the amplification refractory mutation sys-
tem (ARMS-) or mismatch amplification mutation assay (MAMA-) 
PCR techniques. Such assays pool distinct primers, specific for each 
allele, in which the 3′ terminal nucleotide of either forward or reverse 
primer perfectly matches either the variant or reference base. 
Typically an additional mismatch is included within 3 bases of the 3′ 
end to further reduce efficiency for the non-desired allele, and a host 
of other modifications has been reported to further enhance specific-
ity for the mutant allele by this approach (reviewed in [6]). However, 
no gold-standard method has emerged, and restrictive design crite-
ria for primer/probe location render some templates unsuitable. 
Moreover, any conventional qPCR-based approach relies on stan-
dard curves for absolute quantitation and is influenced by the expo-
nential amplification kinetics of the PCR. These are potential sources 
of variability or inaccuracy when quantifying rare targets.
By contrast, digital PCR (dPCR) circumvents several limita-
tions of qPCR and is uniquely suited to quantitation of rare SNVs 
against a complex DNA background [7]. Conceptually, it relies on 
the random distribution of DNA molecules in solution. With 
extensive partitioning and sufficient limiting dilution such that 
some partitions contain no template, single DNA molecules can be 
PCR amplified simultaneously in parallel and the products of each 
individual reaction detected. Enumeration of partitions containing 
a positive reaction thus provides a binary, absolute, and linear 
quantitation of target in the whole sample, across a wide dynamic 
range and without the need for standard curves (Fig. 1) [8]. A 
Poisson correction compensates for the likelihood that some parti-
tions will contain >1 copy of template [9], extending the dynamic 
range beyond the total number of partitions [10]. This approach 
effectively dilutes out background signal and increases the signal- 
to- noise ratio of low-abundance targets. dPCR thus has the capac-
ity to be precise, reproducible, sensitive for rare variants, and 
tolerant of inhibitors or suboptimal amplification efficiency [7]. 
Current dPCR platforms achieve partitioning either by distribut-
ing sample into individual chambers of nanofluidic chips or through 
formation of emulsion droplets containing individual DNA tem-
plates. Each platform has advantages and disadvantages: for exam-
ple, droplet dPCR affords greater partitioning capability, while 
nanofluidic chips provide consistent sensitivity and capacity to 
monitor and review real-time amplification data for each individual 
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reaction. However, in general there is impressive concordance 
between the two formats [11].
Here we describe quantitative, allele-specific, nanofluidic 
dPCR assays for six common IDH1 and IDH2 mutations (IDH1 
R132C/R132G/R132H/R132S; IDH2 R140Q; IDH2 R172K) 
[12]. The method could be easily applied to other SNVs or short 
indels. Allelic discrimination is achieved within each partition using 
TaqMan®-based SNP genotyping [13, 14]. Custom-designed 
assays pool common forward and reverse primers flanking the 
region containing each SNV, and two minor groove-binding 
(MGB) probes specific for either wild-type or mutant allele. Probes 
are 5′-linked to spectrally distinct fluorescent dyes (FAM™ or 
VIC®) and 3′-linked to a nonfluorescent quencher that suppresses 
background fluorescence. As polymerase extends along the tem-
plate strand during each PCR cycle, it cleaves any hybridized probe, 
separating dye from quencher and emitting fluorescence. The end-
point respective change in fluorescence for each dye indicates the 
presence of either or both alleles, albeit in a nonquantitative man-
ner (Fig. 2). In the dPCR context, however, the relative propor-
tion of mutant to wild-type DNA can be precisely determined, 
with high reproducibility and sensitivity to ≤0.1% MAF [12].
2 Materials
 1. Fluidigm qdPCR 37K™ integrated fluidic circuit (IFC) chip(s) 
(Fluidigm). Each chip contains wells for 48 samples each linked 
by nanofluidic circuitry to 770 separate reaction chambers 
within which separate real-time PCR amplifications occur. One 
chip can therefore perform 36,960 separate PCRs (Fig. 3). 
Store at room temperature.
2.1 Equipment
Fig. 1 Nanofluidic digital PCR technique for determining mutant allele frequency 
using Fluidigm 37K IFC chips
Digital PCR for IDH1 and IDH2 Mutations
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 2. IFC Controller Module MX (Fluidigm; see Note 1). This 
instrument is required for priming and loading the IFC chip 
microfluidics. It employs pneumatic pressure to meter samples 
and reagents and to control valves within the IFC.
 3. Biomark™ HD thermal cycler (Fluidigm; see Note 1).
 4. “48.48” prefilled syringes with control line fluid (300 μL) 
(Fluidigm, Cat #89000020). Store at room temperature.
 5. NanoDrop 2000 spectrophotometer.
Fig. 2 Allelic discrimination PCR using TaqMan® SNP genotyping assays. DNA pol DNA polymerase, V VIC® dye, 
F FAM™ dye, Q nonfluorescent quencher
Fig. 3 The Fluidigm 37K™ integrated fluidic circuit chip for digital PCR. The chip 
consists of 48 panel inlet wells through each of which sample reaction mixes is 
pressure loaded into 770 chamber partitions
Daniel H. Wiseman and Tim C.P. Somervaille
paolo.fortina@jefferson.edu
239
 6. (Optional) Agilent® 2100 Bioanalyzer.
 7. Centrifuge suitable for 96-well PCR microplates.
 8. Single-channel pipettes (P2; P10; P20; P200).
 9. 8-channel pipette (P10).
 10. Microcentrifuge tubes (1.5 mL).
 11. 25G sterile hypodermic needles.
 12. Pressure-sensitive adhesive tape.
 1. Genomic DNA. DNA can be extracted with any commercially 
available kit. We recommend QIAamp® DNA mini (Qiagen). 
For very low DNA concentrations, a pre-amplification step 
may be necessary (see Note 2). Genomic DNA is stored in 
microcentrifuge tubes or 96-well plates at −20 °C.
 2. 20× TaqMan® SNP genotyping assay(s) (Thermo Fisher 
Scientific; see Subheading 3.1). Store aliquots at −20 °C.
 3. 20× GE Sample Loading Reagent (Fluidigm, Cat #85000746). 
Store at −20 °C.
 4. 2× TaqMan® Gene Expression Mastermix (Life Technologies, 
Cat #4369016; see Note 3). Store at 4 °C.
 5. Deionized molecular grade water.
 1. Biomark™ Software Package v4.2.2 (Fluidigm), including:
●● Biomark Data Collection software.
●● Digital PCR Analysis software.
 2. Preferred spreadsheet software capable of opening and editing 
.csv files (e.g., Microsoft Excel (Microsoft))
3 Methods
This method describes dPCR using Fluidigm’s suite of nanofluidic 
chips, modules, and Biomark™ HD thermal cycler. For further 
method and troubleshooting, consult Digital PCR Analysis User 
Guide (Fluidigm; PN 68000100; available for download at https://
www.fluidigm.com/documents). As with any PCR-based tech-
nique, adherence to best practice and avoidance of contamination is 
critical. Preparation of reaction mixes should be performed in a 
DNA-free hood in a dedicated PCR pre-amplification area, using a 
separate sterile tube for each IFC to be loaded. All procedures 
should be carried out at room temperature unless otherwise stated.
Discrimination between wild-type and mutant allele for each indi-
vidual reaction chamber within the dPCR chip is achieved using 
allelic discrimination PCR (AD-PCR) with TaqMan® SNP 
2.2 Reagents
2.3 Software
3.1 TaqMan® Assay 
Purchase, Design, 
and Validation
Digital PCR for IDH1 and IDH2 Mutations
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genotyping assays. Large libraries of predesigned, validated assays 
for recognized SNPs are commercially available from Thermo 
Fisher Scientific in various formats. Assays comprise pooled:
●● Unlabeled forward and reverse PCR primers (900 nM final 
concentration).
●● Single VIC®-MGB-labeled probe detecting the wild-type 
sequence.
●● Single FAM™-MGB-labeled probe detecting the mutant/vari-
ant sequence.
Assays are specific for a particular variant, including the respec-
tive nucleotide substitution partner. Non-polymorphism variants 
(not covered by a predesigned SNP assay) will require custom assay 
design. The example IDH1 and IDH2 assays described in this 
chapter were designed using the Thermo Fisher Scientific custom 
design service. Assay IDs and primer/probe sequences are pro-
vided in Table 1.
 1. TaqMan® Assay Purchase and Design: Go to https://www.ther-
mofisher.com, register, and log in. Search for/navigate to 
“TaqMan® SNP Genotyping Assays.” Use the Assay Search Tool 
to identify if the variant has a predesigned assay available. If so, 
proceed to purchase and select the assay size desired (see Note 4). 
If no suitable predesigned assay exists, proceed to custom assay 
design. Choose and submit the DNA sequence for the region of 
interest containing the SNV, in 5′→3′ orientation (see Note 5). 
Indicate the wild-type and variant nucleotides in square brackets 
separated by a forward stroke, as in the example below (where G 
is the reference nucleotide, and A is the variant): 5′…
GTGAACCAGT[G/A]CCAATATGCC…3′. Proceed to pur-
chase custom assay (as above).
 2. TaqMan® SNP genotyping assays are supplied at 40× or 80× con-
centration (see Note 4). Upon arrival immediately dilute to 20× 
concentration with molecular grade ddH2O and aliquot in 20 μL 
volumes (each sufficient for a single full IFC chip run). Aliquots 
should be stored in the dark at −20 °C until use (see Note 6).
 3. (Optional) It is good practice to validate the qualitative perfor-
mance of new custom assays by AD-PCR to confirm good 
separation of homozygous wild type from heterozygous 
mutant (±homozygous mutant) in the relative fluorescence 
plots (Fig. 4). This can be performed on any standard qPCR 
thermal cycler. We validated the assays described here on an 
ABI 7900HT real-time PCR system with SDS software v2.1 
(both Applied Biosystems; see Note 7).
 1. Extract genomic DNA from source cells (e.g., blood or mar-
row mononuclear cells) using commercial kit and manufactur-
er’s protocol.
3.2 Preparation 
of High-Quality 
Genomic DNA Samples
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Table 1 
Primer and probe sequences for the six IDH1 and IDH2 TaqMan® SNP genotyping assays
Mutation
Custom 
assay ID Sequence
IDH1 
R132C
AHD2BZ0 F primer 5′-CTTGTGAGTGGATGGGTAAAACCTA-3′
R primer 5′-CACATTATTGCCAACATGACTTACTTGAT-3′
MUT probe 5′-FAM/AAGCATGACAACCTATG/NFQ-3′
WT probe 5′-VIC/AAGCATGACGACCTATG/NFQ-3′
IDH1 
R132G
AH0JE6I F primer 5′-CTTGTGAGTGGATGGGTAAAACCTA-3′
R primer 5′-TGCAAAATCACATTATTGCCAACATG-3′
MUT probe 5′-FAM/AAGCATGACCACCTATG/NFQ-3′
WT probe 5′-VIC/AAGCATGACGACCTATG/NFQ-3′
IDH1 
R132H
AHCTDTS F primer 5′-CTTGTGAGTGGATGGGTAAAACCTA-3′
R primer 5′-CACATTATTGCCAACATGACTTACTTGAT-3′
MUT probe 5′-FAM/ATCATAGGTCATCATGC/NFQ-3′
WT probe 5′-VIC/CATCATAGGTCGTCATGC/NFQ-3′
IDH1 
R132S
AHFA958 F primer 5′-CTTGTGAGTGGATGGGTAAAACCTA-3′
R primer 5′-CACATTATTGCCAACATGACTTACTTGAT-3′
MUT probe 5′-FAM/CCATAAGCATGACTACCTAT/NFQ-3′
WT probe 5′-VIC/CATAAGCATGACGACCTAT/NFQ-3′
IDH2 
R140Q
AHVJL0G F primer 5′-AAGATGTGGAAAAGTCCCAATGGA-3′
R primer 5′-TGGGCTCCCGGAAGACA-3′
MUT probe 5′-FAM/ACTATCCAGAACATCC/NFQ-3′
WT probe 5′-VIC/CTATCCGGAACATCC/NFQ-3′
IDH2 
R172K
AHGJ8CG F primer 5′-GCTGGACCAAGCCCATCA-3′
R primer 5′-TCCACCCTGGCCTACCT-3′
MUT probe 5′-FAM/ATTGGCAAGCACGCC/NFQ-3′
WT probe 5′-VIC/ATTGGCAGGCACGCC/NFQ-3′
 2. Determine the quantity and quality of each genomic DNA 
sample using an appropriate method (e.g., NanoDrop 2000 
spectrophotometer).
 3. (Optional) Assess integrity of genomic DNA on an Agilent® 
2100 Bioanalyzer, according to the manufacturer’s instructions.
 4. Dilute DNA to 20 ng/μL with ddH2O or TE buffer (see Note 8). 
Store diluted DNA at −20 °C. Avoid excessive freeze-thaw cycles.
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 1. Select 48 samples for inclusion in each IFC chip to be run. We 
recommend including each sample in at least duplicate and 
preferably triplicate wells per IFC chip (see Note 9).
 2. Include appropriate controls, including at least one each of:
(a) Negative DNA control sample (i.e., a sample confirmed 
wild type for the mutation of interest).
(b) No template control (NTC) (i.e., with ddH2O substituted 
for DNA template).
 3. Design an experiment template, allocating a position for each 
sample in 96-well plate format. We recommend allocating the 
48 wells in the left half of a 96-well plate (i.e., wells A1–H6). 
This facilitates easy transfer of DNA/reaction mix samples across 
to the chip using an 8-channel pipette (see Subheading 3.6) and 
automated mapping of sample destination wells using the 
onboard analysis software (see Subheading 3.8).
 1. Carefully remove a new 37K™ IFC chip from its packaging. 
The chip must be used within 24 h of opening the package.
 2. Holding the chip at a ~45° angle with the shorter edge against 
the work surface, slowly inject control line fluid into each accu-
mulator inlet. Inject a full syringe (300 μL) into each accumu-
lator inlet on the chip (see Note 10).
3.3 Planning 
a 37K™ IFC Chip Run 
Experiment
3.4 Prime a New 
dPCR 37K™ IFC Chip
Fig. 4 Example allelic discrimination qPCR cluster plot for TaqMan® SNP genotyping 
assays. Each pooled assay was validated by endpoint AD-PCR using genomic DNA 
from ≥3 primary patient samples known to harbor the relevant IDH1 or IDH2 muta-
tion. Representative plots for IDH2 R140Q are shown. Each sample is plotted as the 
endpoint ratio of corrected fluorescence (ΔRn) for VIC® (wild type; X-axis) versus 
FAM™ (mutant; Y-axis) after 40 PCR cycles. Plasmid standards containing the indi-
cated percentage mutant/wild-type DNA mixes are shown. NTC no template control
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 3. Remove and discard the blue protective film from underside of 
the chip.
 4. Place the chip into the IFC controller module MX.
 5. Follow the on-screen instructions, selecting the “Prime 
(167×)” script (see Note 11).
 1. Table 2 summarizes the relative volumes of each component in 
the assay reaction mix for each 37K™ IFC chip and sample 
panel (see Note 12).
 2. In a DNA-free hood, combine the total required volumes of 
TaqMan® assay, Mastermix, Loading Reagent, and ddH2O in a 
1.5 mL microcentrifuge tube.
 3. Pipette 4.2 μL of this reaction mix (i.e., all components exclud-
ing DNA) into each of the 48 active wells of a 96-well PCR 
microplate according to the experiment template designed in 
Subheading 3.3, step 3 (i.e., the left half of the plate for a 
single chip run).
 4. Remove the microplate from the DNA-free hood, and add 1.8 
μL of DNA (at 20 ng/μL; see Subheading 3.2, step 4) to the 
active well corresponding to its location in the experiment 
template. Each well should now contain 6 μL total volume.
 5. Cover microplate with adhesive seal and centrifuge at ≥1000 
× g for 2 min to collect reaction/DNA mix at the bottom of 
each well.
3.5 Prepare 48 
Assay Reaction Mixes 
for DNA Test Samples
Table 2 
Reaction mix components and volumes
Final volume/inlet (μL)
Volume/inlet with 
overage (μL)
Volume/full IFC chip 
(μL)
TaqMan® Gene 
Expression Mastermix 
(Life Technologies, 
Cat #4369016)
2.0 3.0 180
20× GE Sample Loading 
Reagent (Fluidigm, 
Cat #85000746)
0.4 0.6 36
20× gene-specific 
TaqMan® assay
0.2 0.3 18
PCR-grade ddH2O 0.2 0.3 18
DNA 1.2 1.8 n/a
Total 4.0 6.0 252
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 1. After “Prime” script has completed, remove the chip from the 
IFC controller module MX.
 2. Prepare 1× GE Sample Loading Reagent from the supplied 
20× stock (see Note 13).
 3. Pipette 10 μL of 1× GE Sample Loading Reagent into each of 
the 16 hydration inlets on the chip. Avoid introducing bubbles 
into the hydration inlets through careful ± reverse pipetting.
 4. Pipette 4 μL of each DNA/assay reaction mix into the 48 sam-
ple inlets on the chip, using the pipetting map to guide sample 
transfer (Fig. 5; see Note 14).
 5. Visualize each sample well to confirm that the reaction mix is 
covering the inlet channel and is free of bubbles. Small bubbles 
can be manually cleared using a fresh, sterile 25G hypodermic 
needle. Take care to avoid cross-contamination of DNA/assay 
reaction mix between inlet wells.
3.6 Load DNA/Assay 
Reaction Mixes 
into 37K™ IFC Chip
Fig. 5 Pipetting map from the 96-well microplate layout to 37K IFC chip sample panel inlet wells. We recom-
mend transferring samples from the 96-well plate by column, using an 8-channel P10 pipette, to the chip 
sample wells bearing the matching color
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 6. Place the IFC chip into MX controller module (or Juno™ 
system).
 7. Follow the on-screen instructions, selecting the “Load (167×)” 
script (see Note 15).
 1. After “Load” script has completed, remove the chip from the 
IFC controller module MX.
 2. Remove any dust particles or debris from the IFC surface 
(see Note 16).
 3. Ensure that the Biomark HD™ and the associated desktop 
computer terminal are switched on. Launch the Biomark 
Data Collection program on the terminal and select Start a 
New Run. Ensure that the status indicators for the lamp and 
camera are green.
 4. Place the loaded 37K™ IFC chip into the instrument tray. 
Click Load.
 5. Verify the IFC chip barcode and that the correct chip type is 
automatically detected. Click Next.
 6. Provide a name and select a file storage location for a new IFC 
chip run. Click Next.
 7. Choose the application (Digital PCR) and passive reference 
(ROX). Check Select Probes Manually and choose assay type 
(Two Probes). Select the probe types (FAM-MGB and VIC- 
MGB). Click Next.
 8. Browse for and select the thermal protocoldPCR Standard 
v1.pcl (see Note 17 and Table 3). Confirm Auto Exposure is 
selected. Click Next.
 9. Verify all selected parameters are correct. Click Start Run  
(see Note 18).
 1. Once the thermal cycling run is complete, launch the Digital 
PCR Analysis software on the Biomark HD™ desktop com-
puter terminal.
3.7 Digital PCR 
Thermal Cycling
3.8 Using the Digital 
PCR Analysis Software
Table 3 
Real-time PCR thermal cycling conditions for the default protocol “dPCR standard v1.pcl”
Step Temperature (°C) Time Cycles
Initial incubation 50 120 s 1
Initial denaturation 95 10 m 1
Denaturation 95 15 s 40
Annealing/extension 60 60 s
Hold 4 ∞
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 2. Click Open a Chip Run and locate the saved file containing 
the run data (file extension .bml). The file opens in the Chip 
Explorer panel (see Note 19).
 3. Click Sample and Detector Setup in the Chip Explorer pane, 
followed by New, to assign the sample identity to each well of 
the IFC chip used in the test (or Import, if recalling a saved 
layout template). Select Source 96 Wellplate and Mapping 
48.770-SBS94-Left, to automatically map sample wells from 
the original reaction mix 96-well microplate to their destina-
tion wells in the 37K IFC chip (see Note 20).
 4. Open the sample Editor from the taskbar, and label each sam-
ple well following the layout of the original reaction mix 
96-well microplate template. For each sample specify Sample 
Type (“Unknown” for test samples), the Sample Name and 
specify the identity of the Detector Name (e.g., “IDH1 
R132H” or “IDH1 wild type”), and Detector Type (“Test” 
for test samples) for the respective probes. There is also an 
option to specify sample relative concentration to permit 
onboard analysis of serial tenfold dilutions, if required.
 5. Click Analyze to initiate sample mapping and to update raw 
data output. Labeled sample raw data for the full 37K™ IFC 
chip are now available to view via the Chip Explorer panel (see 
Note 21). Panel Summary displays output for each of the 48 
sample panels on the chip. This can be displayed as a Results 
Table, containing basic identification and raw data for each 
sample, or in Heat Map View, which displays each  sample/
panel as a grid of 770 chambers. Those containing a positive 
reaction are filled in red (FAM; mutant) or blue (VIC; wild 
type). It is possible to toggle between heat maps displaying 
FAM alone, VIC alone, or both together (Fig. 6). Data and 
amplification curves for each chamber for every panel on the 
chip can also be viewed individually in the Panel Details view.
 1. Establish and set optimal analysis settings for the selected 
assays. The Digital PCR Analysis software will automatically set 
default qPCR Analysis Settings, but these may not be optimal for 
all assays. We recommend determining optimal settings for each 
custom assay and manually entering these values in the Analysis 
Settings. Remember to click Analyze in the Task panel to apply 
any changes made and to update results data (see Note 22).
Optimization can be determined by detailed inspection of 
PCR amplification curves for individual sample panels, which 
display superimposed amplification curves for each individual 
chamber reaction for either FAM (red) or VIC (blue) or both 
(Fig. 7). We recommend (a) manual adjustment of baseline cor-
rection (if required), (b) adjustment of Ct threshold to elimi-
nate impact of crosstalk between the FAM and VIC filters 
3.9 Data Analysis 
and Interpretation
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(see Note 23), and (c) adjustment of Ct threshold and Ct range 
to establish a suitable threshold to define a “positive” reaction. 
This should be set at a point that optimally captures every posi-
tive (but no negative) reaction amplification curve within the 
selected Ct range (see Note 24).
The following Analysis Settings are those used within our 
laboratory and deliver good performance for all of the assays 
described in this chapter:
Quality threshold: 0.65
Baseline correction: Linear
Ct threshold method: User (global) (see Note 25)
Ct ranges:  15–35
Ct thresholds:  See Table 4
 2. Check panel template saturation is within the optimal 
range for each sample. The final column in the Panel Summary 
results table (“All Union”) indicates the number of chambers 
containing a positive reaction for one or both probes (/770) in 
that panel. For optimal performance of the Poisson correction, 
Fig. 6 Example heat map outputs for seven (of 48) representative panels from an IDH1 R132C 37K™ IFC chip 
digital PCR run. The left panel (red) indicates the FAM channel (mutant allele), and the right panel (blue) indi-
cates the VIC channel (wild-type allele). Note the “NEG” (sample known to be wild type; panel 42) and no 
template (NTC; panel 48) controls
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Fig. 7 Example real-time PCR amplification curves for a representative panel from an IDH1 R132C 37K™ IFC 
chip run. This sample had a calculated mutant allele frequency of 28.6%. Graphs combine the amplification 
curves from each of 770 individual chamber partition reactions for the FAM (A; red) and VIC (B; blue) detector 
channels. Each curve plotsΔRn (i.e., reporter fluorescence normalized to ROX passive reference signal; Y-axis) 
against PCR cycle number. Crosstalk between the two channels is evident in the gray traces deviating from 
baseline (but these are unequivocally negative reactions, indicated by arrows). Ct range and Ct threshold 
(vertical and horizontal colored lines, respectively) were set for each channel to negate the impact of crosstalk 
while clearly defining all “positive” reactions for each probe. (C) Curves for both channels are displayed simul-
taneously on the same scale. Note that the mutant allele (FAM) assay displays relatively lower amplification 
efficiency than the wild-type (VIC) assay. Nevertheless, all positive reactions for each probe are clearly cap-
tured. This illustrates an important advantage of the binary dPCR output for absolute allele- specific quantita-
tion compared with the “analogue” output of conventional qPCR approaches, in which assay efficiency can 
directly influence the derived relative quantitation
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it is recommended that between 200 and 700 chambers con-
tain a template “hit.” With our recommended input DNA 
concentration of 17–23 ng/μL, this will typically be achieved. 
However, any samples that appear oversaturated (>700) or too 
dilute (<200) should be repeated following further dilution or 
concentration of DNA.
 3. Review IFC chip run controls. Confirm that the negative/
wild-type DNA control samples return zero chambers with 
FAM (i.e., mutant) targets and that the NTCs return zero 
chambers with either FAM or VIC targets. Otherwise repeat 
the IFC chip run with fresh reagents as this may indicate DNA 
contamination that could substantially impact on results.
 4. Inspect raw data. The Panel Summary results table presents 
raw data for each sample panel as a separate row in a spread-
sheet table. Data for each probe detector are presented in a 
separate block of columns. Noteworthy data include the actual 
number of chambers meeting criteria for a positive reaction 
(“Count”) for each probe, the Poisson-corrected positive hits 
(“Est. Targets”) and the associated 95% confidence interval 
(lower, “Est. T-95L”; upper, “Est. T-95U”). The “Est. 
Targets” figure that should be considered the final result for 
that probe for that assay.
 5. Export raw data. Raw data for all chambers on the chip 
(“Detailed”) or summaries for each sample panel (“Summary”) 
can be exported as .csv files to a compatible spreadsheet soft-
ware (e.g., Microsoft Excel) for further analysis. A PDF report 
can also be exported that includes composite real-time amplifi-
cation curves for each sample panel.
 6. Calculate mutant allele frequencies (MAFs). MAFs are not 
automatically calculated by the software but are easily derived 
as the number of estimated targets for mutant (FAM) probe 
divided by the total number of estimated (FAM + VIC) targets 
analyzed in any sample panel:
Mutant allele frequency = Estimated mutant (FAM) targets/
Estimated total (FAM + VIC) targets
Sensitivity can be extended by including multiple sample repli-
cates in the same chip and manually applying the Poisson cor-
rection to the extended and collated dataset for that sample 
(see Note 26). Using two panels per sample, these IDH1 and 
IDH2 assays have been validated as quantitative to ≤0.1% 
MAF. For any new custom assays, we recommend establishing 
the lower quantitative limit through testing serial dilutions of 
known mixes of mutated/wild-type DNA for each SNV of 
interest (see [12]).
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4 Notes
 1. The Juno™ (Fluidigm) is an alternative system that combines 
priming, loading, and qPCR in the same instrument. It can 
therefore replace the IFC Controller Module MX and 
Biomark™ HD thermal cycling system in this protocol.
 2. We recommend diluting genomic DNA to a starting concen-
tration of 17–23 ng/μL but have seen successful panel satura-
tion (i.e., >200 chambers containing template reaction) with 
DNA concentrations as low as ~5 ng/μL. If sample concentra-
tion is below this and further concentration (e.g., by centrifu-
gal evaporation) is not possible, we recommend including a 
pre-amplification step. We have validated this protocol on 
DNA samples subjected to multiple whole genome amplifica-
tion using the REPLI-g mini amplification kit (Qiagen).
 3. Other qPCR mastermixes can be substituted but are not sup-
ported by Fluidigm. We have also validated 2× TaqMan® 
Genotyping Mastermix (Life Technologies, Cat #4371355) as 
an alternative.
 4. Thermo Fisher Scientific supplies TaqMan® SNP genotyping 
assays in three sizes: small (188 μL), medium (625 μL), and 
large (750 μL). Large assays are manufactured at 80× concen-
tration, and small or medium assays are supplied at 40× con-
centration. One small assay provides sufficient reagent for ≥20 
full IFC chip runs of 48 samples each.
 5. It is recommended that submitted template sequences be 300–
600 bases in length. Other factors that can influence the assay 
design success include the presence of polymorphisms close to 
the region of interest and low complexity or repetitive regions of 
DNA. In these cases unique primer/probe design may not be 
possible. We recommend designing assays using FAM™-MGB 
Table 4 
Recommended Ct thresholds for the six IDH1 and IDH2 dPCR assays
Assay FAM (mutant) Ct threshold VIC (wild type) Ct threshold
IDH1 R132C 0.096 0.178
IDH1 R132G 0.05 0.10
IDH1 R132H 0.064 0.10
IDH1 R132S 0.05 0.10
IDH2 R140Q 0.04 0.07
IDH2 R172K 0.056 0.07
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and VIC®-MGB probes. Note however that FAM™-TAMRA™ 
and FAM™-nonfluorescent quenchers are also supported with 
the Biomark™ HD system. Further, other fluorophores with 
excitation between 465–505 nm and 510–550 nm and emission 
between 500–550 nm and 540–600 nm, respectively, should 
also be compatible. See “Custom TaqMan® Genomic Assays 
Protocol: Submission Guidelines” (Thermo Fisher Scientific; 
PN 4367671) for further guidelines and tips on custom assay 
design. This is available for download at https://tools.thermo-
fisher.com/content/sfs/manuals/cms_042307.pdf.
 6. TaqMan® SNP genotyping assays are potentially susceptible to 
light degradation. Aliquoting and storage in the dark at −20 
°C mitigates the need for freeze-thawing and unnecessary light 
exposure.
 7. For more information on the principles of allelic discrimina-
tion PCR, a detailed technical method, and a guide to inter-
preting the results, see “Allelic Discrimination Getting Started 
Guide” (Applied Biosystems, PN 4364015), available for 
download at http://www3.appliedbiosystems.com/cms/
groups/mcb_support/documents/generaldocuments/
cms_042114.pdf.
 8. Each sample well inlet on the IFC chip will contain 1.2 μL of 
DNA sample as part of a combined reaction mix. Poisson dis-
tribution estimates of positive targets are accurate and repro-
ducible for between ~230 and 1900 copies per panel (0.3 < λ 
< 2.5), which equates to a target range of 200–700 (/770) 
chambers containing a template reaction [15]. For the assays 
described in this chapter, we have validated that a starting sam-
ple DNA concentration of 17–23 ng/μL will appropriately 
saturate a sample panel.
 9. All wells of a 37K™ IFC chip must be in use before loading 
and thermal cycling. Batching samples (or increasing number 
of replicates) will maximize the number of chip wells returning 
useful data.
 10. Ensure that the correct prepackaged control line fluid is used 
(i.e., “48.48” syringes with 300 μL preloaded fluid). Other 
kits contain different volumes that will not adequately prime 
the chip microfluidics. Before loading, use the syringe with 
shipping cap in place to actuate both accumulator check valves 
using gentle downward pressure. Only proceed if the poppets 
depress freely. Before dispensing the control line fluid, visually 
confirm that the check valve is open. The O-ring seal at the 
bottom of the valve will be depressed and displaced to the side. 
Take care to avoid any spillage of control line fluid onto the 
chip or inlets and to confirm that the O-ring returns to its nor-
mal position after removing the syringe tip.
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 11. The MX “Prime” script runs for approximately 50 min. While 
the script is running, proceed to prepare the reaction mix (see 
Subheading 3.5). Ensure that the 37K™ IFC chip is loaded 
(see Subheading 3.6) within 60 min of priming.
 12. The volumes in Table 2 are calculated for 60 reactions to 
ensure sufficient overage for accurate pipette transfer from 
96-well plate to 37K™ IFC chip. Multiple TaqMan® assays can 
be used in the same chip (in different sets of wells). Scale down 
components, maintaining the indicated relative proportions, as 
appropriate for each assay, or scale up if more than one chip 
run is planned for the same assay.
 13. Diluting 10 μL of the GE Sample Loading Reagent 20× stock 
with 190 μL PCR-grade ddH2O will prepare sufficient 1× 
Loading Reagent for a single full 37K™ IFC chip.
 14. Use an 8-channel P10 pipette to transfer DNA/assay reaction 
mix from each complete column (i.e., rows A–H) of the 
96-well microplate into the corresponding inlet wells on the 
37K™ IFC chip, according to Fig. 5. Avoid introducing bub-
bles into the sample inlet wells. This can interfere with sample 
uptake during pneumatic loading. Reverse pipetting (with 
slight overage) will avoid bubble contamination and is highly 
recommended.
 15. The “Load” script draws sample through the inlet channels 
into the microfluidic circuit of the IFC chip and partitions into 
770 individual chambers for each sample panel. The script runs 
for ~40 min. The dPCR thermal cycling run should be com-
menced within 60 min of chip loading.
 16. Gentle application and rapid removal of a pressure sensitive 
adhesive tape across the IFC chamber surface is a simple and 
effective method for lifting dust or debris.
 17. The dPCR standard thermal cycling protocol in Table 3 pro-
vides satisfactory performance for all of the IDH1 and IDH2 
assays described in this chapter while permitting simultaneous 
inclusion of different assays in the same IFC chip run. However, 
optimal annealing temperature varies from assay to assay and 
may need optimizing for new custom assays.
 18. Thermal cycling for this protocol takes approximately 90 min. 
FAM™, VIC®, and ROX (passive reference) signals of all cham-
bers for all panels within the IFC chip are automatically 
detected and recorded at the start of each annealing step and 
at the end of the program. Real-time PCR data and PCR 
amplification curves are recorded for each chamber of each 
sample panel.
 19. The first time a chip run .bml file is opened, all data are ana-
lyzed, and the chamber-finding algorithm locates the chamber 
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boundaries of each captured image. It may take several minutes 
for the .bml file to load. If the algorithm cannot locate the four 
corner cells of the chip during the first analysis (rare), an error 
message will appear, prompting the user to manually find them. 
If this occurs, follow the on-screen instructions (Note: adjust-
ing the contrast slider can aid in visualizing the corner cells).
 20. The suggested selections assume that the user has followed the 
96-well plate template layout recommended in Subheading 
3.3 and the left-to-right pipetting scheme outlined in 
Subheading 3.6/Fig. 5 when loading the chip with DNA 
samples.
 21. Raw data will initially be presented using the system’s default 
settings, ranges, and thresholds. These may require manually 
changing (see Subheading 3.9). For a detailed software man-
ual, see Fluidigm’s Digital PCR Analysis User Guide (PN 
68000100; available for download at https://www.fluidigm.
com/documents).
 22. Once determined the same analysis settings should be employed 
each time an assay is run. When optimizing parameters for a 
new assay, we recommend reviewing several chip runs, con-
taining samples with a wide range of MAFs, before confirming 
settings used to report definitive results.
 23. Crosstalk between filters can be observed in the real-time PCR 
amplification curves for DNA samples containing high allelic 
burden for one allele as a distinctive and consistent deflection 
from baseline of a proportional bulk of overtly “negative” 
chamber amplification curves visible in the opposite probe’s 
detector channel. See Fig. 7 for a worked example.
 24. Note that since the output for each chamber reaction is a 
binary readout, the precise positioning of the Ct threshold (in 
relation to the PCR amplification phases) is less critical than for 
conventional qPCR. The foremost consideration is establish-
ing a Ct threshold and range that will reliably and reproducibly 
distinguish positive from negative reaction chambers. Hence 
this approach is more permissive to (modest) deviations from 
optimal in assay amplification efficiency and annealing temper-
ature compared with conventional qPCR.
 25. The “User” (versus “Auto”) settings allow thresholds for each 
probe type to be set manually. We have observed improved 
performance of the assays with manually determined Ct thresh-
olds, based on the individual amplification kinetics and effi-
ciency curve morphologies for each probe/assay. “Global” 
applies the specified Ct threshold to all sample panels on the 
chip simultaneously. The option exists to manually adjust the 
threshold for each probe in each panel individually (“User 
[Detectors]” setting). However, even when including several 
Digital PCR for IDH1 and IDH2 Mutations
paolo.fortina@jefferson.edu
254
assays with different optimal settings within the same chip, we 
find that setting a “Global” threshold for each assay’s settings 
separately, and saving and exporting the data for the entire 
chip, before repeating with each other assay’s settings, is faster 
and more efficient.
 26. The sensitivity of dPCR is highly dependent on the total num-
ber of sample partitions. Whereas droplet dPCR can generate 
many thousands of individual droplet partitions, nanofluidic 
platforms are inherently limited by the number of chambers for 
each sample panel in the chip (i.e., 770 for the 37K™ IFC chips). 
This is counterbalanced by several advantages of the Fluidigm 
system, including consistent and reproducible run sensitivity, 
and access to real-time PCR data for each individual reaction. 
This offers greater control over defining thresholds for a positive 
reaction and monitoring and optimizing assay performance. 
Moreover, the sensitivity of nanofluidic dPCR can be improved 
by increasing the number of panels allocated to a particular sam-
ple on the same chip, thus expanding the number of chamber 
partitions by 770 for each additional panel allocated. To deepen 
sensitivity (rather than simply provide technical replicates), the 
Poisson correction must be applied manually on the expanded 
dataset, using the following calculation:
Estimated targets in panel = LN((y − x)/y) × (−y),
where x = count of positive targets and y = total number of 
chambers across which the sample is partitioned (i.e., 770 × 
number of panels allocated to that sample). Since each cham-
ber on a chip contains a fixed volume (0.75 nL for the 37K™ 
IFC chip), this effectively becomes equivalent to distributing a 
larger starting sample across a greater number of partitions, 
deepening sensitivity accordingly. This affords a degree of con-
trol over balancing sensitivity requirements against throughput 
and overall cost, as demanded by different circumstances.
For further explanation as to the derivation of this calculation, 
see Fluidigm’s technical note “Calculating Copy Number 
Using a 12.765 Digital ArrayTM IFC” (PN 68000119). For a 
detailed explanation of Poisson distribution mathematics as 
applied to dPCR (beyond the scope of this article), see [9].
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Chapter 16
Isolation of Biologically Active Exosomes from Plasma 
of Patients with Cancer
Chang-Sook Hong, Sonja Funk, and Theresa L. Whiteside
Abstract
A method for exosome isolation from human plasma was developed for rapid, high-throughput processing 
of plasma specimens obtained from patients with cancer. This method removes the bulk of plasma proteins 
associated with exosomes and can be used for comparative examinations of exosomes and their content in 
serial specimens of patients’ plasma, allowing for monitoring changes in exosome numbers, profiles, and 
functions in the course of cancer progression or during therapy. The plasma-derived exosomes can be 
recovered in quantities sufficient for the characterization of their morphology by transmission electron 
microscopy (TEM), size and concentration by qNano, protein/lipid ratios, nucleic acid extraction, molec-
ular profiling by Western blots or immune arrays, and functional assays.
Key words Plasma exosomes, Isolation, Cancer, Size exclusion chromatography, Exosome functions, 
Exosome cargo
1 Introduction
Exosomes have been traditionally isolated by a series of differential 
centrifugations aimed at removing first the cell debris and then 
larger EVs followed by ultracentrifugation of smaller exosomes at 
100,000 × g for 2–3 h and by flotation on a sucrose density gradi-
ent to obtain purified exosomes [1]. More recently, this time- 
consuming ultracentrifugation has been replaced by a variety of 
other methods, which aim at a more rapid high-throughput isola-
tion of purified exosomes with a defined size and molecular con-
tent from body fluids [2]. We have modified a previously described 
size exclusion chromatography (SEC) approach [3] to be able to 
reliably and readily recover morphologically intact functionally 
competent exosomes from small volumes (1 mL) of plasma by 
“mini-SEC” in patients with cancer [2]. The methodology of exo-
some isolation from plasma by mini-SEC is described below.
paolo.fortina@jefferson.edu
258
2 Materials
 1. Plasma is obtained from venous blood samples by centrifugation 
at 1000 × g for 10 min. Collect clear plasma and aliquot into 
2 mL cryovials. Store specimens frozen at −80 °C until exosome 
isolation.
3 Methods
Prepare all solutions at room temperature before experiments 
unless specified. Perform all steps in a laminar flow hood. Columns 
for exosome isolation are set up on clean benches. All solutions are 
sterile and no sodium azide is added. Dispose of waste materials 
following the institutional guidelines. Details are as follows:
 1. Thaw frozen plasma and centrifuge at 2000 × g for 10 min and 
transfer clear plasma into new tubes. Recentrifuge at 10,000 × 
g for 30 min and save clarified plasma. Filter the plasma with a 
0.22 μm-pore Millipore filter (see Note 1).
 2. Wash Sepharose 2B solution (Sigma-Aldrich, 60–200 μm 
bead diameter) with 1× PBS three times before preparing SEC 
columns.
 3. Set up a disposable 1.5 cm × 12 cm mini-column (Bio-Rad, 
Hercules, CA, USA, Econo-Pac columns) on the ring stand 
and mark at the 10 mL line, which will be the column bed 
volume. Place a 50 mL Falcon tube for waste collection at the 
bottom of the stand.
2.1 Plasma 
of Cancer Patients  
or Healthy Donors
3.1 Exosome 
Isolation from Plasma 
(Fig. 1)
Fig. 1 Schema of the exosome isolation procedure from plasma
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 4. Load prewashed Sepharose 2B slurry into the column and 
allow PBS to flow through the column by gravity to a waste 
tube. Let the gel settle up to the 10 mL line. After dripping 
stops, close the outlet with a yellow cap and insert a porous 
frit, which are both provided along with the Econo-Pac col-
umns, on the top of the gel (see Note 2) and then wash the 
column with 20 mL of 1× PBS. Now the column is ready to be 
used for exosome processing.
 5. Load 1 mL of the ultrafiltrated plasma from step 1 of 
Subheading 3.1 on top of the column and let it flow through 
the column.
 6. After dripping stops, add 1 mL of 1× PBS to the column and 
let it flow through the column to the waste tube. This is frac-
tion #1.
 7. Repeat step 6 of Subheading 3.1 for fraction #2. Then replace 
the waste tube with a clean 15 mL Falcon tube for collecting 
exosome fractions.
 8. Add 1 mL of 1× PBS and collect fraction #3. Then replace the 
fraction #3 tube with a new 15 mL falcon tube and add 1 mL 
PBS to the column and collect fraction #4.
 9. Repeat step 8 of Subheading 3.1 to collect fraction #5 (see 
Note 3). After fraction #5, stop collecting fractions and discard 
the column.
Concentrate fractions #3 or #4 using 100K Amicon Ultra 0.5 mL 
centrifugal filter (EMD Millipore, Billerica, MA, USA) by centrifu-
gation at 5000 × g for 1–10 min, depending on the final concen-
tration for downstream analysis (see Note 4).
Measure protein concentration in fractions #3 and #4 using a BCA 
protein assay kit (Pierce Biotechnology, Rockford, IL, USA) 
according to the manufacturer’s instructions.
Tunable Resistive Pulse Sensing (TRPS) by qNano (Izon, 
Cambridge, MA, USA) is used to measure the size distribution 
and concentration of particles in fractions #3 and #4. The proce-
dures are performed according to the manufacturer’s instructions 
(see Note 5).
TEM procedures and imaging of exosomes usually are performed in 
imaging facilities and details have been published elsewhere. Briefly:
 1. Put 2 μL of fractions #3 or #4 on a copper grid coated with 
0.125% Formvar in chloroform.
 2. Stain the grids with 1% (v/v) uranyl acetate in ddH2O.
 3. Image exosomes immediately with a JEM 1011 transmission 
electron microscope.
3.2 Exosome 
Concentration
3.3 Protein 
Measurements
3.4 Particle Size 
and Concentration 
Measurements
3.5 Transmission 
Electron Microscopy
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Approximately 10 μg of exosome proteins, either from fraction 
#4 or after concentration from Subheading 3.2, can be separated 
on SDS-PAGE gels and transferred into an Immobilon mem-
brane. Then it can be analyzed by Western blots with antibodies 
of exosomal markers, CD9, CD63, or TSG101, and other cancer 
markers (Fig. 2).
Exosomes isolated by SEC are biologically active and relatively free 
of plasma components and thus optimal for studies of their effect 
on immune cells. In Fig. 3, the effects of exosomes isolated from 
plasma of a normal donor (ND) or from plasma of head and neck 
cancer patients on primary CD4+ T cells or CD8+ Jurkat cells are 
shown (see Note 6).
Primary CD4+ and CD8+ T cells can be isolated from whole blood 
of NDs as follows:
 1. Centrifuge venous blood samples at 1000 × g for 10 min to 
separate plasma (upper level) from other blood components 
(lower level).
 2. Take off and save plasma for exosome isolation.
 3. Dilute the pellet in PBS and load the solution on a Ficoll- 
Hypaque gradient.
 4. Centrifuge at 900 × g for 30 min.
 5. Collect the PBMC layer located at the PBS/plasma interface.
 6. Wash PBMC in PBS at 1000 × g for 10 min.
 7. Resuspend PBMC at 2–3 × 106 PBMC/mL in RPMI MV- 
(Lonza RPMI 1640, 10% (v/v) FBS that is exosome-depleted 
(Gibco), 100 IU/mL penicillin, 100 μg/mL streptomycin, 
and 2 mM/L l-glutamine) and plate for 2–3 h to remove 
plastic- adherent monocytes.
3.6 Western Blot 
of Exosomes
3.7 Functional 
Studies
3.8 Peripheral Blood 
Mononuclear Cell 
(PBMC) Isolation 
and Culture
Fig. 2 Western blot analysis of exosomes isolated from plasma of AML patients 
and a normal donor. Each lane was loaded with 10 μg exosomal protein
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 1. Centrifuge PBMC at 500 × g for 10 min.
 2. Cell separation can be performed using negative or positive iso-
lation kits for CD4+ and CD8+ T cells on an autoMACS cell 
separator (Miltenyi Biotec, San Diego, CA, USA) following the 
manufacturer’s instructions. We prefer negative isolations 
because the cell purity is higher.
 1. Label primary CD4+ T cells of healthy volunteers with 1.5 μM 
CFSE (i.e., CellTrace Proliferation Kit, Thermo Scientific) in 
0.1% BSA in PBS for 10 min at 37 °C [5].
 2. Quench staining with an equal volume of exosome-depleted 
FBS and wash two times in RPMI MV-.
 3. Activate CFSE-labeled CD4+ T cells at a ratio of 105 cells/100 μL 
in a 96-well plate with CD3/28 (i.e., plate-bound CD3 and 
CD28 in solution, 2 μg/mL) and IL-2 (i.e., 150 IU/mL, 
PeproTech) for 24 h. Also, plate resting CFSE+ T cells at the 
same concentration as controls.
3.9 Primary CD4+ 
and CD8+ T Cell 
Isolation
3.10 CFSE-Based 
Proliferation Assay 
with CD4+ T Cells 
(Fig. 3a)
Fig. 3 Functional assays. (a) Proliferating CFSE+ CD4+ T cells are inhibited by exosomes isolated from plasma 
of NDs and HNC patients. (b) Apoptosis in CD8+ Jurkat cells is induced by exosomes of NDs and HNC patients
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Alternatives for T cell activation are CD3/28-coated 
magnetic beads (bead-to-cell-ratio of 1:2, Miltenyi) or 
Immunocult Human CD3/28T cell activator (25 μL/mL, 
Stemcell). In our hands, the human T cell activator (Stemcell) 
was the most reliable, simplest, and cleanest (no beads) way of 
T cell activation.
 1. On day 1, co-incubate 105 CFSE+ T cells with exosomes (2–3 
μg in 50 μL PBS) or no exosomes (50 μL PBS). Resting CFSE+ 
T cells that were cultured on day 0 are another control.
 2. Proliferation can be determined by flow cytometry on day 4 
or 5.
 3. Annexin V-based apoptosis assay with CD8+ Jurkat cells 
(Fig. 3b).
 4. Plate CD8+ Jurkat cells (105 cells in 100 μL RPMI MV- per 
96-well for 24 h).
Alternatively, isolate (see Subheading 3.7) and activate primary 
CD8+ T cells with CD3/28 (i.e., Stemcell 25 μL/mL) and 
IL-2 (150 IU/mL) in a cell incubator at 37 °C and 5% CO2 
for 48 h.
 5. Set up experiment by adding exosomal fraction #4 (i.e., 50 μL 
of 2–3 μg) to your CD8+ cells. Appropriate controls are no 
exosomes (50 μL PBS) as a negative control and heat-killed 
CD8+ cells (56 °C for 30 min) as a positive control.
 6. Incubate for 24 h at 37 °C and 5% CO2.
 7. Apoptosis can be detected using an Annexin V apoptosis detec-
tion kit (Beckman Coulter) by flow cytometry.
4 Notes
 1. Frozen vs. fresh plasma: We compared exosome isolation from 
frozen/thawed plasma to fresh plasma [4]. We observed that 
frozen/thawed plasma decreased the yield of exosomes com-
pared to fresh samples, but biological activity of exosomes was 
not affected.
 2. Inserting the frit on top of Sepharose 2B gel: Porous frits are 
included in the preparation of SEC columns. After Sepharose 
2B gel is settled up to the 10 mL bed volume, using a tweezer 
slowly push the frit into the column. It is important to level 
the frit on the top of the gel. This step may affect exosome 
fractionation.
 3. Fractions 3, 4, and 5: Since the procedure is based on size 
exclusion chromatography, the earlier fractions contain larger 
molecules than the later fractions. Fraction #3 contains a very 
3.11 Experimental 
Setup
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low protein concentration (often below detection level of BCA 
assay). Nevertheless, TEM and particle analysis by qNano 
show exosome presence in fraction #3. Fraction #5 has a high 
protein concentration but contains aggregates of serum pro-
teins and exosomes, as seen by TEM. Fraction #4 is the major 
fraction containing unclustered morphologically intact exo-
somes as seen shown by TEM at the highest concentrations by 
qNano analyses (Figs. 4, 5, and 6).
 4. Exosome concentration: Protein concentrations in fractions #3 
and #4 vary widely among different plasma samples and cancer 
types. Therefore, depending on the analyses, the recovered 
Fig. 4 Protein contents in the fractions recovered after SEC. An aliquot (50 μL) of 
each fraction was separated by SDS-PAGE gels and stained with Coomassie blue 
and analyzed by Western blotting. CD9 is used as an exosomal marker
Fig. 5 Transmission electron microscopy (TEM) of fractions #3, #4, and #5 recovered after SEC of plasma 
obtained from a patient with AML
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fractions may have to be concentrated. Protein spin-column 
concentrators, such as 300K MWCO Vivaspin 500 (Sartorius 
Corp, New York, NY, USA) or 100K MWCO Amicon Ultra 
0.5 mL centrifugal filter (EMD Millipore, Billerica, MA, USA), 
work fine for concentrating exosomes. The concentrating pro-
cedure further removes contaminating serum proteins. 
However, while 300K MWCO removes more contaminants, it 
may also lead to a loss of smaller exosomes.
 5. Particle quantification by qNano: Measuring the size distribu-
tion and concentration of exosomes, especially plasma-derived 
exosomes which are opsonized with immunoglobulins, is often 
difficult. These exosomes have a tendency to form aggregates 
of varying sizes. Thus, we routinely add 0.03% Tween 20 to 
the collected fractions in order to prevent/dissolve the aggre-
gates before placing exosomes in the nanopore (NP150), 
which is used to measure exosomes. We have used a smaller 
nanopore (NP100), but it tended to clog, creating problems. 
Also, we use the reagent kit provided by Izon to coat the nano-
pore and prevent protein binding to the pore. The calibration 
particles, which are included in the Izon kit, are measured 
directly before and after experimental samples under identical 
Fig. 6 Particle measurement by qNano of fraction #4
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conditions, and the size and concentration of the particles are 
determined using the Izon software (version 3.2).
 6. For all functional assays, the amount of exosomes added should 
be titrated. However, in our hands about 2–3 μg exosomal 
protein from SEC fraction #4 (ca. 50 μL) showed reproducible 
and significant in vitro immune reactivity.
Acknowledgments
The development of the method was in part supported by NIH 
grants RO-1CA168628 and R21-CA205644 to TLW.
References
 1. Thery C, Amigorena S, Raposo G, Clayton A 
(2006) Unit 3.22 Isolation and characteriza-
tion of exosomes from cell culture supernatants 
and biological fluids. Curr Protoc Cell Biol. 
doi:10.1002/0471143030.cb0322s30
 2. Hong CS, Funk S, Muller L, Boyiadzis M, 
Whiteside TL (2016) Isolation of biologically 
active and morphologically intact exosomes 
from plasma of patients with cancer. J Extracell 
Vesicles 5:29289
 3. Taylor DD, Chou IN, Black PH (1983) 
Isolation of plasma membrane fragments from 
cultured murine melanoma cells. Biochem 
Biophys Res Commun 113(2):470–476
 4. Muller L, Hong CS, Stolz DB, Watkins SC, 
Whiteside TL (2014) Isolation of biologically- 
active exosomes from human plasma. J Immunol 
Methods 411:55–65
 5. Saze Z, Schuler PJ, Hong CS, Cheng D, 
Jackson EK, Whiteside TL (2013) Adenosine 
production by human B cells and B cell-medi-
ated suppression of activated T cells. Blood 
122:9–18
Isolation of Biologically Active Exosomes from Plasma of Patients with Cancer
paolo.fortina@jefferson.edu
267
Paolo Fortina et al. (eds.), Acute Myeloid Leukemia: Methods and Protocols, Methods in Molecular Biology, vol. 1633,
DOI 10.1007/978-1-4939-7142-8_17, © Springer Science+Business Media LLC 2017
Chapter 17
Generating and Expanding Autologous Chimeric Antigen 
Receptor T Cells from Patients with Acute Myeloid 
Leukemia
Saad S. Kenderian, Carl H. June, and Saar Gill
Abstract
Adoptive transfer of genetically engineered T cells can lead to profound and durable responses in patients 
with hematologic malignancies, generating enormous enthusiasm among scientists, clinicians, patients, and 
biotechnology companies. The success of adoptive cellular immunotherapy depends upon the ability to 
manufacture good quality T cells. We discuss here the methodologies and reagents that are used to generate 
T cells for the preclinical study of chimeric antigen receptor T cell therapy for acute myeloid leukemia (AML).
Key words Chimeric antigen receptor, Acute myeloid leukemia, T cell expansion, CAR T cells, 
Adoptive T cell therapy, Synthetic biology
1 Introduction
Genetic material encoding a chimeric antigen receptor (CAR) or 
transgenic T cell receptor (TCR) can be easily transferred into pri-
mary human T cells ex vivo using viral or nonviral approaches, and 
the T cells can then be further propagated in order to generate 
large numbers of tumor antigen-recognizing effector and memory 
cells [1]. The treatment of B-cell malignancies using this approach 
is particularly advanced. Here, autologous or allogeneic peripheral 
blood mononuclear cells are removed by leukapheresis and can be 
further enriched by elutriation or by positive selection using mag-
netic beads. The resultant product is initially composed of a mix-
ture of lymphocytes, but a pure CD3+ T cell product composed of 
both CD4 and CD8 cells is usually generated within 7–9 days 
(occasionally longer) by exposing the lymphocytes to stimulatory 
anti-CD3/CD28 beads, agonistic anti-CD3 antibodies, interleu-
kin- 2, interleukin-7, interleukin-15, artificial antigen presenting 
cells, or a combination of these. Notably, the transduction of an 
anti-CD19 CAR into the T cells effectively leads to an ex vivo 
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selection procedure, as the T cells are immediately functional once 
the CAR is expressed. Hence, an ex vivo “purge” occurs when 
anti-CD19 CAR T cells are exposed to CD19-bearing cells in the 
product [1–8]. Notably, T cell expansion and gene transfer meth-
odology vary significantly between institutions and indeed may 
need to be adapted for different disease states [4–6, 9].
The successful application of CART cell therapy in acute 
myeloid leukemia (AML) would represent a significant advance in 
the field. Treatment of AML has minimally changed over the last 
few decades and prognosis remains very poor [10]. Since virtually 
all antigens expressed by AML blasts are also present on normal 
myeloid progenitors and since the functional avidity of CAR T cells 
appears to be stronger than that of the soluble antibodies on which 
they are based, we expect that treatment with CAR T cells will result 
in significant marrow toxicity regardless of prior clinical experience 
with antibodies. Several groups have developed CAR T cells directed 
against AML antigens, such as CD123 [11, 12], CD33 [13, 14], 
Le-Y [15], CD44v6 [16], and NKG2D [17]. These CAR T cells 
resulted in potent anti-leukemic activity and disease eradication in 
preclinical models at the cost of permanent myeloablation in 
humanized xenografts in some models [11, 13]. Several methods 
are being employed to avoid this permanent unwanted toxicity and 
to increase the therapeutic index of CART cell therapy. Examples of 
such approaches include RNA modification [13] that results in 
transient expression of CARTs and the use of suicide genes. Notably, 
in the case of mRNA electroporation into expanded T cells, gene 
transfer does not occur until the end of the manufacturing period 
and therefore there is no ex vivo purge [18].
In this chapter, we share our observations and protocols for 
optimizing T cell expansion and generation of CAR T cells in 
patients with AML for preclinical experiments. We outline our 
methods and protocols of T cell expansion, T cell enrichment, gen-
eration of permanently modified lentivirally (LV) transduced- 
CART and transiently modified RNA-electroporated CAR T cells 
from AML patients.
2 Materials
 1. De-identified viably cryopreserved primary human AML speci-
mens are obtained from institutional repositories under IRB- 
approved protocols.
 2. Normal donor peripheral blood mononuclear cells (PBMCs) 
are obtained from institutional repositories under IRB-approved 
protocols, or collected fresh. PBMCs are isolated from periph-
eral blood by Ficoll density gradient (Thermo Fischer Scientific, 
Waltham, MA, USA).
2.1 Primary AML 
Samples
Saad S. Kenderian et al.
paolo.fortina@jefferson.edu
269
 1. T cell Media (TCM): X-vivo 15 media (Fisher Scientific), 
human serum 5% (Gemini Bio-product, Inc., West Sacramento, 
CA, USA), penicillin, streptomycin (10,000 U/mL, Thermo 
Fisher Scientific), and glutaMAX (100×, Thermo Fisher 
Scientific).
 2. Anti-human antibodies are purchased from Biolegend (San 
Diego, CA, USA), eBioscience (San Diego, CA, USA), or BD 
Biosciences (San Jose, CA, USA). Live Dead fixable aqua detec-
tion reagent is from Life Technologies (Frederick, MD, USA).
 3. Anti-CD3/CD28 Dynabeads (Life Technologies).
 4. Surface expression of CAR is detected by staining with an Alexa 
Fluor 647-conjugated goat anti-mouse F(ab’)2 antibody from 
Jackson Immunoresearch (West Grove, PA, USA) if the CAR is 
based on a murine single chain variable fragment. If the CAR is 
based on a human or humanized single chain variable fragment, 
an anti-human IgG(H + L) antibody (Jackson Immunoresearch) 
may be used instead.
 5. Anti-PE, or anti-CD4 and anti-CD8 microbeads (Miltenyi, San 
Diego, CA, USA).
 6. Fetal bovine serum (90%) with 10% DMSO.
 7. Flow buffer is PBS, 2% FBS, 0.02%NaN3. PBS (Invitrogen), 
FBS (Gemini), and sodium azide (Ricca Chemical Company).
 1. mMESSAGE mMachineT7 ULTRA Transcription Kit (Life 
Technologies).
 2. RNeasy plus mini kit (Qiagen, Inc., Hilden, Germany).
 3. OptiMEM (Life Technologies).
 4. ECM830 Electro Square Wave Porator (Harvard Apparatus 
BTX, Holliston, MA, USA).
 5. Gene pulser/Micropulser Cuvettes, 0.2 cm gap sterile electro-
poration cuvette (Bio-Rad Laboratories, Hercules, CA, USA).
3 Methods
 1. Thaw frozen PBMCs from AML patients using warm TCM, 
spin at 500 g for 7 min to remove DMSO, and resuspend in 
TCM. Plate at a concentration of 1 × 106 cells/mL and rest 
overnight in incubator at 37 °C, 5% CO2 (see Note 1).
 2. Take an aliquot for flow cytometry, stain with CD45, CD3, and 
live/dead staining. Acquire using a cytometer to determine the 
percentage and total number of T cells.
 3. Prepare CD3/CD28 Dynabeads: Calculate the number of 
beads needed to reach a 3:1 ratio of beads to total PBMCs. 
2.2 T Cell Expansion
2.3 RNA-Modified 
CART Cell Production
3.1 Expanding T 
Cells from AML 
Patients
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Resuspend beads well by gently pipetting up and down for a 
minute. Do not vortex. Add the required volume of beads to a 
total of 1 mL TCM in a 1.5 mL tube and gently resuspend to 
wash. Place the tube in magnet (e.g., DynaMag-2, Thermo 
Fisher Scientific) and wait for 1 min. Remove media without 
disturbing the beads. Repeat the washing steps three times. 
After washings, resuspend beads in 500–1000 μL of TCM.
 4. Add beads to cells already plated at 1 × 106 cells/mL if using a 
flask. If planning to use multiple individual wells of a plate, add the 
beads to the cells in a conical tube, then distribute 1 mL aliquots 
of the cell/bead mixture. Keep in incubator at 37 °C, 5% CO2. 
The day of stimulation (adding beads to cells) represents day 0.
 5. Beginning on day 3, count cells using Coulter multi-sizer every 
other day. Feed cells with TCM to bring the final concentration 
to 1 × 106 cells/mL (see Notes 2 and 3).
 6. Remove beads on day 6 as follows: gently resuspend cells by 
pipetting up and down several times, collect the cells, and place 
in a 15 mL or 50 mL conical tube. Put the tube in a magnet 
(e.g., DynaMag-15, Thermo Fisher Scientific), and wait for 
2 min to allow the beads to migrate to the side. Remove cell 
suspension from the middle of the tube by aspirating with a 
pipette. Count using Coulter multi-sizer and plate in new flasks 
at 1 × 106 cells/mL in warm TCM.
 7. Record counts and mean cell volume (MCV) and graph to gen-
erate expansion curves (Fig. 1). MCV increases as T cells become 
Fig. 1 Expansion curves and number of doublings after expansion of 5 primary 
AML samples. AML samples were expanded as outlined in Subheading 3.1 of this 
chapter
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activated, then reaches its maximum between day 5 and 7 post-
activation, and then declines as T cells start resting down.
 8. When MCV reaches 300 fL, cells are adequately rested (typi-
cally within 9–14 days) and can be used or frozen for future 
experiments. Freeze cells at up to 10 × 106/mL in 90% fetal 
bovine serum with 10% DMSO in rate-controlled manner. 
Recovery upon subsequent thawing should be higher than 75%.
 9. Figure 1 represents T cell expansion kinetics from 5 AML 
patients (see Notes 4 and 5).
 1. We have found that the presence of residual AML blasts impairs 
T cell expansion. T cells were separated from AML by flow 
cytometric sorting to a purity of 100%. Then T cells were mixed 
with AML cells at different ratios (Fig. 2a), stimulated and 
expanded (as described in Subheading 3.1). There was a signifi-
cant improvement in T cell expansion when AML cells were 
depleted.
 2. To enrich for T cells in primary AML samples, CD3/CD28 
Dynabeads or CD4/CD8 positive selection can be performed.
3.2 Enrichment of T 
Cells Prior to T Cell 
Expansion in AML 
Patients
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Fig. 2 (a) T cells were separated by flow cytometry sorting to >99% purity. T cells were then mixed with AML 
blasts at the indicated percentages on x-axes and expanded in culture as outlined in Subheading 3.1. (a1) 
Shows the total number of T cells pre (black) and post (red) expansion. (a2) Shows the number of doublings 
plotted against the percentage of T cells in culture. (b) T cell expansion curves of bulk unselected AML (left) or 
CD3/CD28 enriched AML growth before (a) and after (b) CD3/CD28 selection (purity 90%)
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 3. Enrichment of T cells using CD3/CD28 beads: Thaw, plate 
AML samples at 1 × 106 cells/mL, and rest overnight (as 
described in Subheading 3.1). Count, prepare, and wash beads 
(as described in Subheading 3.1). Add beads to cells, place cells 
in a 15 mL or 50 mL conical tube, and incubate while rotating 
for 45 min at room temperature. T cells will be tightly bound 
to beads during this time. Place tube in a magnet and wait for 
1 min. Beads (and T cells that are attached to them) will migrate 
to the side. Gently aspirate media from the center of the tube 
(this media contains mostly AML cells at this time, rather than 
T cells that will be bound to CD3/CD28 Dynabeads). 
Resuspend beads (and attached T cells) in TCM, count with 
Coulter multi-sizer, and plate at 1 × 106 cells/mL. Take an ali-
quot for flow cytometry (as described in Subheading 3.1). 
Continue T cell expansion as described in Subheading 3.1. 
Figure 2b represents an example of T cell expansion curve after 
CD3/CD28 enrichment.
 4. Enrichment of T cells using CD4/CD8 positive selection: thaw, 
plate AML samples at 1 × 106 cells/mL, and rest overnight at 
37 °C in an incubator (as described in Subheading 3.1). Stain 
with CD4 and CD8 antibodies conjugated to PE and then use 
MACS enrichment with anti-PE microbeads according to the 
manufacturer’s instructions. Following T cell selection, stimu-
late and expand T cells as discussed in Subheading 3.1.
 1. The CAR lentivirus plasmid is generated as previously described 
[19].
 2. The CAR lentivirus is generated by transfection of 293 T cells 
with the specific plasmid and the supernatant is frozen at −80 
°C as previously described [19].
 3. Start T cell expansion as described in Subheadings 3.1 and 3.2.
 4. On day 1, transduce T cells with lentivirus. Thaw frozen lenti-
viral supernatant gradually at room temperature for 20–30 min. 
Add previously titrated lentiviral supernatant to T cells drop-
wise at a multiplicity of infection (MOI) of 3.0. Resuspend by 
gently swirling the plate.
 5. On day 6, check CAR expression by flow cytometry. Take an 
aliquot of T cells, wash once with flow buffer, stain with anti- 
CAR antibody and live/dead staining, wash twice, then stain 
with mouse anti-human CD45, and CD3. Acquire on a cytom-
eter to determine the transduction efficiency. We typically 
obtain a transduction efficiency of 50–75% (see Note 6).
 6. Continue the rest of expansion as outlined in Subheading 3.1.
 7. Figure 3 represents an example of CD123 directed CAR T cells 
generated from an AML patient. Introducing the CAR trans-
gene provides an expansion advantage to the T cells (Fig. 3a) 
(see Note 7).
3.3 Generating 
Lentiviral-CART 
from AML Patients
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 1. Plate AML samples and start T cell expansion as described in 
Subheading 3.1.
 2. The CAR lentivirus construct is subcloned into the pDA vector 
as previously described [18].
 3. RNA is generated by in vitro transcription using mMESSAGE 
mMachineT7 ULTRA Transcription Kit. RNA is purified using 
the RNeasy Mini Kit as previously described.
 4. When the MCV falls under 300 fL, T cells can be electropor-
ated with RNA or frozen in fetal calf serum with 10% DMSO 
for future use.
 5. Electroporation of T cells: if using frozen expanded T cells, 
thaw in warm TCM, spin at 500 g for 7 min to remove DMSO, 
and rest overnight in incubator at 37 °C, 5% CO2. From now 
on, carry out all procedures on ice.
 6. Transfer cells to a conical 50 mL tube and wash with cold 
OptiMEM three times. Spin at 500 g for 7 min between washes. 
After the third wash, aspirate the supernatant completely, and 
3.4 Generating 
RNA-Modified CAR T 
Cells from AML 
Patients
Fig. 3 (A) Expansion and cell volume curves of T cells from AML samples after transduction with CD123- 
chimeric antigen receptor. Transduction with CD123-CAR and generation of CART123 result in eradication of 
residual AML and increase proliferation of T cells. (B) Flow plot of a final T cell expansion product of an AML 
patient (untransduced T cells). Note that there are residual leukemic cells. (C) Flow plot of a final T cell expan-
sion product of an AML patient (CD123 directed CARTs). Note the transduction efficiency is 72.5%
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resuspend in cold OptiMEM up to 300 × 106 cells/mL. Transfer 
T cells to bullet tubes (100 μL) (30 × 106 T cells) to each bullet 
tube. Add RNA (1 μg for each 1 × 106 T cells) and resuspend 
gently by pipetting up and down several times. Transfer cells 
plus RNA from each bullet tube to a cuvette and keep on ice.
 7. Turn on the ECM830 Electro Square Wave Porator, set the 
machine to 500 V and 700 μs (see Note 8). Place the cuvette in 
the machine, tighten firmly in place and pulse. Wash cuvette 
three times with 1 mL of warm TCM and transfer cells to a six- 
well plate. Feed with TCM to bring the concentration to 2 × 
106 cells/mL. Rest in incubator at 37 °C, 5% CO2.
 8. Rest cells for 2–4 h post electroporation. Then cells can be used 
or frozen for future experiments (see Note 9).
4 Notes
 1. For small-scale expansions we prefer to rest PBMC or T cells at 
1 mL in individual wells of a 24 well tissue culture plate. Larger 
volume work is typically carried out in T25–T150 flasks 
(Corning).
 2. Expect a drop-off in live cell number if counting before day 3.
 3. The media will start to change color, representing metabolic 
activity of the T cells, around day 3 (Fig. 4).
 4. Expansion kinetics are variable between patients and the aver-
age number of doublings after T cell expansion from AML 
patients is 4.
 5. When T cells are stimulated and expanded from AML patients, 
the final product may contain residual leukemia cells (Fig. 3b).
 6. Staining for CAR needs to be performed first if the CAR is 
based on an anti-mouse scFv. Sample needs to be washed twice 
before surface staining is performed.
 7. Transducing with myeloid directed CAR construct (such as 
CART123 or CART33) at the beginning of culture results in 
Fig. 4 An example of changes in T cell expansion media between day 0 and 3 of 
expansion
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eradiation of the residual leukemia in culture, whereas with a 
strategy that incorporates gene transfer at the end of culture 
there may be residual leukemia cells at the end of culture 
(Fig. 3b).
 8. Users are advised to titrate machine settings.
 9. CAR can be detected on the surface of the electroporated T 
cells within an hour, and typically achieves maximal median flu-
orescence intensity (MFI) within 24–48 h. If the T cells are not 
exposed to antigen, the CAR MFI will diminish gradually over 
approximately 5–7 days (Fig. 5) [18].
Fig. 5 Expression of CD33 directed chimeric antigen receptor at different time points (as indicated) after RNA 
electroporation of T cells. Maximum expression of CAR is 24 h after electroporation and declines over a period 
of 5–7 days
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